0000721748-14-000493.txt : 20140516 0000721748-14-000493.hdr.sgml : 20140516 20140516155006 ACCESSION NUMBER: 0000721748-14-000493 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20140331 FILED AS OF DATE: 20140516 DATE AS OF CHANGE: 20140516 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NATIONAL SCIENTIFIC CORP/AZ CENTRAL INDEX KEY: 0001022505 STANDARD INDUSTRIAL CLASSIFICATION: SEMICONDUCTORS & RELATED DEVICES [3674] IRS NUMBER: 860837077 FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-28745 FILM NUMBER: 14851396 BUSINESS ADDRESS: STREET 1: 8361 E. EVANS ROAD STREET 2: SUITE 106 CITY: SCOTTSDALE STATE: AZ ZIP: 85260-3617 BUSINESS PHONE: 480-948-8324 MAIL ADDRESS: STREET 1: 8361 E. EVANS ROAD STREET 2: SUITE 106 CITY: SCOTTSDALE STATE: AZ ZIP: 85260-3617 10-Q 1 nsct033114q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

[x]

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2014

 

[ ]

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT

For the transition period from N/A to N/A

  

Commission File No. 000-28745

  

Cloud Medical Doctor Software Corporation

 

(Name of small business issuer as specified in its charter)

 

(formerly National Scientific Corporation)

 

 Texas 86-0837077
( State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.)

                                                                                                         

1291 Galleria Drive, Suite 200

Henderson, NV 89014

(Address of principal executive offices) (Zip Code)

 

(702) 818-9011

Registrant’s telephone number, including area code

 

Indicate by check mark whether the Registrant (1) has filed all reports required by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days:  Yes [X] No [ ]

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [ ]

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer [ ] Accelerated filer [ ]
Non–Accelerated filer  [ ] Smaller reporting company [x]

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b–2 of the Exchange Act). Yes [ ] No [x]

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

 

Class   Outstanding at  May 1, 2014
Common stock, $0.01 par value   248,256,722

 
 

CLOUD MEDICAL DOCTOR SOFTWARE CORPORATION

INDEX TO FORM 10-Q FILING

FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2014 AND 2013

 

TABLE OF CONTENTS

 

      PAGE
PART I - FINANCIAL INFORMATION   
         
Item 1.  Consolidated Financial Statements (Unaudited)   4 
    Balance Sheets   5 
    Statements of Operations   6 
    Statements of Cash Flows   7 
    Notes to Consolidated Financial Statements   7 
Item 2.  Management Discussion & Analysis of Financial Condition and Results of Operations   26 
Item 3  Quantitative and Qualitative Disclosures About Market Risk   30 
Item 4.  Controls and Procedures   30 

 

PART II - OTHER INFORMATION    
         
Item 1.  Legal Proceedings   31 
Item 1A.  Risk Factors   31 
Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds   32 
Item 3.  Defaults Upon Senior Securities   34 
Item 4.  Mining Safety Disclosures   34 
Item 5  Other information   34 
Item 6.  Exhibits   34 
         
CERTIFICATIONS      

 

31.1 Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act.
31.2 Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act.
32.2 Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act.
32.2 Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act.
 
 

PART I

FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

The accompanying interim financial statements have been prepared in accordance with the instructions to Form 10-Q.  Therefore, they do not include all information and footnotes necessary for a complete presentation of financial position, results of operations, cash flows, and stockholders' equity in conformity with generally accepted accounting principles.  Except as disclosed herein, there has been no material change in the information disclosed in the notes to the financial statements included in the Company's Annual Report on Form 10-K for the year ended September 30, 2013.  In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included and all such adjustments are of a normal recurring nature.  Operating results for the three months ended March 31, 2014 are not necessarily indicative of the results that can be expected for the year ending September 30, 2014.

 

 

CLOUD MEDICAL DOCTOR SOFTWARE CORPORATION
CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
       
   March 31,  September 30,
   2014  2013
           
ASSETS          
           
CURRENT ASSETS:          
  Cash  $7,656   $8,587 
  Accounts receivable   5,176    8,338 
      Total current assets   12,832    16,925 
           
 Software, net   701,611    817,921 
           
    TOTAL ASSETS  $714,443   $834,846 
           
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)          
           
CURRENT LIABILITIES:          
   Accounts payable and accrued expenses   699,559   $361,994 
   Liabilities attributed to discontinued operations   42,873    35,356 
   Lines of credit   87,041    9,796 
      Total current liabilities   829,473    407,146 
           
      TOTAL LIABILITIES   829,473    407,146 
           
COMMITMENTS AND CONTINGENCIES   —      —   
           
STOCKHOLDERS' EQUITY (DEFICIT):          
Preferred stock, $0.01 par value, 4,000,000 shares authorized; 4,000,000 issued and outstanding   40,000    40,000 
Common stock, $0.01 par value, 650,000,000 shares authorized; 246,829,216 and 214,624,216 issued and outstanding   2,468,292    2,146,242 
    Additional paid-in capital   25,214,828    24,783,723 
    Accumulated deficit   (27,838,150)   (26,542,265)
      Total stockholders' equity  (deficit)   (115,030)   427,700 
           
    TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)  $714,443   $834,846 
           
The accompanying notes are an integral part of these unaudited financial statements.

 

CLOUD MEDICAL DOCTOR SOFTWARE CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
             
   Three Months Ended  Six Months Ended
   March 31,  March 31,
   2014  2013  2014  2013
                     
REVENUES  $105,118   $174,214   $222,675   $323,571 
COST OF REVENUES   61,155    61,155    122,310    121,160 
                     
GROSS PROFIT   43,963    113,059    100,365    202,411 
                     
OPERATING EXPENSES:                    
    Selling, general and administrative   1,106,142    224,454    1,328,218    343,325 
    Research and development   30,000    55,000    60,000    95,000 
       Total operating expenses   1,136,142    279,454    1,388,218    438,325 
 Gain on the disposal of assets   —      1,353    —      1,353 
OPERATING LOSS   (1,092,179)   (165,042)   (1,287,853)   (234,561)
                     
OTHER INCOME (EXPENSE)                    
    Interest expense   (279)   (69)   (515)   (196)
Total other income expense   (279)   (69)   (515)   (196)
                     
LOSS FROM CONTINUING OPERATIONS   (1,092,458)   (165,111)   (1,288,368)   (234,757)
                     
INCOME (LOSS) FROM DISCONTINUED OPERATIONS   3,198    (38)   (7,517)   58,946 
                     
NET LOSS  $(1,089,260)  $(165,149)  $(1,295,885)  $(175,811)
                     
NET LOSS PER COMMON SHARE:                    
   Basic and diluted                    
                     
   Continuing operations  $(0.00)  $(0.00)  $(0.01)  $(0.00)
                     
   Discontinued operations  $0.00   $(0.00)  $(0.00)  $0.00 
                     
    Total  $(0.00)  $(0.00)  $(0.01)  $(0.00)
                     
WEIGHTED AVERAGE NUMBER COMMON SHARES OUTSTANDING                    
   Basic and diluted   224,546,327    212,756,568    219,656,908    212,472,748 
                     
The accompanying notes are an integral part of these unaudited financial statements.

 

CLOUD MEDICAL DOCTOR SOFTWARE CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
   SIX MONTHS ENDED
   March 31,
   2014  2013
           
  Net loss  $(1,295,885)  $(175,811)
  Income from discontinued operations   (7,517)   58,946 
         Loss from continuing operations   (1,288,368)   (234,757)

Adjustments to reconcile net loss from continuing operations

to net cash from operating activities:

          
   Depreciation and amortization   122,310    121,160 
   Common stock issued for compensation   666,750    28,155 
   Common stock issued for software sales   5,700    9,350 
   Gain on the disposal of assets   —      (1,353)
   Changes in operating assets and liabilities:          
   Accounts receivable   3,162    3,012 
   Accounts payable and accrued expenses   397,270    88,638 
          Net cash (used in) provided by operating activities   (93,176)   14,205 
           
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
   Proceeds from the sale of assets   —      1,353 
          Net cash provided by investing activities   —      1,353 
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
   Repayment of advances from officer   —      (25,591)
   Proceeds from line of credit   78,245    2,500 
   Repayment of line of credit   (1,000)   (22,152)
   Common stock issued for cash   15,000    141,000 
          Net cash provided by financing activities   92,245    95,757 
           
INCREASE (DECREASE) IN CASH   (931)   111,315 
CASH, BEGINNING OF PERIOD   8,587    51,356 
CASH, END OF PERIOD  $7,656   $162,671 
           
SUPPLEMENTAL DISCLOSURE          
           
Interest paid  $—     $—   
Taxes paid  $—     $—   
           
NONCASH INVESTING AND FINANCING ACTIVITIES     
           
Write-off of related party debt to additional paid-in capital  $59,704   $—   
Common stock issued to purchase software  $6,000   $13,000 
Accrual of software acquisition costs  $—     $23,000 
           
The accompanying notes are an integral part of these unaudited financial statements.

 

CLOUD MEDICAL DOCTOR SOFTWARE CORPORATION

NOTES TO FINANCIAL STATEMENTS

FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2014 AND 2013

(Unaudited)

 

NOTE 1- DESCRIPTION OF BUSINESS

 

Cloud Medical Doctor Software Corporation (the “Company”) was incorporated in Texas on June 22, 1953 as American Mortgage Company. On May 16, 1996, the Company changed its name to National Scientific Corporation. On April 3, 2012, the Company changed its name to Cloud Medical Doctor Software Corporation. 

 

In the year ended September 30, 2011, Cloud-MD introduced the Cloud-MD Office, a “Cloud Based”, 5010 ready and ICD-10 compliant, fully integrated and interoperable suite of medical software and services, designed by experienced healthcare analysts and programmers for healthcare providers, that produces “Actionable Information” to help Independent Physician Practices, New Care Delivery Models (ACO), Healthcare Systems and Billing Services optimize a wide range of business processes resulting in Increased Profits, Higher Quality, Greater Efficiency, Noticeable Cost Reductions and Better Patient Care. Current software product offerings include Practice Management, Electronic Medical Records, Revenue Management, Patient Financial Solutions, Medical and Pharmaceutical Supply Management, Claims Management and PHI Exchange.

 

In the year ended September 30, 2012, Cloud-MD launched Cloud-MD Billing Services which provides management of medical claims from posting physician charges and payments into our medical billing software. The software uses a continuous insurance claim follow-up system to track and research all rejected or denied medical claims; a Comprehensive Reporting module that includes monthly financial statements sent to our clients so they can see how their practice is performing and a variety of detailed reports giving our clients the necessary information and tools used to assist in the increased production which leads to more profit; and patient account inquiries and support to assist patients with their billing and insurance questions.

 

NOTE 2 – BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS

 

The Company prepares its financial statements in accordance with accounting principles generally accepted in the United States of America.  The accompanying interim unaudited financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X. In our opinion, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included.

 

Operating results for the six months ended March 31, 2014 are not necessarily indicative of the results that may be expected for the year ending September 30, 2014. Notes to the unaudited interim financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the year ended September 30, 2013 have been omitted; this report should be read in conjunction with the audited financial statements and the footnotes thereto for the fiscal year ended September 30, 2013 included within the Company’s Form 10-K as filed with the Securities and Exchange Commission.

 

NOTE 3 - GOING CONCERN

 

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. However, the Company has recurring losses from operations and an accumulated deficit at March 31, 2014 of $27,838,150 and needs additional cash to maintain its operations.

 

These factors raise doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company’s continued existence is dependent upon management’s ability to develop profitable operations, continued contributions from the Company’s executive officers to finance its operations and the ability to obtain additional funding sources to explore potential strategic relationships and to provide capital and other resources for the further development and marketing of the Company’s products and business.

 

NOTE 4 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

The Company prepares its financial statements in accordance with accounting principles generally accepted in the United States of America. Significant accounting policies are as follows:

 

Use of Estimates and Assumptions

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and (iii) the reported amount of net revenues and expenses recognized during the periods presented. Adjustments made with respect to the use of estimates often relate to improved information not previously available. Uncertainties with respect to such estimates and assumptions are inherent in the preparation of financial statements; accordingly, actual results could differ from these estimates. The Company’s most significant estimates relate to the valuation of its proprietary technology and its valuation of its common stock.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.  At March 31, 2014, cash and cash equivalents include cash on hand and cash in the bank and the FDIC insures these deposits up to $250,000.

 

Impairment of Long-Lived Assets

 

Long-lived assets are evaluated for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. Each impairment test is based on a comparison of the undiscounted future cash flows to the recorded value of the asset. If impairment is indicated, the asset is written down to its estimated fair value. The acquired software technologies are reviewed annually for impairment.

 

Fair Value of Financial Instruments

 

The Company's financial instruments consist primarily of cash, accounts payable and accrued expenses, and debt. The carrying amounts of such financial instruments approximate their respective estimated fair value due to the short-term maturities and approximate market interest rates of these instruments.  

 

Fair value is focused on an exit price that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.  Within the measurement of fair value, the use of market-based information is prioritized over entity specific information and a three-level hierarchy for fair value measurements is used based on the nature of inputs used in the valuation of an asset or liability as of the measurement date.

 

The three-level hierarchy for fair value measurements is defined as follows:

 

Level 1 – inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets; liabilities in active markets;
Level 2 – inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability other than quoted prices, either directly or indirectly, including inputs in markets that are not considered to be active; or directly or indirectly including inputs in markets that are not considered to be active;
Level 3 – inputs to the valuation methodology are unobservable and significant to the fair value measurement.

The following table summarizes fair value measurements by level at March 31, 2014 and September 30, 2013 for assets measured at fair value on a recurring basis:

 

   Level 1  Level 2  Level 3  Total
At March 31, 2014                    
Software  $—     $—     $701,611   $701,611 
Total Software  $—     $—     $701,611   $701,611 
                     
At September 30, 2013                    
Software  $—     $—     $937,431   $937,431 
Total Software  $—     $—     $937,431   $937,431 

 

Accounts Receivable and Allowance for Uncollectible Accounts

 

Substantially all of the Company’s accounts receivable balance is related to trade receivables. Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in its existing accounts receivable. The Company will maintain allowances for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments for services. Accounts with known financial issues are first reviewed and specific estimates are recorded. The remaining accounts receivable balances are then grouped in categories by the number of days the balance is past due, and the estimated loss is calculated as a percentage of the total category based upon past history. Account balances are charged against the allowance when it is probable the receivable will not be recovered. As of March 31, 2014 and 2013, the Company had no valuation allowance for the Company’s accounts receivable.

 

Income Taxes

 

The Company utilizes the asset and liability method in accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for operating loss and tax credit carry-forwards and for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is recorded to reduce the carrying amounts of deferred tax assets unless it is more likely than not that the value of such assets will be realized.

 

The Company uses the two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not, that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount, which is more than 50% likely of being realized upon ultimate settlement. The Company considers many factors when evaluating and estimating the Company's tax positions and tax benefits, which may require periodic adjustments. At March 31, 2014, the Company did not record any liabilities for uncertain tax positions.

 

Revenue Recognition

 

License revenue consists principally of revenue earned under software license agreements. The Company sells its software to a medical practitioner for direct payment or through a third party leasing company for direct payment to the Company. The third party lease agreement is a non-recourse debt and the Company is not responsible for the default of the medical practitioner. License revenue is generally recognized when a signed contract or other persuasive evidence of an arrangement exists, the software has been electronically delivered, the license fee is fixed or is measured on a paid user basis; and collection of the resulting receivable is probable. When contracts contain multiple elements wherein Vendor-Specific Objective Evidence (“VSOE”) exists for all undelivered elements, we account for the delivered elements in accordance with the “Residual Method.”

 

VSOE of fair value for maintenance and support is established by a stated renewal rate, if substantive, included in the license arrangement or rates charged in stand-alone sales of maintenance and support. Revenue from subscription license agreements, which include software, rights to unspecified future products and maintenance, is recognized ratably over the term of the subscription period.

 

Provided all other revenue criteria are met, the upfront, minimum, non-refundable license fees from customers are generally recognized upon delivery and on-going royalty fees are generally recognized upon reports of new licenses issued. If there is significant uncertainty about the project completion or receipt of payment for professional services, revenue is deferred until the uncertainty is sufficiently resolved. VSOE of fair value of services is based upon stand-alone sales of those services.

Subscription revenue is generated from bandwidth and information storage. In the first year and each year thereafter, the software is purchased and installed the purchaser will pay an annual fee of $1,200, $1,500, $1,800, and $2,400, respectively. Subscription revenue is recognized ratably over the term of the agreement.

 

Transaction revenue is generated from the following services and recognized when a transaction occurs:

 

·Electronic Remittance Advise $0.35 Electronic remittance transaction fee;
·Paper Claims $1.00 Paper claim fee;
·Carrier Direct $0.16 Carrier direct fee;
·Fast Forward $0.35 Fast forward transaction fee; and,
·Patient Credit $2.50 Automatic Debit processing per transaction paid by the patient

 

The Company had not received any transaction revenues in the three and six months ended March 31, 2014.

 

Cost of License, and Subscriptions Revenues

 

Cost of license revenue is primarily comprised of the license-based royalties to third parties and production and distribution costs for initial product licenses. No costs were incurred for license-based royalties during the three months ended March 31, 2014 and 2013.

 

Cost of subscription revenue is primarily comprised of the costs associated with the customer support personnel that provide maintenance, enhancement and support services to customers. No costs were incurred for customer support during the three months ended March 31, 2014 and 2013.

 

The amortization of acquired technology for products acquired through business combinations are considered as the cost of revenues. The acquired software technologies are amortized over their useful lives of 5 years.

 

Deferred Revenue

 

Deferred revenue result from fees billed to customers for which revenue has not yet been recognized or for which the conditions of the arrangement have been modified. The Company recognizes revenue to provide up-front capitalization to Cloud-MD for each provider added to the solution set. The Company also recognizes annual subscription fees for virtual servers and subscription and small usage fees and those revenues are based on a 48-month lease, Cloud-MD would amortize the revenue over the life of the agreement of 48 months. In addition, it features incremental monthly revenue, for the duration of the lease (48 months) based on fees assessed for transactions such as eligibility claims processing, etc. The Company has deferred revenue of $0 as of March 31, 2014.

 

Sales Commissions

 

The Company pays commissions, including sales bonuses, to the direct sales force related to revenue transactions under sales compensation plans which are established annually. The commission payments are typically paid in full in the month or quarter following execution of the customer contracts. The Company paid commissions of $0 and $20,000 for the three months ended March 31, 2014 and 2013, respectively, and $37,000 and $40,260 for the six months ended March 31, 2014 and 2013, respectively.

 

Research and Development and Software Development Costs

 

Capitalization of certain software development costs subsequent to the establishment of technological feasibility. Based on our product development process, technological feasibility is established upon the completion of a working model. To date, costs incurred by us from the completion of the working model to the point at which the product is ready for general release have been insignificant. Accordingly, we have charged all such costs to research and development expense in the period incurred.

 

Share-Based Compensation

 

The Company measures the cost of services received in exchange for an award of an equity instrument based on the grant-date fair value of the award.  Compensation cost is recognized over the vesting or requisite service period.

 

Basic and Diluted Net Income (Loss) per Common Share

 

Basic income (loss) per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the reporting period. The weighted average number of shares is calculated by taking the number of shares outstanding and weighting them by the amount of time that they were outstanding.  Diluted earnings per share reflects the potential dilution that could occur if stock options, warrants, and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company.

 

The Company has 4,000,000 preferred shares that can be converted subject to the limitation of the Company’s authorized shares at 1 preferred share for 150 common shares. The conversion can only take place with the approval of the Board of Directors. At March 31, 2014, the preferred shares could be converted into 600,000,000 of common shares resulting in dilution of common shareholders. The preferred shares are anti-dilutive since the losses the Company has incurred for the periods ended March 31, 2014 and 2013.

 

Diluted loss per share is the same as basic loss per share during periods where net losses are incurred since the inclusion of the potential common stock equivalents would be anti-dilutive as a result of the net loss.

 

Concentration of Credit Risk

 

All of the Company’s cash and cash equivalents are maintained in regional and national financial institutions. The Company has exposure to credit risk to the extent that its cash and cash equivalents exceed amounts covered by the U.S. federal deposit insurance; however, the Company has not experienced any losses in such accounts. In management’s opinion, the capitalization and operating history of the financial institutions are such that the likelihood of material loss is remote.

 

Subsequent Events

 

The Company has evaluated all transactions occurring between March 31, 2014 and through the date of issuance of the financial statements for subsequent event disclosure.

 

Recent Accounting Pronouncements

 

No accounting standards or interpretations issued recently are expected to a have a material impact on the Company’s financial position, operations or cash flows.

 

NOTE 5 – SOFTWARE

 

The following is a detail of software at March 31, 2014 and September 30, 2013:

 

   March 31, 2014  September 30,
2013
           
Source Code License – Antree Systems Limited  $6,000   $—   
Encryption Software Code   15,800    15,800 
Source Code License – MediSouth, LLC   2,500    2,500 
Acquisition of Doctor’s Network of America   10,000    10,000 
Software License   1,200,106    1,200,106 
EMR Certification   23,000    23,000 
Total intangible assets   1,257,406    1,251,406 
Accumulated amortization of intangible assets   (545,795)   (423,485)
Accumulated impairment of assets   (10,000)   (10,000)
Total intangible assets  $701,611   $817,921 

  

The Company’s software was placed into service starting in the second quarter of fiscal year ended September 30, 2012. The amortization expense was $61,155 and $61,155 for the three months ended March 31, 2014 and 2013, respectively. The Company recognized a $0 and $6,000 for impairment of software acquired from Doctors Network of America (“DNA”) operating in Flowood, Mississippi during the six months ended March 31, 2014 and the year ended September 30, 2013, respectively. The Company is currently in litigation with the sellers of DNA relating to the collection of certain medical billings owed to the Company. As a result of the litigation, the Company deemed the assets to be impaired.

 

Source Code License

 

In October 2013, the Company through a purchase agreement with Antree Systems Limited has purchased a complete source code, intellectual property rights, all computer software, patents, or formulas, algorithm licensed or sold under a project known as Compass Rose and appropriate copyrights, patents, mask works, trademarks, service marks, internet domain names and world wide web uniform resource locators (“URLs”) from Antree Systems Limited. The Company issued 200,000 shares of its common stock as consideration for the purchase. The fair value of the consideration and the assets acquired is based on the fair value of the common stock issued in exchange for the software. The total fair value, based on the market price on the date of grant, was $6,000. The Company evaluated this acquisition and determined that it did not meet the definition of a significant business acquisition.

 

Encryption Software Code

 

On November 21, 2012, the Company purchased from CipherSmith, LLC a complete source code, intellectual property rights, all computer software or algorithm licensed or sold under CipherSmith, and appropriate copy rights, patents, mask works, trademarks, service marks, internet domain names or world wide web URS. The Company issued 500,004 shares of its common stock as payment for the acquisition. The fair value of the consideration and the assets acquired is based on the aggregate fair value of the common stock issued in exchange for the software. The total fair value of the shares of common stock issued on the date of grant was $15,800.

 

Doctors Network of America

 

On June 22, 2012, the Company entered into an acquisition agreement that closed on March 16, 2013. The Company agreed to acquire DNA in Flowood, Mississippi from Krooss Medical Management Systems, LLC (“Krooss”) for 500,000 shares of common stock. As of September 30, 2012, 200,000 shares of common stock were issued as a deposit, which was valued at $4,000 based on the market value on the date of grant. At the closing of the transaction on March 16, 2013, the Company issued an additional 300,000 shares of common stock which were valued at $6,000 based on the market value on the date of grant.

 

Subsequent to the transaction closing on March 16, 2013, the sellers refused to pay for medical billing process transaction fees in accordance with their contracts in the amount of approximately $200,000. The Company and the sellers are currently in litigation over the disputed transaction fees of $200,000.

 

NOTE 6- DISCONTINUED OPERATIONS

 

The Company’s former Board of Directors believed that it was in the best interest of the Company to discontinue the former business operation of the GPS operational device business. In 2011, this business was transferred to National Scientific, LLC, a company owned by the Company’s prior CEO, by prior management in which the Company’s former CEO was to pay $100,000 plus 2% of revenues for that technology. The former officer never paid the specific consideration for this transaction.

 

Accordingly, the Company reclassified the assets, liabilities and operations related to its GPS operational device business as discontinued operations.  Consequently, the accompanying financial statements reflect the assets, liabilities and operations of the GPS operational device business as net assets of discontinued operations, net liabilities of discontinued operations and results from discontinued operations.

 

On March 16, 2013, the Company closed the acquisition with the final payment for DNA. Subsequent to the transaction closing, the sellers refused to pay the transaction fees for medical billing contracts that were processed. The Company filed a lawsuit against the sellers for Breach of Contract among other things in June of 2013. During that time, the Company believes the sellers began contacting all billing contract holders and interfered with the acquisition of all the assets from the transaction. Consequently, the accompanying consolidated financial statements reflect the assets, liabilities and operations of DNA as net assets of discontinued operations, net liabilities of discontinued operations and results from discontinued operations.

 

Details of the classifications for net assets, liabilities and operations are shown below.

 

   March 31,
2014
  September 30,
2013
           
Net liabilities of discontinued operations:          
Accounts payable  $42,837   $35,356 
Net liabilities of discontinued operations  $42,837   $35,356 

 

   Three Months Ended
March 31,
   2014  2013
           
Discontinued operations:          
Revenues  $53,766   $900 
Cost of sales   —      —   
Operating expenses   (50,568)   (938)
Gain from write-off of debt   —      —   
Income (loss) from discontinued operations  $3,198  $(38)

 

   Six Months Ended
March 31,
   2014  2013
Discontinued operations:          
Revenues  $131,050   $900 
Cost of sales   —      —   
Operating expenses   (138,567)   (938)
Gain from write-off of debt   —      58,984 
Income (loss) from discontinued operations  $(7,517)  $58,946 

 

NOTE 7 – LINES OF CREDIT

 

In November 2013, the Company entered into a revolving line of credit with Mutual of Omaha in the amount of $65,000 at a 4.00% interest rate per annum which renews annually. As of March 31, 2014, the Company had borrowed $62,612 against the line of credit.

 

The Company has a revolving line of credit with Chase Bank with a balance as of March 31, 2014 in the amount of $24,429 and a borrowing limit of $50,000. The line of credit with Chase Bank has an interest rate of 4.25% per annum and renews annually.

 

NOTE 8 – DEBT MITIGATION PROGRAM

 

The Company determined that the statute of limitations for certain of the Company’s creditors to enforce collection of any amounts they might be owed has now elapsed. Based on the determinations and findings, during six months ended March 31, 2014 and 2013, the Company recognized a gain on the write-off of liabilities in the amount of $0 and $58,984 from third party liabilities, respectively, which was recorded in income from discontinued operations, and additional paid-in capital of $59,704 and $0 for related party liabilities, respectively. The Company will continue to conduct this analysis going forward and write-off obligations when such obligations are no longer enforceable based on applicable law.

 

The following liabilities, through the opinion of legal counsel, were determined by the Company as unenforceable.

 

   Six Months Ended
   March  31,  March 31,
   2014  2013
           
Debt Mitigation Program:          
Accounts payable and accrued expenses  $59,704   $58,984 
Accrued interest   —      —   
Total debt mitigation program  $59,704   $58,984 
Gain on write-off of debt  $—     $(58,984)
Additional paid-in capital (1)  $59,704   $—  

(1)   All amounts that were owed to related parties in prior years were recorded to paid-in-capital.

 

NOTE 9 – COMMITMENTS AND CONTINGENCIES

 

Rent expense for the three and six months ended March 31, 2014 and 2013 was $0 for all periods.

 

The Company entered into an agreement to purchase the assets of DNA in June 2012 and after due diligence by both parties the transaction closed on March 16, 2013. Subsequent to the transaction closing on March 16, 2013, the sellers refused to pay for medical billing process transaction fees in accordance with their contracts of approximately $200,000. In June 2013, the Company sued the sellers in federal court for breach of contract among other causes of action of unpaid medical billing transaction fees of approximately $200,000. The Company believes it will be successful in its litigation. However, if the Company is successful, the collectability of the judgment is highly questionable.

 

The Company has issued shares to new investors since January 2, 2011, that have an anti-reverse common stock split clause if the Company reverse splits the common stock. The reverse split of common stock is determined by management but must be approved by Financial Industry Regulation Authority (“FINRA”). Presently FINRA has denied the Company the right to reverse split the common stock until all Securities and Exchange Commission filings are current and at that point and time the Company will submit a request to FINRA to execute a reverse split of the common stock of the Company. The current investors holding anti-reverse split stock will have the right to hold the same number of shares of common stock as status quo after the reverse split. The anti-reverse split common stock protection is only for stock subject to reverse split and once the Company declares a reverse split and it is completed, the anti-reverse split protection will be terminate and shareholders that received anti-reverse split stock will be held with regular stockholders as the Company proceeds forward. In accordance with the anti-reverse split provision, no further shares will be issued to the anti-reverse split shareholders once the reverse split is approved and completed.

 

As discussed in Note 8, the Company has written off $59,704 and $58,984 in accounts payable, accrued liabilities and notes payable based on the opinion of legal counsel for the six months ended March 31, 2014 and 2013, respectively. However, the related creditors could make a claim in the future in regards to these liabilities.

 

NOTE 10– RELATED PARTY TRANSACTIONS

 

The Company repaid $0 and $25,591 of the advances from the Company’s CEO in the three months ended March 31, 2014 and 2013, respectively. The advances from the CEO are due on demand and do not accrue interest. As of March 31, 2014 and September 30, 2013, there were no amounts owed to the CEO for advances, respectively.

 

NOTE 11 - EQUITY

 

As of March 31, 2014, the Company was authorized to issue 650,000,000 common shares and 4,000,000 preferred shares at a par value of $0.01.  

 

Six Months Ended March 31, 2014

 

Stock Issued for Cash

 

During the six months ended March 31, 2014, the Company issued 35,000 shares of common stock for $15,000 in net cash proceeds as follows:

 

Date   Number of Shares   Proceeds
         
  October 21, 2013       25,000     $ 5,000  
  January 12, 2014     10,000     10,000  
  Total       35,000     $ 15,000  

 

Stock Issued in Connection with Software Licensing and Subscription Agreements

 

During the six months ended March 31, 2014, the Company issued 220,000 shares of common stock valued at $5,700 based on the market price on the date of grant, to customers, in regards to the purchase of software from the Company in accordance with the Software Licensing and Subscription Agreements. The fair values of the shares issued were recorded as a reduction of software revenue recognized during the three months ended March 31, 2014.

 

Date  Number of Shares  Fair Value
       
 December 4, 2013    120,000   $3,600 
 March 4, 2014    100,000    2,100 
 Total    220,000   $5,700 

 

Stock Issued for Assets Acquisition

 

In October 2013, the Company through a purchase agreement with Antree Systems Limited has purchased a complete source code, intellectual property rights, all computer software, patents, or formulas, algorithm licensed or sold under a project known as Compass Rose and appropriate copyrights, patents, mask works, trademarks, service marks, internet domain names and world wide web uniform resource locators (“URLs”) from Antree Systems Limited. The Company issued 200,000 shares of its common stock as consideration for the purchase. The fair value of the consideration and the assets acquired is based on the fair value of the common stock issued in exchange for the software. The total fair value, based on the market price on the date of grant, was $6,000. The Company evaluated this acquisition and determined that it did not meet the definition of a significant business acquisition.

 

In November 2013, the Company issued 180,000 shares of common stock as replacement shares for the 160,000 shares of common stock issued to Antree Systems Limited and 20,000 shares of common stock to Kimberly Ilicerl. The Company intends to cancel the original shares issued because the shares were lost during delivery to Antree Systems.

 

Stock Issued for Services

 

During the six months ended March 31, 2014, the Company issued 31,750,000 shares of common stock as compensation. The fair values of the shares were a total of $666,750 and were recorded at the market price on the date of grant. The issuances of stock were as follows:

 

Date  Number of Shares  Fair Value  Description of Services
                  
 March 5, 2014    31,750,000   $666,750    Compensation 
                 
 Total    31,750,000   $666,750      

  

Six Months Ended March 31, 2013

 

Stock Issued for Cash

 

During the six months ended March 31, 2013, the Company issued 197,500 shares of common stock for $141,000 in net cash proceeds as follows:

 

Date  Number of Shares  Proceeds
             
 October 14, 2012    20,000   $20,000 
 October 14, 2012    15,000    3,000 
 October 14, 2012    18,750    2,500 
 October 14, 2012    18,750    2,500 
 December 6, 2012    15,000    3,000 
 March 12, 2013    20,000    20,000 
 March 12, 2013    20,000    20,000 
 March 31, 2013    50,000    50,000 
 March 27, 2013    20,000    20,000 
 Total    197,500   $141,000 

 

Stock Issued in Connection with Software Licensing and Subscription Agreements

 

During the six months ended March 31, 2013, the Company issued 300,000 shares of common stock valued at $9,350 based on the market price on the date of grant, to customers, in regards to the purchase of software from the Company in accordance with the Software Licensing and Subscription Agreements. The fair values of the shares issued were recorded as a reduction of software revenue recognized during the three months ended March 31, 2013.

 

Date  Number of Shares  Fair Value
             
 October 14, 2012    50,000   $1,300 
 December 6, 2012    100,000    2,800 
 March 12, 2013    50,000    1,750 
 March 21, 2013    50,000    1,750 
 March 21, 2013    50,000    1,750 
 Total    300,000   $9,350 

 

 

Stock Issued for Services

 

During the six months ended March 31, 2013, the Company issued 827,000 shares of common stock as compensation. The fair values of the shares were a total of $28,155 and were recorded at the market price on the date of grant. The issuances of stock were as follows:

 

Date  Number of Shares  Fair Value  Description of Services
                  
 October 14, 2012    10,000   $260    Commission 
 December 6, 2012    100,000    2,800    Compensation 
 March 12, 2013    50,000    1,750    Consulting 
 March 21, 2013    167,000    5,845    Compensation 
 March 21, 2013    500,000    17,500    Compensation 
 Total    827,000   $28,155      

 

Stock Issued for Assets Acquisition

 

During the six months ended March 31, 2013, the Company issued 400,000 shares of common stock for the acquisition of CipherSmith software. Those shares were valued at $13,000 based on the market price on the dates of grant.

 

Preferred Stock

 

The Company has authorized 4,000,000 shares of preferred stock, at $0.01 par value and 4,000,000 are issued and outstanding as of September 30, 2013. Each share of the Preferred Stock has 150 votes on all matters presented to be voted by the holders of our common stock. All 4,000,000 shares of preferred stock have been granted to our CEO & CFO on November 30, 2010 and issued on April 11, 2012 which was valued at the trading price of the common stock of $0.0095 and recorded as an expense of $38,000.

 

On December 17, 2013, the Company amended its Articles of Incorporation that gave the right to the holders of Preferred A shares to convert 1 share of Convertible Preferred A shares to 150 Common Shares of the Company. The holders of the Preferred A shares can convert the shares upon proper notice and approval of the Board of Directors. Presently, the holders of the Preferred A shares have not sent notice to the Board of Directors.

 

NOTE 12 – SUBSEQUENT EVENTS

 

Stock Issued for Services

 

On April 21, 2014, the Company issued 1,407,506 shares of common stock as compensation. The fair values of the shares were a total of $21,253 and were recorded at the market price on the date of grant.

 

In this Quarterly Report on Form 10-Q, “Company,” “our company,” “us,” and “our” refer to Cloud Medical Doctor Software Corporation and its subsidiaries, unless the context requires otherwise.

 

ITEM 2 - MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Forward-Looking Statements

 

Management’s Discussion and Analysis contains various “forward looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, regarding future events or the future financial performance of the Company that involve risks and uncertainties. Certain statements included in this Form 10-Q, including, without limitation, statements related to anticipated cash flow sources and uses, and words including but not limited to “anticipates”, “believes”, “plans”, “expects”, “future” and similar statements or expressions, identify forward looking statements. Any forward-looking statements herein are subject to certain risks and uncertainties in the Company’s business, including but not limited to, reliance on key customers and competition in its markets, market demand, delayed payments of accounts receivables, technological developments, maintenance of relationships with key suppliers, difficulties of hiring or retaining key personnel and any changes in current accounting rules, all of which may be beyond the control of the Company. Management will elect additional changes to revenue recognition to comply with the most conservative SEC recognition on a forward going accrual basis as the model is replicated with other similar markets (i.e. SBDC). The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including those set forth therein.

 

Forward-looking statements involve risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. Factors and risks that could affect our results and achievements and cause them to materially differ from those contained in the forward-looking statements include those identified in the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended September 30, 2013, as well as other factors that we are currently unable to identify or quantify, but that may exist in the future.

 

In addition, the foregoing factors may affect generally our business, results of operations and financial position. Forward-looking statements speak only as of the date the statement was made. We do not undertake and specifically decline any obligation to update any forward-looking statements.

 

Our Company

 

The Company was incorporated in Texas on June 22, 1953 as American Mortgage Company. On May 16, 1996, the Company changed its name to National Scientific Corporation. On April 3, 2012, the Company changed its name to Cloud Medical Doctor Software Corporation. During 1996, the Company acquired the operations of Eden Systems, Inc. (Eden) as a wholly owned subsidiary. Eden was engaged in water treatment and the retailing of cleaning products. Eden’s operations were sold on October 1, 1997. From September 30, 1997 through the year ended September 30, 2001, we aimed our efforts in the research and development of semiconductor proprietary technology and processes and in raising capital to fund its operations and research. Beginning in calendar 2002, we focused our efforts on the development, acquisition, enhancement and marketing of location device technologies. Our revenue was derived from sales of electronic devices, recognized as the product is delivered.

 

On February 4, 2010, the prior Board members Mr. Michael Grollman and Mr. Greg Szabo, voted to discontinue and wind down the operations of the Company's Mobile DVR and Location Products business and operate these remaining Company assets in a Limited Liability Company named NSC Labs, LLC, a company controlled and owned by Mr. Grollman. Mr. Grollman and NSC Labs, LLC entered into an agreement to pay the Company $100,000 plus 2% of revenues. As of this filing, neither Mr. Grollman nor NSC Labs, LLC have paid the specified consideration for this transaction.

 

Accordingly, the Company reclassified the assets, liabilities and operations related to its GPS operational device business as discontinued operations.  Consequently, the accompanying financial statements reflect the assets, liabilities and operations of the GPS operational device business as net assets of discontinued operations, net liabilities of discontinued operations and results from discontinued operations.

 

On November 19, 2010, the prior management was terminated and new management began working on operations related to the Company’s medical billing software. In fiscal 2011, the year of termination of prior management, new management deemed that the above transaction transferring prior operations to NSC Labs, LLC was transacted in full and final settlement of the liabilities to former management including those captioned as “disputed accrued expenses – related party” on the Balance Sheet Since the transaction was related to former management who had the ability to affect the terms and outcomes of the liabilities, the transaction has been subsequently recorded as an increase to additional paid in capital.

 

The Future for Cloud-MD™

 

Our business strategy includes the acquisition of successful billing companies in strategic markets, the acquisition or licensing of useful emerging technologies and the direct sale to physicians of Cloud-MD™ Office software licenses.

 

On the Medical Software and Billing Services side of the equation, Cloud-MD™ has already begun the sale of software licenses and the acquisition of billing companies with the purchase of Doctors Network of America, LLC and is currently in final negotiations with two others billing companies in Texas and we are currently in talks with another medical software company to acquire their software assets and customer base.

 

Our model is effective because we offer:

 

·Software For Life – Buy One Time
·Evergreen Product - Support, Maintenance and Upgrades Included With User License
·Physician Ownership Opportunity – Stock Award With Purchase Of License
·Cloud-MD™ is Publicly Traded NSCT.PK
·Patented Auto Post Feature - To Eliminate Need For Manual Posting of Electronic Remittance Advice (835) By Staff
·Multiple Opportunities to Recover Investment (Meaningful Use Dollars, Stock Award Option, IRS Section 179, Lower Employee and Maintenance Cost)
·State-Of-The-Art Claims Editing and Real-Time Eligibility - Increase Collections and Reduce Days in A/R
·Cloud Based Technology- IPAD, IPHONE, ANDROID, GOOGLE, WINDOWS for Anytime and Anywhere Availability and Eliminates Catastrophic Loss of Data

 

As we move forward building on our current platforms and strengths and gaining significant momentum in acquisitions, capabilities and revenue streams, it is important for Cloud-MD™ to augment its portfolio of capabilities with solutions that complement those offerings currently available. With the addition of a pending acquisition, we will add another dimension to our Cloud-MD™ Office and Billing Services offering that will offer a secure mechanism for providers to exchange patient PHI without the need to have all of the providers on a common EMR platform, but will integrate with our EMR in a manner that offers prospective large clients such as hospitals, ACO’s, etc. the functionality of an Electronic Health Interchange without the huge costs and overhead. In addition, we have recently developed enhanced capabilities within our Cloud-MD™ Office product offering that will offer superior solutions to hospitalists, nursing home practitioners and providers of home health services.

 

The Future for CipherLoc™

 

The digital cipher and encryption market offers seemingly endless opportunity. Our CipherLoc™ Polymorphic Cipher Engine is a ground-breaking; state-of-the-art Polymorphic Key Progression Algorithm (PKPA) based digital encryption solution that has wide-spread applicability throughout the commercial computer, communications and broadcasting industries as well as significant applicability in the government arena.

 

Results of Operations for the Three Months Ended March 31, 2014 and March 31, 2013

 

Revenue decreased to $105,118 from $174,214 for the three months ended March 31, 2014 and 2013, respectively. Our revenues decreased as a result of lower sales activity during the three months ended March 31, 2014 compared to the three months ended March 31, 2013. The lower sales activity is due to the Company’s focus on two potential acquisitions in Texas that deterred our focus to these potentially new opportunities.

 

Cost of revenue did not change for the three months ended March 31, 2014 and 2013, respectively. Our cost of revenue increased during the three months period due to the amortization of the software costs placed into service.

 

Selling, general and administrative expenses increased to $1,106,142 from $224,454 for the three months ended March 31, 2014 and 2013, respectively. The increase in our selling, general and administrative expenses are related to the salaries and stock-based compensation of management of $1,026,373 in the three months ended March 31, 2014 compared to $116,500 in the three months ended March 31, 2013 as well as an increase in the cost of accounting.

 

Research and development costs decreased to $30,000 from $55,000 for the three months ended March 31, 2014 and 2013, respectively. Our research and development costs decrease is related to decreased salary costs for programmers to update software required to be in compliance with the updates and modifications to the Affordable Care Act.

 

Interest expense increased to $278 from $69 for the three months ended March 31, 2014 and 2013, respectively. Our interest expense increased as a result of the increase in outstanding borrowings on our lines of credits.

 

We recorded income from discontinued operations of $3,198 compared to loss of $38 for the three months ended March 31, 2014 and 2013, respectively. The Company is currently engaged in the medical billing operations.  Until October 1, 2009, the Company’s sole sources of revenues were from GPS operational device business.  The Company discontinued its GPS operational device business in February 2010 (See “Note 6 - Discontinued Operations” to the accompanying Financial Statements).   

 

Results of Operations for the Six Months Ended March 31, 2014 and March 31, 2013

 

Revenue decreased to $222,675 from $323,571 for the six months ended March 31, 2014 and 2013, respectively. Our revenues decreased as a result of lower sales activity during the six months ended March 31, 2014 compared to the six months ended March 31, 2013. The lower sales activity is due to the Company’s focus on two potential acquisitions in Texas that deterred our focus to these potentially new opportunities.

 

Cost of revenue did not change for the six months ended March 31, 2014 and 2013, respectively. Our cost of revenue decreased during the six months period due to the amortization of the software costs placed into service.

 

Selling, general and administrative expenses increased to $1,328,218 from $343,325 for the six months ended March 31, 2014 and 2013, respectively. The increase in our selling, general and administrative expenses are related to the salaries and stock-based compensation of management of $1,026,373 in the six months ended March 31, 2014 compared to $274,264 in the six months ended March 31, 2013 as well as an increase in the cost of accounting.

 

Research and development costs decreased to $60,000 from $95,000 for the six months ended March 31, 2014 and 2013, respectively. Our research and development costs decrease is related to decreased salary costs for programmers to update software required to be in compliance with the updates and modifications to the Affordable Care Act.

 

Interest expense increased to $515 from $196 for the six months ended March 31, 2014 and 2013, respectively. Our interest expense increased as a result of the increase in outstanding borrowings on our lines of credits.

 

We recorded a loss from discontinued operations of $7,517 compared to income of $58,984 for the six months ended March 31, 2014 and 2013, respectively. The Company is currently engaged in the medical billing operations.  Until October 1, 2009, the Company’s sole sources of revenues were from GPS operational device business.  The Company discontinued its GPS operational device business in February 2010 (See “Note 6 - Discontinued Operations” to the accompanying Financial Statements).   

 

Liquidity and Capital Resources

 

 We expect to incur substantial expenses and generate significant operating losses as we continue to grow our operations, as well as incur expenses related to operating as a public company and compliance with regulatory requirements.

 

We have an accumulated deficit at March 31, 2014 of $27,838,150 and need additional cash flows to maintain our operations. We depend on the continued contributions of our executive officers to finance our operations and need to obtain additional funding sources to explore potential strategic relationships and to provide capital and other resources for the further development and marketing of our products and business. We expect our cash needs for the next 12 months to be $850,000 to fund our operations. The ability of the Company to continue its operations is dependent on the successful execution of management’s plans, which include expectations of raiding debt or equity based capital until such time that funds from operations are sufficient to fund working capital requirements. The Company may need to incur additional liabilities with related parties to sustain the Company’s existence. There is no assurance that such funding, if required will be available to us or, if available, will be available upon terms favorable to us.

 

The Company has a revolving line of credit with Chase Bank with a balance as of March 31, 2014 in the amount of $24,429 and a borrowing limit of $50,000. We have previously received advances from our Chief Executive Officer which we have used to help fund our operations.

 

In November 2013, the Company entered into a revolving line of credit with Mutual of Omaha for a line of credit in the amount of $62,612 at 4.00% interest rate which renews annually. As of March 31, 2014, the Company had borrowed $65,000.

 

Cash flows from operations. Our cash (used in) provided by operating activities was ($93,176) and $14,205 for the six months ended March 31, 2014 and 2013, respectively. The increase in cash used in operations was primarily attributable to the increase of general and administrative expenses in 2014 as compared to the 2013 period.

 

Cash flows from financing activities. Cash provided by financing activities was $92,245 and $95,757 for the six months ended March 31, 2014 and 2013, respectively. We received cash from the sale of our common stock of $15,000 and $141,000 for the six months ended March 31, 2014 and 2013, respectively. During the six months ended March 31, 2014, received $28,245 from the Chase line of credit and received $50,000 from our Mutual of Omaha line of credit. During the six months ended March 31, 2013, we repaid the Chase line of credit of $22,152, repaid our advances from our CEO of $25,591.

 

Off-Balance Sheet Arrangements

 

We have no off-balance sheet arrangements including arrangements that would affect the liquidity, capital resources, market risk support and credit risk support or other benefits.

 

WHERE YOU CAN FIND MORE INFORMATION

 

You are advised to read this Quarterly Report on Form 10-Q in conjunction with other reports and documents that we file from time to time with the SEC. In particular, please read our Quarterly Reports on Form 10-Q, Annual Report on Form 10-K, and Current Reports on Form 8-K that we file from time to time. You may obtain copies of these reports directly from us or from the SEC at the SEC’s Public Reference Room at 100 F. Street, N.E. Washington, D.C. 20549, and you may obtain information about obtaining access to the Reference Room by calling the SEC at 1-800-SEC-0330. In addition, the SEC maintains information for electronic filers at its website http://www.sec.gov.

 

ITEM 3.         QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

We do not hold any derivative instruments and do not engage in any hedging activities.

 

ITEM 4.          CONTROLS AND PROCEDURES

 

(a)Evaluation of Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and that such information is accumulated and communicated to our Chief Executive Officer and Principal Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures were designed to provide reasonable assurance that the controls and procedures would meet their objectives. As required by SEC Rule 13a-15(b), our Chief Executive Officer and Principal Financial Officer carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, our Chief Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures were not effective since the Company has been ineffective in filing timely.

 

Our Chief Executive Officer and Principal Financial Officer are responsible for establishing and maintaining adequate internal control over our financial reporting. In order to evaluate the effectiveness of internal control over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act, management has conducted an assessment, including testing, using the criteria in Internal Control — Integrated Framework, issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”). Our system of internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Management has used the framework set forth in the report entitled Internal Control-Integrated Framework published by the Committee of Sponsoring Organizations of the Treadway Commission, known as COSO, to evaluate the effectiveness of our internal control over financial reporting. Based on this assessment, our Chief Executive Officer and Principal Financial Officer have concluded that our internal control over financial reporting were effective as of March 31, 2014. There has been no change in our internal controls over financial reporting during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting. The Company has been ineffective in the timely filing of the company’s quarterly filings.

 

a.There were no changes in our internal control over financial reporting that occurred during the six months ended March 31, 2014 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
   
b.It should be noted that any system of controls, however well designed and operated, can provide only reasonable and not absolute assurance that the objectives of the system are met. In addition, the design of any control system is based in part upon certain assumptions about the likelihood of certain events. Because of these and other inherent limitations of control systems, there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote.

 

PART II

OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

We are currently not involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our company or any of our subsidiaries, threatened against or affecting our company, our common stock, any of our subsidiaries or of our company’s or our company’s subsidiaries’ officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.

 

On July 5, 2013, the Company filed a complaint against Krooss Medical Management Systems, LLC, William F. Krooss and Marie W. Krooss in the United States District Court, District of Nevada Case No. 2013-CV-01187-ABG-VCF for the collection of $200,000 of unpaid medical billing fees that were seriously delinquent. After many attempts by the Company to begin collections, the Defendants refused to pay the outstanding balances, however expected the Company to continue to bill for them. The Complaint includes causes of action Breach of the PTAPA, Breach of Billing and Collections Contracts, Negligence, Breach of the Duty of Good Faith and Fair Dealing, Tortious Interference with Business Relations, Fraud, among other causes of action.

 

On August 13, 2013, Krooss Medical Management Systems et al filed a Complaint in Chancery Court of Rankin County, Mississippi Case No. 13-1372 as a strategy to keep the collection matter in Mississippi Chancery Court.

 

Case No. 13-1372 was remanded to the United States District Court, Southern District of Mississippi Jackson Division Case No. 3:13CV507-HTW-LRA.

 

This litigation is a collection matter of unpaid fees by the Defendants and the Company vehemently denies the allegations (Breach of the Permanent Transfer Asset Purchase Agreement (“PTAPA”), Rescission of the PTAPA, Breach of Billing and Collections Contracts, Negligence, Quantum Meruit, Restitution, and Estoppel, Breach of the Duty of Good Faith and Fair Dealing, Tortious Interference with Business Relations, among other causes of action) filed in Mississippi Chancery Court related to this collection matter. The Company does not expect the cost to litigate this matter to adversely affect the Company’s operations. However, the Company has reduced operations in DNA-Cloud in Mississippi as the sellers have interfered with the billing contracts purchased which is one of the causes of action in Complaint, among others. Many of the contracts have been terminated due to the interference by the sellers, and DNA-Cloud has not been able to expand the business because of the reputation of the sellers in Jackson, Mississippi and the surrounding area.

 

ITEM 1A. RISK FACTORS

 

There were no material changes from the risk factors previously disclosed in Part II, Item 1A, “Risk Factors” in our  Annual Report on Form 10-K for the year ended September 30, 2013 during our six months ended March 31, 2014.

 

ITEM 2.  UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS SECURITIES

 

Period from April 1, 2014 to May 2, 2014

 

Stock Issued for Services

 

On April 21, 2014, the Company issued 1,407,506 shares of common stock as compensation. The fair values of the shares were a total of $21,253 and were recorded at the market price on the date of grant.

 

Six Months Ended March 31, 2014

 

Stock Issued for Cash

 

During the six months ended March 31, 2014, the Company issued 35,000 shares of common stock for $15,000 in net cash proceeds as follows:

 

Date   Number of Shares   Proceeds
         
  October 21, 2013       25,000     $ 5,000  
  January 12, 2014     10,000     10,000  
  Total       35,000     $ 15,000  

 

Stock Issued in Connection with Software Licensing and Subscription Agreements

 

During the six months ended March 31, 2014, the Company issued 120,000 shares of common stock valued at $3,600 based on the market price on the date of grant, to customers, in regards to the purchase of software from the Company in accordance with the Software Licensing and Subscription Agreements. The fair values of the shares issued were recorded as a reduction of software revenue recognized during the three months ended March 31, 2014.

 

Date  Number of Shares  Fair Value
             
 December 4, 2013    120,000   $3,600 
 March 4, 2014    100,000    2,100 
 Total    220,000   $5,700 

 

Stock Issued for Assets Acquisition

 

In October 2013, the Company through a purchase agreement with Antree Systems Limited has purchased a complete source code, intellectual property rights, all computer software, patents, or formulas, algorithm licensed or sold under a project known as Compass Rose and appropriate copyrights, patents, mask works, trademarks, service marks, internet domain names and world wide web uniform resource locators (“URLs”) from Antree Systems Limited. The Company issued 200,000 shares of its common stock as consideration for the purchase. The fair value of the consideration and the assets acquired is based on the fair value of the common stock issued in exchange for the software. The total fair value, based on the market price on the date of grant, was $6,000. The Company evaluated this acquisition and determined that it did not meet the definition of a significant business acquisition.

 

In November 2013, the Company issued 180,000 shares of common stock as replacement shares for the 160,000 shares of common stock issued to Antree Systems Limited and 20,000 shares of common stock to Kimberly Ilicerl. The Company intends to cancel the original shares issued because the shares were lost during delivery to Antree Systems.

 

Six Months Ended March 31, 2013

 

Stock Issued for Cash

 

During the six months ended March 31, 2013, the Company issued 197,500 shares of common stock for $141,000 in net cash proceeds as follows:

 

Date  Number of Shares  Proceeds
             
 October 14, 2012    20,000   $20,000 
 October 14, 2012    15,000    3,000 
 October 14, 2012    18,750    2,500 
 October 14, 2012    18,750    2,500 
 December 6, 2012    15,000    3,000 
 March 12, 2013    20,000    20,000 
 March 12, 2013    20,000    20,000 
 March 31, 2013    50,000    50,000 
 March 27, 2013    20,000    20,000 
 Total    197,500   $141,000 

 

Stock Issued in Connection with Software Licensing and Subscription Agreements

 

During the six months ended March 31, 2013, the Company issued 300,000 shares of common stock valued at $9,350 based on the market price on the date of grant, to customers, in regards to the purchase of software from the Company in accordance with the Software Licensing and Subscription Agreements. The fair values of the shares issued were recorded as a reduction of software revenue recognized during the three months ended March 31, 2013.

 

Date  Number of Shares  Fair Value
             
 October 14, 2012    50,000   $1,300 
 December 6, 2012    100,000    2,800 
 March 12, 2013    50,000    1,750 
 March 21, 2013    50,000    1,750 
 March 21, 2013    50,000    1,750 
 Total    300,000   $9,350 

 

 

Stock Issued for Services

 

During the six months ended March 31, 2013, the Company issued 827,000 shares of common stock as compensation. The fair values of the shares were a total of $28,155 and were recorded at the market price on the date of grant. The issuances of stock were as follows:

 

Date  Number of Shares  Fair Value  Description of Services
                  
 October 14, 2012    10,000   $260    Commission 
 December 6, 2012    100,000    2,800    Compensation 
 March 12, 2013    50,000    1,750    Consulting 
 March 21, 2013    167,000    5,845    Compensation 
 March 21, 2013    500,000    17,500    Compensation 
 Total    827,000   $28,155      

 

Stock Issued for Assets Acquisition

 

During the six months ended March 31, 2013, the Company issued 400,000 shares of common stock for the acquisition of CipherSmith software. Those shares were valued at $13,000 based on the market price on the dates of grant.

 

The offer and sale of such shares of our common stock were effected in reliance on the exemptions for sales of securities not involving a public offering, as set forth in Rule 506 promulgated under the Securities Act of 1933 (the “Securities Act”) and in Section 4(2) of the Securities Act, based on the following: (a) the investors confirmed to us that they were “accredited investors,” as defined in Rule 501 of Regulation D promulgated under the Securities Act and had such background, education and experience in financial and business matters as to be able to evaluate the merits and risks of an investment in the securities; (b) there was no public offering or general solicitation with respect to the offering; (c) the investors were provided with certain disclosure materials and all other information requested with respect to our company; (d) the investors acknowledged that all securities being purchased were “restricted securities” for purposes of the Securities Act, and agreed to transfer such securities only in a transaction registered under the Securities Act or exempt from registration under the Securities Act; and (e) a legend was placed on the certificates representing each such security stating that it was restricted and could only be transferred if subsequent registered under the Securities Act or transferred in a transaction exempt from registration under the Securities Act.

 

ITEM 3.  DEFAULTS UPON SENIOR SECURITIES

  

There were no defaults upon senior securities during the three months period ended March 31, 2014.

 

ITEM 4. MINING SAFETY DISCLOSURES 

 

N/A

  

ITEM 5.  OTHER INFORMATION

 

There is no information with respect to which information is not otherwise called for by this form.

 

ITEM 6.  EXHIBITS

 

Exhibits

 

3.1 Articles of Incorporation(1)
3.2 Bylaws(2)
10.1 Employment Agreement between National Scientific Corporation and Michael A. Grollman dated January 2001(4)
10.2 Employment Agreement between National Scientific Corporation and Graham L. Clark dated January 2003(6)
10.3 NSC Consulting Agreement dated August 2001, and Amendments dated August 2002 and July 2003, with Dr. El-Badawy El-Sharawy(6)
10.4 Amended and Restated 2000 Stock Option Plan(3)
10.5 Form of 2004 Stock Retainage Plan Agreement(6)
10.6 Agreement Regarding Management Consulting Services with Stanton Walker of New York dated May 2003(6)
10.7 Agreement Regarding Distribution and Marketing of Gotcha!® Child Safety Product and other products dated December 2002 with FutureCom Global, Inc. (6)
10.8 Purchase Order from Verify Systems, Inc, dated March 2003 for IBUS™ School Child Tracking Systems(5)
10.9 Letter of Understanding and Agreement dated April 2004 Regarding Sales and Distribution of Verify School safety products, and an Unlimited Software License with Anthony Grosso and CIS Services, LLC(6)
10.10 Letter of Intent from Positus, Inc. dba Bike & Cycle Trak, dated February 2003 for Design of Power Sports Tracking System(6)
10.11 Purchase Order from Positus, Inc. dba Bike & Cycle Trak, for Design of Power Sports Tracking System dated March 2003(6)
10.12 Employment agreement of Michael De La Garza(8)
10.13 Employment agreement of Pamela Thompson(8)
14 Code of Ethics(7)
31.1 Certification Pursuant to Section 302 of the Sarbanes-Oxley Act
31.2 Certification Pursuant to Section 302 of the Sarbanes-Oxley Act
32.1 Certification Pursuant to Section 906 of the Sarbanes-Oxley Act
32.2 Certification Pursuant to Section 906 of the Sarbanes-Oxley Act

____________

(1)Incorporated by reference to the Registrant’s Form 10-SB filed on or about January 3, 2000.
(2)Incorporated by reference to the Registrant’s Form 10-QSB for the quarter ended March 31, 2001 and filed on or about May 15, 2001.
(3)Incorporated by reference to the Registrant’s Form 10-QSB for the quarter ended December 31, 2000 and filed on or about February 14, 2001.
(4)Incorporated by reference to the Registrant’s Form 10-KSB for the year ended September 30, 2000 and filed on or about December 19, 2000.
(5)Incorporated by reference to the Registrant’s Form S-8 filed on or around June 3, 2003.
(6)Incorporated by reference to the Registrant’s Form SB2 filed on or around June 24, 2004.
(7)Incorporated by reference to the Registrant’s Form 10-QSB for the quarter ended June 30, 2004 and filed on or about August 16, 2004.
(8)Incorporated by reference to the Registrant’s Form 10-K for the year ended September 30, 2011 and filed on or about October 10, 2013.

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Registrant

 

Date: May 16, 2014

 

Cloud Medical Doctor Software Corporation

 

By: /s/ Michael De La Garza

  Michael De La Garza
    Chief Executive Officer (Principal Executive Officer)

 

 

 

Registrant

 

Date: May 16, 2014

 

Cloud Medical Doctor Software Corporation

 

By: /s/ Pamela Thompson

    Pamela Thompson
    Principal Financial Officer


EX-31.1 2 nsct033114qex311.htm CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 AND PURSUANT TO RULE 13A-14(A) AND RULE 15D-14 UNDER THE SECURITIES EXCHANGE ACT OF 1934

Exhibit 31.1

Certification pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and pursuant to Rule 13a-14(a) and Rule 15d-14 under the Securities Exchange Act of 1934

 

I, Michael De La Garza, certify that:

 

1.I have reviewed this Quarterly Report on Form 10-Q of Cloud Medical Doctor Software Corporation;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluations: and
d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Registrant

 

 

Cloud Medical Doctor Software Corporation

 

By: /s/ Michael De La Garza

Date: May 16, 2014    Michael De La Garza
    Chief Executive Officer (Principal Executive Officer,)
EX-31.2 3 nsct033114qex312.htm CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 AND PURSUANT TO RULE 13A-14(A) AND RULE 15D-14 UNDER THE SECURITIES EXCHANGE ACT OF 1934

Exhibit 31.2

Certification pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and pursuant to Rule 13a-14(a) and Rule 15d-14 under the Securities Exchange Act of 1934

 

I, Pamela Thompson, certify that: 

 

1I have reviewed this Quarterly Report on Form 10-Q of Cloud Medical Doctor Software Corporation;
2Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluations: and
d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Registrant

 

 

Cloud Medical Doctor Software Corporation

 

By: /s/ Pamela Thompson

Date: May 16, 2014    Pamela Thompson
    Chief Financial Officer (Principal Financial Officer)

 

EX-32.1 4 nsct033114qex321.htm CERTIFICATIONS PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 32.1

 

 

CERTIFICATIONS PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

 

 

In connection with the Quarterly Report of Cloud Medical Doctor Software Corporation (the "Company") on Form 10-Q for the period ending March 31, 2014 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Michael De La Garza, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1)           The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

(2)           The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

 

Registrant

 

 

Cloud Medical Doctor Software Corporation

 

By: /s/ Michael De La Garza

Date: May 16, 2014    Michael De La Garza
    Chief Executive Officer (Principal Executive Officer)


EX-32.2 5 nsct033114qex322.htm CERTIFICATIONS PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 32.2

 

 

CERTIFICATIONS PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

 

 

In connection with the Quarterly Report of Cloud Medical Doctor Software Corporation (the "Company") on Form 10-Q for the period ending March 31, 2014 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Pamela Thompson, Principle Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1)           The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

(2)           The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

 

Registrant

 

Date: May 16, 2014

 

Cloud Medical Doctor Software Corporation

 

By: /s/ Pamela Thompson

    Pamela Thompson
    Chief Financial Officer (Principal Financial Officer)

 

EX-101.INS 6 nsct-20140331.xml XBRL INSTANCE FILE 0001022505 2013-10-01 2014-03-31 0001022505 2014-03-31 0001022505 2013-09-30 0001022505 2014-01-01 2014-03-31 0001022505 2013-01-01 2013-03-31 0001022505 2012-10-01 2013-03-31 0001022505 2012-09-30 0001022505 2013-03-31 0001022505 us-gaap:FairValueInputsLevel1Member 2014-03-31 0001022505 us-gaap:FairValueInputsLevel1Member 2013-09-30 0001022505 us-gaap:FairValueInputsLevel2Member 2014-03-31 0001022505 us-gaap:FairValueInputsLevel2Member 2013-09-30 0001022505 us-gaap:FairValueInputsLevel3Member 2014-03-31 0001022505 us-gaap:FairValueInputsLevel3Member 2013-09-30 0001022505 NSCT:AntreeSystemsMember 2014-03-31 0001022505 NSCT:AntreeSystemsMember 2013-09-30 0001022505 NSCT:EncryptionSoftwareCodeMember 2014-03-31 0001022505 NSCT:EncryptionSoftwareCodeMember 2013-09-30 0001022505 NSCT:MediSouthMember 2014-03-31 0001022505 NSCT:MediSouthMember 2013-09-30 0001022505 NSCT:DoctorsNetworkofAmericaMember 2014-03-31 0001022505 NSCT:DoctorsNetworkofAmericaMember 2013-09-30 0001022505 NSCT:SoftwareLicenseMember 2014-03-31 0001022505 NSCT:SoftwareLicenseMember 2013-09-30 0001022505 NSCT:EMRCertificationMember 2014-03-31 0001022505 NSCT:EMRCertificationMember 2013-09-30 0001022505 2013-10-01 2013-12-31 0001022505 2012-10-01 2012-12-31 0001022505 NSCT:AntreeSystemsMember 2013-10-01 2013-12-31 0001022505 NSCT:CipherSmithMember 2012-10-01 2012-12-31 0001022505 NSCT:DoctorsNetworkofAmericaMember 2011-10-01 2012-09-30 0001022505 NSCT:DoctorsNetworkofAmericaMember 2012-09-30 0001022505 NSCT:DoctorsNetworkofAmericaMember 2013-03-16 0001022505 NSCT:DoctorsNetworkofAmericaMember us-gaap:PendingLitigationMember 2013-03-16 0001022505 2010-10-01 2011-09-30 0001022505 us-gaap:SegmentDiscontinuedOperationsMember 2014-03-31 0001022505 us-gaap:SegmentDiscontinuedOperationsMember 2013-09-30 0001022505 us-gaap:SegmentDiscontinuedOperationsMember 2014-01-01 2014-03-31 0001022505 us-gaap:SegmentDiscontinuedOperationsMember 2013-01-01 2013-03-31 0001022505 us-gaap:SegmentDiscontinuedOperationsMember 2013-10-01 2014-03-31 0001022505 us-gaap:SegmentDiscontinuedOperationsMember 2012-10-01 2013-03-31 0001022505 2014-05-01 0001022505 NSCT:MutualofOmahaMember 2014-03-31 0001022505 NSCT:MutualofOmahaMember 2013-10-01 2014-03-31 0001022505 NSCT:ChaseMember 2014-03-31 0001022505 NSCT:ChaseMember 2013-10-01 2014-03-31 0001022505 us-gaap:AccountsPayableAndAccruedLiabilitiesMember 2013-10-01 2014-03-31 0001022505 us-gaap:AccountsPayableAndAccruedLiabilitiesMember 2012-10-01 2013-03-31 0001022505 us-gaap:InterestExpenseMember 2013-10-01 2014-03-31 0001022505 us-gaap:InterestExpenseMember 2012-10-01 2013-03-31 0001022505 2012-10-01 2013-09-30 0001022505 NSCT:AntreeSystemsMember 2012-10-01 2013-09-30 0001022505 NSCT:KimberlyIlicerlMember 2012-10-01 2013-09-30 0001022505 2014-04-01 2014-05-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure NATIONAL SCIENTIFIC CORP/AZ 0001022505 10-Q 2014-03-31 false --09-30 No No Yes Smaller Reporting Company Q2 2014 7656 8587 51356 162671 12832 16925 701611 817921 714443 834846 87041 9796 829473 407146 829473 407146 2468292 2146242 25214828 24783723 -27838150 -26542265 5176 8338 699559 361994 42837 35356 42873 35356 42837 35356 40000 40000 -115030 427700 714443 834846 0.01 .01 4000000 4000000 4000000 4000000 4000000 4000000 0.01 .01 650000000 650000000 246829216 214624216 246829216 214624216 222675 105118 174214 323571 53766 900 131050 900 122310 61155 61155 121160 100365 43963 113059 202411 1328218 1106142 224454 343325 60000 30000 55000 95000 1388218 1136142 279454 438325 -50568 -938 -138567 -938 -1287853 -1092179 -165042 -234561 -515 -279 -69 -196 -515 -279 -69 -196 -1288368 -1092458 -165111 -234757 -7517 3198 -38 58946 -1295885 -1089260 -165149 -175811 -0.01 -0.00 -0.00 -0.00 -0.00 0.00 -0.00 0.00 -0.01 -0.00 -0.00 -0.00 219656908 224546327 212756568 212472748 122310 121160 -25591 -25591 -1000 -22152 15000 141000 -931 111315 59704 -7517 58946 666750 28155 5700 9350 3162 3012 397270 88638 -93176 14205 1353 1353 78245 2500 92245 95757 23000 <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>NOTE 1- DESCRIPTION OF BUSINESS</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">Cloud Medical Doctor Software Corporation (the &#147;Company&#148;) was incorporated in Texas on June 22, 1953 as American Mortgage Company. On May 16, 1996, the Company changed its name to National Scientific Corporation. On April 3, 2012, the Company changed its name to Cloud Medical Doctor Software Corporation.&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">In the year ended September 30, 2011, Cloud-MD introduced the Cloud-MD Office, a &#147;Cloud Based&#148;, 5010 ready and ICD-10 compliant, fully integrated and interoperable suite of medical software and services, designed by experienced healthcare analysts and programmers for healthcare providers, that produces &#147;Actionable Information&#148; to help Independent Physician Practices, New Care Delivery Models (ACO), Healthcare Systems and Billing Services optimize a wide range of business processes resulting in Increased Profits, Higher Quality, Greater Efficiency, Noticeable Cost Reductions and Better Patient Care. Current software product offerings include Practice Management, Electronic Medical Records, Revenue Management, Patient Financial Solutions, Medical and Pharmaceutical Supply Management, Claims Management and PHI Exchange.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">In the year ended September 30, 2012, Cloud-MD launched Cloud-MD Billing Services which provides management of medical claims from posting physician charges and payments into our medical billing software. The software uses a continuous insurance claim follow-up system to track and research all rejected or denied medical claims; a Comprehensive Reporting module that includes monthly financial statements sent to our clients so they can see how their practice is performing and a variety of detailed reports giving our clients the necessary information and tools used to assist in the increased production which leads to more profit; and patient account inquiries and support to assist patients with their billing and insurance questions.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>NOTE 2 &#150; BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>&#160;</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">The Company prepares its financial statements in accordance with accounting principles generally accepted in the United States of America. &#160;The accompanying interim unaudited financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X. In our opinion, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">Operating results for the six months ended March 31, 2014 are not necessarily indicative of the results that may be expected for the year ending September 30, 2014. Notes to the unaudited interim financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the year ended September 30, 2013 have been omitted; this report should be read in conjunction with the audited financial statements and the footnotes thereto for the fiscal year ended September&#160;30, 2013 included within the Company&#146;s Form 10-K as filed with the Securities and Exchange Commission.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>NOTE 3 - GOING CONCERN </b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. However, the Company has recurring losses from operations and an accumulated deficit at March 31, 2014 of $27,838,150 and needs additional cash to maintain its operations.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">These factors raise doubt about the Company&#146;s ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company&#146;s continued existence is dependent upon management&#146;s ability to develop profitable operations, continued contributions from the Company&#146;s executive officers to finance its operations and the ability to obtain additional funding sources to explore potential strategic relationships and to provide capital and other resources for the further development and marketing of the Company&#146;s products and business.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>NOTE 4 &#150; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">The Company prepares its financial statements in accordance with accounting principles generally accepted in the United States of America. Significant accounting policies are as follows:</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>&#160;</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>Use of Estimates and Assumptions</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States (&#147;GAAP&#148;) requires management to make estimates and assumptions that affect (i)&#160;the reported amounts of assets and liabilities, (ii)&#160;the disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and (iii)&#160;the reported amount of net revenues and expenses recognized during the periods presented. Adjustments made with respect to the use of estimates often relate to improved information not previously available. Uncertainties with respect to such estimates and assumptions are inherent in the preparation of financial statements; accordingly, actual results could differ from these estimates. The Company&#146;s most significant estimates relate to the valuation of its proprietary technology and its valuation of its common stock.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>&#160;</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>Cash and Cash Equivalents</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.&#160;&#160;At March 31, 2014, cash and cash equivalents include cash on hand and cash in the bank and the FDIC insures these deposits up to $250,000.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>Impairment of Long-Lived Assets</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">Long-lived assets are evaluated for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. Each impairment test is based on a comparison of the undiscounted future cash flows to the recorded value of the asset. If impairment is indicated, the asset is written down to its estimated fair value. The acquired software technologies are reviewed annually for impairment.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>&#160;</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>Fair Value of Financial Instruments</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">The Company's financial instruments consist primarily of cash, accounts payable and accrued expenses, and debt. The carrying amounts of such financial instruments approximate their respective estimated fair value due to the short-term maturities and approximate market interest rates of these instruments.&#160;&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">Fair value is focused on an exit price that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#160;&#160;Within the measurement of fair value, the use of market-based information is prioritized over entity specific information and a three-level hierarchy for fair value measurements is used based on the nature of inputs used in the valuation of an asset or liability as of the measurement date.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">The three-level hierarchy for fair value measurements is defined as follows:</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="font-size: 10pt; line-height: normal; margin-top: 0; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><font style="font-size: 10pt">&#149;</font></td><td style="width: 5pt"></td><td style="text-align: justify"><font style="font-size: 10pt">Level 1 &#150; inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets; liabilities in active markets;</font></td> </tr></table> <table cellpadding="0" cellspacing="0" style="font-size: 10pt; line-height: normal; margin-top: 0; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><font style="font-size: 10pt">&#149;</font></td><td style="width: 5pt"></td><td style="text-align: justify"><font style="font-size: 10pt">Level 2 &#150; inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability other than quoted prices, either directly or indirectly, including inputs in markets that are not considered to be active; or directly or indirectly including inputs in markets that are not considered to be active;</font></td> </tr></table> <table cellpadding="0" cellspacing="0" style="font-size: 10pt; line-height: normal; margin-top: 0; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><font style="font-size: 10pt">&#149;</font></td><td style="width: 5pt"></td><td style="text-align: justify"><font style="font-size: 10pt">Level 3 &#150; inputs to the valuation methodology are unobservable and significant to the fair value measurement.</font></td> </tr></table> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">The following table summarizes fair value measurements by level at March 31, 2014 and September 30, 2013 for assets measured at fair value on a recurring basis:</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-weight: bold"> <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Level 1</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Level 2</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Level 3</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Total</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-weight: bold"> <td style="text-align: justify; padding-left: 5.4pt">At March 31, 2014</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; padding-bottom: 1pt; text-indent: 9.75pt; padding-left: 5.4pt">Software</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</td><td style="width: 10%; border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</td><td style="width: 10%; border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</td><td style="width: 10%; border-bottom: Black 1pt solid; text-align: right">701,611</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</td><td style="width: 10%; border-bottom: Black 1pt solid; text-align: right">701,611</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; text-indent: 9.75pt; padding-left: 5.4pt">Total Software</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">701,611</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">701,611</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt; font-weight: bold">At September 30, 2013</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-indent: 9.75pt; padding-left: 5.4pt">Software</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">937,431</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">937,431</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; text-indent: 9.75pt; padding-left: 5.4pt">Total Software</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">937,431</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">937,431</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>Accounts Receivable and Allowance for Uncollectible Accounts</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">Substantially all of the Company&#146;s accounts receivable balance is related to trade receivables. Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is the Company&#146;s best estimate of the amount of probable credit losses in its existing accounts receivable. The Company will maintain allowances for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments for services. Accounts with known financial issues are first reviewed and specific estimates are recorded. The remaining accounts receivable balances are then grouped in categories by the number of days the balance is past due, and the estimated loss is calculated as a percentage of the total category based upon past history. Account balances are charged against the allowance when it is probable the receivable will not be recovered. As of March 31, 2014 and 2013, the Company had no valuation allowance for the Company&#146;s accounts receivable.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>&#160;</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>Income Taxes</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">The Company utilizes the asset and liability method in accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for operating loss and tax credit carry-forwards and for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is recorded to reduce the carrying amounts of deferred tax assets unless it is more likely than not that the value of such assets will be realized.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">The Company uses the two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not, that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount, which is more than 50% likely of being realized upon ultimate settlement. The Company considers many factors when evaluating and estimating the Company's tax positions and tax benefits, which may require periodic adjustments. At March 31, 2014, the Company did not record any liabilities for uncertain tax positions.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>Revenue Recognition</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">License revenue consists principally of revenue earned under software license agreements. The Company sells its software to a medical practitioner for direct payment or through a third party leasing company for direct payment to the Company. The third party lease agreement is a non-recourse debt and the Company is not responsible for the default of the medical practitioner. License revenue is generally recognized when a signed contract or other persuasive evidence of an arrangement exists, the software has been electronically delivered, the license fee is fixed or is measured on a paid user basis; and collection of the resulting receivable is probable. When contracts contain multiple elements wherein Vendor-Specific Objective Evidence (&#147;VSOE&#148;) exists for all undelivered elements, we account for the delivered elements in accordance with the &#147;Residual Method.&#148;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">VSOE of fair value for maintenance and support is established by a stated renewal rate, if substantive, included in the license arrangement or rates charged in stand-alone sales of maintenance and support. Revenue from subscription license agreements, which include software, rights to unspecified future products and maintenance, is recognized ratably over the term of the subscription period.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">Provided all other revenue criteria are met, the upfront, minimum, non-refundable license fees from customers are generally recognized upon delivery and on-going royalty fees are generally recognized upon reports of new licenses issued. If there is significant uncertainty about the project completion or receipt of payment for professional services, revenue is deferred until the uncertainty is sufficiently resolved. VSOE of fair value of services is based upon stand-alone sales of those services.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">Subscription revenue is generated from bandwidth and information storage. In the first year and each year thereafter, the software is purchased and installed the purchaser will pay an annual fee of $1,200, $1,500, $1,800, and $2,400, respectively. Subscription revenue is recognized ratably over the term of the agreement.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">Transaction revenue is generated from the following services and recognized when a transaction occurs:</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="font-size: 10pt; line-height: normal; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><font style="font-size: 10pt">&#183;</font></td><td style="width: 5pt"></td><td style="text-align: justify"><font style="font-size: 10pt">Electronic Remittance Advise $0.35 Electronic remittance transaction fee;</font></td> </tr> <tr style="vertical-align: top; text-align: justify"> <td style="text-align: right"><font style="font-size: 10pt; color: #000004">&#183;</font></td><td></td><td style="text-align: justify"><font style="font-size: 10pt; color: #000004">Paper Claim</font><font style="font-size: 10pt; color: #131317">s </font><font style="font-size: 10pt; color: #000004">$1</font><font style="font-size: 10pt; color: #000002">.</font><font style="font-size: 10pt; color: #000004">00 Pa</font><font style="font-size: 10pt; color: #000002">p</font><font style="font-size: 10pt; color: #000004">er claim fee;</font></td> </tr> <tr style="vertical-align: top; text-align: justify"> <td style="text-align: right"><font style="font-size: 10pt">&#183;</font></td><td></td><td style="text-align: justify"><font style="font-size: 10pt">Carrier Direct $0.16 Carrier direct fee;</font></td> </tr> <tr style="vertical-align: top; text-align: justify"> <td style="text-align: right"><font style="font-size: 10pt">&#183;</font></td><td></td><td style="text-align: justify"><font style="font-size: 10pt">Fast Forward $0.35 Fast forward transaction fee; and,</font></td> </tr> <tr style="vertical-align: top; text-align: justify"> <td style="text-align: right"><font style="font-size: 10pt">&#183;</font></td><td></td><td style="text-align: justify"><font style="font-size: 10pt">Patient Credit $2.50 Automatic Debit processing per transaction paid by the patient</font></td> </tr></table> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">The Company had not received any transaction revenues in the three and six months ended March 31, 2014.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>Cost of License, and Subscriptions Revenues</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">Cost of license revenue is primarily comprised of the license-based royalties to third parties and production and distribution costs for initial product licenses. No costs were incurred for license-based royalties during the three months ended March 31, 2014 and 2013.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">Cost of subscription revenue is primarily comprised of the costs associated with the customer support personnel that provide maintenance, enhancement and support services to customers. No costs were incurred for customer support during the three months ended March 31, 2014 and 2013.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">The amortization of acquired technology for products acquired through business combinations are considered as the cost of revenues. The acquired software technologies are amortized over their useful lives of 5 years.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>Deferred Revenue</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">Deferred revenue result from fees billed to customers for which revenue has not yet been recognized or for which the conditions of the arrangement have been modified.&#160;The Company recognizes revenue to provide up-front capitalization to Cloud-MD for each provider added to the solution set. The Company also recognizes annual subscription fees for virtual servers and subscription and small usage fees and those revenues are based on a 48-month lease, Cloud-MD would amortize the revenue over the life of the agreement of 48 months. In addition, it features incremental monthly revenue, for the duration of the lease (48 months) based on fees assessed for transactions such as eligibility claims processing, etc. The Company has deferred revenue of $0 as of March 31, 2014.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>&#160;</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>Sales Commissions</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">The Company pays commissions, including sales bonuses, to the direct sales force related to revenue transactions under sales compensation plans which are established annually. The commission payments are typically paid in full in the month or quarter following execution of the customer contracts. The Company paid commissions of $0 and $20,000 for the three months ended March 31, 2014 and 2013, respectively, and $37,000 and $40,260 for the six months ended March 31, 2014 and 2013, respectively.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>&#160;</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>Research and Development and Software Development Costs</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">Capitalization of certain software development costs subsequent to the establishment of technological feasibility. Based on our product development process, technological feasibility is established upon the completion of a working model. To date, costs incurred by us from the completion of the working model to the point at which the product is ready for general release have been insignificant. Accordingly, we have charged all such costs to research and development expense in the period incurred.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>&#160;</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>Share-Based Compensation</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">The Company measures the cost of services received in exchange for an award of an equity instrument based on the grant-date fair value of the award. &#160;Compensation cost is recognized over the vesting or requisite service period.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>Basic and Diluted Net Income (Loss) per Common Share</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">Basic income (loss) per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the reporting period.&#160;The weighted average number of shares is calculated by taking the number of shares outstanding and weighting them by the amount of time that they were outstanding. &#160;Diluted earnings per share reflects the potential dilution that could occur if stock options, warrants, and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">The Company has 4,000,000 preferred shares that can be converted subject to the limitation of the Company&#146;s authorized shares at 1 preferred share for 150 common shares. The conversion can only take place with the approval of the Board of Directors. At March 31, 2014, the preferred shares could be converted into 600,000,000 of common shares resulting in dilution of common shareholders. The preferred shares are anti-dilutive since the losses the Company has incurred for the periods ended March 31, 2014 and 2013.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">Diluted loss per share is the same as basic loss per share during periods where net losses are incurred since the inclusion of the potential common stock equivalents would be anti-dilutive as a result of the net loss.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>Concentration of Credit Risk</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">All of the Company&#146;s cash and cash equivalents are maintained in regional and national financial institutions. The Company has exposure to credit risk to the extent that its cash and cash equivalents exceed amounts covered by the U.S. federal deposit insurance; however, the Company has not experienced any losses in such accounts. In management&#146;s opinion, the capitalization and operating history of the financial institutions are such that the likelihood of material loss is remote.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>&#160;</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>Subsequent Events</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">The Company has evaluated all transactions occurring between March 31, 2014 and through the date of issuance of the financial statements for subsequent event disclosure.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>Recent Accounting Pronouncements</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">No accounting standards or interpretations issued recently are expected to a have a material impact on the Company&#146;s financial position, operations or cash flows.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>Use of Estimates and Assumptions</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States (&#147;GAAP&#148;) requires management to make estimates and assumptions that affect (i)&#160;the reported amounts of assets and liabilities, (ii)&#160;the disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and (iii)&#160;the reported amount of net revenues and expenses recognized during the periods presented. Adjustments made with respect to the use of estimates often relate to improved information not previously available. Uncertainties with respect to such estimates and assumptions are inherent in the preparation of financial statements; accordingly, actual results could differ from these estimates. The Company&#146;s most significant estimates relate to the valuation of its proprietary technology and its valuation of its common stock.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>Cash and Cash Equivalents</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.&#160;&#160;At March 31, 2014, cash and cash equivalents include cash on hand and cash in the bank and the FDIC insures these deposits up to $250,000.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>Impairment of Long-Lived Assets</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">Long-lived assets are evaluated for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. Each impairment test is based on a comparison of the undiscounted future cash flows to the recorded value of the asset. If impairment is indicated, the asset is written down to its estimated fair value. The acquired software technologies are reviewed annually for impairment.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>Fair Value of Financial Instruments</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">The Company's financial instruments consist primarily of cash, accounts payable and accrued expenses, and debt. The carrying amounts of such financial instruments approximate their respective estimated fair value due to the short-term maturities and approximate market interest rates of these instruments.&#160;&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">Fair value is focused on an exit price that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#160;&#160;Within the measurement of fair value, the use of market-based information is prioritized over entity specific information and a three-level hierarchy for fair value measurements is used based on the nature of inputs used in the valuation of an asset or liability as of the measurement date.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">The three-level hierarchy for fair value measurements is defined as follows:</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="font-size: 10pt; line-height: normal; margin-top: 0; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><font style="font-size: 10pt">&#149;</font></td><td style="width: 5pt"></td><td style="text-align: justify"><font style="font-size: 10pt">Level 1 &#150; inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets; liabilities in active markets;</font></td> </tr></table> <table cellpadding="0" cellspacing="0" style="font-size: 10pt; line-height: normal; margin-top: 0; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><font style="font-size: 10pt">&#149;</font></td><td style="width: 5pt"></td><td style="text-align: justify"><font style="font-size: 10pt">Level 2 &#150; inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability other than quoted prices, either directly or indirectly, including inputs in markets that are not considered to be active; or directly or indirectly including inputs in markets that are not considered to be active;</font></td> </tr></table> <table cellpadding="0" cellspacing="0" style="font-size: 10pt; line-height: normal; margin-top: 0; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><font style="font-size: 10pt">&#149;</font></td><td style="width: 5pt"></td><td style="text-align: justify"><font style="font-size: 10pt">Level 3 &#150; inputs to the valuation methodology are unobservable and significant to the fair value measurement.</font></td> </tr></table> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">The following table summarizes fair value measurements by level at March 31, 2014 and September 30, 2013 for assets measured at fair value on a recurring basis:</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-weight: bold"> <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Level 1</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Level 2</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Level 3</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Total</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-weight: bold"> <td style="text-align: justify; padding-left: 5.4pt">At March 31, 2014</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; padding-bottom: 1pt; text-indent: 9.75pt; padding-left: 5.4pt">Software</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</td><td style="width: 10%; border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</td><td style="width: 10%; border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</td><td style="width: 10%; border-bottom: Black 1pt solid; text-align: right">701,611</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</td><td style="width: 10%; border-bottom: Black 1pt solid; text-align: right">701,611</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; text-indent: 9.75pt; padding-left: 5.4pt">Total Software</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">701,611</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">701,611</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt; font-weight: bold">At September 30, 2013</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-indent: 9.75pt; padding-left: 5.4pt">Software</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">937,431</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">937,431</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; text-indent: 9.75pt; padding-left: 5.4pt">Total Software</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">937,431</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">937,431</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>Accounts Receivable and Allowance for Uncollectible Accounts</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">Substantially all of the Company&#146;s accounts receivable balance is related to trade receivables. Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is the Company&#146;s best estimate of the amount of probable credit losses in its existing accounts receivable. The Company will maintain allowances for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments for services. Accounts with known financial issues are first reviewed and specific estimates are recorded. The remaining accounts receivable balances are then grouped in categories by the number of days the balance is past due, and the estimated loss is calculated as a percentage of the total category based upon past history. Account balances are charged against the allowance when it is probable the receivable will not be recovered. As of March 31, 2014 and 2013, the Company had no valuation allowance for the Company&#146;s accounts receivable.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>Income Taxes</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">The Company utilizes the asset and liability method in accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for operating loss and tax credit carry-forwards and for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is recorded to reduce the carrying amounts of deferred tax assets unless it is more likely than not that the value of such assets will be realized.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">The Company uses the two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not, that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount, which is more than 50% likely of being realized upon ultimate settlement. The Company considers many factors when evaluating and estimating the Company's tax positions and tax benefits, which may require periodic adjustments. At March 31, 2014, the Company did not record any liabilities for uncertain tax positions.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>Revenue Recognition</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">License revenue consists principally of revenue earned under software license agreements. The Company sells its software to a medical practitioner for direct payment or through a third party leasing company for direct payment to the Company. The third party lease agreement is a non-recourse debt and the Company is not responsible for the default of the medical practitioner. License revenue is generally recognized when a signed contract or other persuasive evidence of an arrangement exists, the software has been electronically delivered, the license fee is fixed or is measured on a paid user basis; and collection of the resulting receivable is probable. When contracts contain multiple elements wherein Vendor-Specific Objective Evidence (&#147;VSOE&#148;) exists for all undelivered elements, we account for the delivered elements in accordance with the &#147;Residual Method.&#148;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">VSOE of fair value for maintenance and support is established by a stated renewal rate, if substantive, included in the license arrangement or rates charged in stand-alone sales of maintenance and support. Revenue from subscription license agreements, which include software, rights to unspecified future products and maintenance, is recognized ratably over the term of the subscription period.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">Provided all other revenue criteria are met, the upfront, minimum, non-refundable license fees from customers are generally recognized upon delivery and on-going royalty fees are generally recognized upon reports of new licenses issued. If there is significant uncertainty about the project completion or receipt of payment for professional services, revenue is deferred until the uncertainty is sufficiently resolved. VSOE of fair value of services is based upon stand-alone sales of those services.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">Subscription revenue is generated from bandwidth and information storage. In the first year and each year thereafter, the software is purchased and installed the purchaser will pay an annual fee of $1,200, $1,500, $1,800, and $2,400, respectively. Subscription revenue is recognized ratably over the term of the agreement.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">Transaction revenue is generated from the following services and recognized when a transaction occurs:</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="font-size: 10pt; line-height: normal; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><font style="font-size: 10pt">&#183;</font></td><td style="width: 5pt"></td><td style="text-align: justify"><font style="font-size: 10pt">Electronic Remittance Advise $0.35 Electronic remittance transaction fee;</font></td> </tr> <tr style="vertical-align: top; text-align: justify"> <td style="text-align: right"><font style="font-size: 10pt; color: #000004">&#183;</font></td><td></td><td style="text-align: justify"><font style="font-size: 10pt; color: #000004">Paper Claim</font><font style="font-size: 10pt; color: #131317">s </font><font style="font-size: 10pt; color: #000004">$1</font><font style="font-size: 10pt; color: #000002">.</font><font style="font-size: 10pt; color: #000004">00 Pa</font><font style="font-size: 10pt; color: #000002">p</font><font style="font-size: 10pt; color: #000004">er claim fee;</font></td> </tr> <tr style="vertical-align: top; text-align: justify"> <td style="text-align: right"><font style="font-size: 10pt">&#183;</font></td><td></td><td style="text-align: justify"><font style="font-size: 10pt">Carrier Direct $0.16 Carrier direct fee;</font></td> </tr> <tr style="vertical-align: top; text-align: justify"> <td style="text-align: right"><font style="font-size: 10pt">&#183;</font></td><td></td><td style="text-align: justify"><font style="font-size: 10pt">Fast Forward $0.35 Fast forward transaction fee; and,</font></td> </tr> <tr style="vertical-align: top; text-align: justify"> <td style="text-align: right"><font style="font-size: 10pt">&#183;</font></td><td></td><td style="text-align: justify"><font style="font-size: 10pt">Patient Credit $2.50 Automatic Debit processing per transaction paid by the patient</font></td> </tr></table> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">The Company had not received any transaction revenues in the three and six months ended March 31, 2014.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>Cost of License, and Subscriptions Revenues</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">Cost of license revenue is primarily comprised of the license-based royalties to third parties and production and distribution costs for initial product licenses. No costs were incurred for license-based royalties during the three months ended March 31, 2014 and 2013.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">Cost of subscription revenue is primarily comprised of the costs associated with the customer support personnel that provide maintenance, enhancement and support services to customers. No costs were incurred for customer support during the three months ended March 31, 2014 and 2013.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">The amortization of acquired technology for products acquired through business combinations are considered as the cost of revenues. The acquired software technologies are amortized over their useful lives of 5 years.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>Deferred Revenue</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">Deferred revenue result from fees billed to customers for which revenue has not yet been recognized or for which the conditions of the arrangement have been modified.&#160;The Company recognizes revenue to provide up-front capitalization to Cloud-MD for each provider added to the solution set. The Company also recognizes annual subscription fees for virtual servers and subscription and small usage fees and those revenues are based on a 48-month lease, Cloud-MD would amortize the revenue over the life of the agreement of 48 months. In addition, it features incremental monthly revenue, for the duration of the lease (48 months) based on fees assessed for transactions such as eligibility claims processing, etc. The Company has deferred revenue of $0 as of March 31, 2014.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>Sales Commissions</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">The Company pays commissions, including sales bonuses, to the direct sales force related to revenue transactions under sales compensation plans which are established annually. The commission payments are typically paid in full in the month or quarter following execution of the customer contracts. The Company paid commissions of $0 and $20,000 for the three months ended March 31, 2014 and 2013, respectively, and $37,000 and $40,260 for the six months ended March 31, 2014 and 2013, respectively.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>Research and Development and Software Development Costs</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">Capitalization of certain software development costs subsequent to the establishment of technological feasibility. Based on our product development process, technological feasibility is established upon the completion of a working model. To date, costs incurred by us from the completion of the working model to the point at which the product is ready for general release have been insignificant. Accordingly, we have charged all such costs to research and development expense in the period incurred.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>Share-Based Compensation</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">The Company measures the cost of services received in exchange for an award of an equity instrument based on the grant-date fair value of the award. &#160;Compensation cost is recognized over the vesting or requisite service period.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>Basic and Diluted Net Income (Loss) per Common Share</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">Basic income (loss) per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the reporting period.&#160;The weighted average number of shares is calculated by taking the number of shares outstanding and weighting them by the amount of time that they were outstanding. &#160;Diluted earnings per share reflects the potential dilution that could occur if stock options, warrants, and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">The Company has 4,000,000 preferred shares that can be converted subject to the limitation of the Company&#146;s authorized shares at 1 preferred share for 150 common shares. The conversion can only take place with the approval of the Board of Directors. At March 31, 2014, the preferred shares could be converted into 600,000,000 of common shares resulting in dilution of common shareholders. The preferred shares are anti-dilutive since the losses the Company has incurred for the periods ended March 31, 2014 and 2013.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">Diluted loss per share is the same as basic loss per share during periods where net losses are incurred since the inclusion of the potential common stock equivalents would be anti-dilutive as a result of the net loss.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>Concentration of Credit Risk</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">All of the Company&#146;s cash and cash equivalents are maintained in regional and national financial institutions. The Company has exposure to credit risk to the extent that its cash and cash equivalents exceed amounts covered by the U.S. federal deposit insurance; however, the Company has not experienced any losses in such accounts. In management&#146;s opinion, the capitalization and operating history of the financial institutions are such that the likelihood of material loss is remote.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>Subsequent Events</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">The Company has evaluated all transactions occurring between March 31, 2014 and through the date of issuance of the financial statements for subsequent event disclosure.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>Recent Accounting Pronouncements</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">No accounting standards or interpretations issued recently are expected to a have a material impact on the Company&#146;s financial position, operations or cash flows.</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-weight: bold"> <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Level 1</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Level 2</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Level 3</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Total</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-weight: bold"> <td style="text-align: justify; padding-left: 5.4pt">At March 31, 2014</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; padding-bottom: 1pt; text-indent: 9.75pt; padding-left: 5.4pt">Software</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</td><td style="width: 10%; border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</td><td style="width: 10%; border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</td><td style="width: 10%; border-bottom: Black 1pt solid; text-align: right">701,611</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</td><td style="width: 10%; border-bottom: Black 1pt solid; text-align: right">701,611</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; text-indent: 9.75pt; padding-left: 5.4pt">Total Software</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">701,611</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">701,611</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt; font-weight: bold">At September 30, 2013</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-indent: 9.75pt; padding-left: 5.4pt">Software</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">937,431</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">937,431</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; text-indent: 9.75pt; padding-left: 5.4pt">Total Software</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">937,431</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">937,431</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> 1200 1500 1800 2400 40260 0 20000 37000 0 250000 600000000 701611 937431 701611 937431 701611 937431 701611 937431 <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>NOTE 5 &#150; SOFTWARE</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>&#160;</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">The following is a detail of software at March 31, 2014 and September 30, 2013:</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-weight: bold"> <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">March 31, 2014</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">September 30, <br />2013</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-weight: bold"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 56%; text-align: justify">Source Code License &#150; Antree Systems Limited</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">6,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">&#151;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Encryption Software Code</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">15,800</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">15,800</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Source Code License &#150; MediSouth, LLC</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,500</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,500</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Acquisition of Doctor&#146;s Network of America</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Software License</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,200,106</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,200,106</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">EMR Certification</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">23,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">23,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total intangible assets</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,257,406</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,251,406</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accumulated amortization of intangible assets</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(545,795</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(423,485</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Accumulated impairment of assets</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(10,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(10,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total intangible assets</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">701,611</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">817,921</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">The Company&#146;s software was placed into service starting in the second quarter of fiscal year ended September 30, 2012. The amortization expense was $61,155 and $61,155 for the three months ended March 31, 2014 and 2013, respectively. The Company recognized a $0 and $6,000 for impairment of software acquired from Doctors Network of America (&#147;DNA&#148;) operating in Flowood, Mississippi during the six months ended March 31, 2014 and the year ended September 30, 2013, respectively. The Company is currently in litigation with the sellers of DNA relating to the collection of certain medical billings owed to the Company. As a result of the litigation, the Company deemed the assets to be impaired.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>Source Code License</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">In October 2013, the Company through a purchase agreement with Antree Systems Limited has purchased a complete source code, intellectual property rights, all computer software, patents, or formulas, algorithm licensed or sold under a project known as Compass Rose and appropriate copyrights, patents, mask works, trademarks, service marks, internet domain names and world wide web uniform resource locators (&#147;URLs&#148;) from Antree Systems Limited. The Company issued 200,000 shares of its common stock as consideration for the purchase. The fair value of the consideration and the assets acquired is based on the fair value of the common stock issued in exchange for the software. The total fair value, based on the market price on the date of grant, was $6,000. The Company evaluated this acquisition and determined that it did not meet the definition of a significant business acquisition.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>Encryption Software Code</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">On November 21, 2012, the Company purchased from CipherSmith, LLC a complete source code, intellectual property rights, all computer software or algorithm licensed or sold under CipherSmith, and appropriate copy rights, patents, mask works, trademarks, service marks, internet domain names or world wide web URS. The Company issued 500,004 shares of its common stock as payment for the acquisition. The fair value of the consideration and the assets acquired is based on the aggregate fair value of the common stock issued in exchange for the software. The total fair value of the shares of common stock issued on the date of grant was $15,800.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>Doctors Network of America</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">On June 22, 2012, the Company entered into an acquisition agreement that closed on March&#160;16, 2013. The Company agreed to acquire DNA in Flowood, Mississippi from Krooss Medical Management Systems, LLC (&#147;Krooss&#148;) for 500,000 shares of common stock. As of September 30, 2012, 200,000 shares of common stock were issued as a deposit, which was valued at $4,000 based on the market value on the date of grant. At the closing of the transaction on March 16, 2013, the Company issued an additional 300,000 shares of common stock which were valued at $6,000 based on the market value on the date of grant.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">Subsequent to the transaction closing on March 16, 2013, the sellers refused to pay for medical billing process transaction fees in accordance with their contracts in the amount of approximately $200,000. The Company and the sellers are currently in litigation over the disputed transaction fees of $200,000. </p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-weight: bold"> <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">March 31, 2014</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">September 30, <br />2013</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-weight: bold"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 56%; text-align: justify">Source Code License &#150; Antree Systems Limited</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">6,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">&#151;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Encryption Software Code</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">15,800</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">15,800</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Source Code License &#150; MediSouth, LLC</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,500</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,500</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Acquisition of Doctor&#146;s Network of America</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Software License</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,200,106</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,200,106</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">EMR Certification</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">23,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">23,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total intangible assets</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,257,406</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,251,406</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accumulated amortization of intangible assets</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(545,795</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(423,485</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Accumulated impairment of assets</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(10,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(10,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total intangible assets</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">701,611</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">817,921</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> 1257406 1251406 6000 15800 15800 2500 2500 10000 10000 1200106 1200106 23000 23000 -545795 -423485 10000 10000 701611 817921 200000 400000 200000 100000 200000 500004 6000 13000 6000 2800 6000 15800 500000 200000 300000 4000 6000 200000 61155 60005 <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>NOTE 6- DISCONTINUED OPERATIONS </b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">The Company&#146;s former Board of Directors believed that it was in the best interest of the Company to discontinue the former business operation of the GPS operational device business. In 2011, this business was transferred to National Scientific, LLC, a company owned by the Company&#146;s prior CEO, by prior management in which the Company&#146;s former CEO was to pay $100,000 plus 2% of revenues for that technology. The former officer never paid the specific consideration for this transaction.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">Accordingly, the Company reclassified the assets, liabilities and operations related to its GPS operational device business as discontinued operations. &#160;Consequently, the accompanying financial statements reflect the assets, liabilities and operations of the GPS operational device business as net assets of discontinued operations, net liabilities of discontinued operations and results from discontinued operations.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">On March 16, 2013, the Company closed the acquisition with the final payment for DNA. Subsequent to the transaction closing, the sellers refused to pay the transaction fees for medical billing contracts that were processed. The Company filed a lawsuit against the sellers for Breach of Contract among other things in June of 2013. During that time, the Company believes the sellers began contacting all billing contract holders and interfered with the acquisition of all the assets from the transaction. Consequently, the accompanying consolidated financial statements reflect the assets, liabilities and operations of DNA as net assets of discontinued operations, net liabilities of discontinued operations and results from discontinued operations.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">Details of the classifications for net assets, liabilities and operations are shown below.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-weight: bold"> <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">March 31, <br />2014</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">September 30, <br />2013</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-weight: bold"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net liabilities of discontinued operations:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left; padding-bottom: 1pt">Accounts payable</td><td style="width: 8%; padding-bottom: 1pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</td><td style="width: 12%; border-bottom: Black 1pt solid; text-align: right">42,837</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 8%; padding-bottom: 1pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</td><td style="width: 12%; border-bottom: Black 1pt solid; text-align: right">35,356</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net liabilities of discontinued operations</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">42,837</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">35,356</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt"></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-weight: bold"> <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="7" style="text-align: center; border-bottom: Black 1pt solid">Three Months Ended <br />March 31,</td></tr> <tr style="vertical-align: bottom; font-weight: bold"> <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2014</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2013</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-weight: bold"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Discontinued operations:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%">Revenues</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">53,766</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">900</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Cost of sales</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating expenses</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(50,568</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(938</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Gain from write-off of debt</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Income (loss) from discontinued operations</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,198</td><td style="padding-bottom: 2.5pt; text-align: left"></td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(38</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-weight: bold"> <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="7" style="text-align: center; border-bottom: Black 1pt solid">Six Months Ended <br />March 31,</td></tr> <tr style="vertical-align: bottom; font-weight: bold"> <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2014</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2013</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-weight: bold"> <td style="text-align: left">Discontinued operations:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 56%">Revenues</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">131,050</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">900</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Cost of sales</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 56%; text-align: left">Operating expenses</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">(138,567</td><td style="width: 1%; text-align: left">)</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">(938</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Gain from write-off of debt</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">58,984</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Income (loss) from discontinued operations</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(7,517</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">58,946</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>&#160;</b></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-weight: bold"> <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">March 31, <br />2014</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">September 30, <br />2013</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-weight: bold"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net liabilities of discontinued operations:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left; padding-bottom: 1pt">Accounts payable</td><td style="width: 8%; padding-bottom: 1pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</td><td style="width: 12%; border-bottom: Black 1pt solid; text-align: right">42,837</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 8%; padding-bottom: 1pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</td><td style="width: 12%; border-bottom: Black 1pt solid; text-align: right">35,356</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net liabilities of discontinued operations</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">42,837</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">35,356</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt"></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-weight: bold"> <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="7" style="text-align: center; border-bottom: Black 1pt solid">Three Months Ended <br />March 31,</td></tr> <tr style="vertical-align: bottom; font-weight: bold"> <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2014</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2013</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-weight: bold"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Discontinued operations:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%">Revenues</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">53,766</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">900</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Cost of sales</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating expenses</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(50,568</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(938</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Gain from write-off of debt</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Income (loss) from discontinued operations</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,198</td><td style="padding-bottom: 2.5pt; text-align: left"></td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(38</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-weight: bold"> <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="7" style="text-align: center; border-bottom: Black 1pt solid">Six Months Ended <br />March 31,</td></tr> <tr style="vertical-align: bottom; font-weight: bold"> <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2014</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2013</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-weight: bold"> <td style="text-align: left">Discontinued operations:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 56%">Revenues</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">131,050</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">900</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Cost of sales</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 56%; text-align: left">Operating expenses</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">(138,567</td><td style="width: 1%; text-align: left">)</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">(938</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Gain from write-off of debt</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">58,984</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Income (loss) from discontinued operations</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(7,517</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">58,946</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> 100000 -58984 58984 3198 -38 -7517 58946 248256722 <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>NOTE 7 &#150; LINES OF CREDIT</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">In November 2013, the Company entered into a revolving line of credit with Mutual of Omaha in the amount of $65,000 at a 4.00% interest rate per annum which renews annually. As of March 31, 2014, the Company had borrowed $62,612 against the line of credit.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">The Company has a revolving line of credit with Chase Bank with a balance as of March 31, 2014 in the amount of $24,429 and a borrowing limit of $50,000. The line of credit with Chase Bank has an interest rate of 4.25% per annum and renews annually.</p> 65000 50000 0.0400 0.0425 50000 18370 <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>NOTE 8 &#150; DEBT MITIGATION PROGRAM</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">The Company determined that the statute of limitations for certain of the Company&#146;s creditors to enforce collection of any amounts they might be owed has now elapsed. Based on the determinations and findings, during six months ended March 31, 2014 and 2013, the Company recognized a gain on the write-off of liabilities in the amount of $0 and $58,984 from third party liabilities, respectively, which was recorded in income from discontinued operations, and additional paid-in capital of $59,704 and $0 for related party liabilities, respectively. The Company will continue to conduct this analysis going forward and write-off obligations when such obligations are no longer enforceable based on applicable law.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">The following liabilities, through the opinion of legal counsel, were determined by the Company as unenforceable.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-weight: bold"> <td>&#160;</td><td>&#160;</td> <td colspan="7" style="text-align: center">Six Months Ended</td></tr> <tr style="vertical-align: bottom; font-weight: bold"> <td>&#160;</td><td>&#160;</td> <td colspan="3" style="text-align: center">March&#160;&#160;31,</td><td>&#160;</td> <td colspan="3" style="text-align: center">March 31,</td></tr> <tr style="vertical-align: bottom; font-weight: bold"> <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2014</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2013</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-weight: bold"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.75pt">Debt Mitigation Program:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left; padding-left: 5.75pt">Accounts payable and accrued expenses</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">59,704</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">58,984</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.75pt">Accrued interest</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.75pt">Total debt mitigation program</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">59,704</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">58,984</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.75pt">Gain on write-off of debt</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(58,984</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.75pt">Additional paid-in capital (1)</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">59,704</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 2.5pt; text-align: left"></td></tr> </table> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"></p> <table cellspacing="0" cellpadding="0" style="width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 20px; text-align: right; line-height: 115%"><font style="font-size: 10pt">(1)</font></td> <td style="width: 7px">&#160;</td> <td style="text-align: justify; line-height: 115%"><font style="font-size: 10pt">All amounts that were owed to related parties in prior years were recorded to paid-in-capital.</font></td></tr></table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-weight: bold"> <td>&#160;</td><td>&#160;</td> <td colspan="7" style="text-align: center">Six Months Ended</td></tr> <tr style="vertical-align: bottom; font-weight: bold"> <td>&#160;</td><td>&#160;</td> <td colspan="3" style="text-align: center">March&#160;&#160;31,</td><td>&#160;</td> <td colspan="3" style="text-align: center">March 31,</td></tr> <tr style="vertical-align: bottom; font-weight: bold"> <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2014</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2013</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-weight: bold"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.75pt">Debt Mitigation Program:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left; padding-left: 5.75pt">Accounts payable and accrued expenses</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">59,704</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">58,984</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.75pt">Accrued interest</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.75pt">Total debt mitigation program</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">59,704</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">58,984</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.75pt">Gain on write-off of debt</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(58,984</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.75pt">Additional paid-in capital (1)</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">59,704</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 2.5pt; text-align: left"></td></tr> </table> 58984 59704 58984 59704 58984 <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>NOTE 9 &#150; COMMITMENTS AND CONTINGENCIES</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">Rent expense for the three months and six ended March 31, 2014 and 2013 was $0 for all periods.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">The Company entered into an agreement to purchase the assets of DNA in June 2012 and after due diligence by both parties the transaction closed on March 16, 2013. Subsequent to the transaction closing on March 16, 2013, the sellers refused to pay for medical billing process transaction fees in accordance with their contracts of approximately $200,000. In June 2013, the Company sued the sellers in federal court for breach of contract among other causes of action of unpaid medical billing transaction fees of approximately $200,000. The Company believes it will be successful in its litigation. However, if the Company is successful, the collectability of the judgment is highly questionable.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">The Company has issued shares to new investors since January 2, 2011, that have an anti-reverse common stock split clause if the Company reverse splits the common stock. The reverse split of common stock is determined by management but must be approved by Financial Industry Regulation Authority (&#147;FINRA&#148;). Presently FINRA has denied the Company the right to reverse split the common stock until all Securities and Exchange Commission filings are current and at that point and time the Company will submit a request to FINRA to execute a reverse split of the common stock of the Company. The current investors holding anti-reverse split stock will have the right to hold the same number of shares of common stock as status quo after the reverse split. The anti-reverse split common stock protection is only for stock subject to reverse split and once the Company declares a reverse split and it is completed, the anti-reverse split protection will be terminate and shareholders that received anti-reverse split stock will be held with regular stockholders as the Company proceeds forward. In accordance with the anti-reverse split provision, no further shares will be issued to the anti-reverse split shareholders once the reverse split is approved and completed.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">As discussed in Note 8, the Company has written off $59,704 and $58,984 in accounts payable, accrued liabilities and notes payable based on the opinion of legal counsel for the six months ended March 31, 2014 and 2013, respectively. However, the related creditors could make a claim in the future in regards to these liabilities.</p> 0 0 0 0 59704 58984 <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>NOTE 10&#150; RELATED PARTY TRANSACTIONS</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">The Company repaid $0 and $25,591 of the advances from the Company&#146;s CEO in the three months ended March 31, 2014 and 2013, respectively. The advances from the CEO are due on demand and do not accrue interest. As of March 31, 2014 and September 30, 2013, there were no amounts owed to the CEO for advances, respectively.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>NOTE 11 - EQUITY</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><font style="font-size: 10pt; line-height: 115%">As of March 31, 2014, the Company was authorized to issue 650,000,000 common shares and 4,000,000 preferred shares at a par value of $0.01. </font>&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b><u>Six Months Ended March 31, 2014</u></b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>&#160;</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b><i><u>Stock Issued for Cash</u></i></b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b><i>&#160;</i></b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">During the six months ended March 31, 2014, the Company issued 35,000 shares of common stock for $15,000 in net cash proceeds as follows:</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="width: 100%; font-size: 10pt; border-collapse: collapse"> <tr style="text-align: center; vertical-align: bottom"> <td colspan="3" style="margin-top: 0; margin-bottom: 0; line-height: normal; border-bottom: Black 1pt solid">Date</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="margin-top: 0; margin-bottom: 0; line-height: normal; border-bottom: Black 1pt solid">Number of Shares</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="margin-top: 0; margin-bottom: 0; line-height: normal; border-bottom: Black 1pt solid">Proceeds</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td colspan="3" style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</td> <td>&#160;</td> <td colspan="3" style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</td> <td style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</td> <td colspan="3" style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify; width: 1%">&#160;</td> <td style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify; width: 30%">October 21, 2013</td> <td style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify; width: 1%">&#160;</td> <td style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify; width: 7%">&#160;</td> <td rowspan="2" style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify; width: 1%">&#160;</td> <td style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: right; width: 25%; vertical-align: bottom">25,000</td> <td style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify; width: 1%">&#160;</td> <td style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify; width: 7%">&#160;</td> <td rowspan="2" style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify; width: 1%">$</td> <td style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: right; width: 25%; vertical-align: bottom">5,000</td> <td style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify; width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</td> <td style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify; padding-bottom: 1pt">January 12, 2014</td> <td style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</td> <td style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</td> <td style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: right; vertical-align: bottom; border-bottom: Black 1pt solid">10,000</td> <td style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</td> <td style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</td> <td style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: right; vertical-align: bottom; border-bottom: Black 1pt solid">10,000</td> <td style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</td> <td style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify; padding-bottom: 2.5pt">Total</td> <td style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</td> <td style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</td> <td style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify; padding-bottom: 2.5pt">&#160;</td> <td style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: right; vertical-align: bottom; border-bottom: Black 2.5pt double">35,000</td> <td style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</td> <td style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</td> <td style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">$</td> <td style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: right; vertical-align: bottom; border-bottom: Black 2.5pt double">15,000</td> <td style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</td></tr> </table> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b><i><u>Stock Issued in Connection with Software Licensing and Subscription Agreements</u></i></b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">During the six months ended March 31, 2014, the Company issued 220,000&#160;shares of common stock&#160;valued at $5,700 based on the market price on the date of grant, to customers, in regards to the purchase of software from the Company in accordance with the Software Licensing and Subscription Agreements. The fair values of the shares issued were recorded as a reduction of software revenue recognized during the three months ended March 31, 2014.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="text-align: center; font-weight: bold; vertical-align: bottom"> <td colspan="3" style="border-bottom: Black 1pt solid">Date</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="border-bottom: Black 1pt solid">Number of Shares</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="border-bottom: Black 1pt solid">Fair Value</td></tr> <tr style="text-align: center; font-weight: bold; vertical-align: bottom"> <td colspan="3">&#160;</td><td>&#160;</td> <td colspan="3">&#160;</td><td>&#160;</td> <td colspan="3">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left; vertical-align: top">&#160;</td><td style="width: 26%; text-align: left; vertical-align: top">December 4, 2013</td><td style="width: 1%; text-align: left; vertical-align: top">&#160;</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 26%; text-align: right">120,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 26%; text-align: right">3,600</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: left; vertical-align: top">&#160;</td><td style="padding-bottom: 1pt; text-align: left; vertical-align: top">March 4, 2014</td><td style="padding-bottom: 1pt; text-align: left; vertical-align: top">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">100,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,100</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left; vertical-align: top">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left; vertical-align: top">Total</td><td style="padding-bottom: 2.5pt; text-align: left; vertical-align: top">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">220,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,700</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b><i>&#160;</i></b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b><i><u>Stock Issued for Assets Acquisition</u></i></b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">In October 2013, the Company through a purchase agreement with Antree Systems Limited has purchased a complete source code, intellectual property rights, all computer software, patents, or formulas, algorithm licensed or sold under a project known as Compass Rose and appropriate copyrights, patents, mask works, trademarks, service marks, internet domain names and world wide web uniform resource locators (&#147;URLs&#148;) from Antree Systems Limited. The Company issued 200,000 shares of its common stock as consideration for the purchase. The fair value of the consideration and the assets acquired is based on the fair value of the common stock issued in exchange for the software. The total fair value, based on the market price on the date of grant, was $6,000. The Company evaluated this acquisition and determined that it did not meet the definition of a significant business acquisition.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">In November 2013, the Company issued 180,000 shares of common stock as replacement shares for the 160,000 shares of common stock issued to Antree Systems Limited and 20,000 shares of common stock to Kimberly Ilicerl. The Company intends to cancel the original shares issued because the shares were lost during delivery to Antree Systems.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b><i><u>Stock Issued for Services</u></i></b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b><i>&#160;</i></b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">During the six months ended March 31, 2014, the Company issued 31,750,000 shares of common stock as compensation. The fair values of the shares were a total of $666,750 and were recorded at the market price on the date of grant. The issuances of stock were as follows:</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-weight: bold"> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Date</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Number of Shares</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Fair Value</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Description of Services</td></tr> <tr style="vertical-align: bottom; background-color: White; font-weight: bold"> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 20%; text-align: right"><font style="font-size: 10pt">March 5, 2014</font></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 19%; text-align: right">31,750,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 19%; text-align: right">666,750</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 19%; text-align: right"><font style="font-size: 10pt">Compensation</font></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: left"></td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt">Total</font></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">31,750,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">666,750</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b><u>Six Months Ended March 31, 2013</u></b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>&#160;</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b><i><u>Stock Issued for Cash</u></i></b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b><i>&#160;</i></b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">During the six months ended March 31, 2013, the Company issued 197,500 shares of common stock for $141,000 in net cash proceeds as follows:</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="text-align: center; font-weight: bold; vertical-align: bottom"> <td colspan="3" style="border-bottom: Black 1pt solid">Date</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="border-bottom: Black 1pt solid">Number of Shares</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="border-bottom: Black 1pt solid">Proceeds</td></tr> <tr style="vertical-align: bottom; background-color: White; font-weight: bold"> <td style="text-align: left; vertical-align: top">&#160;</td><td style="text-align: left; vertical-align: top">&#160;</td><td style="text-align: left; vertical-align: top">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left; vertical-align: top">&#160;</td><td style="width: 26%; text-align: left; vertical-align: top"><font style="font-size: 10pt">October 14, 2012</font></td><td style="width: 1%; text-align: left; vertical-align: top">&#160;</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 26%; text-align: right">20,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 26%; text-align: right">20,000</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: top">&#160;</td><td style="text-align: left; vertical-align: top"><font style="font-size: 10pt">October 14, 2012</font></td><td style="text-align: left; vertical-align: top">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">15,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: top">&#160;</td><td style="text-align: left; vertical-align: top"><font style="font-size: 10pt">October 14, 2012</font></td><td style="text-align: left; vertical-align: top">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">18,750</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,500</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: top">&#160;</td><td style="text-align: left; vertical-align: top"><font style="font-size: 10pt">October 14, 2012</font></td><td style="text-align: left; vertical-align: top">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">18,750</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,500</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: top">&#160;</td><td style="text-align: left; vertical-align: top"><font style="font-size: 10pt">December 6, 2012</font></td><td style="text-align: left; vertical-align: top">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">15,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: top">&#160;</td><td style="text-align: left; vertical-align: top"><font style="font-size: 10pt">March 12, 2013</font></td><td style="text-align: left; vertical-align: top">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">20,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">20,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: top">&#160;</td><td style="text-align: left; vertical-align: top"><font style="font-size: 10pt">March 12, 2013</font></td><td style="text-align: left; vertical-align: top">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">20,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">20,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: top">&#160;</td><td style="text-align: left; vertical-align: top"><font style="font-size: 10pt">March 31, 2013</font></td><td style="text-align: left; vertical-align: top">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">50,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">50,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left; vertical-align: top">&#160;</td><td style="padding-bottom: 1pt; text-align: left; vertical-align: top"><font style="font-size: 10pt">March 27, 2013</font></td><td style="padding-bottom: 1pt; text-align: left; vertical-align: top">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">20,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">20,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left; vertical-align: top">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left; vertical-align: top"><font style="font-size: 10pt">Total</font></td><td style="padding-bottom: 2.5pt; text-align: left; vertical-align: top">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">197,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">141,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b><i><u>Stock Issued in Connection with Software Licensing and Subscription Agreements</u></i></b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">During the six months ended March 31, 2013, the Company issued 300,000&#160;shares of common stock&#160;valued at $9,350 based on the market price on the date of grant, to customers, in regards to the purchase of software from the Company in accordance with the Software Licensing and Subscription Agreements. The fair values of the shares issued were recorded as a reduction of software revenue recognized during the three months ended March 31, 2013.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="text-align: center; font-weight: bold; vertical-align: bottom"> <td colspan="3" style="border-bottom: Black 1pt solid">Date</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="border-bottom: Black 1pt solid">Number of Shares</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="border-bottom: Black 1pt solid">Fair Value</td></tr> <tr style="vertical-align: bottom; background-color: White; font-weight: bold"> <td style="text-align: left; vertical-align: top">&#160;</td><td style="text-align: left; vertical-align: top">&#160;</td><td style="text-align: left; vertical-align: top">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left; vertical-align: top">&#160;</td><td style="width: 26%; text-align: left; vertical-align: top"><font style="font-size: 10pt">October 14, 2012</font></td><td style="width: 1%; text-align: left; vertical-align: top">&#160;</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 26%; text-align: right">50,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 26%; text-align: right">1,300</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: top">&#160;</td><td style="text-align: left; vertical-align: top"><font style="font-size: 10pt">December 6, 2012</font></td><td style="text-align: left; vertical-align: top">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,800</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: top">&#160;</td><td style="text-align: left; vertical-align: top"><font style="font-size: 10pt">March 12, 2013</font></td><td style="text-align: left; vertical-align: top">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">50,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,750</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: top">&#160;</td><td style="text-align: left; vertical-align: top"><font style="font-size: 10pt">March 21, 2013</font></td><td style="text-align: left; vertical-align: top">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">50,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,750</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left; vertical-align: top">&#160;</td><td style="padding-bottom: 1pt; text-align: left; vertical-align: top"><font style="font-size: 10pt">March 21, 2013</font></td><td style="padding-bottom: 1pt; text-align: left; vertical-align: top">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">50,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,750</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left; vertical-align: top">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left; vertical-align: top"><font style="font-size: 10pt">Total</font></td><td style="padding-bottom: 2.5pt; text-align: left; vertical-align: top">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">300,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,350</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b><i>&#160;</i></b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b><i><u>Stock Issued for Services</u></i></b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b><i>&#160;</i></b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">During the six months ended March 31, 2013, the Company issued 827,000 shares of common stock as compensation. The fair values of the shares were a total of $28,155 and were recorded at the market price on the date of grant. The issuances of stock were as follows:</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="text-align: center; font-weight: bold; vertical-align: bottom"> <td colspan="3" style="border-bottom: Black 1pt solid">Date</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="border-bottom: Black 1pt solid">Number of Shares</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="border-bottom: Black 1pt solid">Fair Value</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom">Description of Services</td></tr> <tr style="vertical-align: bottom; background-color: White; font-weight: bold"> <td style="text-align: left; vertical-align: top">&#160;</td><td style="text-align: left; vertical-align: top">&#160;</td><td style="text-align: left; vertical-align: top">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left; vertical-align: top">&#160;</td><td style="width: 20%; text-align: left; vertical-align: top"><font style="font-size: 10pt">October 14, 2012</font></td><td style="width: 1%; text-align: left; vertical-align: top">&#160;</td><td style="width: 5%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 19%; text-align: right">10,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 19%; text-align: right">260</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td> <td style="width: 1%; text-align: center; vertical-align: bottom">&#160;</td><td style="width: 19%; text-align: center; vertical-align: bottom"><font style="font-size: 10pt">Commission</font></td><td style="width: 1%; text-align: center; vertical-align: bottom">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: top">&#160;</td><td style="text-align: left; vertical-align: top"><font style="font-size: 10pt">December 6, 2012</font></td><td style="text-align: left; vertical-align: top">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,800</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom"><font style="font-size: 10pt">Compensation</font></td><td style="text-align: center; vertical-align: bottom">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: top">&#160;</td><td style="text-align: left; vertical-align: top"><font style="font-size: 10pt">March 12, 2013</font></td><td style="text-align: left; vertical-align: top">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">50,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,750</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom"><font style="font-size: 10pt">Consulting</font></td><td style="text-align: center; vertical-align: bottom">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: top">&#160;</td><td style="text-align: left; vertical-align: top"><font style="font-size: 10pt">March 21, 2013</font></td><td style="text-align: left; vertical-align: top">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">167,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">5,845</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom"><font style="font-size: 10pt">Compensation</font></td><td style="text-align: center; vertical-align: bottom">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left; vertical-align: top">&#160;</td><td style="padding-bottom: 1pt; text-align: left; vertical-align: top"><font style="font-size: 10pt">March 21, 2013</font></td><td style="padding-bottom: 1pt; text-align: left; vertical-align: top">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">500,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">17,500</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><font style="font-size: 10pt">Compensation</font></td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left; vertical-align: top">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left; vertical-align: top"><font style="font-size: 10pt">Total</font></td><td style="padding-bottom: 2.5pt; text-align: left; vertical-align: top">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">827,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">28,155</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: center; vertical-align: bottom">&#160;</td><td style="padding-bottom: 2.5pt; text-align: center; vertical-align: bottom">&#160;</td><td style="padding-bottom: 2.5pt; text-align: center; vertical-align: bottom">&#160;</td></tr> </table> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b><i><u>Stock Issued for Assets Acquisition</u></i></b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">During the six months ended March 31, 2013, the Company issued 400,000 shares of common stock for the acquisition of CipherSmith software. Those shares were valued at $13,000 based on the market price on the dates of grant.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b><u>Preferred Stock</u></b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>&#160;</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">The Company has authorized 4,000,000 shares of preferred stock, at $0.01 par value and 4,000,000 are issued and outstanding as of September 30, 2013. Each share of the Preferred Stock has 150 votes on all matters presented to be voted by the holders of our common stock. All 4,000,000 shares of preferred stock have been granted to our CEO &#38; CFO on November 30, 2010 and issued on April 11, 2012 which was valued at the trading price of the common stock of $0.0095 and recorded as an expense of $38,000.</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">On December 17, 2013, the Company amended its Articles of Incorporation that gave the right to the holders of Preferred A shares to convert 1 share of Convertible Preferred A shares to 150 Common Shares of the Company. The holders of the Preferred A shares can convert the shares upon proper notice and approval of the Board of Directors. Presently, the holders of the Preferred A shares have not sent notice to the Board of Directors.</p> 35000 197500 220000 300000 6000 13000 5700 9350 180000 160000 20000 31750000 827000 1427506 666750 28155 30684 150 .0095 38000 <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>NOTE 12 &#150; SUBSEQUENT EVENTS</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify"><b>&#160;&#9;</b></p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify; font-style: italic; font-weight: bold; text-decoration: underline">Stock Issued for Services</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; line-height: normal; text-align: justify">On April 21, 2014, the Company issued 1,407,506 shares of common stock as compensation. The fair values of the shares were a total of $21,253 and were recorded at the market price on the date of grant.</p> 1353 1353 All amounts that were owed to related parties in prior years were recorded to paid-in-capital. EX-101.SCH 7 nsct-20140331.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - 1. DESCRIPTION OF BUSINESS link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - 2. BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - 3. GOING CONCERN link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - 4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - 5. SOFTWARE link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - 6. DISCONTINUED OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - 7. LINES OF CREDIT link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - 8. DEBT MITIGATION PROGRAM link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - 9. COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - 10. RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - 11. EQUITY link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - 12. SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - 4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - 4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - 5. SOFTWARE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - 6. DISCONTINUED OPERATIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - 8. DEBT MITIGATION PROGRAM (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - 3. GOING CONCERN (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - 4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value of Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - 4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - 5. SOFTWARE - Software (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - 5. SOFTWARE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - 6. DISCONTINUED OPERATIONS - Discontinued Operations (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - 6. DISCONTINUED OPERATIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - 7. LINES OF CREDIT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - 8 - DEBT MITIGATION PROGRAM - Debt Mitigation Program (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - 8. DEBT MITIGATION PROGRAM (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - 9. COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - 10. RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - 11. EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - 12. SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 nsct-20140331_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 nsct-20140331_def.xml XBRL DEFINITION FILE EX-101.LAB 10 nsct-20140331_lab.xml XBRL LABEL FILE Level 1 Fair Value, Hierarchy [Axis] Level 2 Level 3 Antree Systems Limited Property, Plant and Equipment, Type [Axis] Encryption Software Code MediSouth Doctors Network of America Software License EMR Certification Research and Development Assets Acquired Other than Through Business Combination by Transaction [Axis] Cipher Smith [Member] Doctors Networkof America [Member] Pending Litigation [Member] Litigation Status [Axis] Discontinued Operations [Member] Disposal Group Name [Axis] Mutualof Omaha [Member] Credit Facility [Axis] Chase [Member] Accounts Payable and Accrued Expenses Debt Instrument [Axis] Accrued Interest Related Party [Axis] Kimberly Ilicerl Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS CURRENT ASSETS: Cash Accounts receivables Total current assets Software, net TOTAL ASSETS LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) LIABILITIES CURRENT LIABILITIES: Accounts payables and accrued expenses Liabilities attributed to discontinued operations Lines of credit Total current liabilities TOTAL LIABILITIES COMMITMENTS AND CONTINGENCIES STOCKHOLDERS' EQUITY: Preferred stock, $0.01 par value, 4,000,000 shares authorized; 4,000,000 issued and outstanding Common stock, $0.01 par value, 650,000,000 shares authorized; 246,829,216 and 214,624,216 issued and outstanding Additional paid-in capital Accumulated deficit Total stockholders' equity (deficit) TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Preferred Stock, Par Value Preferred Stock, Shares Authorized Preferred Stock, Shares Issued Preferred Stock, Shares Outstandng Common Stock, Par Value Common Stock, Shares Authorized Common Stock, Shares Issued Common Stock, Shares Outstanding Income Statement [Abstract] REVENUES COST OF REVENUES GROSS PROFIT OPERATING EXPENSES: Selling, general and administrative Research and development Total operating expenses Gain on the disposal of assets OPERATING LOSS OTHER INCOME (EXPENSE) Interest expense Total other income expense LOSS FROM CONTINUING OPERATIONS INCOME (LOSS) FROM DISCONTINUED OPERATIONS NET LOSS NET LOSS PER COMMON SHARE: Basic and diluted Continuing operations Discontinued operations Total WEIGHTED AVERAGE NUMBER COMMON SHARES OUTSTANDING Basic and diluted Statement of Cash Flows [Abstract] Net Loss Income from discontinued operations Loss from continuing operations Adjustments to reconcile net loss from continuing operations to net cash from operating activities: Depreciation and amortization Common stock issued for compensation Common stock issued for software sales Changes in operating assets and liabilities: Accounts receivable Accounts payable and accrued expenses Net cash (used in) provided by operating activities CASH FLOWS FROM INVESTING ACTIVITIES: Proceeds from the sale of assets Net cash provided by investing activities CASH FLOWS FROM FINANCING ACTIVITIES: Repayment of advances from officer Proceeds from line of credit Repayment of line of credit Common stock issued for cash Net cash provided by financing activities INCREASE (DECREASE) IN CASH CASH, BEGINNING OF PERIOD CASH, END OF PERIOD SUPPLEMENTAL DISCLOSURE Interest paid Taxes paid NONCASH INVESTING AND FINANCING ACTIVITIES Write-off of related party debt to additional paid-in capital Common stock issued to purchase software Accrual of software acquisition costs Accounting Policies [Abstract] 1. DESCRIPTION OF BUSINESS Organization, Consolidation and Presentation of Financial Statements [Abstract] 2. BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS 3. GOING CONCERN 4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Research and Development [Abstract] 5. SOFTWARE Discontinued Operations and Disposal Groups [Abstract] 6. DISCONTINUED OPERATIONS Debt Disclosure [Abstract] 7. LINES OF CREDIT Other Income and Expenses [Abstract] 8. DEBT MITIGATION PROGRAM Commitments and Contingencies Disclosure [Abstract] 9. COMMITMENTS AND CONTINGENCIES Related Party Transactions [Abstract] 10. RELATED PARTY TRANSACTIONS Equity [Abstract] 11. EQUITY Subsequent Events [Abstract] 12. SUBSEQUENT EVENTS Use of Estimates and Assumptions Cash and Cash Equivalents Impairment of Long-Lived Assets Fair Value of Financial Instruments Accounts Receivable and Allowance for Uncollectible Accounts Income Taxes Revenue Recognition Cost of License, and Subscriptions Revenues Deferred Revenue Sales Commissions Research and Development and Software Development Costs Share-Based Compensation Concentration of Credit Risk Subsequent Events Recent Accounting Pronouncements Fair Value of Financial Instruments Software Discontinued Operations Debt Mitigation Program Accumulated Deficit Statement [Table] Statement [Line Items] Software Total Software FDIC Insured Cash Subscription Revenue, Year One Subscription Revenue, Year Two Subscription Revenue, Year Three Subscription Revenue, Year Four Deferred Revenue Sales Commissions Preferred Stock, Shares Outstanding Preferred Stock converted into Common Stock, Shares Common Stock Intangible assets Accumulated amortization of intangible assets Accumulated impairment of assets Intangible assets, Net Amortization Expense Stock issued Purchase of Asset, Shares Stock Issued Purchase of Asset, Value Stock Issued, Acquisition, Shares Shares Issued Shares Issued, Value Amount Due from Acquisition Accounts payable Net liabilities of discontinued operations Revenues Cost of sales Operating expenses Gain from write-off of debt Income (loss) from discontinued operations Sale of Assets, Purchase Price Revolving Line of Credit, Borrowing Capacity Line of Credit Interest Rate Line of Credit, Amount Outstanding Total debt mitigation program Gain on write-off of debt Additional paid-in capital Gain on the Write-Off of Liabilities Additional Paid-In Capital for Related Party Liabilities Rent Expense Payable Write Offs Repayment of Advances from Related Parties Preferred Stock Shares Authorized Preferred Stock Shares Outstanding Preferred Stock, Voting Rights Preferred Stock, Trading Price of the Common Stock Compensation Expense Stock Issued for Cash, Shares Stock Issued for Cash, Value Stock Issued for Software Licensing and Subscription Agreements, Shares Stock Issued for Software Licensing and Subscription Agreements, Value Stock Issued for Assets Acquisition, Shares Stock Issued for Assets Acquisition, Value Stock Issued for Replacement, Shares Stock Issued for Services, Shares Stock Issued for Services, Value Earnings per share, basic, for continuing operations. Earnings per share, basic, for discontinued operations Subscription Revenue, Year One Subscription Revenue, Year Two Subscription Revenue, Year Three Subscription Revenue, Year Four Antree Systems Encryption Software Code MediSouth Dr.s Network of America Software License EMR Certification Cipher Smith Mutual of Omaha Chase Bank Kimberly Ilicerl Assets, Current Assets Liabilities, Current Accounts Payable and Accrued Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Weighted Average Number of Shares Outstanding, Basic and Diluted Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Indefinite-Lived License Agreements Deferred Revenue [Default Label] Sales Commissions and Fees Amount of Impairment to Carrying Amount of Regulatory Assets EX-101.PRE 11 nsct-20140331_pre.xml XBRL PRESENTATION FILE EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0!,"'?^XP$``$,7```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F,U.XS`4A?=(O$/D+6I< M._S-J"D+?I:`!#R`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```/__`P!02P,$%``&``@````A`+55,"/U````3`(```L` M"`)?]=J>*V?5@^@8B)G:13'&HX<85?=WFQ?>*24FV+7 M^ZBRBXL:NI3\(V(T'4\4"_'L)MI<3_3_MCAQ(DN)T$C@\SS?BG-`Z^N!+I]HJ?B]SCSBIX3A363X M8<'%#U1?````__\#`%!+`P04``8`"````"$`+K7Y<_$!```Z%@``&@`(`7AL M+U]R96QS+W=ON_#^$T5`VTTXNP%P%U.?IH[M:?/]T^^KU+^4>QVXVQRKOT ML39=2N-7:V/3^8.+BV'T?;ZS&<+!I;P,6SNZYL5MO>7EU4-; MF_#0DICJ^3CF1_]_\V&SV37^?FA>#[Y/?WF&_3F$E]AYG_*F+FQ]JDTI17NZ M0[+(FHW]AYSLAZZ<:R2'5\IR>(7DR,V<&G961&J8YU90Y MF924TN_184)RY$)9CEP@.5?*:JZ0&&)E-<10CK8Y!-WA2V5W^!*Y(]J1+#"2 M9=9(CNFXSXPK>'A?(SNT1Q=/KC80"`*!\_N$*BYY"5LU*Y]*_$_34DH?1+A! M=EO9TA2W21B0D M)&FK(2B'M8'-$-@\*[!+Y$XS4TH?*0S/4**=?(*C3QN9!)%)VL@DB$S1!H/` MU-'F`L2"=J=@HTC;&H+>L#8R&2*39T5FR3L0@?"`*=J9(S!S1!N?`O&IC2M, MJ]QCS<^AA>3V[(OO^@T``/__`P!02P,$%``&``@````A`./Z@8C0`P``?@L` M``\```!X;"]W;W)K8F]O:RYX;6R4EMMNHT@0AN]7VG=`W.]PLG-2G!$&[&UI M#%X:)\I5JV/:<6LP6-`>)V\_!1Z3`C;>G2N[@?JI^NOKHN^_ONTR[8)[RK,C%1'\7E?[UX<\_[H]%^?VE*+YK M()!7$WVKU/[.,*KU5NQX]:78BQSN;(IRQQ4LRU>CVI>"I]56"+7+#-LTKXP= ME[E^4K@K_X]&L=G(M?"+]6$G6^TA_N-S(3CZ>*-+[?AWP' M>;]ENI;Q2@6I5"*=Z&-8%D?1N5`>]M.#S.#NK6,ZNO'0%KDLM51L^"%3"91W M5@>_[)%M7]5/UE8\2G&L/H+JI?;V)/.T.-:/@K7O[9JBW<-TVS MO?:WD*];=;X(\@;2;QR$]S2_6MZ4=W:$0:=8D"NIWAG)3^[+`EI8NTZ@,DO7 MRCL)?TJ26G7B6&7*,YZO!:/UTQ5;Y?S0V(7B;11O_T?\DI?0I*U0`MN+T!@`4VCS`W]VGVH9AZ$'ND8@1FR!BA:)HN#;VX")BS=.'EF2>R& MU/5J#CIF7*$66$,6+1;\LR+),ZX`LV<-X+-L:/^40AB4P(+'NA`:W^[G$6;0^DT(`8%6:(PIM"Y@R!+^DL&7"(5B&F'4]B;;IS0V2E@'(VD/ MD/R4JX$.YM,>\-G;T,P7BLNL8B$O8=ZA?.R.S@#2RTV"V-9;&],.BYY!EX4@ M]D,(XVX/./V8%8P6&W6$;\"Y.BR"83]]09L7_/J<(9&N,_*'0"KC3DT#@C]O MNB^K-=*Q\4Z`1<^;"SK0-JR#-X(]X'![#HY?,YA+YXP?`X M>%/`XC=T.G4Y>%/`HJ=S>5+B2>%@FF'1$[HX*ADV"#?>&&PO=V]R:W-H M965T&ULE)G;CJ,X$(;O5]IW0-QWP.8<=7K48&9WI%EIM=K# M-4U(@B:$".CIF;??,B;!5>1`^F*Z0WTNZG>Y[(KG^=./:F]\+YJVK`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`;OR#%`&/^""!A_B/")$R$!?B]L4*4 M,->)M$KH]X)$MS/FV%Z$'0@$V+9#5T6J`]SF+KN2LN`191(FQ4866ZP0F->K MQ7:7$'>)]!:!$B=[$FW'O[TU2I@DCLQ[K!"5.,9LG[EDGTMT@G/7]6BUZ0!S M>,AIP:8ZX;B.P\=UC\1%CXB3,!87C(N]7W6Q0I0XQX8?O.@2W>YY$[O0[?YT M?*K;(S0>R6+0L-:5\(&YI0VYT+:$,*#:)HW1#`GO)`XA+A.>#5S M3![EL]=E3Q.)9-G%`X,*CQS2R<`,T^!XQ"YF^$BO^\`YE,?]?(&J.="/N8`$ M%S/%J."?F!UQ%I#J3`CC>S8M3T$0'@8AG8<4,]QQ/:W!PS+EJ3]?INH1X#0] M;XX!V1UBIAB41U*&]Q%Q'TEO(EBD//[GBU3-`LKEN'\-]:@8KS_8GZ#:J$)D M]XE9,&3V&'&?8CN+QK8"ZY*G_WQ=DB9%.#H>="GFNBYDG^I"Y@NZD/VZ+GGV MS]>E.@64+]JN,+V;Z&O/]1+!8V1',WD+@\I0>Y9,M9&0#? MXSS7=SC9R!,,,1YXOD=/-$&@")#()F>&O,^5(0VO8]P->.".D!*K;FS5C695 M--LB*?;[ULCK=WD;ZT`UGY^>;XI?N;SI(\]CMH3[Q^ES`3?+_7/K/``N=H_9 MMO@C:[;EH37VQ09>92\"R'ZCKH;5AZX^]O>K;W4'5[K]GSNXPB_@9M->`+RI MZ^[T0=Y?GO]3X.5_````__\#`%!+`P04``8`"````"$`93M5ZM0#``#8#``` M&0```'AL+W=O.;,V)E,[E^+ MW'G!C!-:3MW0"UP'ERG-2+F=NC]_/-Z-7(<+5&8HIR6>NF^8N_>SCQ\F!\J> M^0YCX0!#R:?N3H@J\7V>[G"!N$0]VO81ZGA5C<=^H*DC'*Z$1[0^3K0;LYC?^P#TVR2 M$_X_VH*O"-.1G>H'TNOM/#9TRV.P'ECB$CF5B2O2TQ3T%1H/&B6#*E M-(<`X-ND>RYH\5N#5$8U M270D@:LAB;QH%(?Q0+)<\>P=/>%Z]`P#KQ_%PY%:_XIG_^@)UW>N"1&IE.%Z MVYJ^UDR58(D$FDT8/3C0UZ`*KY#<)6$";$9['75=C4O%@"I(D@?),G5A0X+. M'#KH9=8;1!/_!:J>'C'S+B:T$0N#D"66M,NV8=4P^)!`G054[3]D(5ED%F;] MN3&GN3(0\+&2@`9J)G&^_8WB$@R-WE`\:B\TUYBQ MJD<\'@9].Y"%?JZWE-+;6NAN<9`/];]U&^I MN#"06GEM&*IL[^(ST3<\K.AAF6;T:@L,Y5%SX00R)9!^=B+]H:WP7$-T3.+$,[B^O12[`=?7>S:,SE4NGGC-L:)O;W4#J<,W MAD;X+9^5@;3C#Z'5;Y=?H>'5&)W>"5W3HFM:=DTKRV1UA-S_S9C^]26LWXYP M2-<'1>*$JC7OFN10*.L+7+7*>LC3$T:!V18O<)YS)Z5[ M.<`-X'"NK?5P^:#4;=GGJ[U MZT@"``!&"``` M&0```'AL+W=O3[!PZ2?7=IKM@2G9`L1:-L(\] M:4`DFW^K6J7IN@'?#\F8LCUW?W-"+P73RJC2AD`7N4!//<^B601,JT4AP`&F MG6A>+H.K9'Z=Q$&T6O0)^BOXUAQ<$U.K[1=W$3C,K"_`)(OCV+\_TH<0ST\P@H>Z,\_K=!UFZH3C,'[!]^0]N@@> MZ$Z>_#A=A\E[OVCWZ?V1W_P]N@@>ZCXUJM-UF#,JC1O`X.MZN]*X:!!!-JRT MP[SI?':L_WJ'(7BH.ZRTP^PJ/89IAUGWO_3SQ0L?&TSGHTR\'DF/'H1R4OP= MR#5=,DWS8?7=.'?33G)=\4^\:0QA:H.C.H&N\4_]-G(UZC<"_P*F>$&ULC)1=;YLP%(;O)^T_6+XOYB.D*0JIFD7=*JW2 M-.WCVC$'L(HQLIVF_?<[Q@E+UW9*+@B&X^>\[SG'+*^?5$<>P5BI^Y(F44P) M]$)7LF]*^O/'[<6"$NMX7_%.]U#29[#T>O7QPW*OS8-M`1Q!0F]+VCHW%(Q9 MT8+B-M(#]/BFUD9QATO3,#L8X-6X274LC>,Y4USV-!`*';#GT_)3,N MCNQQ\0JOI##:ZMI%B&-!Z&O/5^R*(6FUK"0Z\&4G!NJ2WB3%>D;9:CG6YY>$ MO3VY)[;5^\]&5E]E#UAL;)-OP%;K!Q]Z5_E'N)F]VGT[-N";(174?->Y[WK_ M!633.NQVCH:\KZ)ZWH`56%#$1&GN24)W*`"O1$D_&5@0_C3^[V7EVI)F\RB_ MC+,$P\D6K+N5'DF)V%FGU>\0E!Q0`9(>(/A_@"3S:);FEXLS*"PH&@UNN..K MI=%[@D.#.>W`_0@F!9*/SH*.R>M[5M&CA]QX2DEQVM&%Q?8\KK(\6[)'K*DX MQ*Q##%[_QF3S*8:AGDD4"CD5]7:9C[E]L,_MR^[%K,.#%XGRV=N)LI>)O/L, MI^/_"?VFDLY.C*3I8N('#2$&FSN9?48J[$)2>Q_ M4T"H<9CR,`0*3`.?H.LL$7KG)SC!C=/3Z7#=I./YF%[@<`^\@7MN&ME;TD&- M6^/H$@V;<#S"PNEA'+&M=CC6XVV+7S'`-L41!M=:N^/"'\#IN[CZ`P``__\# M`%!+`P04``8`"````"$`U7Z:0/,$``#@$P``&0```'AL+W=O&.`F: M@"-@)C/_OM=<0K#)`/.2#W-\['/NM7WQ^MM[=M;>6%&F/-_H9+[0-98G?)_F MQXW^\]]HMM2ULHKS?7SF.=OH'ZS4OVU__VU]Y<5+>6*LTH`A+S?ZJ:HN*\,H MDQ/+XG+.+RR')P=>9'$%?XNC45X*%N_K3MG9,!<+Q\CB-->1855,X>"'0YJP M@">O&X9G`--VO4]!@;!=*]AA MHS^1540Q:=GYKY8E?_RC2_8\T9^`VQ$E$X)GS%P']OA=-T-GH M]8[J"/Q=:'MVB%_/U3_\^B=+CZ<*PDU!D1"VVG\$K$S`4:"9FU0P)?P,$X!/ M+4M%:H`C\7O]?4WWU6FC6\Z\[B;FDA#KC4S%05NU2$%?Q=EWPJP:I!Q,O+[%(9+("9F&/ M!2:CF-:PS_P"HP3)DV#9Z+!FH'L)07[;6I2LC3<(3-)@_#[&,67([@8181"\ MP:WASJNPAC?$K4N$#;7_!FALA4(,ND(?Q_^F1X"%GANKCPW`W0I4Y]Y'.)8L M+^A#%)*PCU!)HC[$]-IQ),765Q0+,(2^*]!R6MXZ&CYBO#J^CN=1>A^X!NP0 M`%G>NF3+%,$813A*$74I+(=XWGT,2;XMR[]E]G#@12?5!E?6X"/&K6VPS:6K MA'F'SX=<&&$(1QFB+H-%+7H/E>0!3&)ZT@NPHMU>*-H1@]K)@A*RE`$[">#: M)KE'!Y=T%V":IN-2F2'L`BS3HJZRY",$P.>#+)/4PWXV7;T`J^J5D7W$H'J' M$*I,?3?R/.@^)Z9I$<7>4`80XBB`"`$3M+M?T2[`JG9E:_(1TT2>P,*S%<2N MBS!=SZ9JZ+L`8BV7IIH]81=A6TO+5!R.$#!!OZC?.N?:\*H78%6_,K*/F,()3-(T0(VCRC2V^IF!@]X&@7D)3]WE<<$ `8LJ\?41,^3`*"(8 M182CB&@((3E`H)"9G@0U6O;`[!V!#0CC`YN_I1P.NP8PX%(PQA&.:=B`AH2!$FQ4;:SW01,,`$33L!$CS"/MT8BRJ?I9F"Q M)9NA;HXUY4;'5)C1!774RJA!8"[,/$MY'L@,<#Y21UERX0A%U#X?3P>(VA<< M$&AE/[#5`U*\50-H.!W&,<$$GK#!-`OOP2GYB.237!`E52<7)NZ06(C).:&L M?A_N-80C^,)D$4^)^$YZ/NLG1+?[S*6DEPY=`-0*MC(!<;'2"XGB`EZ&PO=V]R:W-H965TG)PWA"2S_/DK M/4L?I"B3/%O)ZF0J2R2+\WV2'5?R/W\[/Q:R5%91MH_.>496\B2P95#7J11!3^+HU)>"A+MZYO2 MLZ)-IW,EC9),9@IF\1V-_'!(8F+G\7M*LHJ)%.0<59!_>4HN9:.6QM^12Z/B M[?WR(\[3"TB\)N>D^JQ%92F-3?^8Y47T>H9^_U)G4=QHUS\Z\FD2%WF9'ZH) MR"DLT6Z?GY5G!936RWT"/:!EEPIR6,DOJAFJJJRLEW6!_DW(M6S]+96G_.H6 MR3Y,,@+5!I^H`Z]Y_D91?T]#<+/2N=NI'?BSD/;D$+V?J[_RJT>2XZD"NPWH M$>V8N?^T21E#14%FHAE4*<[/D`!\2FE"AP94)/I5?U^3?75:R?I\8CQ-=15P MZ964E9-025F*W\LJ3_]C4-VCNXAV$X'OFXBJC1;1;R+P_1#1%H9JS$>D,KNI MP/=#96Q_H.=U4>#[(3(ZE?E-Y:FM,C85>$[K5)[O(IHVF6G&TV*,02J,*V;S MPR+=F"P,8S9?/`F-5MB@J<>@'571>EGD5PD>;!@6Y26BTX1JJB#=C#XV5N[C M\:OA"..0JKQ0F94,78615L(S]+'6=6.I?,"XCV^,U67F&H]L&H2."SU<$YWU"`;PI;`07J?2\ZU)DK M>O^CWM26TK2V32Y6$WCD@NO8)73]B<_6[C)SG4>V7437%SSC=!F4C-LE<$,> M0_CJHGS]/@8EL^MA9E,^X:"/02F'PPSG)4QV([RD-./`#@<"'`B;P..IUF^J:S7AC+<8\ MUS/W7%4--'=OV'7XO$]_2,'F%*;3*5+8"A4<(>$*"4](^$)B)R0"(1$.$9R5 ML,08826EL96HT!9C((&OK-HPXJDV&Q;[\(\?#;908MN64'LDG#;0UX;;!F8] M"EX;Z%/PVX!!%="0W#%@H!*!D`B'",Y(6"..,)+2V$BTG+`8,Y#^AA',R#D4 M`-DH%-BV!;0%%G#:E[OZ;ONRJG?:]]K7N[?[[$+B1TCOGZ'!&V` MS@UX<@F'VN#,I%O?$6[6.+83+62M&S3DIQBQQGX)]Z^7 M]S`[7'4U$W93<+*!XG#H^M(7MU03CH"ZO*.:<,[3C7NJ"6&ULE)==;YLP&(7O)^T_(.X;,(201$FJDJK;I$V: MIGU<.V""5<`(NTW[[_<:TP0;2D,ODE`>'X[/ZR\VMR]%;CV3FE-6;FTT[SY\V)U8_\HP088%"R;=V)D2U M=AP>9Z3`?,8J4L*=E-4%%G!9'QU>U00G3:,B=SS773@%IJ6M%-;U-1HL36E, M[EG\5)!2*)&:Y%B`?Y[1BK^I%?$U<@6N'Y^JFY@5%4@<:$[%:R-J6T6\_G8L M68T/.?3[!4=IN$0@]D[%9-TJU] MA]9[%-K.;M,$])>2$^_\MGC&3E]JFGRG)8&TH4ZR`@?&'B7Z+9'_@L9.K_5# M4X&?M960%#_EXA<[?27TF`DH=P`]DAU;)Z_WA,>0*,C,O$`JQ2P'`_!I%50. M#4@$OS3?)YJ(;&O[BUD0NCX"W#H0+AZHE+2M^(D+5OQ3$&JEE(C7BL!W*X*\ MR2)^*P+?%Q%O&:!@\;$51W6K2>D>"[S;U.QDP=`#X[S"'P(>3@> MR$6VN9.-FJ9`(U1EQP-_9).36-3EN3L+0 M"=OJF$-GW:8#D6)6C74H9#AW%SJQ-PC4)31O\*"NM^L"E(UTCQ[R=0>18L+& MXTTP#\)5H!-[C9A[_GQY(32/<]WC>'X2-KV%^I,CQ;3>D`M_.K`?`31G,(>Z MZ8T[D[#NS/>-014I1CD+7;1`1NGW76")PI5W`31GBRG.)&PZ,^NI&'C\>5S. MC=#&",U;.,6;A$UOESZK^:`8E=JB7TUU6[-^Z9WF3&Z;G>5DO)X2UIUYKCG2 M%*,]VDAMC-"\K:9XD[#NS??-U!2C4D/!LC<)WK^O^4*PWEX?6D.;SHR1%+70 M6&RCB.[/V"/&BXK4L@YKTWF<]Y-K(16=%_22>_^^[FS2QH#Z.X/G]9)3T&AR M8XCN3Z[05T\'I-;S#Y)34#OH!E;>5F4(T+U-VA30T*Y@+/I1"XUFIW2&$=T? M,!.RD[0Y*\SY*L]]`+71P$$<];;]443W-VF#0/T=PC.WIJB%AL-I%NK]**+[ MF[1)P!'\BOP4I(Y-GM_?)UJ5(4!Y4\=T=0"M\)'\P/61EMS*20JKA3L+H>^U M.J2K"\&JYJ!Y8`(.U\W/#%ZF")Q"W1G`*6/B[4*^!IQ?SW;_`0``__\#`%!+ M`P04``8`"````"$`B262FP,$``#!#P``&0```'AL+W=O8V!BT^(T%VTPCU_.>XY-CM>/KV5AO6#*7@0*3=HOBXL9^\5>+YMK-= M-PGZG>,KN_ENL3.Y?J%Y]CVO,&0;ZB0J<"#D6:#?,C$$DYW![*2IP+_4RO`1 M70K^@UR_XOQTYE#N&3@2QE;96X19"AD%F8D_$THI*2``^&N5N5@:D!'TVOR_ MYAD_;^P@G,SF;N`!;ATPXTDN)&TKO3!.RO\DY+524L1O16!&*^+YGQ8)6Q'X M_T?$7\R\66@.Q9&VFBQ%B*/MFI*K!4L/`FOVYYI]R8S9-Q*1)*1]?SJP;Q1(Q@C%_O(S]@6LVO<6^KM/,K-F MWVJK=M_=^W!C1!TA>@-M=MS=^W!V,D8HKCWH7>ZO>D/KOO5-WT+RI:^%OE=N MPLM,KVBD`%/7#S6%6`&"^4`A:8'WUYUJ7O0^=R]Y3W9*Z@_>0EOS+207+*Q7 M\5&1?8N\'U_;QLE'C:C$9I5D-!8U$:))NDE$U]6.OP/@&*+O@N"FMY(]4`N- MN-V;D:A%9$)"F58]L;%91YR<1,CO1R-3(D]&LNMH$&'CE@;C[P5=.$P[O0WX`!5HQ/^!]%37C&KP$=XE#N9 M0YQ4'L'D!2=U78@'](?O[?\```#__P,` M4$L#!!0`!@`(````(0`BK*I\3@,``,D)```9````>&PO=V]R:W-H965T;UPRCK'$J"]MSG,`N$:E,Q1"Q:SAHGI,4)S0]E;@2BH3A M`@G0SX^DYIJM3*^A*Q%[.-4W*2UKH-B3@HCGAM0TRC3Z=*@H0_L"XGYRYRC5 MW,W#A+XD*:.>=&N]"T-ZLF/S\) M/O/>?X,?Z?D#(]EG4F%(-I1)%F!/Z8.$?LJD"9SMB?=]4X"OS,APCDZ%^$;/ M'S$Y'`54VX>`9%Q1]IQ@GD)"@<;R?,F4T@($P*]1$MD9D!#TU*QGDHGCVIP% MEA\Z,Q?@QAYS<4\DI6FD)RYH^4N!W)9*D7@M":R:Q+.\A>_Z@62YX#EK/6%M M/5W'FGM^N&CVO^`Y;SUA_K(%#4#C)"Q!K1J=>&-UUV&C$6#TJN M%R_!<$I[RF9!,%*O,`/UHT3&&M+)5X9ETX#^8KD8Q;OK.0PR#[OTQ&)))I9=WS)0$P[5_./](UF&M9BD<:LP;K_K7'FEA@%#8YFX*+B1TI,<6P'T8V?M)NI=D].1?0N3 MMIE+8[L7Q:_A$R^"ZP1TC/!W000IG]JW83O)[TT[;_?-0XTA"[-2X*OSST^YUYS6=Z]B!(],Z6YK&(245V)?A^"6X);;F;Q8!> M<*JDEID9`9WGA`X]+[R%!TRK9(/NA:<`/A5*6D7UI?LK#5\;SPD"W M)V#(^HK2UX1I"@4%FM&XD4%E"0+@%PEN;P84A+PT_P>>FB+&X70TF?EA`'"T M8]H\<$N)$=UK(\5?!PJLJ(YD?"2!C"-),+Z6Q'."&G\),62U5/*`X,[`D;HF M]@8&$1"WQIR,SNK_G((Z2W)O66(,EQU,:.C.\RJ,Y24'C'K(68Z[D,V M+<2ZMKQ)&WCC#?HIVQ9ANP>6.E]0K%-?[S>JE6_!5GY[[MH%@+OSWS8*A#B?:P^FBKW[M,(OF3OK]O3"WO;]O9X/*.CU/BSX MS,?L3.O:82[UZ4-$XA"N%I/%S#_K-`Q0J^.X/U_,W_:=-S<>W?@03.5LP\I2 M(RKW=O2%4.,NVDWE^[%]J\[BZR""=WT83V"*-W&O2X`I6I.&ULE)5=;YLP%(;O)^T_6+YO")"/!85434BW2ITT3?NX=HP! MJQ@CVVG:?[]C'%B`KNUNDMAY_7#>?,-*&5"DI9<5B_,PTOMY\_+`^2?6@"\8,`D*E8UP84T>>IVG!!-$3 M6;,*_LFD$L3`4N6>KA4C:7-(E%XPG2X\07B%'2%2[V'(+..4)9(>!:N,@RA6 M$@/QZX+7NJ4)^AZ<(.KA6%]1*6I`''C)S7,#Q4C0Z"ZOI"*'$GP_^3-"6W:S M&.$%ITIJF9D)X#P7Z-CSREMY0-JL4PX.;-J18EF,;_QH/\/>9MWDYQ=G)WWQ M&^E"GCXKGM[SBD&RH4RV``>FB+&X6(R7TY# M'^3HP+2YY1:)$3UJ(\5O)_+/*`<)SA`X<8;XP7LAG@NH\9<00S9K)4\(>@8> MJ6MB.]"/`-P:MPE8/+'6^(%F7OEXN5!N^%=OPV^=NW0:P.S_#4,>* M1=AWDXPE`\A^K+B`].R$_V/'BF,\NXQ^.>\'MW4:J'CG<-97[-Y4)&\J]J\I M>OX@V,MRV38,X9:^7C9["'07'L+E(,5;I^GY'-1IYR2KIFVO@OE\->BQY&T& MS!X;RHL,Y].-%G?U!%,YV[&RU(C*HQT;(3R\V^TFVDU@.W*PO_4CN"?C_00F M8+/O=0=@`M4D9U^)RGFE4-1TLH1L*#?#W,+(NAD$!VE@]C0_"WC5,+B! MTPF(,RE-N[#WK'MY;?X```#__P,`4$L#!!0`!@`(````(0!Q<]4W4P0``%P0 M```8````>&PO=V]R:W-H965T&ULE)C;;JLX%(;O1YIW0-PW M8&-.49*M':K.;&FV-!K-X9J`DZ`&'`%MVK>?998+V*0IN6E"^;WXO(XXJV]O MYE)5'QMO_/&_K;Y]9?5 M1=3/S9'SU@(+5;.VCVU[7CI.DQUYF38+<>85W-F+NDQ;N*P/3G.N>9IWB\J3 M0UTW<,JTJ&RTL*SGV!#[?9'Q1Y&]E+QJT4C-3VD+_,VQ.#Y.L.\WPM+LPW9W,3%?%EDM&K%O%V#. M0=#IGF,G=L#29I47L`/I=JOF^[7]G2P32FQGL^H<]&_!+\WHN]46WNLC_ M*"H.WH8XR0CLA'B6TA^Y_!'8POA]F%' M($`/#7*@N9&N"1]*W[O!1Y>US;7K#P0]MN`7]([7N&1BOG%=R?*,]F!2WFYE<9/ANJ"M$1`GZ M+HACWQ\:52=(Q@(O('$\I(4&2(!F[+QYA-TJ`W&H,D14&F1D-`K-\&H"S_=& MO45'O&\28!?7>IKAG"U!#:)%H_B8C)F#0&D4 M&8W9U&MH1;G5#5=A0<*H>4*,]O)\`*NUN270\8TK(LF6P^G9C M(=-QP1Z>`8);CRY'@P4!9$-#:R(5%F M'IDOHPFNH:%D1?2(5MU0&.&?!'B MZ?!@D\X\'@X/%!X>$7\29ET4^(S28$@6#9$:0^0V8J"L9=A%#5-9X.\:(5Y^ZDLQ,MG.JZKT&PO M=V]R:W-H965T&ULE)9=;YLP%(;O)^T_(-^7KP#Y4$A5J+I5 MVJ1IVL>U`R98!8QLIVG__8[M-(U)PY)OSSGV,%9WKZTC?-,N*"L2U'@ M^L@A7<%*VFU2]/O7P\T,.4+BKL0-ZTB*7HE`MZO/GY8[QI]$38AT(*$3*:JE M[!>>)XJ:M%BXK"<=7*D8;[&$4[[Q1,\)+O6@MO%"WT^\%M,.F80%OR2#514M MR#TKMBWII`GAI,$2_$5->_&6UA:7Q+68/VW[FX*U/42L:4/EJPY%3ELL'C<= MXWC=0-TO082+MVQ]%/I8JJ]@L'D]$`1V%&#>,55+!&A"`=Z>E:FE` M1_"+/NYH*>L431(WGOJ3`'!G381\H"H2.<562-;^-5"PCS(AX3X$CON0(+PZ M9+(/@>-[2#B+@SCYOXIGRM)=NL<2KY:<[1Q8>B`N>JP6>V#?.#`(_"-5TH/S+M10\T!KT(S/(5%M%OG[9XOD88:E!VR]74_!`+;9OG!ED3&V, ML-22:]04/%!+!FH&&5,;(RRUZ35J"AZH30=J!CF_SLY?M[34+GGQTT/!`ZW9 M0,L@IF-);!::;S/Y.&/IS:_14_!`[_VYI!\+F4&,7A@ELW`>!H-)SRTFB)(P M.F8L/6C_%>W3M"V8#'J3[9EQ0QLZHV@V5+-5]'A#OF.^H9UP&E+!4]-WI_"K MXF8[-2>2]7IK6#,)VZ#^6,/?'@+[AN\"7#$FWT[4AGWX([7Z!P``__\#`%!+ M`P04``8`"````"$`TL?2<\,[``!=M@``%````'AL+W-H87)E9%-T&UL[)W9;AS)N>?O!YAW2`CR2`V0;"ZB%O=R4.*BYK%$TJQ2]_$(_/9?/E^/LH_%;#Z'<^_>W2U6$Q___77\_Y5<9W/-R;38LR3 MB\GL.E_PY^SRZ_ET5N2#^551+*Y'7V]O;C[_^CH?CA]E_M9\6*[4>=!*3YKO!^#. MBLOA?#'+`?DXORZ:HYX<=WI')\>=MUEW[^C@N'=T>+27[9VU!\SOY0W#3'/=GW=QM/BHWU;N9MF'9VES_XZUOG!:S MX40X'V3[^:+U<@>J#(PRAZ/\LCG+DXM\-&^]L[>?!IGW2*?PZ6#[&@^7Q:S?VF^]N1X MTOPIG>G'R6@Y7N2S&V`;K7B]'/MDGIT5T\EL@91DW46^6,ZSL*WVFG\JYLU% M`^RV2K8'7B\GLS9!N]?Y"#"2I?8FU]-\W!H9IN/I]00D+";]#VM9]RJ?%?/L M9+DP\072)A0E6P1*!%H?(FPMB)_\)6FO\U$^[A?`B5*89T_? MC_/E8+@H!E_Q[^Y^]OBKYH+=8HK@;IK@[C0?[KT_.T.2LDZW>]#K_K[U.)]? M-7_K]$W[S+-9T2^&'_/S49M2ORU;%PLF@][ M)SW$W*%J/HLPOSWJO#YZ>]0[.F@#7@(YS6\,0M.!>;\_6\+GQ6=T[;P-]MMA M?CX<#1=#."!?+&;#\R68S1:3;(#4H1R'8[V.II[E"S1H:T]OAV->G5QD_5D! M59J0U]$RJE9K#;3M)QML#M@[>??NJ/<.TG6SSO$^6A!U>/SFX!C%V&T.?O++ MS[_\W/RQVSO9^\,/)V_W#\ZZ3[*#/[X_ZOVI1?_367%1H'<&&#,3C\>;&YM; MV13=\S$?+:'=LS44J/X_F[ODY,O%U60V_&LQ^"9Y.)1F&1@1)K>+5A#%V]9Z MOFLKW;;:]K/G:R^W7ZUM;SVWA;:WGJT]WWYF?S]L_'>:#P?KPW'6 MSZ=#>+F)/?AK>;T%F22X]W`X1LD,0.#,JV4[+,0]\P0]5R45J0-)1Y M6Y?7=?^M@->'W0OURN&K05XY]`[C(ZMI9#(MRRV*,=AZYOA]<#\?F42Z&'UOL>%;,<:+Z5S9T M4'PL1I.I)*"YNFOMH/3Q7&ZS'F]PS3,\"61-]F(ZF0,&TK3:_%5[>LO&FVN> M]'XX.,N.CM'S!]G3L.N6J!^-%P7>RB*"U)PE0`Y`LVSH)`S`-T<*ANSP[.1= ML"3OA>P`XLEQ"[P(F%[[RM_;/^JZ$7I_L'_'F\<'O6S5AE_G\V'?*3$HV M(=QS\RO7\7;[N_\P,VUX:2[PT\'1FQ]Z`-_Y$6Y[SD?:_;P^*"G^8$I728;.[A.F6'H\FGASEII63!,,FKMZO=XV*1O9W, MYTTH@JA>S";7#_9:F":S%X*/2.X,_+^<+27.'R2>U?%<*>+NT&9>'BM+94>:N5&-S=2 M#@E.K._\'A]6?&'8?;J[^C'U1[WZ6S2+XI!8"3I0*'L=OU7PIE"-QQ_1)V)_2IF MN`^ZPZ/C#FXO^NH.Z(@[\YOHWN2#CXJA`JB3"]RW8M9*2&LEBB[<-[L31:CGLX-.%\NQ?^#_^@I;DHFNS6WJM[7L]<&;H^-C MT_F'&<;VZ&1_]<`#8@V,^.HAW?>GIV\/%)00N\D>H.C?GQTT9RJMEGSLYL-> M_AG"K'IR?')LC)EP(\"LHGYSSI]F!,CKT%G<."O<:R>&P1,?%.<+Z:3\P9[_ MOV^U/.!5-&7.Z1+G(I\C"$&)-.%"OF=+]Q'B$/B>$"'XW/W)O!TV=T;X-M=* M]J%]K_)%]@D7()M\0KQ-&5>[4Q2+9IJ2BIIE-[@Z9-I'_]OGMT?-#V6(*RDNR>3D8$1*Q^A_4ZZ1UD6^L/ MG7QO-%D.LG?$U,0P&1F8!5N*"81L;S(CJ^3&X:DTS]__]C^AR92WM[+=MZM;N#\LY(SLU89HRW/%M&U"`W`4?I`_0-"FT M-F,'`HVR'*)<_S#D"$BP6LKK+_; M!TV+V62P[#/.H!(1]/N):_CH_ M]$$AUG"\6,LNEJ/1C>8N+J$9!XI5X,'9>S#ZB ML>=K2.]\>*G$)89-CNT,)`O:JR(?+:[Z!+Y,GH]N$"-;!5/#FM<0&-T/!R7C M@A6:,:M)%7]KYW-ML8.E)"D@R)+T.;L5B:^*T=32R_@6`VBEQ\PJT#GOUB1"A"KO3=9%",\`T[>R=?K64_5!!W`;>X=H!?#RVJ@4R^ M90]!9@DDQ"09@TCI:`'S&$6(V1-!GHM>Q@5/1A MO#&R$B7^S%06,)\1II&#JXV/JU=9BRX9:0-RK9Q!3'9*ANHZ[Q<\DQKI+J=3 M.#%=>F^4#T%]]9/M\O2'H^S@L\MW2T,^0*:0ZE*F1OER3,%G4/W2HO&GJR%! M*4B3TS;/KDO4B,Y1(OH.J;G01)I&YFG)><`ZDV.J70?'1TB'72?+63D'N4[% MS"6A-K*>W+;H\N(_,@.B:WG/R5(SS)=P'.EG6QX9&A'@K"^GV=R85O*@)-$' M6QC^"_$U)FM6_!FJLF_$#C$9\J_Z5KYA*:G267&%DXZ,0.M8*[B&?Q`^$TP4 MN5@'O*A8!?V"0P1!R=C'Y,A<[!BVVQ^).>=L3&KL!N]XC`XILJO))_TPG(%K M%U2BA0PMH@J9^:!@+R?1B5K!50#Y@V*1$^@,V(U`FV>7!"P@4$B-JTA3CLF, MS^>JB`RKE6<2_`<`=MK/87$`U9MAK:F+*J[`<'$5MA_YP!5Q)#$U1=B* M)'>+Y;=[A'!,)X@0;$'!WW!VW.15'$1E25`(_8F`5Y2^Q\?81H'_QY]@4!Q(LR]JO MY$"(*IK,!B8OANU`(W$,-I^8>4I,&1-6<#+/98YE#8TAWH]5V/&LF^44@FNR MD?WRLX#1?.:9:$:SH,-KJL&A(+0:K*L7Z%7AP9B>='$T)['F(S&6JJ1I7=PCN^TC\2Y&=JK`R[6*"[OJ_;6#* M3.`F4W)[DS%NB#SB)"?Q%(TEN3+)O,C&*JA+`:D7916ZJ(>'!"GE!"PU:LG%2Y@'<_+JCH1W/AY]=9\V#[T5%'3T?2^H9[`2L MBQ*,(=@?C@>8*B4OA0C-$FF.MCNE5P:U!T\+3;EH?W;$-6'<8# MZQI<,4R;D(E&]5ACLASA@"VI!>#+42``QL$2SPX@I9\M\=DG![24;,ARY'@E M)4/?R9E-X,7Y3>]T)ZM(,+D>XGQ095I\9/D_*.JX,+M2`M@5MX9").!$[T,6\IJ4%GS?XKR=C>S-B4)XTK![ M!V?'W];;.]1U\OOY%/?GNT=3J(-'63SZ_EAQV$ZV7G\U:[S[?0]TU+1-)>L) MBU2T80&IQT@`\`:Q;MSFK%8D*S1.0-EM6G`MV$9Q64%T(0[4OZG1EA9#9`PH M%Y+S['(BF6`8&9_Q1O8#<3/>>#WJ(F:'>Z*V4$(3%DASE:@,TU+X$6RF60>D M7*DK2#Y>S@,37X2&K,LH2L(@NVR`U) M2"U1BI!Z1QT56! MQ=D1UBM1P:Z=B"\68%)1B.-/Y`"VOFI)IL\07&2SF&G#BQOW/U.@(Z0JV:/1 MB4EPD^;X83'86DZQ"I6';'*5[#14=8+'9&%,A=*U$A$#^Y>5^Y&L0.R$=VS: MXC,\$52Q90Q-@[H@`!5^0#6UD5@3)+!,SHVL"L/),B`_SEFIK.;,G2:W+ MQE_GLP^4AX$D&)F4!,$7]05CE-GB1HQ*]_V[=YVS/\DI[!Z].59S5D>=)7M[ M)^^M.2$[/7E+Q;I=&C0E],P0'2`T^'7_WRLX3& M;3G6(^8YP08OJ=])J$BJ*FN\%-]2BXY['L*>:PZL"M.O?#7SWC>3.05A$"1P M/Q&(^S(KL2CB39?GHR%MF0.<3P`"A@A$`W1-J7+7S-,6#G^L'_-K?P*GT"J# M$V6NJ7:O--:$:`^2*OHI!AM96G&[SLF;F)_`\ZGPQA;TWM+9IL(U<3QNON>[ M-6A(<#WY:$993.#,(BW.2A^'Q/=R]S\2X$I/;F3O2\6L:+*YXGR)[UJM)32D M=!66AF.Y31`@&'*6P2FXDT>):2UF0A>-R#YAW)0?9Z.8$/F3\CX'0Z612H/" MKDLPV@;D6DDK)0FC/)9C$\0(>VIG*D&3,@=7!&D$_$3QBZ)_-9Z,)I>>T]3C MUGB,FMH(K>K84H]6T16.[!\'2`KO@YJ5LARTKUC80A.XA@CG"FL*@4;T^@[E M5ZE0YC58(PV^"%U7EQ2'1LC<0LZCI2P65S-2'98K@<%G&1&G&1H\9/,X)+4! M%A+&O_S<:3HO6$G5:@5\\X72_-L#-D\&'#:((P/9S_/Q!_M1:#[+1P>$>H.9[&&]W8ROEQ_2V!DJG%%>Z$-4*[5 M&--T!SQ9.-WX4481B8A3?B+K)%>0$:*+4.4)/V6]JNQJ?SC#X5/T(X,=PK.0 MF=+^R#G/;F1)775%E1)4D.(U"1S(]RRX-`"+NF.BV`UMJ&F0909`;*@CJ%EB6\$WCCPKH7@GH1J%8U$@;+<-1`(B2_2%=EP8@9-*3V8\,$R"?X M4EIIH+YCZ210'462Q15QV_PNR58,L^[#F),L)=$R7``JU56H^)6/\?L5C]8) MVV*C0ZWQ8]S#8=GI=C160L(D:I6!#4+Y1)%:;(Z#C^,K+JP@&YV!.Z78748( MR9$6,^2B4KP7U82!'VNMJ&Y)5([TK3<8R;C`=.[JY8T+/IN_((2SQ6`=E#I8 MA6`L#FSKEH.@>;98)Y%_'55'S!^FT[J7"&49*+:26YHP9X(,4R1-)!K>G7?@ M@PMU2T,UL>18SKUAKA\DZ5,5Q*O%F''FYY<-!;PDFRXA50'3]D%>>BZ[D)?^ M@=(GFEUL.X,@.-)T?W@FX+Q8?%(2+&P*B2#A-)SBL:%M70:O*9<@"J9PY!+8 MKGXB:QKT6OH<6E>\ZRP?S+$OL.X"6,N+R<10F27(EP,@-4!>R)KS9=:M5)B. M-]4*;5'GZR.4E"P"FH,XTUF^6I_$>@DYDAC2S:4*D#R.92%,B(?C*?VXGI$. M&Q.12E.H&#?B.CI>6,%(^'2MS+#4I'N/Y?XAJ-4CJ]S1'9[RW__VOYO+O374 M;%DP$?86N+S:UG5!B_(@V'/0\)#7,GJE^",PQZJ[#+5#G%`='%'<#H.*9.R%U MK1/7-%]<;'&N[)`9)4U:*?!DX^@W?C>3-:XC<"TK$!(>#0@'^@MI0N6(XU]K M_%MY,1G)L#!\%S#'6HH'@&&,F8P.$+2!AN>8$4/S-YHP3E>?_+?/O9HV.[^* MGY;C!(.B0>J`!FY<+:XM:R7I\3A1^%H838B>0!=:`S5:&LQ4$+'W.(HF"&#S M73T7)7A6Y%5%Z,`U07T@>:1MJ@7,>X"B(8N./AFV8]<@?JNQV#H+XZ-WFJ,[ M3:";`V+G1_/WQ\T?_OZW_[[J[(/U?Y;](\V76+Z-H-:@:-3/RE,P9M<[JHA: MR4<8)88BR$<*AFH>Z(1WFG-U:_ET.?O!,PM.AV>UXH*0(!R[P:WSPT#H^-C6 M)/::*42LALWQ*.RGTA&IGIFL\:>[=A!6@I3O6BX&<)HTW"5Z>,O`\4B'*E-4#U:P0*O>EY7X\]M9QE@!T],:L' MF001KLR"E"9I6+!O"8^0#,&F>->A+RFM*A-#0!]!M]C-,Q&)8Z?#,O@AJ,&+ MX4RN5N7DHDRB=Q!A]9&1B(X"_!92JK=@*?*-O\B6QMGE;+*<0G%PK%(.!^OD M`J)&M.'QTCJ$V.T@OW%J)IPWS8$0;])MB<9'P!R)\D`PGOUP6@9SGBO'T<>H MJKDJL/K"3XSYVE2U+&`QK\_FI\1#GIL,<[@"_7K)IH!$0);DI$[!! M'$S@*#E+(Q(I,$X9>V0F1.*,6=[%W)P5"I23>3O-H@$%Q$F2%JC6%U]IO50" M2NFH@&CI_B/OV+>.R*;*Z%7S922E1V8-;-OFK*6&_P;3(']'M`W+&CL#%998 MJ?B%>BZ5\,%/!E+PY&^HP0J76@$80Z)Y2.>NHK`RDZ7=AD0X0B,I,OVA"8(X M6VBSSCA._PW\:411B#YM,-D/DA-*^3,F',8SK8"0>0[(GT577KNO9*@L2S5# MZ:6]6;>3?WA$"1O;^JM!YU=Z68TN&N6:PQIK1\$.A M0)']F0-:YF,\;F7S%H('/\F4AN&6!CIBN)8`]U(AA6\,NL6GR3J5K*DG;I2O M@>(1=<:2\)[SC?Y:QBRLX=HR9:H!..W<.MALH(-Y8GK+5X(X\04S>6$5*X6C MVNEF(N1W*S'T[H)/A=7L1.6/(1',G/1'``5$LF8$]G$[RJ04@Q=1+AWQ-,=, MHI_A?[F21`#T^CGAM5%X)73MR21$=P:9H#,RA%R+X:7'I:AQM`(890)`'8?* MX1P&E+ES"LZ.ES- M*7!5(N3BVAP"C-=%@.4,W-@!A6".(C]HF%.)0X;4"!1;1`N*HLM5;X=9M?*J M36YD3<0S7]5_$;2$DE+&HKF%K_P%>0@M^I9V\^`?%3Y?@@3E&*.6D.Y`O&D)S;3"9Z2`I&.(O!%_HFX*-RY]EF#*.8+#J&&]E/\A;C5E5S\FX, M#GLOU*^7`:\QF9`S0QUD/Q;CP62VWHUN^'%BAU'P/ M#PC8L7%SV'(Y-_*L9(>EC1/*-H?)`FM4VF,H)+/:&9WQ`]7.WIGOM\'*3>D3 M0$)+$N*+B2Q>P@1+XPN'L844)*&=\$NL\*G0`,98H/<&R.^X^,1:\@1,(Y<- M8A_U=VR#"G8_DC1E$=9U-R)Z\HQE\O%@W>[/\=-W`O86Z#90,ZY#+$K3^OW9 MT,KE*+"F?HCJ,D!6,N5:1@7M"D6!V"['(GG-E1JF0]1@8IYDQ`%B!.?I:&@5L\I;7"G]%GT%>?3")Y-Z`]5LYKM[`J^(FP\(ET1J*"^M&R&L=`2.@`$DIGFRTLZP3-71!`TD78@E'5_T MK$BR5>M`EJ>F].(Q/[$R@R]P$Q@$<\;@&R('5F'!TBU180SR#^HS*<&$,<_WAKC5NKUO2_N^%_7^I_-=OC[;5G^C=( M50R$PASAQ]VV[\0JW2E?I2UM890<6%G^N1VAABIKS)%IC^0Q@!,0@F'$')93 M3N@$G+43HK_\GZ;>38ZWG!7J8355VQE\5`L3'[>'DGL^&^O4BIZQPXS]OZP>[L\R:)KY[A,Z9S/3CU[:,76_6 M;C2=AY[2AP%$_7]S\]D7`NC[QUN_!AFVMNWR"R#C^\"&_XQM>B9 MJR"K]A/61LFL6HE9[TMOK#D>JGOV3@EB"1*S/;Q<8M''VQOT!','SD0M67UR M2^?\BNU2B"LE))%.9=]*WB$U._6YFDOT4/@A>*0IIXSIO):N6"6=+RA#2[!+ M_7G+D%3T/4<66BK6C@BB]M^ZR^5Z/M7HN@#.')E6XU-\-7HJB88F&E2]"P4D MJT_K"@:(101J&!W*Z^Z5*"=I<5>,U&(S`R@-AQ=-G=/TXC=\R8FPH];F:N-! MZ6"#"&"'%L,29%R.U3FM\-1.7.,\4@F3'4:/W@9'TM;G6`V-6(0,O'E+8OE6 MM,YO\0GN0)`#3,)JHMLS6-,*#D)==`!+!U_!W&0\IK'`4CCL7^%+ZG%3V1V3 M&NM[3X0Q2#A?5MI)$!\GOAMC<52Y_)=!E1B?;$YY-X@8I>PB*IN'/%8/%,:! MU9E[D3+&^;'-60QW3KN/_$SW_9RW=2#)98(G,MM>3M4Y!?;2D109!TTT$592RM] M8)'AVL!*UTM4U0>C:C()YUP46;N1+56UZ\L+L?;>9GFVO;SS=+[KS'53%HO&I;BS>;>O.LB&?6@7X?+13NA+/WNS%_ MG#[8DTO0G&:OKJ-`9-\/.96Y)ABYFMRMM'2(53P7D:-*JELU3.2(C>B6N49^ M2?Z:_'`BVRKFHMK2,A_FO*2+!-&"76^;1&F+>*FIQS1HR3#Q39V#X+&`;IM M!_ATK-/-=\A92<9,$U7VA3Q%U?'O+0,S]9OI2`&)51L8$XW2TJ:/''83U(0% M4@2&Z25*)^2TO3HEB"2#I7.%@70/ M'B$NPGT4)@`YYL/B#T;S;_7THU*KCMQ*,PN;7($R7JR+8FGN5]S%0YM'!\Q3 MD&$`0#'LER7>TO+$&[M0)E9[HI=?M3!K=0E5J!9NP(HJ4Y(QO^TOTUU71]Z. M\/0M30/<6H96`@@T5=85*IMX\SE`OUH8GJK1P-^9:["`Y0&]K?"Q:IU.:0T*94K3_AD%?KE)G\A5M>:$P>GBPJ]/KU49?AWWX@5/4_!# M-8"$FBTG=)6)3>80)T02J?S&1&0%H8QCF>N!5;YQ?IV69Q8'(JK"*IN8,@;' M=BP_IG(MB4DN"-%%-CB*"*3YB+J/1N!ZMEOX'%8W#%JJN"2-O6YP8JEF?0\' M\?NH5[FR<7'T^H&9?&E,(5JTQ4DY^8PPTMB472_Y;5A00$ZHH^7VHI06%_9 M6P'+^W++2Y<7&;!4D M6O\_6<,(Q>N)LAR`Y(D3RMBWEI0;T$@Y*=_IN3C>17;ZZ%++-;Q5\7M M47"L":H2&N19<\YS)`]>.3==V!@3]$9,XM-5TI#$\.H=%J]XO&;[APC00 M_-EK$!80?V@>$7\C4FYM M1-[W&]T-`B'\>V`+9]QDDHFB0-8WNGT(#W#%U0-CPFVY&B0H&:C*"ZT&3G7V M[K%3:!^UD*XZ;VN(+*]%$1"-6-DT+#-#)PQ"Z*F,U%B-/^,T6]0PHDFM'69X M-:&E$$*J]86")(?5@-%]A&L,08M'NI5W>T!DV?:96W12TY7EK.2CU<(FLR5V M8#8V_]4C/S,E,9DCD,W9`=C4`.CW:L]8['AWE(*5Q!>'2O!#=;JXM;,SW#)& M=)PHPNPIU5AN:/1$62LX((^8]&&:JV"-D"QKG=5H,-?]0J==FR_';ZP"I&0A M[>S+W9FEF25208?_^@MU6&E_J815>XV-1&NQ4=,R-N3,==#3#OVU]KA+9>[D ML/=3IWV=Y]EM(=,]-S/MVIF*VV85-U0Q*2HS1XAH'S/E42;5,*4K*-_NWF^= ML:\-::JHKMV;`/)(?[X-W0.Z1:J#BJ.N&2_H>RLCW;ZH^H!DRHVW'I0!HZ9Z MZ"KOJ`H`P8*3@V_?[C7?ZB3W@\+0^W85I@D^'K3B*J^6X)3MA4\_G! MN[-L#W_$SDI+E3<'^+D)F)3>'NLZ\D[(YC`DH;P4I9F,O??EI[O/=M=>O-IM M3MJZ_/SIL^V=M6N'-%#LRU,6WF*J>(%OHK5Q MK=L^6`4!B9R*'5&.5&64899/:5=EL#[.MM-F17/R"B77%(&C<79"KZINAVT? M>(CFE<,<\9[C*N]LR%FM+BT^BJ^(GW!,E5Q2>E[7X/#WP+K&%L*K7P!!_@>O MA92&]V<1*N(1Z#W"^ZH3=(U,IWRW.7;-2A/Z0`M_Y*-+';.]NH9\U@J&WZ*W MB$8\_\H60EN1G\1!ILQPXL^;I-%0A3:6(&5IS<1DG))/N'VP1):K(BS M,N``SNP#_XZJ(/QI%EZ.](!R+QREFX*A,BL@%4!DM[I^*LX!;8AL7.PQ.7]V=NYR8O)UFI,-UG97`FUXQ!MQ<`1IK433"'M8<$!VX]E+G?H MHS*)5/.)D[Y!9A'CU=_2GA)V++4!,D7(`Z\&'V75/-55&M$%`E6UE)=FCIK& MX?$31-5L:_5EA'_0#@GAL;!T=`LM(Z94A)2IT%-'7>RJUW[DB20F6)N,??0F M?G@D5%9B'_4U'^DR)%"VL,*R1V;>4ANO)"FKCJ:H!L$J$2FG^,C($3`T1>G]&"-9+ ME&1PI]6*1GO1/3*0=A(:'U=D_[("D%_2_XU5696.1RV>O-VD-RT)W%O>LXXI:7`N.MLB9W.='NOJ%ZYR=4I6:4LVL.`JR%G$(9)#05L;IFZ'/ MQ$-`5),B(`O=8O^R])6"9!""VGELGV);J?1LT$JE9^D[<;>NSI*C&E1Y$F[K M/4.VW7O?=@0"]XANU4<4=EIFIKXS*^U8$C?9@'N4->,0M/8=&VBR6I)G"!Y8 MNI=RFZOW%'TY,JF4=HV!U-4?IGN?G M+1Z6]X1WV$Y9XQ9S([ANE0E)OO"!"#/4YRHP0E^$3T!]E>5.A1+5O76]+VP05YT MD/3-$%AT*PCXE'QSMOT[[;;L:Y&X>+8P5IK#`;TP5_CB#OEL$J#>GF#N7#Q! M4_RBH''["%?BUI1AX'36<8R9_YZ!).QBQI&^KK%R2@0QEM8?" M&[CT`7`J\`CA(2_=`K5]D+6&G]O'FJ![E2!4^F^9M$4Q7(*[K(H4M4DHX5?B M#I11M_"FKW3Z1YW$(UAXDI15EOEV[>]DB'JTH>O%/`FGN4[7_$T#4*ESXW4S M9L$HZ(1(+V%"O]R9FZGR3_JT2>V>@@B&EGA-=P.M4:![+[3:*.LCJPQ4DBE+ M%2"JYDPQS#V??6[[8Y"+'/7*3B%9<8[#Z96]5`)U\'P3QXE\M*>9#L^U<`6.@+ M"8=\/X3T_R'FW[=4MN6,A*"HH@CPR;KZV<`*VCMUE;P`[F_C-CWH//G4$C.7 M,2Z9;]KX8U1!J@-OE_%6\ES*=JG2(>*GXV7_^-3--WMV6^4[F/^VS]#O5_8W MU;0M&,]4MN$6E>8*>[&I1CUWS8?!@4$<0GZU->(IEU/N/G_9?/'IJYW6;_8Y M4),!77I8?G],!WJ;KQ_5FECLG5O4://-I^UUNWQGX"X,/MWB&O+=YR]:4[U8 MV]UJ_?J"T\+ZWI>N=>93PDWWE/V>6%EGWOF/$JS':V[ M5NKQHOR.R>BCE%C]TWNNI]YQH266`O8^NV:%:A#WI+BU)BHOT25^;LVO<>@@I9`;EXU99T3%M)1BM_)RZ"B#NL*G/#9 M[&?;KTSQ\ZY![@@FGZ0)'H=+6LW,U8'W%1,(#&!NX$DOCM05=4SK\T@C4__96PR4M\4A*?0Y(*A0+PJHPN^QH!EI+NRQ M6SC.64HWFPI_8[Y5A%+T,DZ8X!(==\\+T M-+BHW>\N%>F-9$DN0OW/Z[P;FB&24K@2Q)HM)LFO M,O'5?;^!A>Q8=YDJ(7]`;<./>N=M)Z`'4:IB>D(Q:2F_VD)T"ZTCQN#XARJQ M<`R^&$$,_+Z2TV#)>GPII<)7%)VW!41+?YF^445UA2-B]N-=55@[]8_TM2PZ M7H?=F!OU2%/@O3@M\XK\E&4Z/')]\J\YV(PSB:V$#OJ\5]LT/W76;;[?J5)= M3?9ZNM4J5;_"[>4KTD<]?1NUF_'Y:/ZV;R(<\.7:]@<1T!]LP:^9$+?@,\M) MIQ](T>K#;>TK4W^_:NDSC&OT?DPNQ!@P"7T/1")RRP20%,J=O7">-W;)4EA` M2*Q+[5N,(L;KB"\0HGVC:D=3VY3$[5+98.LZ/[8%F: MXX4V\BW<*4<4AQJ32!G-UD5@CP!"`^J)U.4#)=+:M*J>D6((P>TA=:I^?H>EJ( M^9(D3QH[C"_8&.?R]%VW7K5!(E@Z!-@;FC[)$IXO4:Y+$J/X)L9PRJ(B6H?E MG>A'V#_.U=YDR5?;.-O,#>,ZDJ#2-5]L/K->CPWZY.@=L]X*^]$\'>X:T\K`ZU$-^B5H&UDFXOY/:.$H>?-%DDIW!;)@?6@1CJ*@\+CB MR_.]$29C1+H$Y0_+&S?V$'R^$_[AYZC`4P-D\-V".OP6)G)*@NCCF);-2)\H$0N_-+"IT9#!.9G M:>LDH6%(\*X`+H$G:A)VQPT6BO/,L*GM/*:]C`?P/N.Q^40@6UA'(/@2<,B- M4:6EL"]2J)%NJ"'Q=WN6V$+2M+OKA M7)]_UBEHF[BQH(/@Q%N08>,C="6^ZZ0`JZ6<"S\EBEN6O.-9\*4=^40G'T/Y M[*53(NY9JE$>%UTZJ!U%D8D;'F($7E6"'#DN\TMX],'W2UQ7(]>81\A'5_>RT<];[4]8[ZQQW.WOZY&JWZ9B>A=K%J84Q MOH,K6#NB9_9$;ZL%\&>3>NGDIA,!A,WW%L7A&^N7]EDZ[[I53?E;.DF(#PU M4`G[7/,%2_OE2]S/\\O/Y;+)_3#-'&J#)9KDZ5I[SI%W:HC@>W32-P>551H< M[KL_!5LG0-#C.YZE#$H>K$6DV]I:]#%M.FKM0YI4/+!N_M+*0$7/`+2OJ-K' M^#6!/2ZO_.X:49O/3]7]@/5J_E[#!(`0N?)977,`S*`U6M#=FT&\TIM-.C'N M:\W^&U&XO6V]C[_\O!J)O_R<]*+0@PXJRP2+M-;U_1V$2$<\+4_VK:7IJR@6 M^L7NQ9@5*]6BWI,);'20E-\K"&<2[L&=*\6J'=(TF[81-A_8RM17F6&3K&.= ME,(*L5P)I?P"-3TD6<&07=2D]ZKNEED[++_#=";=C"^P6M6IR+9QTP[<,FI3XC2)*?O"%&Y;;T`29(-LTWI1Q M'YO;IKFWUSXO(%OS_/ES+6$$:3"_HKX'B+DO*8J[6R-9-B7L:]VA:(OJ2D=> MN@V%HG?<7A.]=QNFG>;P!U/#W9F*U=R4;;VB)EAK%J])C!N=9UO_F-6)30OW MFRV4N^C5T_DU!CL]\J\=OZZO;N M/T/@D>1PU5!3,/&+PMT$S2>_$9>Z4O4.7$9SUNC<27KU2[]$:DZG7U+KD3A( M?`!%ZSQ(JLSWL$,6+=8Y+<,#,S%-;*3VS^K(5212A1@!0E3JM)S--#*)`_JB M%5TD`4<]/%%\&(RW'B177X12>3OR"Y_9M%5CC-O8AF4R=??"1TM0$'RJ",(A M70)-\A6>]E26T\YH:5!94RL3,A=VDT\J"<2GS/*`?7L2V>YK,ZS[2J3TU?^9 M_9?\>OI-MG=XHJ"X/%2RPU6\U(#=,`:,\+Q#I^@H4W::A]NA`Z+>>"ZC26[? M4I.,)F\')?1C"GN,\S9?N2367$Z=[9')LSQ^!I4#.I1Y^KKN"UC47C.;#LT^Z"3_[GB\'P3++;,()2/* MA&$U\'++`DUIWN(HZ_\E[6IVI(9A\*OD@,0@=6:U6D"<5IKM_*C2=%JU.XM6 MB,,>N,)AD!!OP[/P9'S.?YTZ;=EKFSBNX\2N_<7I+P\]8A1(A*K]$Z5#>:,( MPKG7A0*F$$502XI<31$>1YG__9,`R:%H1NOM.2N&Y;%KXQ;5J\D[^NCF`9,Z M4/A7FRW4SOYP]QJSQ27[GJ1?U]ONF=!JW&(FMF797'1"6K7-J:*< MM%JU]K[Z))V]D,XCI?J5QK0CPL:'^`<>7-PQ:N79O"[?Y-J`\VT<5M M]Y`-8M0H=&JM"/UM>G+Q0TXO7F/K$$!R$R3.=S55XB%I4-#!?C[\>"R$MZI= MP0O^(N;>L3Q#IV`/:@-5V9,[P*G"B=@HQ!DT>#[W,KFNU'C)2I^I55]J[8I\ MY13@+X*\<:82"CM=KL,70<""M*4Z1'+(16S\P3L^5@M_A\*`IX!WDMC:QD61 M]\;;XN2TFCION'6G^HE)"L`YA1OO59F(P4BO)SJAF.M4H'2./_`ICF(\)S-, M0BU^69C;W7D;"``Y1;5#"%.C!Z,Q>=.,U<%QM!B`'NR+W^7%-25UE&8LP\6" MQ1"KH[T&(52B[P&")ZM@`JR%\K/7DAO/Q9)"P?U'SUB5!H>-P0P,6_IJ;/$6 MS'W"57'$7`G30%?%/7@4,JJKOL`R_N8,#GO`K)BTGNI&$AS#ME!!HQZ9O;G$ M_R?0[<*R_X34FX`SIC?CKH.7GZ@T<`A,*KPU1RVT.XB'&@EIEW'BV[CW3@!< M3CG?9[ZOXB"4Y/M_1E+_V[I!2A\3=@K863YR!)ML"96+N+TME:OSI,/D=8;. M%*#2"W:&8FK$H[`C.JGK[U/XOD36^>S\,C[<:39:D8-D=BP7@!>Y5$/>>,EX MMUDKR9P7Y[M8*!01M$ MO7^1+I)RYAPDO/.Q=B4H@3&+UL!1`(W\5-%.Z4Q`TGC2"&K]7Y8=G+,-Z]O=X>OZ^^>/5?[8H<[)_#G^N!M7]=L M?Q6L'?]AKO_USKR8ZMHNLORUY0:^/==?[)W^W&M4IE MLP\%\9ZS"H-=L(G>@KA>L-DX*[N(0#&`>_NSF M>O>S]L5R8\\!\*$&WNQAO/JN4MUG>(_ M3A>SHMHN:;J*>5'PX2FZLE@1/>'#_5PW3>"00;^/;J4!ZTC9;-D'?6=3=CD^ MFV4C+C=[;=X]D[[9/]5?LA\"P?'4*'<8;L^"SD/**S@0P*RY"9Z%G8B1V) MLL$(7I,S*4/&Z+,9H,P$V)\QL3'ARGBJBT)*]9W'1I;\.Z@*QW6SM+?U?SZ(;1>!D,V`Q;;81>XSAI1 M/"S9BB/)W>7EK;F\97H),E$4)4)-VM]"CT;I,]]&\!#>B;^L-)S[T M,R5).N0]WAY&(0F?X!XLU"S2@CM`3J0I(;B'#!OSXQVB-I(]Q&PD.PC:2/80 MM1%*YUAQI9YK=VG MJ:W`+X7:6`SQQ9HH1RRMV:-H9\T.1ZRLV4/41CYOTNARPK/6!=+S$20'_N9^ MW@X&*(IW3/$FMX$$[CHV4B=# M-LP`5K;K?L8Q^>^;;!H`G;6;Z^<-.6L&3F7"TTKPI!Q\"^WKY&T\Y,SLTV?E-3`7;BFWR_-."S57RS^P@G6>SWJ`>B_D^#")[ M%;'SKUB2E>$9E>`9)()$\)RBWRC1#WX2]LE^B&YA/7+S`<\ MTRQ):@@!3>HJ/#(10(!& M2$48`(^2JB`)R8T89W0#@:"*(4DV#%51),6@BB/S4`Q5422!H(HA:214423% MH(HC22A4422!`!Y1PI`T$JHHDF)0Q9%Y*$:J*))`4,60)!*CCBFR1]NF<1.5 M]$]G_5;]4^UY4]M('90MFB#NZ>[QZBE>.4(LV%J*+*7Q6D0++W#`WJGV&(3. MS[#(Q&L25[#!#G6\AC5R5G3+U]#:WMG/L!2-#ST];PYZO6QUF72(Q3'R;=84 MZWF1@^/J6]L'OBWU9NXY."R@:[5N(\K%O2;HGQ.P(*RD'0IO.6KGDZS4$;66 MTX015G<\7]J#P+94[6&-@]C+QM!E"D@J;N0YS&2=^'365LHU%%\6O=<$\#5A MH<["DY2:417-K:Y#F?!$(^=!KJ1U-SKLWDC(-#E8\$",.)A%"JLF/2$`=8QLW5`)M3LY!?VY`)G9]Q`THAM'RM=KHD+?-J-YDUL9T2:5A4F*SV2ATA)G!$21M/!IDP`VGSX. MUE(V/=8CKETDID)>$IXL".%LEWRMTDT8>)?1I:-T*T"4R[D!Z/6LOO#:\4EJ<\T&K<&<@^ M+'3"6F9(SA7Z/_4.C5<;WJ;AZJ)93_&=G$]=`*R=UI!1EW,6QV;PHRJ^Y]5H#%2;#$IUT?'F\%D.LF M=CR,Q`V9IG,HRG(-T#:O,Z$AI9T-)",X$SC&@Q^)IW"'8$L=7HWVU3H,\*KG9.7EDLUFW94+J_0 M@\7T:SH$G#'<%&RK6J9-F^H,X"=1+99E)^.K)G0E^.CJ"\*>3T+A0]7H*#0> MMILA5=S%0A&B5]=*&G9YC9AXU'"ALE%PV0B[-@^NQB/W-N/O;)9=NZ?A0U3@ MV8/]WVH7VKL55C`01IQ&F/KW>\>%FR3C17EX7>4*KAX(O$6\,;D2KDI6UFH? M(O4065#I366!A!@7=BZI++@.I:DL4!_+&H&U1!;<]JVQ+"C'1!9>"9W;:$`. M-L4%NR2R>-^/!7UO'(LC3N<(+C19!!>5E<<1*3JW$9[KTEA6'D>\7IG(`I.; MXLKC"`B)+`.4-)65QQ&B0&5!NC65E<71X'T_%O3]Y=$X\KF*%_B*X**R\CCR MN3H2S%4J*X\CGZMH1Q!*O4]?-%45AY'GB<,09Z@-N9QY'T_%O3](:/R M&3\4S/A82AX[>$=\A&T<$1_%4O*H\5D^$LSR6$H>+SZ_#<'\CJ7DD0)YQ"(# MOA"W*(O1B/>N(>C=A;5.69=/&!QG1&#`4VI7>Q>>'AS@LX?9!>S89B4&X>U* MA"0]VJLG;0GW(\T$\?6`PZB(H-OGK6OY5A2$+QI>M)Z)XX,^%A3WQR#(?,1+ MP(F6"*`_P9.:X2'0&O@E]A"?PWAB91,Q62WP[L$[6#41`WO':/C\&P@R16H4 M[!V+X4D5YT\B:#[XVWT6(9Y+<>@6$?'1\9_L-9\YO(>'`%)$TB=['X56EG]\ M20T%'?,)[V*;R>`I(GY\8'K+W63^^0EN6ILZ$?L7I'9P#BT"_"_[B+@1]R)" ML,DI(N3.B>!^XVD1O_\SNY,_)%/RJ^^=+T'$ M1,SU_/U'?$0"5#'<`!GHYN,.;KL/?[5]Z,SU_]PN)K/WM^;P8MI?3"^,D3V^ MF(T7[R_&QG+Q_KTYZP_[R_^"R_#![U?PY/`3'JS.'@`/-^88&%<[%QZ_'B;& M)N`_Y]OF.OD0PV?W10?8<,/PU(C>+GLP_:9F66%.B0-))?1O:XX`!P[IAEP&[ M[3!L*]`"NW2?)EN'K0/Z%?9(2K(8RTO2!AO6U8=$(G]\_]_C(W7UVH.(H4,B M).5QVZM=KGJ(Q#X?TSAH>W>&_4L;'I(*QV/,>$S:WIQ([]K6^^]=Q9LJ)!%! ML#Z6F[CMA4HEFY6*]&$8R\L\(3',3;B(L()7$53&`A\!W8A5UJK59B7"-/90 MC",@>WLRH3Y!0TW2V\J(]QB\QDKJ`9^)@29-G!4&.Y[6-$+.99<)=(A9VP,^ M8WXT)`^4AQB6"B;:7M7\O,K6U0K>3!`6#?!TVM+$6:]?Y&K9/1+(#LXS+M;K51K;OX M`OWU)9E;G4ZGT4IEL40-R#[6E_`;U69]>\W!&Y#%-Y;P]?O/R\1?E>%G$__K#)[_\_'DY$#)H(=&++Y_\]NS)BZ\^_?V[QR7P;8%' M1?B01D2B6^0('?`(=#.&<24G(W&^%<,04V<%#H%V">F>"AW@K3EF9;@.<8UW M5T#Q*`->G]UW9!V$8J9H"><;8>0`]SAG'2Y*#7!#\RI8>#B+@W+F8E;$'6!\ M6,:[BV/'M;U9`E4S"TK']MV0.&+N,QPK')"8**3G^)20$NWN4>K8=8_Z@DL^ M4>@>11U,2TTRI",GD!:+=FD$?IF7Z0RN=FRS=Q=U."O3>H<],9&R;,UM`?H6G'X# M0[TJ=?L>FT1.[P:3?$45*&'=`X+&(_D%,(48SVN2J#[W$W M0_0[^`''*]U]EQ+'W:<7@CLT<$1:!(B>F8D27UXGW(G?P9Q-,#%5!DJZ4ZDC M&O]=V684ZK;E\*YLM[UMV,3*DF?W1+%>A?L/EN@=/(OW"63%\A;UKD*_J]#> M6U^A5^7RQ=?E12F&*JT;$MMKF\X[6MEX3RAC`S5GY*8TO;>$#6C\S210*:D`XD2+N&\:(9+:6L\ M]/[*GC8;^AQB*X?$:H^/[?"Z'LZ.&SD9(U5@SK09HW5-X*S,UJ^D1$&WUV%6 MTT*=F5O-B&:*HL,M5UF;V)S+P>2Y:C"86Q,Z&P3]$%BY"<=^S1K..YB1L;:[ M]5'F%N.%BW21#/&8I#[2>B_[J&:+T5';:S76&A[R<=+V)G!4ALZ%8JNU'N_*J8E+\@58IA_#]31>\G<`6Q/M8>\.%V M6&"D,Z7M<:%"#E4H":G?%]`XF-H!T0)7O#`-005WU.:_((?ZO\TY2\.D-9PD MU0$-D*"P'ZE0$+(/994FRE)")J(*X,K%BC\@A84-=`YMZ;_=0 M"*%NJDE:!@SN9/RY[VD&C0+=Y!3SS:ED^=YK<^"?[GQL,H-2;ATV#4UF_US$ MO#U8[*IVO5F>[;U%1?3$HLVJ9UD!S`I;02M-^]<4X9Q;K:U82QJO-3+AP(O+ M&L-@WA`E<)&$]!_8_ZCPF?W@H3?4(3^`VHK@^X4F!F$#47W)-AY(%T@[.(+& MR0[:8-*DK&G3UDE;+=NL+[C3S?F>,+:6["S^/J>Q\^;,9>?DXD4:.[6P8VL[ MMM+4X-F3*0I#D^P@8QQCOI05/V;QT7UP]`Y\-I@Q)4TPP:&PO M=V]R:W-H965T4!\#VX?C,F?&PN7UI:O3,I.*B3;'O M>!BQEHJ^N>1 MY[I*\2)RPMA;^`!'>Z;T`S>4&-&#TJ+Y:4&^$360!"<2>)Y(_-!9!F&<_`_+ MXL2R?&,)KI7BVK!ZES*BR78CQ1%!Y8%PU1%3Q_X:B,_VV&`&P_[D%\1H2.X, M2XKAR(`5"G+\O%VL_(W[#(FA)\R]Q<#]#1,OIYC=)<^,)3LC3,XAA"$.L'8< MQ^_3>Y9KP$:NR9'1?V\G@E[YTH^CV:X[NS[6'DR59Y>(:#%`)DHAC=`4 M0V+>3/.2@=>*MQBHQ@$SM_6?B.QOB(EZD'*]>@.&`S-2MDCFZBTF[JWWET$< M>M$TOMT8L?`!`-<4DHTA21"/`1/U8-+UZ@UXKGXUW?C>8E:VY+THF3L_7H^B M",1/":#UF4TL09#X83BL6^&VL=DCVS!9LAVK:X6H.)BF92IVF!WZZ5U@*GLV MOX,^VW1DGTFLN2M0C4K@-)S8M`D;:>T`RVZOE'LA88.U[]6\$-C M<'(\!\"%$/H\,.=R^$5N?P$``/__`P!02P,$%``&``@````A`.L:"0=&!@`` M,R```!D```!X;"]W;W)K&ULG)G;CN(X$$#?5]I_ MB/+>!"<0+FIZ-)#+CC0KK59[>4Z'`-$0@I+T],S?;SEE".70KK#]T#3AI&P? MEYVB_?SI1W&TOF=5G9>GE2U&8]O*3FFYS4_[E?WW7]'3W+;J)CEMDV-YRE;V MSZRV/[W\^LOS>UE]JP]9UE@0X52O[$/3G)>.4Z>'K$CJ47G.3O#)KJR*I(&W MU=ZISU66;-N;BJ/CCL>^4R3YR<8(RVI(C'*WR],L*-.W(CLU&*3*CDD#_:\/ M^;F^1"O2(>&*I/KV=GY*R^(,(5[S8][\;(/:5I$NO^Q/996\'F']\$6>5F5=[IH1A'.PH_TQ+YR%`Y%>GKO=1_-'4R:#/)91EG9L'YA6FI(N.\O MWLQ[=KY#DJ2*62,#OV^8"64V_3B^2Y'@@LBTD6V'EPM=7$%OB2[$Y988+\#O MKBN>?[W)`357/Y`^MW[NI_!%@X2EADM#:[S@MD8F8N9K/=O@Y[0CLVM'VO$% M]Y@Y9<(^HVF+^H2O35#<1]S%M1TB!5;%<"D2AA5\(WNJ=7^-"*R2ZWSHB<$2 M`4N$2,S:R?"G8_RY#K"5';%18G,4H@DVC>&:)$PU>;,I[=T:&9,GE@A8(D0" M/4WN6F)CQ*88Q!$,9K@C"5-'4VVUK!$Q*6*)@"5"),2XS:7Q:*RMZXB-$'\< M@>B!)\9P/1+6]&AK?(T(-/[A2F.)@"5")#[6PT:(/XY`],`3:[@>"6MZ]`6& MB$D/2P0L$2)A6F!LC-@4@RB21?7-`][\`),P5>3-N@=CNT6ND3$Y8HF`)4(D M3([8&+$I!G&T>,21A'5'^BZ$C,D12P0L$;)$Q!)QG_!FW>.96(+U3%))UHH> M7#.G5'N7[JNK*S"G%&02QB,!CX0\$O%(K!!XD:7N8C19D)]Y^-3MNU2AK#P' MKT:!=2I4'-?=VIN/M9I`049U&,>`!'R4D$% MM2LUI3V4UP(A@X8-CP0\$BH$-R]/5IITSB("B,4,$$K$QE:H*%F0#A>%Y2L5 MI7U76`N$C*)8)."CA`I!4>*>*&Q&`1/14QD;6Z&B9$UZ(VK@]H65+!76K6ZU M?;$%\4:P2,`CH4+0APO_UM(3)R*$)X%>:IEZ0HU!!OP/8_(N;<.?:]_GUO+? M00`94XQ%`CY*J!`T!O]RT6Q$Y/,%+%9](9IZ06W)FO7Q_,)*E^:77I8*MF#> M*$1EQIUY#P@A5Y+N(B1$FUR:C8@0^-U0]V7J*O4E2]C'?6'A2WWI):I@Z^>- M0M"7WW,1D,]=>$[1<8;D\_[]$?E*MK=>T6[OE,IR.B*K>L#/DK((Q&/ MQ`I1NX5\+G2I257!KC-\IW(EK:V^11<9=RH%&55A'`,2\%%"'HEX)#8BU)6L M6`?OZG"RV7,U[Z65J0AN=6Y4'*,K-DK(1XEX1)[6RC%A6M&R'TWA62R>[!59 MM<\VV?%86VGY)L]9/?BV?;UZ/0/^[,J#*NWZ1BSAB*U_/11+.$>#Z\[U!CBR M/2?[[/>DVN>GVCIF.VAJ/)J!L0H/??%-4Y[;<\;7LH'#VO;/`QS.9W!X-QX! MO"O+YO)&-G`][G_Y#P``__\#`%!+`P04``8`"````"$`NI;:=,,#``"7#0`` M&````'AL+W=O*^P6" MBJ,E;@U,S3E;M5NU=3ZO(T2E!@@GB>/,O]]N@DJ"SN*-"CR\_::33MK5E[>J M=%Z9D`6O8Y=X@>NP.N-Y4>]B]Y^_GS\_N(Y4M,YIR6L6N^],NE_6OWU:';EX MD7O&E`,*M8S=O5+-TO=EMF<5E1YO6`U/MEQ45,&EV/FR$8SF[4M5Z8=!$/D5 M+6I7*RS%&`V^W189>^+9H6*UTB*"E52!?[DO&GE2J[(Q2#G:Z/#,2_\A0]* MZU5>P`@P[8Y@V]A]),N41*Z_7K4)^K=@1]G[[<@]/_XNBOQ;43/(-LR3HIN_ M6,DRQ7*8.=?!&=EP_H*O?H5;`021+8!!Y/^G,(\A1O'/8?J_3R&?VVG[(9R< M;>FA5'_RXQ^LV.T51)I!&C`;R_S]B>$,53->@@1\.E6!ZPG22-^T MNR)7^]B=1-YL'DP(X,Z&2?5I>/6?AD@GI47"3@2^C_IYN/#F)%A, MYN-%)IT(?'J**KE>"'QU8K6!;-A37/EF"[O6D0#:0 M?40X=J&:8+P29N9U':S\5\A]UA&))N#S3!"32$\$3A]X.!N!S(PW@C`:P=E" M9XF^T8\;6G$U$;:NIV0>79P;-B`'XVT@'+O3WF@G9M1$$S#%YWQ,32+]B#"< M09CQSA"&A=J+.S/C)IKH.XM,(AT2%^^&,Q`9[PQAT]G%B.WA$0MHQ9A9=HI!^86%62#I$;WA;W>$/8\G:1U=N&1@QO5IVD0^0B M8E0!@>.LGS@\9R9P[Q=;*KYEN;0*,6F58]>P:15->H6YY1-WX-$33/1^W=]) MB%6.2<=\[$_K])E;_NXZ"8C>UPU_UM)/.J8?.[3K]@ISRQ_NV./SA[0YOZ%= MND0SAC^KBM(KS"U_UD$Q8B8_J[Z_2`OG?@;U#(P],A'!3RD+'] MZ;97MW$5$SN6LK*43L8/V,82R/WY[KDO[QKF\P/H/SR^)Q@>W'W6E?>"^&"LB9%D1\BCS09RVFS3='O M7X\WM\@3$C";@O$:2[CEVT"TG."\&U1701R&DZ#&M$$Z8@/ M)7MQ]-X3)=M_X33_1AL"U88^J0YL&'M6Z%.N/H+!P.Q2LI8!0+PZM54/1I0$?S:7?TX M&D_^KQ+H:755>L`2+Q><[3UX]$!($^9#VS.F5BDUB?(68#$H#?(`EU.Y8\W[N#G(*A2\@;Y*!"0VXW M@95F9IWZ-(PFD66_/@9FR724O`.&&?S,Y68*MLW>9ZS--#/]V.P8<)F-KC%3 ML&UFM6NE&7@VAKJ.S*JN7811-0BYO&H*MMWL?FK&<$LL.2=BV$VNL5.P;6?W M5#-..R=BV$VOL5.P;6<59J49P\XJG8LPW-2F>;28N/^G"K;=[+YJQG"S]-=. MQ+";76.G8-O.[JMFG'9.Q+"+8&N[O'@=;?M9_\=5#QF"5FN=B.EG[13NYD9Z M<8?%:E@M3E?A'G(L=@;A6NW@"'%-]<[M$79WN\@4.38)@SAKIX\E>L-M\99\ MQWQ+&^%5I("ZA/X4>L/UH43?2-9V&^N&23A,=&]+.#P2V'5#'^"",7FX4<>> MX3BZ_`<``/__`P!02P,$%``&``@````A`!IK&;2D!0``YA4``!D```!X;"]W M;W)K&ULK%C;;NHX%'T?:?XAROLA)"$!(N"H0*Z: MD4:CN3RGP4!4@E&2EIZ_/]OQ);'-H-+I2U,6*VM[+V_;&R^^OUC4T#G0N\*\^'I?GW7]&WF6DT;7[>Y2=\1DOS!VK,[ZM??UE<<.WN@R9?E46-&[QO1R!GT8'J.<^M MN05*J\6NA`R([4:-]DOSR0XR>V):JT5GT#\ENC:#_XWFB*]Q7>Y^*\\(W(9Y M(C/PC/$+H:8[`L'+EO9VU,W`'[6Q0_O\]=3^B:\)*@_'%J;;@XQ(8L'NQQ8U M!3@*,B/'(TH%/L$`X*]1E:0TP)'\O7M>RUU[7)JN/_*F8]<&NO&,FC8JB:1I M%*]-BZM_*#(1;S2U MQW/W@8'`VN@TX/GY@HUH)QUCK'EAD;SB"E262W*A"J0*0"L0HD*I"J0#8`++!%>`,E_!7> M$!GB#<]JS8'>+$[7&$%DEB8L:5$D MTXF<^)I2;!B(X"B4C:`(05I?42Q$!M8BA!$& MN/9,<8F1[KDD*,(E#0DU)-*06$,2#4DU)!LBDDNP%4LNW3Z:^*Y"V)T9/(DU M0_K%M-&0+44\6-7"0F>B6!@*$I>.-"36D$1#4@W)AHB4N_]0[H0MY\Z00>X: MLJ6(G+L_ELLG%"21NX;$FG0B.`-;765QIH+$I;,A(MDQ5>R@)\^(G,WML2Q> MUABF#R;Q1HFX<,+0(R"XQ9."2AFPIXOK=0>6,;26+4'S/LX@T)-94$\$A MQQ^HNK+MJ?B>JV9#1/*&=.3#4_F&!]`YLSVE7PO9BY-)MTR\^72LK).HC\]]C/5H2<_J1ZE%2Y5HL_E,B9;U M.A!-=I)T<,/U\JF]Q*9]()R]/)LU@Y3Z4KLUSNJ+9\LA^C.+K,"00[`ABLFR M/>56HK),-:1[)ZN[K95O=W&W%`/KRUJ(E<,%$9M^]&RWE+*CA04$HFQ&YK&+GA-AQZ>43O4*H M4'U`&W0Z-4:!7\G%$FPOJX6`Z:W7>A+`[P$04/"M%T"O?`/W@\B_@2=^`,WD M#?XT@/9,QY-I``V6CL,MW%/7]"CC69/;N1O\M1/`#V-=9^T&\&M0QY\FP1.] MY;-$!+AEN^0']'M>'\IS8YS0'LP:=[UN3>_IZ(<67\!$N&O#+=RO=?\>X3X5 MP?DQ'L%2VF/<\@\0V1(WM*N?````__\#`%!+`P04``8`"````"$`Z"1FQSX+ M``#G-0``&0```'AL+W=O08=_>3)^/QY=X-FO7S_5NU9XU M+_4>CCPVA]WJ"'\>GF;MRZ%>/72-=MN9/Y^?SW:KS7ZJ,\2'C^1H'A\WZSII MUJ^[>G_420[U=G6$\V^?-R\M9MNM/Y)NMSI\>WWY;=WL7B#%_6:[.?[LDDXG MNW5;N_A#I=YOUH6F;Q^,9I)OI$Y5COII=S2#3[?7# M!D:@9)\;Z9T75^%\.KN][@3Z[Z9^:ZW_3]KGYBT_;![^M=G7H#9<)W4% M[IOFFPHM'Q2"QC/1.NNNP'\.DX?ZI,7\GQ4:NTB0M2%V0NR%U0N*!T066!&&B:.*(XMYB^Z!>%$%203)!,U'&IX2* MYF/7Q)X2@B2"I()D@N2"%(*4@E0V80-5'HN-5,V)"5XVKO!_1-'LS#(K@6)$HE2B3*) M9,%N?7]2$\6QV36ADC6:I+!,V3@P>\P:A;3Q6'H")09%,(_(2`6.!T\I"@LDDRB7Z0N*LM+/(UY_)45A M^HHAKHSR5;8R>K:<70`_/F_6WQ8-C`3&,U`E`6Q-S895NS.X`-CE0KEW51&V M8`(E)BHXU[OTTFT@`#-GU`91+CLK**K;/\\]9YJ6%(!I*H:X3,J5V3(- MR`&/3GH]M(EC>FCDZV=$:C^^]`1*$/G]<%-$I&V&B*)R1)2^0$11)2+*52'J MHOB8E>DZ8B8J[,><(+KH46I00%&9C,H1452!B'*5 M,E?%HK@,RF;9,GQNAFBSQM31R`=W8ZESSF?STM-1\(``RS0Q2-G]%9AGM+<2HW1O011$SD`JUAM76/F[OZ^P=HE, M88V<^G-D6'HFBFHF,2B"V_:8PKIAI-;![[>#"O6M9Z])PFVR0O=QUUR9_:HK#TNYNI`QBZN@H"R4F"NYQ5&V^<`T41>KH7-;-,9=1A42E M1!5#7!UE7O_V]/2U!;:G)R++(DB4&!2%[UD$"B!A=&?0!E$N,Q?4\!V+0`&8 MIF*(RW2:K_:EKS8(K@1VMY0H042W]101W=8S1!25(Z+T!2***A%1K@J1M`C^ M:;ZZ"W?6#VVBG27:??1H&L('*I,@HMMZ:I!M$614CHAR%8@H5RES52R*7WIE M4NT9,NX.U7=LSA,7@]37`/T-QP_=9W`413+H7,Q$2"]@&H9Z#D7!Q;ES=\Y, MA.T%9&\%1=%IBMY*;*C\\/?;J[DSC(JRP#"XD,H1GR"D-M!L33&>&LK*$M)] M;N?W422D050#J8F">J)<7N3MZ"& M>,5*C.(].AO(BAH.]\@E_1*O[TNO;Y`Z&4MI9]Q+C**Z21#IMQ34MC%%!!75 MYQHH2[.[L,O2($I?8"Y*7R(:35]AU$!9*A=JE^7GS)3VLJQ:C;WEU>HL9$NU M$KK5:A"X)4LP9QN08D/CK[TK,='[_K$$MV<)J5]T[1G7_F,?OTO![M$$1E=)2HD2B5*),HERB0J)2HHHAKH4RQG8- MCM^0`^VC[6(SR++I2XD2@_B^)G0*)Z4H+)Q,HERB0J)2HHHA+L.7./=`.G># MF#HZRD*)B?K%OH:B2!V=R][7R*A"HE*BBB&NCFO8/[50!=+'([+V-1(E!KV_ MKZ$`$D9W9N]K9.:"&KZSKZ$`S%PQQ&4ZS>,KM^286X/4UHF6L<#U^!A%VY,$ M$6U/4D2T//RN MGYLI1.&U21#9YD&X[M1$A7[GNKW`FT>.\;.$5%W!:+1[DH3!8(-FWS* M`GWQ@E)6^`0EM7-F2FJDUG]+2=?DJW7'<0(&P0T5!4@QRG:1TDW)ACDVM.[] M,JK$J-'T%6O(Q5+F^P2Q5+AS]];(L9ZNR0],%-5!@HAN^ZE!:I98PCLS.:.& M5I1E6[KOC'*,HAX+1-1C.=RC:_*IX7"/7-(O,?F!-/D&<;L6NB;?1$'Q8@TF M!L$#?42I0=%HW634(S;,9?I"IB\1Z75I9#4;!:ZJ<+U4P[7+LG/W3>U M3V;36B.G4EV#K]Y2@Q)G"Z1&OWA<;QI&L"Q0\$6T6HW_G7;UWOZL-3O:RWVW:R;E[5^_RPD-Y>]UC_V&`1SO'7!NZ1 MJQC>+8(AN]R#%O!6S=`1^.4"O'LR=,2'(YUO$-D".-*9#/=(`/WHA<`Y`C^0 MN!O.!:F&>H?.!^.AZZ&>[\+X#L0=&$8(6@WQ*(97,`?BSV-X8W&`7\3PTMX` MOXSAO;4!'GCQ`KRZ/`+[KG@Y>`2V7S"Z(3E@ZP%'AK*![8XS,+NR'[#-T&;H MR,*?QPO]5-ZY3$LXLAP\`E]YP1494AB^[H$C@V?M^W$&+GG@W."(^NI!'EEX M8:S>M9!'X/V4>#EX!%Y3B=4;)[(-O(\!1X:RP>LHL7K-0K8IX(AZP63H"!2- M;C/KA8.?V;RLGNI_KPY/FWT[V=:/,&WGW3>1!_U#'?W'T7PC>=\&PO=V]R:W-H965T1355'UJTB6#GW[YX_]KO>]/-;;ZG#7#P:C?J\\;*JG[>'EKO^? MO](_;OJ]^K0^/*UWU:&\Z_\LZ_Z?]W__V^U'=?Q6OY;EJ4<1#O5=__5T>EL. MA_7FM=ROZT'U5A[HR'-UW*]/].?Q95B_' M$J-Z?MYNRKC:O._+PTD%.9:[]8G.OW[=OM4FVGYS2;C]^OCM_>V/3;5_HQ"/ MV]WV]+,)VN_M-TOQ3P,*-U0GBCDO MAHLA1;J_?=I2!E+VWK%\ONL_!,MB/.\/[V\;@?Z[+3]JY_][]6OUD1VW3__8 M'DI2FZZ3O`*/5?5-FHHGBP]E<_K]]WIW]5'7FY?7D]TN:>4 MD4QL^?0S+NL-*4IA!N%41MI4.SH!^F]OOY6E08JL?S2_']NGT^M=?SP=A#?3 M8#HC^]YC69_2K8S9[VW>ZU.U_Y^R"G0L%2744>C71)D-IO/1.+@BR%@'H5\= M)%P,YL%H,9[3F9P9?:(=Z5<[SL[:4[0F9_HU`TT'DW`ZOVE.]\Q(%+?QI%_M M>?[,YMJ>?LU(EZ5$T[,9B'XO2FFA[>G7#'1A2@&5G*H`67OJXG8F-525TQ1B MO#ZM[V^/U4>/9C>51OVVEFM%L)313`DJ'=NB_%5-4C'**`\RS%V?$J9JJVDB M?;\/1\'M\#L5_T;;K-#&LXB,A:QT&3;V0>*#U`>9#W(?"!\4#AB2+*TV-"%^ MAS8RC-3&9+4RP!&+2Q49"^,2^R#Q0>J#S`>Y#X0/"@R5 M3FMDW&(@"9`42`8D!R*`%"YAHM".Q$3IWO_-6BNM>>Z*4.XFK0A(#"0!D@+) M@.1`!)#")2Q1VDI9HE_<;608KH`B$]K`G*OO+QRMD9$I!I(`28%D0'(@`DCA M$B:*[.;=+?C\U9?6/'=%*'>35@0D!I(`28%D0'(@`DCA$I8HS6C1&IG0 MA4N8%++58EJHF3"0S?+I=;OYMJIH(!JNHQC&E)ONNF04KE$3F#991R2#')4T MFMJ:21"EB#*,E6LTGIFVSUMTA35H=6&("R.;LR51J'-+3)( MW?>HSE(YAF'KF!@K&RLUR%IE!ME8N4'62AAD8Q4&-58\9]EWN3G+8@AG\IZO MZ_H3;@M`=6PL?84FE)]3JC->JI%LL*ARPDF;?FP0K5.M8S"=<\=$6TW"YFK/ M1J,1-TAM&'-%,H/L8+E!9P<3VFI,W81S2C=\Q,+&HA&YL+)9==IBA05JSD-+*+5:*M='V%4]0(?#*,G!MD(XO/ M(A?,ATLD.[(I)I$)I)"H;LHA(&77!1H*[N:Q`;9 MJYUHI.LHH`>;PH&TRO;]R8* MG\(:>=7I]QO&RJE.@^P\2PRB]=)1VMN64V-%L]FQ\I4V5G;$W"`[HC#H[(B% ML?K5B%QI_W[@2XMEB+<)&GDU[:\#VLJM:8/ZE_)W M)(WX#*=R2AZN[=A54C MKD_H=SS6RNJC8CD/?1*T2A%EB')$`E'!$-='=N2N/N?W9+H!@#)1R,DFTE8. MBA$EB%)$&:((Q'`VZ1`V*^7H2!9;1[-T)(A21!FB')%` M5##$]9%MKZO/)S6ANF16$PHY"48AH!A1@BA%E"'*$0E$!4,\YZXV7-Y#7[MW M8%,N.Q>U`C@U,8)6L;4R!1!;1X,21"FB#%&.2"`J&&+Z4&-U34TTYKQCULBM M"40QH@11BBA#E",2B`J&>,Y=+>T7^HDQ-K4:>>N$?Z-FK4P!Q(@21"FB#%&. M2"`J&.+Z^.WH^75BC&VG1JPFE)6#8K1*$*6(,D0Y(H&H8(CGW-5C?F&=&&./ MJ9'73W@WW)&ULC6A8CDM1H)6*:(,48Y(("H8XOI%JJ14P`1HAA1 M@BA%E"'*$0E$!4,\9]GBN?NE[">^LDZH5M'=2,<*>>N$=],?62M;$ZVC00E: MI8@R1#DB@:A@B.MS78])+RBA)J"AC+254R8QH@11BBA#E",2B`J&>,Y=/:;< M:J[L)^BK5A"C[1Z=?B+T'I-%VI'ITSK:F@"4HF.&*$^]L6JX][5^,)?=W;/-""(U,ZTCS7@B,S M.C*3[W7@R-Q\*^P?"6^6LD/L\`D7=*1Y0^C[C$<4K7D*!$?D-\G-RV9ME'\D)!]Z\M%U;N1#]_Q=1T@WNC/N.D*ZT3UAUQ'2C>Z^11@/:,)ZKZF3^H%,:MO],X?[_````__\#`%!+`P04``8`"````"$` MBM5S<^(<```OQP``&````'AL+W=O2C+5$=_?R9K=O78[2N+J.$[9[NZ9;[^'(B'@X(_( MD_[[X=_+5^>+R]__[^'AT]WGQ=WUT_OKG_L?XN6S[?/]Q=/\G_??AR]/CC87W]:=/H M[MO1\OCX_.CN^O;[X=3#VX=?Z>/^\^?;FW5T?_/GW?K[T]3)P_K;]9,<_^/7 MVQ^/IK>[FU_I[N[ZX8\_?_SCYO[NAW3Q^^VWVZ?_;#H]/+B[>9M_^7[_C\]\'CU_O_TX?;C]5M]_7,CM$XV$70/!Y_6GZ___/8TW/^=K6^_?'V2O,_D1QI_ MLK>?_A.M'V_DE$HW;Y9G8T\W]]_D`.1_#^YNQ]>&G)+K?V_^_?OVT]/7]XRV/V#GL\-+K8- M?O5X9W.Z/+NXW)SG'3_HU=Q0_OVU8US(:VB*5'Z6N6,C[F([9!_/(1FT@6\A]['K&D.)TH M&^?B%X_8Q+FP>3YSQ$?3P-N,X^CZZ?K#NX?[OP_DW5%2>OQQ/;[7+MZ.W9D1 M/+TFMF/Z9T-:QO+8RV]C-^\/I;V,UD=Y(_KKP^+D]-W17_+><3/7?`S4Z(J5 MJ1C?*,9N(Q]B'Q(?4A\R'W(?"A]*'RH?:A\:'UH?.A]Z'P8'CB2>;48R&EXC MH[&;,2-S=C\:L*$MO4!,A6D2^1#[D/B0^I#YD/M0^%#Z4/E0^]#XT/K0^=#[ M,#B@`I'WF-<(9.SF_:&\_=A!LSS6"7R<:L8WQ&V1-ZY6VY)M2I`8DD!22`;) M(06DA%20&M)`6D@'Z2&#*RHT.<^O$=K8C;Q9RFZV@?"M;B[:E=JV9)L:)(8D MD!2207)(`2DA%:2&-)`6TD%ZR."*2DVNR:^1VMC-)C5SMC].,KBB0I*;'Q52^/;?W"N,U3J+ M24XW)?>/'EO M5R?^A:-C[$8G,HEW[;CP1L>VR,0606)(`DDA&22'%)`24D%J2`-I(1VDAPRN MJ)#&!0.5TN[AL2G7:M*@2&SONQHPS63E)MF\]C^.2ULRBKPKRJ4W9FR5:1B18E)"2DD9*2<5 MI))4D6I20VI)':DGR4JN.85RV9,33-:U4\$[D7F7'.*8DY%)%B M4D)*21DI)Q6DDE21:E)#:DD=J2<-BG06XP34S>*%5YUQANE==F;RKCM7_AB: M&JK<0+'MRXRTA)22,E).*D@EJ2+5I(;4DCI23QH4Z=S&*:B;VS-C:)ZQNF]Q M$ZGK$"@:EYNG-T)SXF-20DI)&2DG%:225)%J4D-J21VI)PV*=!;C3-/-XJ5C M:)JQ2NCF7'\C46W5;V2K3,"+%I(24DC)23BI():DBU:2&U)(Z4D\: M%.G-"C268SS43>+EXZA:5ZK0II(7X=.%_YU:%MEQQ`H7H`24DK*2#FI()6D MBE23&E)+ZD@]:5"DN*2RG2;\:0Q-)2,X3!Z?^ M$P=S0R?*B!23$E)*RD@YJ2"5I(I4DQI22^I(/6E0I',;Y_IN;L]-"C268SS=S>+<0R=R>3FF4RF M:;_*9"9YQ[./L)WZCR$LYZJ+[1IX9,EM:#^+5<<[7B)QO`MYW%PN>KL/>=-2 M7RD-[3YD4^4V9(<`)V@GG4BA218E)"2DD9*2<5I))4D6I20VI)':DG#8IT M%OYL:QI#;\;O_SQ]O;WYX^.]O$_*J`QD="+?69F^R7+"29@A^]6)%2F:Z42] M49QY*[JQK3+C+"&E[#ZS5>[;B;?8E=LJTWU!*ME]9:O<[KUU@-I6F>X;4LON M.UMEN[_T#KZW1:;W09%.>YQTN=?10*KRAK^-=2SW+D83C4N7]OIYYD_;3N:J MZ3N'FV\E&5IN+ZFQ(?M)EPW&L1A-)0J M\U**#$F>3D/O=BDV5=+>J;+W1ILWB<14V*T,[]UB;JLO-%_4NCA?G"^]VH#$E=G>M(;N[SM#.W?6FZN>[&TS)9G?Z M=12>/IBKY/;3OHZFAN-]H=,0KZ.Y2N['G"J\ MCK8'8;I/N:U,U7CS_^A!^'>$' M;$TKN[O.T,[=]:;JY[L;YI+II].O(W\*[+\?_>O^Q\]N#MS+"*?&)Q,Y;S4K M4F3(#JAX)KG$F2@25J6&;%5FR/:5LZ^"5:4AVU=ER/95LZ^&5:TAVU=GR/;5 MLZ]!5>F,QJGJ'I?T>69KKT5!/56I0SPWML(CGON02 M9^-!56JJ[*LY,P=A^\I-E>VK8%5IJFQ?%:MJ4V7[:EC5FBK;5\>JWE39O@95 MI>(99Y`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`T/>S<),WACR/\ZT5=OK$"DF):24 ME)%R4D$J216I)C6DEM21>M*@2.?FKS4\,X:F!03W+>Z,:PJDB!23$E)*RD@Y MJ2"5I(I4DQI22^I(/6E0I+-XI36%,ZXIS.3=R_D?+MLJ.X:XIL"JA)22,E). M*D@EJ2+5I(;4DCI23QH4Z=SV6U,XXYK"3.HZ-%4Y%+$J)B6DE)21.%ZZJ8?O=@PDW[ON_"?X;%5)J2(%),24DK*2#FI()6DBE23 M&E)+ZD@]:5"D<_/7'W;/8\^YS#"3^]Y'BD@Q*2&EI(R4DPI22:I(-:DAM:2. MU),&13H+?TWAI6.(BPWGV\4&YW.]"_^S<5MEQ]"VH:&850DI)66DG%202E)% MJDD-J25UI)XT*-*Y^>L/SXPA+C.<3Z3&$"AB54Q*2"DI(^6D@E22*E)-:D@M MJ2/UI$&1SL)?4QC'T/+L^2\GGG-UP9#,F>R'X1?^A^&FRCY&%UER&]I/`/41 M^S/O9UX]G&"?3S0^Z[SK..>&[G'.#>56U6EH/V71Q[G?3/.<,TU#SYS/N:%[ MG%MRC].N9.OC#,W"?ND5P&G7^4S/'/%> M_&SW%3O2)%I)B4D%)21LI)!:DD M5:2:U)!:4D?J28,BE<7%*]UZ;_K1M]XS>;?>_K*#K3+W"!$I)B6DE)21M*@2&?Q2K?>%[SUGDE_A'3A+SO8*CN&IKZ6/(7P*R578,37TYZ<:L M2D@I*2/EI()4DBI236I(+:DC]:1!D0QMJ\R`B6Q# M0S$I(:6DC)23"E))JD@UJ2&UI([4DP9%.K?]UA0NN:8PD_/FM2)%I)B4D%)2 M1LI)!:DD5:2:U)!:4D?J28,BG<4KK2E<F<,4UA9G:4WABFL*,^GKT)7_G(*MLF-HZLM)-V950DI)&2DG M%:225)%J4D-J21VI)PV*=&[[K2E<<4UA)NO0E?^<@JVR8VC;T%#,JH24DC)23BI( M):DBU:2&U)(Z4D\:%.G<]EM3N.*:PDQJ#$U5#D6LBDD)*25EI)Q4D$I21:I) M#:DE=:2>-"C26836%%XR'^*:PM5$DHBS+G?E/Z=@J\R`B4@Q*2&EI(R4DPI2 M2:I(-:DAM:2.U),&13JW_=84KKBF,),S8%:DB!23$E)*RD@YJ2"5I(I4DQI2 M2^I(/6E0I+)8'+_2HL+4D5Y5,.8-(_L]KFEISBG;CJ.`Q0%+`I8&+`M8'K`B M8&7`JH#5`6L"U@:L"U@?L$&;%^5^ZPR+8RXT&'-'5L"B@$D\4W].6XD')O'` M)!Z8Q`.3>&`2#TSB@4D\,(D')O'`)!Z8Q`.3>%SSXGFEI8?%,=<>C'DCS7^@ MP2ES1MK4G1.;1`F3*&$2)4RBA$F4,(D2)E'")$J81`F3*&$2)4RBA$F4,(G2 M-2_*_58C%L=&`2#TSB@4D\,(D' M)O'`)!Z8Q`.3>&`2CVM>/*^T0+$XY@J%,6]ZY3_VX)0Y(VWJSEWH"]1)E*B3 M*&$2)4RBA$F4,(D2)E'")$J81`F3*&$2)4RBA$F4KGE1[K=FL3CFHH4Q9P3) M2)OJ').1!I.1!I-X8!(/3.*!23PPB0&`2#TSB@4D\,(D')O'`)!Z8Q`.3>&`2#TSB<=/&G%&U"E@4,(G'70W8+'9)/#")!R;QP"0>F,0#DWA@$@],XH%)/#") M!R;QP/J`23QNG1?/.,-VXWGAEW47BVFJKG.;S+NF^8]CF*;.]4NBW#8UHT^B MA$F4,(D2)E'")$J81`F3*&$2)4RBA$F4,(D2)E'")$J81.F:%^4X&W>CW/W] MW85$Y7\)WI@>:>XL?S.")!Z8Q`.3>&`2#TSB@4D\,(D')O'`)!Z8Q`.3>&`2 M#TSB@4D\,(G'-2^><8;MQO/BD39-U6579FA\7"PF4]>TY;'_T(939II*E-NF MQB1*F$0)DRAA$B5,HH1)E#")$B91PB1*F$0)DRAA$B5,HH1)E*Y-41X]?EVO MGZ+KI^L/[^[6#U_6J_6W;X\'-_=_?I??=C:NH3A^\+#^_/Y0HEF\E=A[==C-LVOTR- M?5Z.VR[#[:[&;9N_.XEVBV/9)C=-@6.YDF;RF5A@BWR^,O88;"6+^^.V\-D\ M'L^F+!D'^QS/IJQ7!K>-9U/""VR[DF;R%%9HBS22YWQ"6R0`>>HDM$5.OSS7 M$-HB)U\^90]MD5,OG^,&MEQ*&WG:/[1%VLCSY*$M;`EBLYZ?+\;&B+ MG')YFC.T14ZX/"\8V'(I;>1;I:$MTD:^MQC:(N=:OD47VB+G6KZG%=HBYUJ^ M-13:(N=:OI<2V'(A;>2WEX2V2!OY_1BA+7*NY; MV'(IYUJ^_QS8"A;;(N9;?.Q7:(N=:?@M2 M:(N<:_D].X$M9_*3RB\]#VV1HY9?JQW83J6-_''D0&^GTD;^_&YHBYQK^6.PH2UR MKN7O[06V+*6W9;"WI?2V#/:VE-Z6X=XDA64PA:6DL`RFL)04EL$4%M)F$6RS MD#:+1< M_^1.0\ZUK,D$DEO(N5X$S_4XL$(MI$&P7DYS\"S+20Z>8SG%P3.\N1$)G>'H MY/1MD(_#,N"_G;[] M[2=WA./0&UL<;6_/'C^\^W']95U?/WRY_?YX\&W]66Y?C]^,O]+KX?;+."^9 M_L_3_0^YK3T\^/W^Z>G^;O.?7]?7G]8/8X$4?[Z_?S+_9]S!W_9H`(``!8'```8````>&PO=V]R M:W-H965T&ULE%7+;MLP$+P7Z#\0O$=/QXX%RX'3(&V`%BB* M/LXT14E$1%$@Z3CY^^Z*MFK%2:M>!'$UG-G9)5>KZR?5D$=AK-1M3N,@HD2T M7!>RK7+ZX_O=Q14EUK&V8(UN14Z?A:77Z_?O5GMM'FPMA"/`T-JV12?0J>8>=AU%URK#BBVLI'NN2>E1/'LOFJU8=L&?#_% M,\:/W/WBC%Y);K35I0N`+O2)GGM>ALL0F-:K0H(#+#LQHLSI)LYNEC1B:WU_J.1Q6?9"B@VM`D;L-7Z`:'W!89@.^ MZ?TG(:O:0;5#<)^6Y^M1NF6/KE=%[`NT&M.T8'IXX M`^+7`\\_F`$1@NB@#&K3E1&, MRE@53.7&!TYEDM=ETK$,%GWV9M&/1G$3X$Y-)/.!WV?@,4`U&)T-B)%1H)EN M%,'0"R`?:,]K[$$3I`$R71K!O?10Y$/D5"A.X]==SO]'"L%CJ4-DUA_6TV.R M&//VE^8*[M[?3RKN&@L<(J.>IF^<&1RXDR\%@L=2A\BYE^68%[TDBW]ZP5UC M@4-D["5]T1<_A_QE5\)4XH-H&DNXWN&,2>#Z#M%A_&T2K/_+^"S;]&,Q'#[` M6.I8);XP4\G6DD:40!D%"S@IQ@\VOW"Z@\QA.&D'`ZE_K>'_(^`&1P&`2ZW= M<0'"X?!'6_\&``#__P,`4$L#!!0`!@`(````(0`X2180LP(``#<'```8```` M>&PO=V]R:W-H965T&ULC%5;;]HP%'Z?M/]@^;TQ"10*(E1T M5;=*JS1-NSP;QTFLQG%DF]+^^YT30Y84VO(2)8?/W^78/BROGW5%GJ1URM0I MC:,1);(6)E-UD=+?O^XNKBAQGM<9KTPM4_HB';U>??ZTW!G[Z$HI/0&&VJ6T M]+Y9,.9$*35WD6ED#;_DQFKNX=,6S#56\JQ=I"N6C$93IKFJ:6!8V',X3)XK M(6^-V&I9^T!B9<4]^'>E:MR!38MSZ#2WC]OF0AC=`,5&54K7\>)F M3MEJV?;GCY([UWLGKC2[KU9EWU4MH=FP3;@!&V,>$7J?80D6LZ/5=^T&_+`D MDSG?5OZGV7V3JB@][/8E!,)#&@(?TYI M`L(J\V5*Q]/H:/_!E#@[:.S3"CPMV1-T0^PQ-P$#S_^8 M#L'`36<);/0MG6[/01G!J(SM0BLWH="724[+C( M5_J"<3([G78ZE'Q?"L%#J7VEO1B#+LZ&O!@EF7R8!5<-!?:5X=Y>G6( M,%L<0@E+=3LW6?<#S*V&%_*!VT+5CE0R!\I1-(.38L/D M"Q_>-.`#.2K02%5NJI;I56:IGT\.\:`58R1[33MO]^U M36AHTHZ^`+XW&)`FU( MDY-:-BQ#STRCJ_7G3ZN]5`^Z8LP$P-#H#%7&M"G&FE9,$!W*EC7PIY!*$`-# M56+=*D9R-TG4.(FB.1:$-\@SI&H,ARP*3MF-I#O!&N-)%*N)@?QUQ5M]8!-T M#)T@ZF'77E`I6J#8\IJ;9T>*`D'3N[*1BFQK\/T43PD]<+O!";W@5$DM"Q," M'?:)GGI>XB4&IO4JY^#`ECU0K,C0)DZOXQCA]WWT'>A*[K\JGG_G M#8-JPSK9%=A*^6"A=[D-P61\,OO6K<`/%>2L(+O:_)3[;XR7E8'EGH$C:RS- MGV^8IE!1H`F3F66BLH8$X!D(;K<&5(0\N?>>YZ;*4+((+V>SZ?QR`31;ILTM MMYPHH#MMI/CK4V8*MLJVM3>7:!XYEDO,RDX_(6'"&IL?))U'/ZY4]!BK>&YSVB(%!H!EO MT()A#8"\ISVMK0>-D`;(>&D+=M)]<;O(L5"?O>'LL MAKSNR$T@H_=WJ)TU%.@BPS5]8Z_8?CWZ,%CP4*J+G'I9#GFME\D1V?IAM_3^#^#_3IEI3LGJB2 M-SJH60&<46C[LO*=W@^,;"%1Z+/20(-VGQ7&PO=V]R:W-H M965T&ULK%G?;^)&$'ZOU/\!\1Y@U]C&*,DI-GMMI5:JJOYX M=L`$ZP`CV[G<_?>=]:SMF8&`4_7EN*R_;YAO9G8_8.\_?3OL1U^SLLJ+X\-8 M36;C479<%YO\^/(P_NO/SW>+\:BJT^,FW1?'[&'\/:O&GQY__.'^K2B_5+LL MJT<0X5@]C'=U?5I.I]5ZEQW2:E*S M8'I(\^,8(RS+(3&*[39?9ZMB_7K(CC4&*;-]6D/^U2X_56VTPWI(N$-:?GD] MW:V+PPE"/.?[O/[>!!V/#NOE+R_'HDR?]Z#[FYJGZS9V\\=9^$.^+HNJV-83 M"#?%1,\U1]-H"I$>[SQEXP M\<.9IP`^>LZJ^G-N0XY'Z]>J+@[_($BY4!A$NR#P>B'(%:+GB/#JB(N)FL\" M^]Y7:'-'@]?V_>"MKQ`@7*,27@>\SQ1KU)1\E=;IXWU9O(U@CJ$*U2FUNT(M M(51;:WSCKOKO%1^J;H,\V2@/8]B`4-<*)N;KX\*_GWZ%)J\=)#Z'*(Y(6H3M MJ(VZD@N&+$PA_TX$5.I_$&&C6!'M^\?M0J]*BY1;1$M9M0L])?`XQ[00X#`1 M,#!4Q.5I;PMNP0]C&):^X`%_GQ@AT-,.,N>(I$5TV;<+[U),BY#)0R;#D[=@ MV)0DLT7(4XL1$C6C=*=TY"_D0"4(P0.@&1?."?V%$A-F"(65'HHT/'L+%MDO M1/8("3'[T%="78+/2>J4X"^BN>BE(026>/"1Q"U8)!Z)Q!'B$E=ZL?`"H2U! M",F=<;0W#WTAUQ`*RS[DV=NS9PY*KT^^)?')CV9"!4(@TKN3WR*ZR6\7WJ68 M%B$GWW[J(`?H]>0MF+<@$C,:(P1;H+3VE%"7((`T@#.4"@3#$`:K?\13M_7W MP*VO2[`D(4&(04FB`]/4/9`(=A.T`(3#I,MP?< MBAL]SQ<,0QE<@+4T(F!@%]`(X4SNMFDD'"I6B&%"^&9/.DBOXR;)4!*78@V. M2+F^%Q3:(>U%)$8W=ABLJJ<"T:O$/:>#A%$=8Z8$PU`&3][Z&TE^8!_0%9D( MX3^Q0HQ+*0IU>+8?$$%E4,YB$7C"28P+VE"X#NCW?]!A66)7"R>*[=<(P*". MN\A3H5":.`3503EJKF>BPX92N`YK?!_O!]HE5*_?%Z)TL6HMM<>(K9-TD'Y? MW"092N)2K/T1*3?V!9HE&RGY44.UADHDB!,GZ3"]!F1A`]6%,ZJ-"@PNP)H@ M$3!P;Z!U4B%*6D&L6G^]IJ3%]$IPY7TEA,&56#/\N!*T4#I5:B8_>ZC69XD2 M>=RVD%Y(N_(NR71Q95>T\._K8]6@^0Y7,W$ZQ@X$F[;;/G,Y5QVF$^%6W,&@ M?5]^+C.4P_JA/V3?#5IJ$/G%#H39A`L]%T=.X@#DE&(4[3V M)A3S3``"J`!&F9^+-BYHP^$"K%%^>$-KM%=XVV[.U4RX6>Q`*"32%P8)HU`A MN.(H_OFW.1?S@@YKE$3'C4:@K?+\I5_;'\V@6SY^DP:_%J=1][S?R,APK5/* M4Z*YAG)X'X1=W\@?W93G+WU:(PBS6?CR9X[$/:?EIPP?'$ZTU%`*3]]:W_#R MHU'R]*5':^JV82!S2=QSFCYEP(?=(!0M,Y3#\[>&-SQ_M$<8UG[\Y5?E6+<> MVH/$695TD'Z";I(,)7$-U@N':T#G9#V0OUG%^H*]"K](.DPOXC;+4!9387\$ M&*ZB08L357YGB1T(-F?7KC-7[C"=BF[E?9;I,,#B*H0O#_O$Y^'7:SY7HMZQ M`S$UXF3J(+T8C'R%9"B):Q$F/5#+!;-68@/$'G5>/PIG`I`X@/WVW_5.R5-U MY5!,G2B;N16)2X9M08=PH&3+DL,HCM#80Q">RL&YN[OGY%AC#.6=40RE?"!Z:+S\1I"DZT+52)QVF'S\,C3^IZTL2$'#NZQZ\TPR/[N0#2"L/NE1?`^*EW*'K'S)DFR_KT;KXM7><0;PT:=;[>Y?GYKJBO48 M[F6;2TRYKI?))?Q*+^$R"E(3^"?/APO>9@[$$RA%>_4[[1[!U>LI?W^$==G*!'<`%;U'#IVOQW!Y?L&=STS28`WA9%W?X! M24V[:_O'?P$``/__`P!02P,$%``&``@````A`'-G`M%"`@``$`4``!D```!X M;"]W;W)K&ULC)1;C]HP$(7?*_4_6'XGSH6[2%8+ MB':EKE15O3P;QTDLXCBRS>W?=QP#A66[X@5B"J:5484-`$>\T?O,$S(A0,IFN8`$KNU(\R+%S]%TD6"2S;K^ M_!9\;ZZND:G4_HL6^3?1<&@VC,D-8*W4QDE?NB^]R*W58J3 M83`8A4D$+HA/*0^(3)`'WI_OQHQ#B#77YEM32;*;5 M'L'.P"--2]T&1E,`NV`)M.?]8)#(U3R[HJX4U`:&L&1E\]-XG#VR?/O6;2M;<7C\;).!J\T<#*.\Y9,QSTXW@XN'"\ M/[_4?N@M+?DKU:5H#*IY`:G#8`3QM5]I?["J[8:[5A96L;NLX,W#8?)A`.)" M*7L^N#_-Y5V6_04``/__`P!02P,$%``&``@````A`#K\W%2J`@``5`<``!D` M``!X;"]W;W)K&ULE%5=;YLP%'V?M/]@^;T8"#0- M"JG25=TJK=(T[>/9,0:L8HQLIVG__:XQI:'I*OK"Q^7XG'ONM2_KRT?9H`>N MC5!MCJ,@Q(BW3!6BK7+\^]?-V05&QM*VH(UJ>8Z?N,&7F\^?U@>E[TW-N47` MT)H6D^B>4,MY&]JT9EG-LGFT$FJ[_?=&5.R`XJ=:(1]ZDDQDBR[ MK5JEZ:X!WX]10MDS=_]R0B\%T\JHT@9`1WRBIYY79$6`:;,N!#AP94>:ESG> M1MG5"I/-NJ_/'\$/YN@9F5H=OFI1?!.B:D&$H`KDL+M#"@( M?>SO!U'8.L=Q$B1QNKR(`(]VW-@;X3@Q8GMCE?SK4='`Y5GB@07N`\OB/$B7 MX6(&"?$9]0:OJ:6;M58'!)L&)$U'W1:,,B!^VQ%8<=BM`^<8-C7D:J`+#YLX MC=;D`4K'!LR5Q\!UQ+P@"(B.RJ`V7]F!G;*KK4OER@>.9>(QD8G,XB,R#ISC MY"CY.'WA]`VT;#29O*P/-?(,.##T`\I'VM+8>-$,:(/.E';B7'HL[1(Z% MXG3QMLOSCT@Y\%1JB"3]^3O>'LLI;W_D8CBY[^]0MVHJ,$2F/?U/Q]RXGGT8 M''@J-41.O:RFO+V7$*K[OA>W:BHP1*9>TE=]\5/,'W+)=<6_\*8QB*F]FU`Q M'-LQ.@[/;>SJ_SJ>9-M^J)+Q`PRUCE;\CNI*M`8UO`3*,%B"%^W'HG^QJH/, M8;(I"].L?ZSA[\7AY(8!@$NE[/,+")/Q?[CY!P``__\#`%!+`P04``8`"``` M`"$`!!OGM.H"``#%"```&0```'AL+W=O\,EMP:%5.E6W:VTE5:KO3P[8,`J8&0[3?OW.V,3!$G: MLB\(#\?GS)GQA?7-2U629ZZTD'5,@XE/":\3F8HZC^GO7_=7UY1HP^J4E;+F M,7WEFMYL/G]:'Z1ZT@7GA@!#K6-:&--$GJ>3@E=,3V3#:_B2254Q`T.5>[I1 MG*5V4E5ZH>\OO(J)FCJ&2(WAD%DF$GXGDWW%:^-(%"^9@?QU(1I]9*N2,705 M4T_[YBJ150,4.U$*\VI)*:F2Z"&OI6*[$GR_!#.6'+GMX(R^$HF26F9F`G2> M2_3<\\I;><"T6:<"' B>)93+=!=!M,J;=9VP+]$?R@>^]$%_+P58GTNZ@Y M5!OZA!W82?F$T(<40S#9.YM];SOP0Y&49VQ?FI_R\(V+O##0[CDX0F-1^GK' M=0(5!9I).$>F1):0`#Q))7!I0$782TQ#$!:I*6(Z74SF2W\:`)SLN#;W`BDI M2?;:R.JO`P4V*<=E4[MCAFW62AX(]!O0NF&X>H((B"_G`DD@=HO@F,)Z!!D- M!7S>A(OEVGL&TTF+N748>':8H$-X(-HI@]IX902C,E8%4[EU@;Y,>%EF.I3! MHD^A=>\;Q4DQG?5,A(OKCM]EX#!0^<[HK$,,C`+->*,(AEX`>4=[7F,'&B$- MD+[T./,XR:;0%;N-]`7#Q>JRV\50\OTZ(W@HU49F=M'VE\MRR(M69I#0^_PX M:#!.WIO('@HU4;.K:R&O*XK'ZY)G#44:"-#+V_LM@#XQYNQ MZ*'8,71N)\`MWZN3;8V_FGS8'3OQ1*4]/H:>WMC:P7\=(19]HM:>(A<\73@V M@OF'/<)]>]*D8VCH:'JRXMREX4[FBJN`:<_64*#E+N&W,#(!NH#5XDT<'W8UP)^ M%SB@['4_()M_````__\#`%!+`P04``8`"````"$`1[EN@(X) M```M*@``&0```'AL+W=OPG[U7;UK,%M-)==PVN_KX\C#]^Z_DE]OII.O+XZ[< M-\?J8?JMZJ:_KO[[G_N/IOW2O595/P&%8_W[4SB?=]O7ZE!VL^94'>&; MYZ8]E#W\V;[,NU-;E;NAT6$_=Q>+Y?Q0ULR_?)V^F7;'$X@\53OZ_[;(#J='+9A_G)LVO)I M#^/^ZOCE%K6'/XC\H=ZV3=<\]S.0F_,+I6.^F]_-06EUOZMA!,SV25L]/TP? MG;#P%M/YZGXPZ']U]=%I_Y]TK\U'VM:[W^IC!6[#?6)WX*EIOC!JOF,0-)Z3 MULEP!_YH)[OJN7S;]W\V'UE5O[SV<+L#&!$;6+C[%E7=%AP%F9D;,*5MLX<+ M@'\GAYJ5!CA2?AT^/^I=__HP]9:SX&;A.4"?/%5=G]1,3RQKYH#)^BL3.[#0)_>7MSN0@PAV'`IQ"YF3G^8GG%()9"`C[E M=5QK!,RJX3+@4VBX,]\-;FX'-\\X>"<:PJ>\_HL:.E`Q_`:RTN$W!VX#[6K. M;_Q01U'9EZO[MOF8P.2$6]N=2C;5G9"I805Q"5E3GY44U!)3>60R#U,8.%1+ M!_/@?>4YP?W\'6IW*SAKRG%,Q@89K%"9;&0#L0TD-I#:0&8#N0T4&C`'6Z0W MX.3/\(;),&]P5&L$E%FN900RL$ED`[$-)#:0VD!F`[D-%!I@&.&-&`'+VB?+ M#-8$:_4PA8DM:\)U;\V!KCG'@8XER3>14@X`3I'8U/2 M4W9)3[G1DQ=X@36"0N_)L)4EMW_OZZ!B&BL@J]@L!S;(4I44"2C0]RSJ+;+8 MXO:^&C,7I6^4NPBIWC+4.=M;CBS>VYC!*#WT9CK,0J(^:^W*_:LY@76C2[>V M;#E,QK*80_KJ+5@:%`G(VN6L.!4K%M9B0J&40AF%<@H5!F3:`\Z?M>>BG8WE M0-L=#FE6;`1+@R(!P>ZF9C+-`(JEW.'RT!"AE+(R"N44*@S(=(>ER'/%"0'@($2X,BA+08@)#22A!2K!0AE3$RA!0K1TAI%0@-+'/,+"M> M,68>+<%#]'/-GO=`#5A+])VYBVV0I1;-""&UM,8"TB,!9:4(*:T,(:654ZW" M8)DVL%AXA0T\11HVB&`).Z'A?Y'#("`\C.Q5G^7P.!=[-TMJ< M$Z6#TJF`M,B1*9:Z3-);C@U9WGU?W2VL811*!?HRC62Q\PHC>4HUC!3!%::2 M9B1Y5"-9.-K($9"J@5A`4$]*RPFL72NA#5.$]!(C\OE%\@5JC6SJ+*=>81:/ MM899(NE",M/,LA_GP/K,IJA6!Y&`M-08(TN/HZYOG:@2U5#KT7[6EJ+6\/AX M"+N9:HAW+$>6V:-U,BQ4P_$>S?IC&56WU,Y)EVUU/.D:3HOP"U6@.6T?>QS! M4G43(<2??[.#88P0S&FI-5*6LDZZE\ZBFVT0D7H;&N2"M6CQM)FBU&[D!'.U^YE&7^0L8SG&3]02^-&L#0HHE!,H81"*84R M"N44*@S(]((%8WT>G\]B+L_1^H05D!;3-Q2*!&2>:WRK<&+%PL))*)12**-0 M3J'"@$P;?DIR=VER%Y#A#F=I4"18WSG7*)9RAVOIYQK*RBB44Z@P(-,=%K?U M(OFAQ=[EH=VH'0%IYQID*2@2T.?G&D50QG!E:(-02I4SU?"33&"%UA$@04JP4(:65 M(:18.4)*JT"('G5<%J&OL($G;L,&#C&GE0TDXP_]@`WJ%D<(Z>&!I.Y8L'QW M2-V.YRP"*W@G2@CO>XJ0ZBY#Z&QWN6!!.!X/^4H%^C(+BD7A*YQD=&M#XA#L M\;J3=LAG9THKMPI(SZW(@NJ3=X6F*=HPQ8;ZWL][U.1S9)V5+PQYTZSK0KY+ M0[Z`6!=R@*YOAWQDJ3J($%+;?BP@XT3D^M9,3E1#K41@+[SN!Y9^L'&)6LDRAO3A10OLM1%9"BO[W)DEPG+5[<>ASW,PM?P2M>P*=JX M&\+[$W"G;=R#5\!&\$<_?(0+'6G@A_![^@CN0L]\;[>[<-UP#2F-MH'$'6Y& MOX'@#6IC%PRA$[X94X/`%29\6[6N``(3M!F]:L<)U_!D?.3:X!OV+)]^`S]V M@,=C)L.#?OAFO(T7LH?65`T>4D.;L6_60;@>'OQ;H]D$X68,CX(0WAJ@/43+ M$'XLIW@:A/"3.<6S((17!$;P90@_CP,^EQ<$+^N=RI?J][)]J8_=9%\]0[DN MAA<&6OZZ'_^C%[\^/34]O*8'BP*\R06O95;PM&,Q@Q7PN6EZ_(-U(%_T7/T# M``#__P,`4$L#!!0`!@`(````(0#B;+*HA08``-\9```9````>&PO=V]R:W-H M965T7]D#@7+A$P*B%7S4BCT5R> MTQ`@*B$H2=MS_GZVXTM\X=`B]:4IB[V7[>5E>\>L?OM>GR=O9=M5S65MH*EE M3,I+T>RKRW%M_/-W]&UA3+H^O^SS3=MKN4%OCDT;9WW\+$]FMVU+?/]D%2?3=NR9F:=5Q># M,/CM9SB:PZ$JREU3O-;EI2^A_=ZJN'6.KB\_0U7G[\GK]5C3U%2B> MJW/5_QA(C4E=^.GQTK3Y\QG&_1VY><&XAP\:?5T5;=,UAWX*=";IJ#[FI;DT M@6FSVED>0Y!L:MG1,`-_MI-]>[7O3VO#\:;VPD/>#.(GSV771Q7F M-";%:]H#$I23PI"1HNO`\=[:8?[XG$#F, M!YZ49/XXR8R2P)/WY-'1P`(;.@)/SC&.YHZ62YH(3YJX$";D3B("\Y"YQ"ZB MTS3.@IYI$B\,UMKE?;Y9MY*_,-[%S0F*T>@^2(@$5@[V+:G0J$*A"I0*P"B0JD*I`) M@`FR<&W`XE^A#:;!VK!1;1DPBF4K0K`(EK)3@5`%(A6(52!1@50%,@&0A'"^ M1@A,LS9@S7.3V)8R\BV)0=`3'J3X*.`A7!T-"34DTI!80Q(-234D$Q%))!C7 M5[@%T\!BA&:X`+!!R_[8TJ![*O$0KI*&A!H2:4BL(8F&I!J2B8BD$FS6FDJV M-P7XP1T'$PTZL?%M">(.)_"P?004&9?>CB++88MRT=Q>RLJ&/(#11AH2:[0) M03S82/BDV98G4Z<\B%%G(B*I!*>1IA+RIOAP[$]5\;)MH!UH[<;1[\#0R)Z, M262%""(J1!%!(8)X0RDR\(0:$FE(K/$D!'%F@]*VA1Q%#?X]5T-$)#7FBAHW M1@VU!QLVCI:'31!['%)`$5+9#"<-16R^2X<4<3@2:3&QQI-H,:G&DXDQTD!Q MI:X>QO8,5W.W9EH8,TZ4QTP05W:DLHT$),AV^1!W%($>-,T)JD)E15DIKW;8.C90D) MXHH[L6TI6@0DR!F]M2.(O>2BAI3('?1"WD(33$N)-=I$BTD_HLW$%$D97.@] M(,T0+FM#(<5?RM0$-$HT&(/&73ID7,1/MJ?)H^?$#!JMFS!H9$X_8LZD'%DB M7!2*:_&^>Q`.5R0B$!AA=*]M*>=-0!-%`U%(=!"%7&HA6'+JFM.38ITZT:/2 M#ZDS*4D6"1>,#XA$ZDNH;=C&L,6%'NAFBQN.C93!!2QJG.T=@\;9#BGD$A\A MN)U`EK+C17I:S*"1/&'02)Y^@CR3TF2A<-4H"D5>LQX\T'%1J)J,0++)D/9> M1:(DDQ'()1<%^`@,*;U+CVSGALEX:VP"8YHD4">,9Z1.&?13ZHQ&$-/+VN%: M4M3N@Y5(2T_19`123*:\>02(1HT^V#%H]$%((6XR;^[J)N/MC3)IY(E.GFKD M2"//I#19*%Q.BD)ADWVJ?,"W2*JQ"*082RGB`IHHS/Z.0M+N1;@<>/!SW%:O M!Z(Q48Q2BNA8;S$9$YG<*8N26U0V@VQ,O-VBK"XN3U5U'Z[)$2ERP>VLKUL* M*>Y4ZPP6);J3<$$9R+A"%@7?"$HKQW+$HN1-5U.:TH\M)BQQ;#%ET-T6,Q;U MLQ9EI2'J"Y3&+,J)3"#%T]H^0*(D3U-(K*;ULACN?G&+#GX#>]O,+313-^*( MA@B+(V998P69,.ANBIN^W"1=`-W?+@\T?$GUW^"CNI? M;%T?[A%NX)Z_G=W``\\/;N$[SXO*A;ZX@+MRQ-SW&ULK)G;;N,V$(;O"_0=#-VO M90'$KK MW[Y7Y]%KT;1E?=E8SGABC8I+7A_*R]/&^OM;^.7!&K5==CEDY_I2;*P?16O] MMOWUE_5;W3RWIZ+H1A#ATFZL4]==/=MN\U-19>VXOA87^.58-U76P9_-D]U> MFR([]$[5V78GDX5=9>7%HA&\YIX8]?%8YH5?YR]5<>EHD*8X9QWTOSV5UY9' MJ_)[PE59\_QR_9+7U15"/);GLOO1![5&5>XE3Y>ZR1[/,.[OSBS+>>S^#Q2^ M*O.F;NMC-X9P-NTH'O/*7MD0:;L^E#`"(ONH*8X;ZZOCI:YCV=MU+]`_9?'6 M*O\?M:?Z+6K*P^_EI0"U89[(##S6]3,Q30X$@;.-O,-^!OYL1H?BF+V+,IT,9XO)],^ MR`W'*7.$)W-TEGYX(Y+*7#?=V%Y=:W!$_> MW;N&N6)^\.0]!(UO".I`!M$)):E$YPK$Q1XV380^K_RLR[;KIGX;P6(%!=IK M1I:^XY%H/*-H")%C/TLQR"T2Y2L)L[%@O)`\+:R+UZT[7ZSM5\CEG-GLL(VC M6^RY!4E<$M8W06""T`21"6(3)"9(%6"#+$(;T/XSM"%AB#9\5#L.%+$,(;@% M=_%-$)@@-$%D@M@$B0E2!6A"0$I]AA`DS,:"-2R29#G3![ZC)@YT1-@8)GMA M(L1!)$`D1"1")$8D0215B:81#.LS-")A8"U",T(`O)*8T2V5A(E0"9$`D1"1 M")$8D0215"6:2K#W?H9*)$RO$A_=CI(I[)R*;DL]N_;"B+OYB`2(A(A$B,2( M)(BD*M%$@7-&$V7X-.=;+;'6QT[)K"\=^GUSCXB/2(!(B$B$2(Q(@DBJ$FV@ M<)!J`R6'S1)D>>=A0\+H"E`""JBS_V#,OC`2LX](@$B(2(1(C$B"2*H23112 MFZLG\.W9)];ZV"E19Q\1'Y$`D1"1")$8D0215"7:0&%M:@/]8*E!PN@*4&+, M_LJ8?6$D9A^1`)$0D0B1&)$$D50EFBBDYM)4N3W]O;D^>H;4!,#(QRC`*,0H MPBC&*,$HU9`^9E)PW9_R#JW/X$SD4[?C2!95>XQ\AN;@+P^%F;$M!-**AP\Q MBC"*,4HP2C6DRT#*K7?(0*LS30:&5!D0\DDU!2M&EV$QT=='(*VD#,*1HXA9 M.;+%6#HJ*D^-JBV15CQ6JB%=&5)EJ)E%FJ3`-RP+5>Z,&J,E4/BEQZOR=7KKV#D,^1*Q9@P)&,%7(D MK2*.9/B8(VF5<"1CI1SU5OJ8217UCC'3H@LTY'KNR/L2F'`7#F2Y*RS05919 MS82C+QUYK("AJ;0*L57$D;2*.5J*\`F.E6I6N@RDQGJ'#+0DTV2@R(632X<:365IZ3.D^3ESH](.F-5LUB^A^6HY,=90*.-P-2/<6BRM9"]1:XG1 MVL/JP6@ME7&@-5U)4IBI2GYLKZ'EG28P14:>N?J"WSO,2N:&SQ%]@4<69<`1 M3(>8+&=NG&0AMY))%7$DP\<["V!WWL$F3I:NEXX`C2I"`.=Y*1Q%'IB-J+69QM&ZBUA*CM:%T5%O3I225 MHBKEQ]*1UIN:PA09Z6BLD[W#K&2^^!S!AJCD'EKPS/%F"H4\EIJAJ,686]UL M,>%6:HON8JZOKY1;P3(3O7<=::6)[YK%^(?$[Z/H-3I#6MZX"W.W959J>G.D MEK`HX0)N16J?U^W0;BL[(-*;.\F]/>;H9FL)MX+J4$B*-J-4:U%7&<*C%._? MW)#2[EM]_5EII]0R4+'T59MRKG-$J[8OYH'.?IXK=1[W4'/#<>2N2GM-/\;0 ME^95T3P5^^)\;D=Y_4(^M,"FN%T+3+\"[9R)1ZX_(+7YR\R#=V,#?.[!ZZ$! MOO#@;?$B,:%+[@,_0+?#'[.A1K1SHVT/H.&A^TAP8&X\\@?A_(%GV"+V+7 M[*GX(VN>RDL[.A='F,A)?[MHZ#&PO=V]R:W-H965TXV M;70Z:K5JM:F=W."L<@/ MW]* M?`@_)E&PM8*S#Z,->6(9>`G#5R:=;1F"QAII/4XS8$?*UM^Y;\?$"3^F?K`_ M))#N!EP1NS!S^W/HQQZ,*-A4:@WFY(5'Z`#\54X!*PT8$?='^OD1;)-#5S6: ME4:K:N@@5U[\.!D'S%)5O+67&36F8"GYF)WJ[H]6KS`8]ZY@&? MZ%%Y:C3JS:?6_1T!97HU\(E74VGIU;;Q@`?,C-0#/K_>D79F`I]?[@B439:; MTK@^/B:Z@3;P)>O,XRG6F^@"7[X^+GH+;>#+HYW1>.VF4V'H)FZO$X4?"JPO M4)WQQ66KE6[JD#>!CF,KO/4,W.MH[3#\O MT_2I1A<5`U2PN<9LAS(8R6`L@XD,IC*8R6`N@X4,+!DL9;"2P5H&M@PV,G!* M0(/TY#F"&OX=.6(V+$Y:*Z*!GD MDCQ+A(P(&1,R(61*R(R0.2$+0BQ"EH2L"%D38A.R(<0I$R%I,,Z_(VG,!A9+ M"),G1*_+2UTFNI6U7))GC9`1(6-")H1,"9D1,B=D08A%R)*0%2%K0FQ"-H0X M92)D#8XC5[)688>2Y!!XK_T0T@`+YY5#FP'[$-^=F$F:,QSK?D:*Q7!`R)`3 M`S;M(M,-:84D[(@EA;N:9L+2T9RUR$UBM" MUL3:SC6%]9/4Z4VN06>G3(34PL`*J;V20C@$8PZ96LPA)S4X]Y?RTY`6QTS$ M#]WIF2(CZ8U%6AZCC!CYSC@FF@GQF1+-C/C,B69!?"RB61*?%=&LB8]--!OB MXY0U0B[@2"GD@A\#'YQFS$1,$21-$X$[7RU$Y(M.D]T6;W1)N3:`L2S;HGVC(3/:4GZ595;^K247E%0JU) M*/N>4)M/0SGE4$+1P''__Q<-,Q&+AI,:W/^5$ML6$SO@(B.]P^?W"AF!O:#4 M3"Z:3%3>F/6&7#1Y![`@)R3:])YHLWNBS4FT!8EFW1-MF8G8MO?>NUHT)-2: MA++O";7Y-)13#B44#:3U9M%\#R]0#EJ M!:H*+XNJEJ@JO%94M495X653U095A9E=4/>IU%2A%LC*L+9B&Z&VZ#JU^$(%K;%6$LQ'=#+=!U:_#L?&ULE%5;;YLP%'Z? MM/]@^;V82](4%%*EJ[I-VJ1IVN79,0:L8HQLIVG__8XQ1=!$$WT!?/C\?>?B M<[R]?98->N+:"-7F.`I"C'C+5"':*L>_?SUU+ZT=2<6P0,KIX"W]*I26UL-05,9WFM.@WR8;$87A- M)!4M]@R97L*ARE(P?J_84?+6>A+-&VK!?U.+SKRR2;:$3E+]>.RNF)(=4!Q$ M(^Q+3XJ19-G7JE6:'AJ(^SE:4?;*W2_.Z*5@6AE5V@#HB'?T/.:4I`28=MM" M0`0N[4CS,L?[*+M+,=EM^_S\$?QD)M_(U.KT68OBFV@Y)!O*Y`IP4.K10;\6 MS@2;R=GNA[X`/S0J>$F/C?VI3E^XJ&H+U5Y#0"ZNK'BYYX9!0H$FB->.B:D& M'(`GDL*=#$@(?>[?)U'8.L?Q)EAOPB0".#IP8Q^$H\2('8U5\J\'10.5)XD' M$G@/),GU4A+B'>KCNZ>6[K9:G1"<&9`T'74G,,J`^')`$(G#[ATXQW"FP5<# M17C:)>%F2YX@;VRQT#9Q@!7(V(6(-`L#]"!H09`/M*>Y]:#%D@#9+FT`_?2 M8W('RU0H"=/+45Z_1\J!YU*#9285A9>E-N^1LTTF*XS2Y+.7F]N*V M<."YU&!9]4-E>NA!?,KKYD@*T^C_;>Q`F48;"!.FH_ M'OW"J@X\AQ&G+(RU_K.&6XQ#"XBK5IQD+H7R:2&,SN[R_7R^EDUY`F,E;K-:1Q-*(%6Z$*V54Y__KB[N*3$ M.MX6O-$MY/0%++U>??RPW&GS:&L`1Y"AM3FMG>LRQJRH07$;Z0Y:_%)JH[C# MI:F8[0SPHC^D&I9,)@NFN&QI8,C,.1RZ+*6`6RVV"EH72`PTW&'\MI:=/;`I M<0Z=XN9QVUT(K3JDV,A&NI>>E!(ELONJU89O&O3]',^X.'#WBQ-Z)8715IO?9R.*K M;`&3C67R!=AH_>BA]X7?PL/LY/1=7X!OAA10\FWCONO=%Y!5[;#:R:A&PP`GT1)WQF8$/[R<'5.I[,HN9S'\P7BR0:LNY.> MDQ*QM4ZKWP$5[[D"2[)GP?>!91'-T\DT_C<)"Q'U!F^YXZNET3N"38.2MN.^ M!>,,B=]VA%8\=NW!.<6FQE@M5N%IE:2S)7O"U(D]YB9@\#E@X@'!4'101K7S ME3W8*_O<^E!NPL:Q3/*VS/1_9#PXI[.CX)-T/O`&Y8#!L@T&_Z9@9!!ISC?H MP5@#)!]H3W,;0&=((^18VO?K%+O^_>KZ0WT(0Y+W.\>"2;H8\C%RNQA+OB_E MP6.I_?NK-\6(WA?PI\8"^YUQ;=-77L($"!=$@:G@$S2-)4)O M_>U.L.6'W6'PK!,?\^O]6;;N!Q(;/N!`Z'@%#]Q4LK6D@1(I)U&*7DP8*6'A M=(>1XU30#B=!_[/&R0_8]9,(P:76[K!`83;\EZS^````__\#`%!+`P04``8` M"````"$`;-.`4B`;``"GVT> M[[:?[A^_?#C_WW_E_UB>GSV_W#Y^NOVV?=Q\./]K\WS^SX___5_O?VR??GO^ MNMF\G%&$Q^+Y^]/ MF]M/.Z>';Q>3R\O%Q.YBW#]])H8V\^?[^\VZ?;N]X?-XXL+\K3Y=OM" MQ__\]?[[,T=[N'M-N(?;I]]^__Z/N^W#=PKQZ_VW^Y>_=D'/SQ[NKJLOC]NG MVU^_T>?^,YG=WG'LW7\@_,/]W=/V>?OYY1V%NW`'BI]Y=;&ZH$@?WW^ZIT]@ MTW[VM/G\X?R7Y'I(+B_/+SZ^WV7H_^XW/YZ#?Y\]?]W^*)[N/S7WCQM*-PV4 M'8)?M]O?K&GUR2)RO@#O?#<$P]/9I\WGV]^_O?S/]D>YN?_R]87&>TX?R7ZR MZT]_I9OG.THIA7DWF=M(=]MO=`#TY]G#O:T-2LGMG[N_?]Q_>OEJO=\MY_/9 M8GE%87[=/+_D]S;F^=G=[\\OVX?_]U8^EHLR\5'H;Q]ELCKH,/4.]#<[+-\E ML\L%'>2A'5J:C_>@8]$,V27&`K/CH?WE-#8 MN53:07196KR;+.?)_-BG2O:C0/_@O5T&PW#@.!/.?4*Y8=\C1TJ?W!TI_<.[ M3!?OYE>7T^1(_A-*O',]-@(7KM!V=9O>OMQ^?/^T_7%&9P/ZB,_?;^VY);FV MX;ABW6?'Q\G5\OW%W_07+GS-C=HDVB+ M-5O8B6'#IC'(8I#'H(A!&8,J!B8&=0R:&+0QZ&+0QV`(P`4E?S\"5#$_8P1L M&#L"G+L;!L&01.EF"W9)8Y#%((]!$8,R!E4,3`SJ�Q:&/0Q:"/P1``E6XZ MQ_V,=-LP'\YID@<%O]+YO7$V]I2P-YIID_7>9#\&0#(@.9`"2`FD`F*`U$`: M("V0#D@/9`B)&A#*X<\8$!N&3F*TFWVR\13DC0Z-R-YD/R)`,B`YD`)(":0" M8H#40!H@+9`.2`]D"(D:$;H._8P1L6%V(\*9O'%D2M=#&:/E930E]D;LE@+) M@.1`"B`ED`J(`5(#:8"T0#H@/9`A)&H`Z#JL!F!\^:AZO:6NL\ M.Q)6-9`42`8D!U(`*8%40`R0&D@#I`72`>F!#"%12:5SJ4KJ&ZO:AM'9=F1) MTRFHZDETKMX;[:L:2`8D!U(`*8%40`R0&D@#I`72`>F!#"%1`V"%IAJ!PV6] M,]>9]H@NBYS%-:(4488H1U0@*A%5B`RB&E&#J$74(>H146]F5X8N$SK+5CV% M)X\WUKG5]E&A>[2D\U90Z=.HTL6*!RE%E"'*$16(2D05(H.H1M0@:A%UB'I$ M@T)Z1*S`"D?D2-T[/4;K<\[?C15&-!9+T:QK1"FB#%&.J$!4(JH0&40UH@91 MBZA#U",:%-)9MK(IS/);Z][+KS#]#M'U-*S[6*!:046#%%QU4T09HAQ1@:A$ M5"$RB&I$#:(648>H1S0HI$?$RJ9P1([4O5=98>(="E*ZMMW".,N`,K3*$16( M2D05(H.H1M0@:A%UB'I$@T(ZRU8;A5EV=?_.MHE?OM[?_7:SI9,UG9 MDA6@%%'FT6*R3VF.5@6B$E'%L9)]+(-6-:)&(9T9JV1.R(P3/BHS#BVD_M:) M1[-=DWQ&=R.B-GG*%N*4(&HE# M'T3E?!*+P+BB_[7]_G>7J^#DN@NCD^Y1N%A`E"+*$.6("D0EH@J1050C:A"U MB#I$/:)!(9W]GR0.)R@./8K$873*7HL55WB**$.4(RH0E8@J1`91C:A!U"+J M$/6(!H7TB)PF#B^L`I2B588H1U0@*A%5B`RB&E&#J$74(>H1#0KI M+/\D<3A!<>@1Y5I.F9-E=(-S+592]Z`7,[3*$16(2D05(H.H1M0@:A%UB'I$ M@T)Z1*QH"Z^]AQ?3$Z?QPB6,1T&1KQ&EB#)$.:("48FH0F00U8@:1"VB#E&/ M:%!(9]E*L3#+\=7V5>+0/EL3K7`\FI)Z.2`.Q4JJWL4B1T89AQ>]F(MC MAV+%L4I$%88W8A6$7T4:H!8K#M\HI#-M=5R8Z2/U[&2?JF>O!"4SZPF@%%'F M$:VY^#ASM"H0E8@JC&70JD;4**0S8^7/"9EQ:DEEQJ$K4;_KB4>V@_''QUFR M2*(;+BE;B%/FT53D=^X1/?7'N2L\FCG=F="#H:!6T*O"V$:LI,IP,:UW-UW$ M.VLD#!VBSJP536%FWS:[G?12"7?H:K;/RGKBD1.QL^3J$A(.3IEWHO,39S=G MY)[IM(^N%8R\G+#YCJ9BR297^T`5(XEM&$GLFI&+/2'IJ3M`#1OL(NOL6I7S MGV?7:26578=4.>^1E`JH0_MHJFT5A17MD*IHCT2D%]YQZB;+9+2BG5S_)'4X177HD5:'JZC!M!8K/E^DB#)$ M.:("48FH0F00U8@:1"VB#E&/:%!(C\AIZG"*ZM"C<)6,*$64(D2#0CK+8^K03I,3'^VF$VR\3O9(J\-)=.ED2#0GI$3E.'4U2''JFZ=U8!2M$J0Y0C*A"5B"I$ M!E&-J$'4(NH0]8@&A726Q]7AZ76/^G#JD*[[%=3]WDKJ'E`FL=@J1U0@*A%5 MB`RB&E&#J$74(>H1#0KI$3E-15KY'0ESCX(B7R-*$66(T:"0SG*L2)UN.KWN4:I.'8K6.=%]GK58<46GB#)$.:("48FH0F00 MU8@:1"VB#E&/:%!(CXC5CJ'6.MP]F3JI&8HJC]3ZWED%*$6K#%&.J$!4(JH0 M&40UH@91BZA#U",:%-)9MKHKS/);Z][I-Y5^AZ+S??R(E/T^`YVO@I-3BBA# ME",J$)6(*D0&48VH0=0BZA#UB`:%U(C8?*D1.5SW.W.M:ST*4KI&E"+*$.6( M"D0EH@J1050C:A"UB#I$/:)!(9WE<5U[XB-2,U2U'MDKS;X?0E^]8=I M)!`?>8N[Z]"J9RN207)*645S?E".>O!BY?RF>P*4RUA8>$1W(_@3K3TB@Q1\QD%9 MZ>1;\8H+K%,O-$X"A\NKF4-J0CEDM>2^4."6`?IE'JDYY4,%MPS8RO7P_VY. MP5%5["5RMG]R= MG:->]TA?@5?Q,\IBM:][1!FB'%&!J$14(3*(:D0-HA91AZA'-"BD1^0TV3U' MV>U1L()9(TH198AR1`6B$E&%R""J$36(6D0=HA[1H)#.18BW$BF.5B"H,;\0J#!^MT6JQXO"- M0CK3L48^W."8HQCV:"F*:8TH191Y=!7FSX4/6E(%6TF[IF0DTK1B)+$,([&J M&4FLAM'.2F?&2JQ0P![)C%-DH5*=.Q0\I+9FY*3=+$GB=D;*%L&3;1Z%,M6C M0-D5'I$BWWV1;Z3O@TX5AC9B)46&&O7HWAJ)0V6H,QO+RB.91?DX=RA\*),1 M/Y0YDEEPRKQ3^%`F(RF;PB/J$MK,CGS'JT2GBI&T5`PC"5WKT%/HU37*1V:1JD5G15\[=T]DC]2BMY#JR'P<58O.*N@S%MZ* M:W$LB^!486C#**Q%Y^A#VV\"QUD,(^LLQOKL2"VB#)L[I&K1(Z[%R2SJ#Z7H ME'FD:M'%"O08S,Z/!R5Q<5IFFIGKC651V$M M,N):G,ZBVTXI6P2UZ%%8BXRD8`J/N&!&KCCH5#&2O1E&$KH^&KI13CJ-L6@Z M7(STO>^XO^]16(R,N!A'TNCB!$Z9=PJ+T:.@K@J/^.PUED87.G"J,+3!T/71 MT(URTFD\3>G0^Q@@C0ZI:O1H7XV+Z+F(U,<)G#*/5#6Z..&9T5OY:AR[[\5Q MI,XJ1F$U0NCZ:.B&X^Q"ZS3^%"E#7Y^'[#H4U-O:6UWMBW01G<)3M@A6EQZI M(G6AZ<8`*XC"6U%K^N]6E]Y"%:F+$X0V'$="UXS^-G2C0NOLQO+E34)Q@:K& MHZ`,UX)D81PW"E,QXM1E'JGR=3LD`J;KW>DGN=*9H ME2'*$16(2D05(H.H1M0@:A%UB'I$@T(ZRU9^A%E^:]T[&:/2[Z6/NAV]BN3& M>K&WDKH'E*%5CJA`5"*J$!E$-:(&48NH0]0C&A32(V*E3#@B1U;:3OFHQ#ND MZAY0:M^[II^5S1#EB`I$):(*D4%4(VH0M8@Z1#VB02&597H?FLYR?+5]53-\ M%T6K18^.-,/%:E_UB#(.+PW87*QD(3*!9KA8&13;'B\(U" M.M.G*4=ZK5>\*/G,=:!AZ]$ ME"RH3X=HI/A$L?96M%?7QL6>#UN(4^:1JD\OTF0^%M[J4'V"4X6AC4=!Z=/3@H^\VYG.N14YX34JSOGKVCU73BNI:Y=#X3-@WBI`*:(,48ZH0%0BJA`9 M1#6B!E&+J$/4(QH4TMFWX@>S?W*[AY:6<,US2+=[5M&74=;>D:SXRI@BRA#E MB`I$):(*D4%4(VH0M8@Z1#VB02$U(O3%'3TBAR^3.W.MO#P*BGR-*$64(

D2#0CK+L1A[8[N'M%A<]QY1UT%.[+!H7XO5ONX1 M98AR1`6B$E&%R""J$36(6D0=HA[1H)`>D=-$X!)%H$=ANP=1BBA#E",J$)6( M*D0&48VH0=0BZA#UB`:%=)9C11A?;5_5[EFB4/3H2+M'K*3J7:SPV4<.+Y(F M%T>95-CN$2L.7R*J,+P1JR`\M'O$BL,WB%H,WXE5&#YZ5*(7*PX_**0'TNJL M\,)]Y#+A9%FX/%HZ1#.2=[=&E"+*/*)+&#OFC.0J7C"2#E#)2*PJ1A++,!*K MFI'$:AB)5T7S@0^T1#0KI+%L==D*6G6Q3678HE%7V9_FLC&7ECYTI MMI##SCP*M$_N4:"0"H_XT:.153\Z51C:B)44+':FV-&)[TG\/$`C43C[+;O( M?:?.(RIUMNH%R>ZGE]%+[`:Q(D<];%;AG3!L3A"J87.(VAU\4&O[Y34[;-QJ MP+X76XA3YE&@J')&4KF%1X?Z7NA5,9+=&482N]:Q1_I>Z-,RDLB=1S15."&] M(!FE2?S(\2!6,$I6$YXP2DY"JE%R2$TNCWAR85O-"A([CN'D]1,%G6C/8S#+J";!'.,!(@C=>A0<=N>1FF/N`-0<&QF]O54\>JM8\K]I4;Z+HCL!'H57,4%2 M:=!V%",^V6<>A;//H[#MR,C5QG(R,OLXD,RKBI',$<.!#K<=V6D>RM\RB39#I][H>YBY,-(*NOQ!J6F\5H!11ABA' M5"`J$56(#*(:48.H1=0AZA$-"NGLQYV#-_9R5MA2\,A>'H/SH1#0KI$8F[#(<7#2ML)W@4%/D:48HH0Y0C M*A"5B"I$!E&-J$'4(NH0]8@&A726XQ;`6^L>>P,KARC]4O?3^$52:[&2NM\[ M,LK0*D=4("H158@,HAI1@ZA%U"'J$0T*Z1$YK5VPPG:!1ZKNG56`4K3*$.6( M"D0EH@J1050C:A"UB#I$/:)!(9WE6-V_M>Y1]J\D2LR'R]DE\Y31HJ>8_"]]0@2A%E MB')$!:(2487((*H1-8A:1!VB'M&@D,ZRE7]AEFW=DS0Y]>WY*RD2#0BK+].VA*,UO/.&[ M0%I@,8M*/WJKQCHPXT)/1U@VPO(15HRP2H%_19Z7G]D2U7 MY$./\HQM(1]W/R[>SY+20X]!C/@L*3ONYE_L,RFW4B,^Z&7M M8ULH;V[-$4>;40[<61FVT!'0"1TU_9#QB,^$CII^4'=L"QTU_0CL MV!8Z:OHQTK$M=`2N?1@?-0W/Z.C823\6*:$C3D:/.*$C3D:/.*$C3D:/.*$C M=I?DZ+CHMCT=V-AG^26Y_F4\%H4:.V*;KC%NAWB$_S*[_L6>;4>R2$D<'44: M^-%QMU-L+`Y-EM&YU?38#?>A9C&O[6`5NN5E2&MVM_&BD;F;)=4IO,TK7[M7U+.VZAM[)? MVQ>LXQ9ZH3HE>6S+S9P^#SU3BS[T?8 M%IH2],+*L2TT*>C%B;@E3ZZN\V3,Q]`6,[KE9C*_3NFG5D>BT1;[&Z^XA7[3 M]=K^/"MNN9DL*-I8M='/I%*TL2WTHZ<4;6S+34+'EHSM)Z@60UN:T2TW M"1U;,K:?G+:4HUL,;6G[3O_3 M_1>[,'7_>=E^IX7F^=FOVY>7[TUC;!-MC`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`N=J_J'/MZ+ M=V>+PXNCL^UO[4('JT[BUQZPSF4A_WC=`4N28S,PD2Y^\X!UI`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`7K9KDV5R6WR;KRK4D1*28EI)24D7)202I)%:DF M-:26U)%ZTN"0FX4,.M&&=NG$U':\3FPDKQ/S;^#5OF1%*\J(%),24DK*2#FI M()6DBE23&E)+ZD@]:7#(S4W-+-C7OA?:T#@1X5SB1K+>^/4Q*"+%I(24DC)2 M3BI():DBU:2&U)(Z4D\:''*S4*-S.PMU(R@S#Z_]WLSQ.,IW0AK):T/^YZ73 MBE:4$2DF):24E)%R4D$J216I)C6DEM21>M+@D)M;>#+C];D%9S.\CT=7Q[\Q MFV%J]-U#1(I)"2DE9:2<5)!*4D6J20VI)76DGC0XY`:I9@[\!KC+'?TX`^$T MP'E2PKX1]+)='\]5)C=0S*J$E)(R4DXJ2"6I(M6DAM22.E)/&AQR?5@ MZH0S%1.YN9WY3QB9*I,;YC-B5B6DE)21-#CDYJ;& M^O;\PPMM:)P:L*<93D9R[A]`$:MB4D)*21DI)Q6DDE21:E)#:DD=J2<-#CE9 MG/IS"JH?6LI?ZWCI>XB;%=W9!4W2C9A/`<_\C^%UE7FF,#)DKV@^/G2/V!]Y M;S][3CG`GD@]MK7M.*<5[>,<23TG9*UH/J)QC_-U(\U3CC0UO?!^3BO:QSF3 M?9QF&MP]SM`H[+?.``Z[3B=ZX8BG*ON(9[*/V,P;ND?LCS\V'R#\SI=G3SD4 MT?3"(4\KVH<\DWW(9IK&/63_-OV%DY9WXZ>XJ5Z3(E),2D@I*2/EI()4DBI2 M36I(+:DC]:3!(3<+B=KI?G:\]3Y5V_&N@"-YMPW^M,.THM5[1:28E)!24D;* M206I)%6DFM206E)'ZDF#0VYN_JWWKKG-]^1VP_7&M:O3J4HNI?.UWESIQV]I MF)KY_H\4DQ)22LI(.:D@E:2*5),:4DOJ2#UI<,@-\HWNVT]YWSZ1^R#2F9?M MVE29W,9MV0\BL2HAI:2,E),*4DFJ2#6I(;6DCM23!H?WUXU>SCAZFZ,3F20O]+J_.1K)ZK#4I(L6DA)22,E).*D@EJ2+5I(;4 MDCI23QH<W$YAH3)"@V6])5"2DE M9:2<5)!*4D6J20VI)76DGC0XY`1Y_D:S&9OMN+,9$WF=F)?MVE3I1")23$I( M*2DCY:2"5)(J4DUJ2"VI(_6DP2$WM]?-9IQS-F,BNQ,C1:28E)!24D;*206I M)%6DFM206E)'ZDF#0VX6:N;`'A6KB^$.G=CY.`-A/VXQD=>)F4]GQT]#3)5I M0^.VK'1C5B6DE)21NS$=-6V3LS4F""GC5O?KV=50DI)&2DG%:225)%J4D-J21VI)PT.N4&^T53( M.:=")O(Z,2_;M:DRN8W;LD=BK$I(*2DCY:2"5)(J4DUJ2"VI(_6DP2$W-W\J M9/M(['R>\=#O\FHBZS*W)D6DF)204E)&RDD%J215I)K4D%I21^I)@T-N%J'9 MC%TZ,-#CD9''Q1K,9F^VXLQD3N9W8A?]LAJF:VQ`I)B6DE)21M+@D)N%FCFPKV<[WE!>\N)= M6V4ZJ"A@<<"2@*4!RP*6!ZP(6!FP*F!UP)J`M0'K`M8';'#-B_)UDQ2+0\Y2 M:+.[MH!)/..Z5IW$`Y-X8!(/3.*!23PPB0SP,=?BD',CVKP.T9Q`.3 M>&`2#TSB@4D\,(D')O'`)!Z8Q`.3>&`2#TSB@4D\,(D')O'8YL43FD#9J:5Q M!F5Q.,^$F$OFXL)_IL,JLRZ:\ZK:)$J81`F3*&$2)4RBA$F4,(D2)E'")$J8 M1`F3*&$2)4RBA$F4MGE1^G,J.W>(\VR+'9OW),!J<3B5;>\0YR*=HS13F&0+ MDVQADBU,LH5)MC#)%B;9PB1;F&0+DVQADBU,LH5)MC#)UC8OVS>:HUD<GG+%7=T081(E3**$290PB1(F4<(D2IA$"9,H81(E3**$290PB1(F M4<(D2MN\*/UIF^U3GXO#>7I&MR!I>J-9G9_$`Y.6!I-X8!(/3.*!23PPB0^L^' M+$R9CCP*6!RP)&!IP+*`Y0$K`E8&K`I8';`F8&W`NH#U`1M<&Z,\>/IZ>_L< M73]??WQ_?_OXY79]^^W;T][-PU_?9>2V6!S+'V.??>_Q]O.'_2L9C5S*?T[5 M'SKSEDES.[J4[4,LV?\@-ZRT.95EX?Q=RF/(Q3N!(+N1`Y$.%T!(Y M#)FVYI*KBPOU)F\&POY!R"(U1/52/7\9.(YS>5GRA%]HB1R[/&\66'(AARY/-(66R('+\S6A)7+8\@1' M:(F^; MA9;(ZY%O/X66R.L)[N?J7-JJ7R5([1$7JE\62"T1%ZI/+H>6B(G M<7@_9W+4\AMH`NN,:MK4[EV.3W M;P66G,DY*K_AB4NNCL\OKX+')G_.ZE+]12:NLSJ6_5_(6!T!))07Z'?6B)I""_)9U+KHZ7 MEU?R1\2X1/ZVJ[S2X+$=R[')'\`,K2/')G^.,;1$CDW^X%]HB1R;_/FYT!(Y M#\+'MI04QC_@[O4;5T>2J?QUW,#69(GZF^&A);*U<1CC;6UU+)F.=]58(IF& M][.4=9;!\V`IZRR#Q[:4]WH9?*^7\EXO@^_U4M[K9?"]7LHK789>Z=5"TI;9 MG,![($L&^84OH25R!.,#F?Y[L)`CD+NGT#J2=G`_5XO3RROY50\6`3/ M@X6VO>5G&B+8)AR3,%#DB,* M'M#F=BMXPBSDA`GN(SHZO$SD5^H\#KF<0Z&3^.I8^H!0O;J.*#^8S[FGC^]_7'^YK:\?O]Q]?]K[=OM9 M;MX/WZE?M?-X]T7-;8W_\_SP0V[J]_?^>'A^?KC?_//K[?6GVT=5(,6?'QZ> M]?^H'?Q\>/QS,T#X^/\"````__\#`%!+`P04``8`"````"$`W5=;EC(!``!` M`@``$0`(`61O8U!R;W!S+V-O&UL(*($`2B@``$````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````````````````````G)%!3\,@&(;O)OZ'AGM+Z=RBI&6)FIU<8N+, MC#>$;RNQ4`)HMW\OZ[HZHR>/Y'UY>+Z/5$*2T7KX-&U%EQ0X)-(,IX*6Z$Z!$LQ]J(& MS7T6&R:&F]9I'N+1;;'EXIUO`1=Y/L,:`I<\<'P`IG8DH@$IQ8BT'Z[I`5)@ M:$"#"1Z3C.#O;@"G_9\7^N2LJ578VSC3H'O.EN(8CNV=5V.QZ[JLF_0:T9_@ ME^7#4S]JJLQA5P(0.^RGX3XLXRHW"N3MGNW>7)-X7Y?X=U9*T=M1X8`'D$E\ MCQ[M3LEZ_6B!6Y.0JS:O)3ZUAOML!.I!X-_$$X#UWC__ MG'T!``#__P,`4$L#!!0`!@`(````(0`VXNH*,0,``)H)```0``@!9&]C4')O M<',O87!P+GAM;""B!`$HH``!```````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M`````)Q636^C,!"]K[3_(>+>DJ_-=BM"18"DEAK(8J=53Y8+3F.50(3=M-U? MOP,H"6F=;+EVEK0TOI,BSH=$Y;QLMGL5Y(K+'H3$GX[,+ MHR45RQ*6YAD?&F]<&E?V]V_6K,C7O%""RQ:$R.306"JUOC1-&2_YBLES,&=@ M6>3%BBGX+![-?+$0,??R^'G%,V5VV^V!R5\5SQ*>G*UW`8TZXN5&?35HDL>982: M"1@..1*A4B[#Q8P52D.Y-VARKEC4C&M"VRI2Z`WJ9PKTHBBKJRWR)O-=#B.6 MLBSF%%?)T7G&GA.A>/(99R`)+;/D"JH()=O%+"6L"6'%%"_[2M)\04-HSJK< MLC[G$Q"7R24=I_G+*4B'>CYV(S0C*`QH.*:C.4:!C['V@"X=.1CATF\6^=@/ MB+/%H8!H(3TZ"5$PH6X8N'X4:'WZ%,^G4R>Z+P-C-`G0&+E.0*CCNN%<"_E! M<3@F=T[D:\T#ZB$,1Q(4S'V/AC,_JICJT_I);\J0/I,+D&I$Z!01 M-*G3GD7A)'*F6@:_(.,I^$Y!)$R=P"L5`#H3/W"1GG2G32/_QB%`>.9$Y)Z2 MR`FPXY82ZXEW.M3_/4?D7DNATP5=1Q@\@`/U;TLF6L?3^G>^@.EJ,?NB4<(> M8%BU7D=K5X&TD*.E.0YYUY?4XXJ)5-*`%3!HVE-.R]3[`J:OQ31DPO!;?X%? MQ9;>O_P/LQ`;K@4<5]@3,OY?"`BGA7R8JFT2E<9:R/$Z>OQ!7Y13D"/$3H^F MOMU/SB;5)K,;SH.\X2=^I"JZ<=U#FT<<7(+OKKT;D3W)^9KD'EP?VWO]<-/" M2VBI!&Z\K7V_85W#E5ZD91!WR;)'GFQ]/AK*5\AM_=2R._WS=J\-#XS&GF7N M'U7V7P```/__`P!02P$"+0`4``8`"````"$`3`AW_N,!``!#%P``$P`````` M````````````````6T-O;G1E;G1?5'EP97-=+GAM;%!+`0(M`!0`!@`(```` M(0"U53`C]0```$P"```+`````````````````!P$``!?&PO M=V]R:W-H965T&UL4$L!`BT`%``&``@````A`&4[5>K4`P`` MV`P``!D`````````````````=Q0``'AL+W=O@"``!&"```&0````````````````"" M&```>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`-5^FD#S!```X!,``!D````````` M````````/1X``'AL+W=O&PO=V]R:W-H M965T&UL4$L! M`BT`%``&``@````A`(DEDIL#!```P0\``!D`````````````````I"P``'AL M+W=O,```>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A M`$M@?D^L`@```0<``!D`````````````````83<``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``& M``@````A`%`)%L'F`@``C0D``!@`````````````````S3X``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`+J6VG3#`P``EPT``!@`````````````````2IL``'AL+W=O9H`(``!8'```8```````````` M`````#S;``!X;"]W;W)K&PO=V]R:W-H965T M&UL4$L!`BT`%``&``@````A`"Q-,M32`@``*`@``!@````` M````````````^^```'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A``0;Y[3J M`@``Q0@``!D`````````````````]/```'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`,@S0*#\!@``DAT``!D````` M````````````E@0!`'AL+W=O&PO=V]R M:W-H965T&UL M4$L!`BT`%``&``@````A`.-&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`-U76Y8R`0``0`(``!$`````````````````XE`!`&1O8U!R;W!S+V-O M&UL4$L!`BT`%``&``@````A`#;BZ@HQ`P``F@D``!`````````````` M````2U,!`&1O8U!R;W!S+V%P<"YX;6Q02P4&`````"T`+0`M#```LE XML 13 R33.htm IDEA: XBRL DOCUMENT v2.4.0.8
9. COMMITMENTS AND CONTINGENCIES (Details Narrative) (USD $)
3 Months Ended 6 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Mar. 31, 2014
Mar. 31, 2013
Commitments and Contingencies Disclosure [Abstract]        
Rent Expense $ 0 $ 0 $ 0 $ 0
Payable Write Offs     $ 59,704 $ 58,984
XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 R25.htm IDEA: XBRL DOCUMENT v2.4.0.8
4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) (USD $)
3 Months Ended 6 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Mar. 31, 2014
Mar. 31, 2013
Sep. 30, 2013
Accounting Policies [Abstract]          
FDIC Insured Cash $ 250,000   $ 250,000    
Subscription Revenue, Year One     1,200    
Subscription Revenue, Year Two     1,500    
Subscription Revenue, Year Three     1,800    
Subscription Revenue, Year Four     2,400    
Deferred Revenue 0   0    
Sales Commissions $ 0 $ 20,000 $ 40,260 $ 37,000  
Preferred Stock, Shares Outstanding 4,000,000   4,000,000   4,000,000
Preferred Stock converted into Common Stock, Shares Common Stock     600,000,000    
XML 16 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8
4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
6 Months Ended
Mar. 31, 2014
Accounting Policies [Abstract]  
4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 4 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

The Company prepares its financial statements in accordance with accounting principles generally accepted in the United States of America. Significant accounting policies are as follows:

 

Use of Estimates and Assumptions

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and (iii) the reported amount of net revenues and expenses recognized during the periods presented. Adjustments made with respect to the use of estimates often relate to improved information not previously available. Uncertainties with respect to such estimates and assumptions are inherent in the preparation of financial statements; accordingly, actual results could differ from these estimates. The Company’s most significant estimates relate to the valuation of its proprietary technology and its valuation of its common stock.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.  At March 31, 2014, cash and cash equivalents include cash on hand and cash in the bank and the FDIC insures these deposits up to $250,000.

 

Impairment of Long-Lived Assets

 

Long-lived assets are evaluated for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. Each impairment test is based on a comparison of the undiscounted future cash flows to the recorded value of the asset. If impairment is indicated, the asset is written down to its estimated fair value. The acquired software technologies are reviewed annually for impairment.

 

Fair Value of Financial Instruments

 

The Company's financial instruments consist primarily of cash, accounts payable and accrued expenses, and debt. The carrying amounts of such financial instruments approximate their respective estimated fair value due to the short-term maturities and approximate market interest rates of these instruments.  

 

Fair value is focused on an exit price that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.  Within the measurement of fair value, the use of market-based information is prioritized over entity specific information and a three-level hierarchy for fair value measurements is used based on the nature of inputs used in the valuation of an asset or liability as of the measurement date.

 

The three-level hierarchy for fair value measurements is defined as follows:

 

Level 1 – inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets; liabilities in active markets;
Level 2 – inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability other than quoted prices, either directly or indirectly, including inputs in markets that are not considered to be active; or directly or indirectly including inputs in markets that are not considered to be active;
Level 3 – inputs to the valuation methodology are unobservable and significant to the fair value measurement.

The following table summarizes fair value measurements by level at March 31, 2014 and September 30, 2013 for assets measured at fair value on a recurring basis:

 

   Level 1  Level 2  Level 3  Total
At March 31, 2014                    
Software  $—     $—     $701,611   $701,611 
Total Software  $—     $—     $701,611   $701,611 
                     
At September 30, 2013                    
Software  $—     $—     $937,431   $937,431 
Total Software  $—     $—     $937,431   $937,431 

 

Accounts Receivable and Allowance for Uncollectible Accounts

 

Substantially all of the Company’s accounts receivable balance is related to trade receivables. Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in its existing accounts receivable. The Company will maintain allowances for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments for services. Accounts with known financial issues are first reviewed and specific estimates are recorded. The remaining accounts receivable balances are then grouped in categories by the number of days the balance is past due, and the estimated loss is calculated as a percentage of the total category based upon past history. Account balances are charged against the allowance when it is probable the receivable will not be recovered. As of March 31, 2014 and 2013, the Company had no valuation allowance for the Company’s accounts receivable.

 

Income Taxes

 

The Company utilizes the asset and liability method in accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for operating loss and tax credit carry-forwards and for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is recorded to reduce the carrying amounts of deferred tax assets unless it is more likely than not that the value of such assets will be realized.

 

The Company uses the two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not, that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount, which is more than 50% likely of being realized upon ultimate settlement. The Company considers many factors when evaluating and estimating the Company's tax positions and tax benefits, which may require periodic adjustments. At March 31, 2014, the Company did not record any liabilities for uncertain tax positions.

 

Revenue Recognition

 

License revenue consists principally of revenue earned under software license agreements. The Company sells its software to a medical practitioner for direct payment or through a third party leasing company for direct payment to the Company. The third party lease agreement is a non-recourse debt and the Company is not responsible for the default of the medical practitioner. License revenue is generally recognized when a signed contract or other persuasive evidence of an arrangement exists, the software has been electronically delivered, the license fee is fixed or is measured on a paid user basis; and collection of the resulting receivable is probable. When contracts contain multiple elements wherein Vendor-Specific Objective Evidence (“VSOE”) exists for all undelivered elements, we account for the delivered elements in accordance with the “Residual Method.”

 

VSOE of fair value for maintenance and support is established by a stated renewal rate, if substantive, included in the license arrangement or rates charged in stand-alone sales of maintenance and support. Revenue from subscription license agreements, which include software, rights to unspecified future products and maintenance, is recognized ratably over the term of the subscription period.

 

Provided all other revenue criteria are met, the upfront, minimum, non-refundable license fees from customers are generally recognized upon delivery and on-going royalty fees are generally recognized upon reports of new licenses issued. If there is significant uncertainty about the project completion or receipt of payment for professional services, revenue is deferred until the uncertainty is sufficiently resolved. VSOE of fair value of services is based upon stand-alone sales of those services.

Subscription revenue is generated from bandwidth and information storage. In the first year and each year thereafter, the software is purchased and installed the purchaser will pay an annual fee of $1,200, $1,500, $1,800, and $2,400, respectively. Subscription revenue is recognized ratably over the term of the agreement.

 

Transaction revenue is generated from the following services and recognized when a transaction occurs:

 

·Electronic Remittance Advise $0.35 Electronic remittance transaction fee;
·Paper Claims $1.00 Paper claim fee;
·Carrier Direct $0.16 Carrier direct fee;
·Fast Forward $0.35 Fast forward transaction fee; and,
·Patient Credit $2.50 Automatic Debit processing per transaction paid by the patient

 

The Company had not received any transaction revenues in the three and six months ended March 31, 2014.

 

Cost of License, and Subscriptions Revenues

 

Cost of license revenue is primarily comprised of the license-based royalties to third parties and production and distribution costs for initial product licenses. No costs were incurred for license-based royalties during the three months ended March 31, 2014 and 2013.

 

Cost of subscription revenue is primarily comprised of the costs associated with the customer support personnel that provide maintenance, enhancement and support services to customers. No costs were incurred for customer support during the three months ended March 31, 2014 and 2013.

 

The amortization of acquired technology for products acquired through business combinations are considered as the cost of revenues. The acquired software technologies are amortized over their useful lives of 5 years.

 

Deferred Revenue

 

Deferred revenue result from fees billed to customers for which revenue has not yet been recognized or for which the conditions of the arrangement have been modified. The Company recognizes revenue to provide up-front capitalization to Cloud-MD for each provider added to the solution set. The Company also recognizes annual subscription fees for virtual servers and subscription and small usage fees and those revenues are based on a 48-month lease, Cloud-MD would amortize the revenue over the life of the agreement of 48 months. In addition, it features incremental monthly revenue, for the duration of the lease (48 months) based on fees assessed for transactions such as eligibility claims processing, etc. The Company has deferred revenue of $0 as of March 31, 2014.

 

Sales Commissions

 

The Company pays commissions, including sales bonuses, to the direct sales force related to revenue transactions under sales compensation plans which are established annually. The commission payments are typically paid in full in the month or quarter following execution of the customer contracts. The Company paid commissions of $0 and $20,000 for the three months ended March 31, 2014 and 2013, respectively, and $37,000 and $40,260 for the six months ended March 31, 2014 and 2013, respectively.

 

Research and Development and Software Development Costs

 

Capitalization of certain software development costs subsequent to the establishment of technological feasibility. Based on our product development process, technological feasibility is established upon the completion of a working model. To date, costs incurred by us from the completion of the working model to the point at which the product is ready for general release have been insignificant. Accordingly, we have charged all such costs to research and development expense in the period incurred.

 

Share-Based Compensation

 

The Company measures the cost of services received in exchange for an award of an equity instrument based on the grant-date fair value of the award.  Compensation cost is recognized over the vesting or requisite service period.

 

Basic and Diluted Net Income (Loss) per Common Share

 

Basic income (loss) per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the reporting period. The weighted average number of shares is calculated by taking the number of shares outstanding and weighting them by the amount of time that they were outstanding.  Diluted earnings per share reflects the potential dilution that could occur if stock options, warrants, and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company.

 

The Company has 4,000,000 preferred shares that can be converted subject to the limitation of the Company’s authorized shares at 1 preferred share for 150 common shares. The conversion can only take place with the approval of the Board of Directors. At March 31, 2014, the preferred shares could be converted into 600,000,000 of common shares resulting in dilution of common shareholders. The preferred shares are anti-dilutive since the losses the Company has incurred for the periods ended March 31, 2014 and 2013.

 

Diluted loss per share is the same as basic loss per share during periods where net losses are incurred since the inclusion of the potential common stock equivalents would be anti-dilutive as a result of the net loss.

 

Concentration of Credit Risk

 

All of the Company’s cash and cash equivalents are maintained in regional and national financial institutions. The Company has exposure to credit risk to the extent that its cash and cash equivalents exceed amounts covered by the U.S. federal deposit insurance; however, the Company has not experienced any losses in such accounts. In management’s opinion, the capitalization and operating history of the financial institutions are such that the likelihood of material loss is remote.

 

Subsequent Events

 

The Company has evaluated all transactions occurring between March 31, 2014 and through the date of issuance of the financial statements for subsequent event disclosure.

 

Recent Accounting Pronouncements

 

No accounting standards or interpretations issued recently are expected to a have a material impact on the Company’s financial position, operations or cash flows.

EXCEL 17 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\R9C(Y-#,U,E\X.3EC7S1A.&9?83)C95]A-#$X M-S@T-C0V93`B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I% M>&-E;%=O#I% M>&-E;%=O#I.86UE/E-T871E;65N='-?;V9?3W!E M#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-T871E;65N='-?;V9?0V%S:%]&;&]W#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/C%?1$530U))4%1)3TY? M3T9?0E5324Y%4U,\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7;W)K#I7;W)K#I7;W)K M#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/CE?0T]-34E4345.5%-?04Y$7T-/ M3E1)3D=%3D-)13PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/C$P7U)%3$%4141?4$%25%E?5%)!3E-!0U1)3TY3/"]X.DYA;64^#0H@ M("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I%>&-E;%=O#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/C5?4T]&5%=!4D5?5&%B;&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H M965T4V]U#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/C1?4U5-34%265]/1E]324=.249)0T%. M5%]!0T-/530\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7;W)K#I%>&-E;%=O M#I%>&-E;%=O#I%>&-E M;%=O#I%>&-E;%=O#I% M>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/C$P7U)%3$%4141?4$%25%E?5%)!3E-!0U1)3TY37SPO>#I. M86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/C$R7U-50E-%455%3E1?159%3E137T1E=&%I;'-?3CPO>#I. M86UE/@T*("`@(#QX.E=O6QE#I!8W1I=F53:&5E=#X-"B`@/'@Z4')O=&5C=%-T#I0#I0#I0&UL/CPA6V5N9&EF72TM/@T*/"]H96%D/@T*("`\8F]D>3X-"B`@(#QP M/E1H:7,@<&%G92!S:&]U;&0@8F4@;W!E;F5D('=I=&@@36EC'1087)T7S)F,CDT,S4R7S@Y.6-?-&$X9E]A,F-E7V$T,3@W M.#0V-#9E,`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\R9C(Y-#,U M,E\X.3EC7S1A.&9?83)C95]A-#$X-S@T-C0V93`O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)V9A;'-E/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N M/CPO'0^)RTM,#DM,S`\2!A(%9O;'5N=&%R>2!&:6QE2=S(%)E M<&]R=&EN9R!3=&%T=7,@0W5R'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'!E;G-E'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)SQS<&%N/CPOF5D.R`R M-#8L.#(Y+#(Q-B!A;F0@,C$T+#8R-"PR,38@:7-S=65D(&%N9"!O=71S=&%N M9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S2`H9&5F:6-I="D\+W1D/@T*("`@("`@("`\=&0@8VQA M7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAAF5D/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#`P,"PP,#`\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6%B;&4@86YD(&%C8W)U960@97AP96YS97,\+W1D/@T*("`@("`@("`\ M=&0@8VQA2!O<&5R871I;F<@86-T M:79I=&EE'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO6UE;G0@;V8@;&EN92!O9B!C'0^)R9N8G-P M.R9N8G-P.SQS<&%N/CPO'0^)R9N8G-P.R9N M8G-P.SQS<&%N/CPO'0^)SQS<&%N/CPO65A'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2<^/&(^3D]412`Q+2!$15-#4DE05$E/3B!/ M1@T*0E5324Y%4U,\+V(^/"]P/@T*#0H\<"!S='EL93TS1"=M87)G:6XM=&]P M.B`P.R!M87)G:6XM8F]T=&]M.B`P.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!T M97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$ M)VUA'0M86QI9VXZ(&IU2<^ M)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.B`P.R!M87)G M:6XM8F]T=&]M.B`P.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!T97AT+6%L:6=N M.B!J=7-T:69Y)SY);B!T:&4@>65A2!E>'!E2!-;V1E;',@*$%#3RDL($AE86QT:&-AF4@82!W:61E(')A M;F=E(&]F(&)U2!-86YA9V5M96YT+"!#;&%I;7,-"DUA;F%G96UE;G0@86YD(%!( M22!%>&-H86YG92X\+W`^#0H-"CQP('-T>6QE/3-$)VUA'0M M86QI9VXZ(&IU2<^26X@=&AE('EE87(@96YD960@ M4V5P=&5M8F5R(#,P+"`R,#$R+`T*0VQO=60M340@;&%U;F-H960@0VQO=60M M340@0FEL;&EN9R!397)V:6-E'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQP('-T>6QE M/3-$)VUA'0M86QI9VXZ(&IU2<^/&(^)B,Q-C`[/"]B/CPO<#X-"@T* M/'`@2<^5&AE M($-O;7!A;GD@<')E<&%R97,@:71S(&9I;F%N8VEA;`T*2!A8V-E<'1E9"!I;B!T:&4@56YI=&5D(%-T871E2!A8V-E<'1E9"!A8V-O=6YT:6YG('!R M:6YC:7!L97,@9F]R(&EN=&5R:6T-"F9I;F%N8VEA;"!I;F9O2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.B`P.R!M M87)G:6XM8F]T=&]M.B`P.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!T97AT+6%L M:6=N.B!J=7-T:69Y)SY/<&5R871I;F<@"!M M;VYT:',-"F5N9&5D($UA2!B92!E>'!E M8W1E9"!F;W(@=&AE('EE87(@96YD:6YG(%-E<'1E;6)E65A65A3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\R9C(Y-#,U,E\X.3EC7S1A.&9?83)C95]A-#$X-S@T M-C0V93`-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,F8R.30S-3)? M.#DY8U\T83AF7V$R8V5?830Q.#'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M2<^/&(^3D]412`S("T@1T])3D<@0T].0T523B`\+V(^/"]P/@T*#0H\ M<"!S='EL93TS1"=M87)G:6XM=&]P.B`P.R!M87)G:6XM8F]T=&]M.B`P.R!L M:6YE+6AE:6=H=#H@;F]R;6%L.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V M,#L\+W`^#0H-"CQP('-T>6QE/3-$)VUA'0M86QI9VXZ(&IU M2!A8V-E<'1E9"!I;B!T:&4@56YI M=&5D(%-T871E2<^)B,Q M-C`[/"]P/@T*#0H-"@T*/'`@2<^5&AE28C,30V.W,-"F%B:6QI='D@=&\@8V]N=&EN=64@87,@82!G M;VEN9R!C;VYC97)N+B!4:&4@86-C;VUP86YY:6YG(&9I;F%N8VEA;"!S=&%T M96UE;G1S(&1O(&YO="!I;F-L=61E(&%N>2!A9&IU28C,30V.W,@8V]N=&EN=65D(&5X:7-T96YC92!I M28C,30V.W,@97AE8W5T:79E M(&]F9FEC97)S('1O(&9I;F%N8V4@:71S(&]P97)A=&EO;G,@86YD#0IT:&4@ M86)I;&ET>2!T;R!O8G1A:6X@861D:71I;VYA;"!F=6YD:6YG('-O=7)C97,@ M=&\@97AP;&]R92!P;W1E;G1I86P@28C,30V.W,@<')O9'5C=',@86YD(&)U'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$ M)VUA'0M86QI9VXZ(&IU6QE/3-$)VUA'0M M86QI9VXZ(&IU2<^5&AE('!R97!A2!A8V-E<'1E9"!I;B!T:&4@ M56YI=&5D(%-T871E2!A=F%I;&%B;&4N(%5N8V5R=&%I;G1I97,@=VET:"!R97-P96-T M('1O('-U8V@@97-T:6UA=&5S(&%N9"!A2!A;F0@:71S('9A;'5A M=&EO;B!O9B!I=',@8V]M;6]N('-T;V-K+CPO<#X-"@T*/'`@2<^/&(^)B,Q-C`[/"]B/CPO M<#X-"@T*/'`@2<^/&(^0V%S:"!A;F0@0V%S:"!%<75I=F%L96YT6QE/3-$)VUA'0M86QI9VXZ(&IU2<^5&AE($-O;7!A;GD@8V]N2<^)B,Q-C`[/"]P/@T*#0H\<"!S M='EL93TS1"=M87)G:6XM=&]P.B`P.R!M87)G:6XM8F]T=&]M.B`P.R!L:6YE M+6AE:6=H=#H@;F]R;6%L.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY,;VYG+6QI M=F5D(&%S2!N;W0@8F4@9G5L;'D@2<^/&(^)B,Q-C`[/"]B/CPO<#X- M"@T*/'`@2<^ M/&(^1F%I6QE/3-$)VUA'0M86QI M9VXZ(&IU2!O9B!C87-H+"!A8V-O=6YT&EM871E(&UA6QE/3-$)VUA'0M86QI9VXZ(&IU2<^1F%I2!F;W(@9F%I2!A6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$)VUA'0M86QI M9VXZ(&IU6QE/3-$)V9O;G0M2<^#0H\=&0@'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P M<'0G/B8C,30Y.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@-7!T M)SX\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y)SX\9F]N M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/DQE=F5L(#$@)B,Q-3`[(&EN M<'5T6QE/3-$ M)W9E'0M86QI9VXZ(&IU6QE/3-$)W=I9'1H.B`Q-7!T.R!T97AT+6%L:6=N.B!R:6=H="<^ M/&9O;G0@2<^/&9O;G0@0T*:6YC;'5D92!Q=6]T960@<')I8V5S(&9O0T*;W1H97(@=&AA;B!Q=6]T960@<')I8V5S+"!E M:71H97(@9&ER96-T;'D@;W(@:6YD:7)E8W1L>2P@:6YC;'5D:6YG(&EN<'5T M6QE/3-$)V9O;G0M6QE/3-$)W=I9'1H.B`U<'0G/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&IU6QE/3-$)V9O;G0M2<^)B,Q M-C`[/"]P/@T*#0H\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG M/3-$,"!S='EL93TS1"=B;W)D97(M8V]L;&%P6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E M;G1E6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X\ M=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C M,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W=I9'1H.B`S)3L@<&%D M9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@ M,3`E.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@'0M86QI M9VXZ(')I9VAT)SXF(S$U,3LF(S$V,#LF(S$V,#L\+W1D/CQT9"!S='EL93TS M1"=W:61T:#H@,24[('!A9&1I;F'0M86QI9VXZ M(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`S)3L@<&%D M9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@ M,3`E.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@'0M86QI M9VXZ(')I9VAT)SXF(S$U,3LF(S$V,#LF(S$V,#L\+W1D/CQT9"!S='EL93TS M1"=W:61T:#H@,24[('!A9&1I;F'0M86QI9VXZ M(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`S)3L@<&%D M9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@ M,3`E.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@'0M86QI M9VXZ(')I9VAT)SXW,#$L-C$Q/"]T9#X\=&0@6QE/3-$)W=I9'1H.B`Q M)3L@8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N M.B!L969T)SXD/"]T9#X\=&0@6QE/3-$)W=I9'1H.B`Q)3L@<&%D9&EN9RUB M;W1T;VTZ(#%P=#L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\+W1R M/@T*/'1R('-T>6QE/3-$)W9E'0M:6YD96YT.B`Y+C'0M86QI9VXZ(&QE9G0G M/B0\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`R+C5P M="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$U,3LF(S$V,#LF(S$V M,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[('1E M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I M;F6QE/3-$)V)O6QE/3-$)V)O'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE M/3-$)W!A9&1I;F6QE/3-$)W9E6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P M.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\ M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D M/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R M:6=H="<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@ M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X\=&0@ M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P M.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)W!A M9&1I;F'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO M=&0^/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)W!A M9&1I;F'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO M=&0^/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)V)O'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T M=&]M.B!";&%C:R`Q<'0@'0M86QI9VXZ(')I9VAT)SXY,S6QE/3-$ M)W9E'0M:6YD96YT.B`Y M+C'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL M93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B;&4[('1E>'0M M86QI9VXZ(')I9VAT)SXF(S$U,3LF(S$V,#LF(S$V,#L\+W1D/CQT9"!S='EL M93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M86QI9VXZ(&QE9G0G M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)V)O M'0M86QI M9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F2<^)B,Q-C`[/"]P M/@T*#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.B`P.R!M87)G:6XM8F]T=&]M M.B`P.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!T97AT+6%L:6=N.B!J=7-T:69Y M)SX\8CY!8V-O=6YT2<^)B,Q-C`[/"]P/@T*#0H\ M<"!S='EL93TS1"=M87)G:6XM=&]P.B`P.R!M87)G:6XM8F]T=&]M.B`P.R!L M:6YE+6AE:6=H=#H@;F]R;6%L.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY3=6)S M=&%N=&EA;&QY(&%L;"!O9B!T:&4@0V]M<&%N>28C,30V.W,-"F%C8V]U;G1S M(')E8V5I=F%B;&4@8F%L86YC92!I6UE;G1S(&9O2!H860@;F\@=F%L=6%T:6]N M(&%L;&]W86YC92!F;W(@=&AE($-O;7!A;GDF(S$T-CMS(&%C8V]U;G1S(')E M8V5I=F%B;&4N/"]P/@T*#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.B`P.R!M M87)G:6XM8F]T=&]M.B`P.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!T97AT+6%L M:6=N.B!J=7-T:69Y)SX\8CXF(S$V,#L\+V(^/"]P/@T*#0H\<"!S='EL93TS M1"=M87)G:6XM=&]P.B`P.R!M87)G:6XM8F]T=&]M.B`P.R!L:6YE+6AE:6=H M=#H@;F]R;6%L.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\8CY);F-O;64@5&%X M97,\+V(^/"]P/@T*#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.B`P.R!M87)G M:6XM8F]T=&]M.B`P.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!T97AT+6%L:6=N M.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)VUA'0M86QI9VXZ(&IUF5S('1H M92!A&5S+B!5;F1E2UF;W)W87)D M&ES=&EN9R!A"!B87-E M"!R871E'!E8W1E9"!T;R!A M<'!L>2!T;R!T87AA8FQE(&EN8V]M92!I;B!T:&4@>65AF5D M+CPO<#X-"@T*/'`@2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.B`P M.R!M87)G:6XM8F]T=&]M.B`P.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!T97AT M+6%L:6=N.B!J=7-T:69Y)SY4:&4@0V]M<&%N>2!U"!P;W-I=&EO;B!F;W(@2X@5&AE('-E8V]N9"!S=&5P(&ES('1O M(&UE87-U"!B96YE9FET(&%S('1H92!L87)G97-T(&%M;W5N M="P-"G=H:6-H(&ES(&UOF5D('5P;VX@=6QT:6UA=&4@6QE/3-$)VUA'0M M86QI9VXZ(&IU2<^/&(^4F5V96YU92!296-O9VYI M=&EO;CPO8CX\+W`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`T*8V]M<&QE=&EO;B!O6UE;G0@9F]R('!R;V9E65A2!A;B!A;FYU86P@9F5E(&]F("0Q+#(P,"P@)#$L M-3`P+"`D,2PX,#`L(&%N9"`D,BPT,#`L(')E2X@4W5B6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$)VUA'0M86QI M9VXZ(&IU2<^#0H\=&0@'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I M>F4Z(#$P<'0G/B8C,3@S.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=W:61T M:#H@-7!T)SX\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/D5L96-T6QE/3-$)W9E'0M86QI9VXZ(&IU6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&-O;&]R.B`C,#`P,#`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`[/"]P M/@T*#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.B`P.R!M87)G:6XM8F]T=&]M M.B`P.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!T97AT+6%L:6=N.B!J=7-T:69Y M)SY4:&4@0V]M<&%N>2!H860@;F]T(')E8V5I=F5D#0IA;GD@=')A;G-A8W1I M;VX@2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS M1"=M87)G:6XM=&]P.B`P.R!M87)G:6XM8F]T=&]M.B`P.R!L:6YE+6AE:6=H M=#H@;F]R;6%L.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\8CY#;W-T(&]F($QI M8V5N2<^/"]P M/@T*#0H-"@T*#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.B`P.R!M87)G:6XM M8F]T=&]M.B`P.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!T97AT+6%L:6=N.B!J M=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)VUA'0M86QI9VXZ(&IU0T*8V]M<')I6%L=&EE2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL M93TS1"=M87)G:6XM=&]P.B`P.R!M87)G:6XM8F]T=&]M.B`P.R!L:6YE+6AE M:6=H=#H@;F]R;6%L.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY#;W-T(&]F('-U M8G-C0T*8V]M<')I6QE/3-$)VUA'0M86QI9VXZ M(&IU2<^5&AE(&%M;W)T:7IA=&EO;B!O9B!A8W%U M:7)E9"!T96-H;F]L;V=Y#0IF;W(@<')O9'5C=',@86-Q=6ER960@=&AR;W5G M:"!B=7-I;F5S6QE M/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$)VUA M'0M86QI9VXZ(&IUF%T:6]N('1O M($-L;W5D+4U$(&9O2<^/&(^)B,Q-C`[/"]B/CPO<#X-"@T*/'`@2<^/&(^4V%L97,@0V]M;6ES6QE/3-$)VUA'0M86QI9VXZ(&IU7,@8V]M;6ES2!P86ED(&-O;6UI"!M;VYT:',@96YD960@36%R8V@@,S$L(#(P M,30@86YD(#(P,3,L(')E2X\+W`^#0H-"CQP('-T>6QE/3-$ M)VUA'0M86QI9VXZ(&IU6QE/3-$)VUA'0M86QI9VXZ(&IU2<^)B,Q-C`[/"]P/@T*#0H\<"!S M='EL93TS1"=M87)G:6XM=&]P.B`P.R!M87)G:6XM8F]T=&]M.B`P.R!L:6YE M+6AE:6=H=#H@;F]R;6%L.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY#87!I=&%L M:7IA=&EO;B!O9B!C97)T86EN('-O9G1W87)E#0ID979E;&]P;65N="!C;W-T M2!U6QE/3-$)VUA'0M86QI9VXZ(&IU M6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$)VUA'0M M86QI9VXZ(&IU2<^5&AE($-O;7!A;GD@;65A6QE/3-$)VUA'0M86QI9VXZ(&IU M2<^)B,Q-C`[/"]P/@T*#0H\<"!S M='EL93TS1"=M87)G:6XM=&]P.B`P.R!M87)G:6XM8F]T=&]M.B`P.R!L:6YE M+6AE:6=H=#H@;F]R;6%L.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY"87-I8R!I M;F-O;64@*&QO2!A M=V%R9',@=F5S=`T*6QE/3-$)VUA M'0M86QI9VXZ(&IU2!H M87,@:6YC=7)R960@9F]R('1H92!P97)I;V1S(&5N9&5D($UA6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$)VUA'0M86QI9VXZ(&IU28C,30V.W,@8V%S:"!A;F0@8V%S:"!E M<75I=F%L96YT'!O'!E2<^/&(^)B,Q-C`[/"]B/CPO<#X-"@T*/'`@2<^/&(^4W5B6QE/3-$)VUA'0M86QI9VXZ(&IU2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS M1"=M87)G:6XM=&]P.B`P.R!M87)G:6XM8F]T=&]M.B`P.R!L:6YE+6AE:6=H M=#H@;F]R;6%L.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\8CY296-E;G0@06-C M;W5N=&EN9R!06QE/3-$ M)VUA'0M86QI9VXZ(&IU2<^3F\@ M86-C;W5N=&EN9R!S=&%N9&%R9',@;W(@:6YT97)P7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'0^)SQP('-T>6QE/3-$)VUA'0M86QI M9VXZ(&IU2<^)B,Q-C`[/"]P/@T*#0H\=&%B;&4@8V5L;'!A9&1I M;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=B;W)D97(M8V]L;&%P M6QE/3-$)W9E2<^)B,Q-C`[/"]T M9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,3(E M.R!T97AT+6%L:6=N.B!R:6=H="<^-BPP,#`\+W1D/CQT9"!S='EL93TS1"=W M:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T M>6QE/3-$)W=I9'1H.B`X)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA M;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E M6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0G/B8C,38P.SPO=&0^/"]T6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W9E6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT)SXQ,"PP,#`\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!R:6=H="<^,3`L,#`P/"]T9#X\=&0@6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXQ+#(P,"PQ,#8\+W1D/CQT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^ M,2PR,#`L,3`V/"]T9#X\=&0@6QE/3-$)W9E6QE M/3-$)W!A9&1I;F6QE/3-$)V)O'0M86QI9VXZ(')I9VAT)SXR,RPP,#`\ M+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!T97AT+6%L M:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXQ+#(U-RPT,#8\+W1D/CQT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^,2PR M-3$L-#`V/"]T9#X\=&0@6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F'0M86QI9VXZ M(')I9VAT)SXH,3`L,#`P/"]T9#X\=&0@6QE/3-$ M)W!A9&1I;F6QE/3-$)V)O6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0G/BD\+W1D/CPO='(^#0H\='(@6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('!A9&1I;F6QE/3-$)V)O6QE/3-$)V)O'0M86QI9VXZ(&QE9G0G/B8C M,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$ M)W!A9&1I;F2<^)B,Q-C`[)B,Q-C`[/"]P/@T*#0H\ M<"!S='EL93TS1"=M87)G:6XM=&]P.B`P.R!M87)G:6XM8F]T=&]M.B`P.R!L M:6YE+6AE:6=H=#H@;F]R;6%L.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY4:&4@ M0V]M<&%N>28C,30V.W,@65A2X@5&AE($-O;7!A;GD@2!I2!D965M960@=&AE(&%S6QE/3-$)VUA'0M86QI9VXZ(&IU M6QE/3-$)VUA'0M86QI9VXZ(&IU7!T:6]N(%-O M9G1W87)E($-O9&4\+V(^/"]P/@T*#0H\<"!S='EL93TS1"=M87)G:6XM=&]P M.B`P.R!M87)G:6XM8F]T=&]M.B`P.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!T M97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$ M)VUA'0M86QI9VXZ(&IU2!P=7)C:&%S960-"F9R;VT@0VEP:&5R4VUI M=&@L($Q,0R!A(&-O;7!L971E('-O=7)C92!C;V1E+"!I;G1E;&QE8W1U86P@ M<')O<&5R='D@2!R:6=H=',L('!A=&5N=',L(&UA2!I M6QE/3-$)VUA'0M86QI9VXZ M(&IU2<^/&(^1&]C=&]R6QE/3-$)VUA'0M86QI9VXZ(&IU2!I2!A;F0@=&AE('-E;&QE2!I;B!L:71I9V%T:6]N(&]V97(@=&AE(&1I3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R9C(Y-#,U,E\X.3EC7S1A.&9? M83)C95]A-#$X-S@T-C0V93`-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO,F8R.30S-3)?.#DY8U\T83AF7V$R8V5?830Q.#'0O:'1M;#L@ M8VAA'0^)SQP('-T>6QE/3-$)VUA'0M86QI M9VXZ(&IU2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=M87)G:6XM M=&]P.B`P.R!M87)G:6XM8F]T=&]M.B`P.R!L:6YE+6AE:6=H=#H@;F]R;6%L M.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY4:&4@0V]M<&%N>28C,30V.W,@9F]R M;65R($)O87)D#0IO9B!$:7)E8W1O2!O=VYE9"!B>2!T:&4@0V]M<&%N>28C,30V M.W,-"G!R:6]R($-%3RP@8GD@<')I;W(@;6%N86=E;65N="!I;B!W:&EC:"!T M:&4@0V]M<&%N>28C,30V.W,@9F]R;65R($-%3R!W87,@=&\@<&%Y("0Q,#`L M,#`P('!L=7,@,B4@;V8@2X- M"E1H92!F;W)M97(@;V9F:6-E2<^06-C;W)D M:6YG;'DL('1H92!#;VUP86YY(')E8VQA6EN9R!F:6YA;F-I86P@6QE/3-$)VUA'0M86QI9VXZ(&IU2<^3VX@36%R8V@@,38L(#(P M,3,L('1H92!#;VUP86YY(&-L;W-E9"!T:&4@86-Q=6ES:71I;VX@=VET:`T* M=&AE(&9I;F%L('!A>6UE;G0@9F]R($1.02X@4W5B2P@=&AE(&%C8V]M<&%N>6EN9R!C;VYS;VQI9&%T960@9FEN M86YC:6%L('-T871E;65N=',-"G)E9FQE8W0@=&AE(&%S6QE/3-$)VUA'0M86QI9VXZ(&IU2<^1&5T86EL2<^)B,Q M-C`[/"]P/@T*#0H\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG M/3-$,"!S='EL93TS1"=B;W)D97(M8V]L;&%P6QE/3-$)W9E6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P M.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\ M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D M/CPO='(^#0H\='(@6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P M.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\ M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D M/CPO='(^#0H\='(@6QE/3-$)W=I9'1H.B`U-B4[('1E>'0M86QI9VXZ(&QE9G0[('!A9&1I M;F6%B;&4\+W1D/CQT9"!S='EL M93TS1"=W:61T:#H@."4[('!A9&1I;F6QE/3-$)W=I9'1H.B`Q)3L@8F]R9&5R+6)O='1O M;3H@0FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T)SXD/"]T9#X\ M=&0@6QE/3-$)W=I9'1H.B`Q)3L@8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T M('-O;&ED.R!T97AT+6%L:6=N.B!L969T)SXD/"]T9#X\=&0@6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)W!A M9&1I;F2<^/"]P/@T*#0H-"@T*/'`@6QE/3-$)W9E6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E M6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF M(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T6QE/3-$)W=I9'1H.B`Q)3L@ M=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q M,B4[('1E>'0M86QI9VXZ(')I9VAT)SXU,RPW-C8\+W1D/CQT9"!S='EL93TS M1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D M('-T>6QE/3-$)W=I9'1H.B`X)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^ M)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$U,3LF(S$V,#LF(S$V,#L\+W1D M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT M9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L M969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H M="<^)B,Q-3$[)B,Q-C`[)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W9E M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/BD\+W1D/CQT9#XF(S$V M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^*#DS M.#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/BD\+W1D/CPO M='(^#0H\='(@'0M86QI9VXZ(&QE9G0G M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V)O6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I M;F6QE/3-$ M)V)O6QE/3-$)W9E6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0G/CPO=&0^/'1D('-T>6QE/3-$)W!A M9&1I;F2<^)B,Q M-C`[/"]P/@T*#0H\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG M/3-$,"!S='EL93TS1"=B;W)D97(M8V]L;&%P6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W9E M6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@ M6QE/3-$)W=I9'1H.B`X)2<^)B,Q-C`[/"]T M9#X-"B`@("`\=&0@'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I M9'1H.B`X)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE M/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\ M+W1R/@T*#0H\='(@6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T6QE/3-$)W=I9'1H.B`U-B4[('1E>'0M86QI9VXZ M(&QE9G0G/D]P97)A=&EN9R!E>'!E;G-E6QE/3-$)W=I M9'1H.B`X)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@'0M86QI9VXZ(&QE9G0G/BD\ M+W1D/CQT9"!S='EL93TS1"=W:61T:#H@."4G/B8C,38P.SPO=&0^#0H@("`@ M/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^)B,Q M-C`[/"]T9#X\=&0@'0M M86QI9VXZ(&QE9G0G/BD\+W1D/CPO='(^#0H\='(@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O'0M86QI9VXZ(')I9VAT)SXU."PY.#0\+W1D/CQT9"!S='EL93TS M1"=P861D:6YG+6)O='1O;3H@,7!T.R!T97AT+6%L:6=N.B!L969T)SXF(S$V M,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL93TS1"=B M;W)D97(M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ M(')I9VAT)SXU."PY-#8\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O M;3H@,BXU<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T6QE/3-$)VUA'0M86QI9VXZ M(&IU3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R9C(Y-#,U,E\X.3EC7S1A.&9?83)C M95]A-#$X-S@T-C0V93`-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M,F8R.30S-3)?.#DY8U\T83AF7V$R8V5?830Q.#'0O:'1M;#L@8VAA M6QE/3-$)VUA'0M86QI9VXZ(&IU M6QE/3-$)VUA'0M86QI9VXZ(&IU7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2<^/&(^3D]412`X("8C,34P.R!$14)4($U)5$E'051)3TX@4%)/1U)!33PO M8CX\+W`^#0H-"CQP('-T>6QE/3-$)VUA'0M86QI9VXZ(&IU M28C,30V.W,@8W)E9&ET;W)S('1O(&5N9F]R8V4@8V]L;&5C M=&EO;B!O9B!A;GD@86UO=6YT"!M;VYT:',@96YD960@36%R8V@@,S$L(#(P M,30@86YD("`R,#$S+"!T:&4@0V]M<&%N>0T*2P-"G=H:6-H('=A2!W:6QL(&-O;G1I;G5E('1O(&-O;F1U8W0@=&AI7-I2<^)B,Q-C`[/"]P/@T*#0H\<"!S M='EL93TS1"=M87)G:6XM=&]P.B`P.R!M87)G:6XM8F]T=&]M.B`P.R!L:6YE M+6AE:6=H=#H@;F]R;6%L.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY4:&4@9F]L M;&]W:6YG(&QI86)I;&ET:65S+"!T:')O=6=H#0IT:&4@;W!I;FEO;B!O9B!L M96=A;"!C;W5N6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$ M)W9E6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT M9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L M969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H M="<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P M.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\ M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D M/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R M:6=H="<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W9E'!E;G-E6QE/3-$)W=I9'1H M.B`X)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE M/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\ M=&0@'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT M9"!S='EL93TS1"=W:61T:#H@,3(E.R!T97AT+6%L:6=N.B!R:6=H="<^-3@L M.3@T/"]T9#X\=&0@6QE/3-$)W!A9&1I;F6QE/3-$)V)O'0M86QI9VXZ(')I9VAT)SXF(S$U,3LF(S$V,#LF(S$V,#L\+W1D/CQT M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!T97AT+6%L:6=N.B!L M969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A M9&1I;F6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!R:6=H="<^-3DL-S`T/"]T9#X\=&0@6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT)SXU."PY.#0\+W1D/CQT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W!A9&1I;F6QE/3-$)V)O M6QE/3-$)W!A9&1I;F'0M M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)V)O M6QE/3-$)W9E6QE/3-$ M)V)O6QE/3-$)W!A9&1I;F'0M86QI9VXZ M(&QE9G0G/B0\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C M:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$U,3LF(S$V M,#LF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU M<'0[('1E>'0M86QI9VXZ(&QE9G0G/CPO=&0^/"]T6QE/3-$)VUA'0M86QI9VXZ(&IU6QE M/3-$)W=I9'1H.B`R,'!X.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG M:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0M6QE/3-$)W=I9'1H.B`W<'@G/B8C M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IUF4Z(#$P<'0G/D%L;"!A;6]U;G1S('1H870@=V5R92!O=V5D('1O(')E;&%T M960@<&%R=&EE'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2<^/&(^3D]412`Y M("8C,34P.R!#3TU-251-14Y44R!!3D0@0T].5$E.1T5.0TE%4SPO8CX\+W`^ M#0H-"CQP('-T>6QE/3-$)VUA'0M86QI9VXZ(&IU2<^4F5N="!E>'!E;G-E(&9O2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL M93TS1"=M87)G:6XM=&]P.B`P.R!M87)G:6XM8F]T=&]M.B`P.R!L:6YE+6AE M:6=H=#H@;F]R;6%L.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY4:&4@0V]M<&%N M>2!E;G1E2!F;W(@;65D:6-A;"!B:6QL:6YG('!R;V-E2!B96QI979E2!I2!Q=65S=&EO;F%B;&4N/"]P/@T*#0H\<"!S='EL93TS1"=M87)G:6XM=&]P M.B`P.R!M87)G:6XM8F]T=&]M.B`P.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!T M97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$ M)VUA'0M86QI9VXZ(&IU2!M86YA9V5M96YT(&)U="!M M=7-T(&)E(&%P<')O=F5D(&)Y($9I;F%N8VEA;"!);F1U0T*4F5G=6QA M=&EO;B!!=71H;W)I='D@*"8C,30W.T9)3E)!)B,Q-#@[*2X@4')E2!D96-L87)E2!P6QE/3-$)VUA'0M86QI9VXZ(&IU2!H87,@=W)I='1E;B!O9F8@)#4Y+#2X@2&]W979E'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!4'0^)SQS<&%N/CPO2<^/&(^3D]412`Q,"8C,34P.R!214Q!5$5$ M(%!!4E19#0I44D%.4T%#5$E/3E,\+V(^/"]P/@T*#0H\<"!S='EL93TS1"=M M87)G:6XM=&]P.B`P.R!M87)G:6XM8F]T=&]M.B`P.R!L:6YE+6AE:6=H=#H@ M;F]R;6%L.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP M('-T>6QE/3-$)VUA'0M86QI9VXZ(&IU2X\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\R9C(Y-#,U,E\X.3EC7S1A.&9?83)C95]A-#$X-S@T-C0V93`- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,F8R.30S-3)?.#DY8U\T M83AF7V$R8V5?830Q.#'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^)SQS<&%N/CPO'0^)SQP('-T>6QE/3-$)VUA'0M M86QI9VXZ(&IU6QE/3-$)VUA'0M86QI9VXZ M(&IU6QE/3-$)V9O;G0M6QE/3-$)VUA'0M86QI9VXZ(&IU M"!-;VYT:',@16YD960@36%R8V@@,S$L(#(P,30\ M+W4^/"]B/CPO<#X-"@T*/'`@2<^/&(^)B,Q-C`[/"]B/CPO<#X-"@T*/'`@2<^/&(^/&D^/'4^4W1O8VL@ M27-S=65D(&9O2<^1'5R:6YG('1H92!S:7@@;6]N=&AS(&5N9&5D($UA6QE/3-$)W=I9'1H.B`Q M,#`E.R!F;VYT+7-I>F4Z(#$P<'0[(&)O6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE M/3-$)VUA6QE/3-$)W!A9&1I;F6QE/3-$ M)VUA6QE/3-$)W!A9&1I;F6QE/3-$)VUA6QE/3-$)VUA'0M86QI9VXZ(&IU3L@ M=VED=&@Z(#,P)2<^3V-T;V)E6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$)VUA'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,C4E M.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SXR-2PP,#`\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=M87)G:6XM=&]P.B`P.R!M87)G:6XM8F]T=&]M.B`P.R!L M:6YE+6AE:6=H=#H@;F]R;6%L.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!W:61T M:#H@,24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VUA'0M86QI9VXZ(&IU3L@=VED=&@Z(#$E)SXD/"]T9#X-"B`@("`\=&0@3L@=VED=&@Z M(#$E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@2<^)B,Q-C`[/"]T9#X-"B`@ M("`\=&0@2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@ M2<^)B,Q-C`[ M/"]T9#X-"B`@("`\=&0@2<^)B,Q-C`[/"]T9#X\ M+W1R/@T*/'1R('-T>6QE/3-$)W9E2<^ M)B,Q-C`[/"]T9#X-"B`@("`\=&0@2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@3L@<&%D9&EN9RUB;W1T;VTZ M(#(N-7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=M87)G:6XM M=&]P.B`P.R!M87)G:6XM8F]T=&]M.B`P.R!L:6YE+6AE:6=H=#H@;F]R;6%L M.R!T97AT+6%L:6=N.B!R:6=H=#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@ M8F]R9&5R+6)O='1O;3H@0FQA8VL@,BXU<'0@9&]U8FQE)SXS-2PP,#`\+W1D M/@T*("`@(#QT9"!S='EL93TS1"=M87)G:6XM=&]P.B`P.R!M87)G:6XM8F]T M=&]M.B`P.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!T97AT+6%L:6=N.B!J=7-T M:69Y)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=M87)G:6XM=&]P M.B`P.R!M87)G:6XM8F]T=&]M.B`P.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!T M97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL M93TS1"=M87)G:6XM=&]P.B`P.R!M87)G:6XM8F]T=&]M.B`P.R!L:6YE+6AE M:6=H=#H@;F]R;6%L.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXD/"]T9#X-"B`@ M("`\=&0@2<^)B,Q-C`[/"]T9#X\+W1R/@T* M/"]T86)L93X-"CQP('-T>6QE/3-$)VUA'0M86QI9VXZ(&IU M2<^)B,Q-C`[/"]P/@T* M#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.B`P.R!M87)G:6XM8F]T=&]M.B`P M.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY$ M=7)I;F<@=&AE('-I>"!M;VYT:',@96YD960@36%R8V@@,S$L(#(P,30L#0IT M:&4@0V]M<&%N>2!I6QE/3-$)VUA'0M86QI9VXZ M(&IU6QE/3-$)W1E>'0M86QI9VXZ M(&-E;G1E6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^ M)B,Q-C`[/"]T9#X\=&0@'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I M9'1H.B`X)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@'0M86QI9VXZ(')I9VAT)SXQ,#`L,#`P/"]T9#X\=&0@ M'0M86QI9VXZ(')I9VAT)SXR+#$P,#PO=&0^/'1D('-T>6QE/3-$ M)W!A9&1I;F'0M86QI9VXZ(&QE9G0G/B8C,38P M.SPO=&0^/"]T'0M86QI9VXZ M(&QE9G0[('9E6QE/3-$)V)O6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL93TS1"=B;W)D M97(M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I M9VAT)SXU+#6QE/3-$)W!A9&1I;F2<^/&(^/&D^)B,Q-C`[/"]I/CPO8CX\+W`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`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L M969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H M="<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\ M='(@6QE/3-$ M)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@ M6QE/3-$)V9O;G0M'0M86QI9VXZ(&QE M9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`U)2<^)B,Q-C`[ M/"]T9#X-"B`@("`\=&0@6QE/3-$ M)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@ M'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S M='EL93TS1"=W:61T:#H@,3DE.R!T97AT+6%L:6=N.B!R:6=H="<^-C8V+#6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F M="<^)B,Q-C`[/"]T9#X\=&0@'0M86QI9VXZ M(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q.24[('1E M>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P M<'0G/D-O;7!E;G-A=&EO;CPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=W:61T M:#H@,24[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0G/CPO=&0^/'1D('-T>6QE/3-$ M)W!A9&1I;F'0M86QI9VXZ(')I9VAT)SXF(S$V M,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!T97AT M+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG M+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B M;W)D97(M8F]T=&]M.B!";&%C:R`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`[)B,Q-C`[ M/"]P/@T*#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.B`P.R!M87)G:6XM8F]T M=&]M.B`P.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!T97AT+6%L:6=N.B!J=7-T M:69Y)SX\8CX\=3Y3:7@@36]N=&AS($5N9&5D($UA6QE/3-$)VUA'0M86QI9VXZ M(&IU6QE/3-$)VUA M'0M86QI9VXZ(&IU2<^/&(^/&D^)B,Q-C`[/"]I M/CPO8CX\+W`^#0H-"CQP('-T>6QE/3-$)VUA'0M86QI9VXZ M(&IU6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0G/B8C,38P.SPO=&0^/"]TF4Z(#$P M<'0G/D]C=&]B97(@,30L(#(P,3(\+V9O;G0^/"]T9#X\=&0@6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG M;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W=I M9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL M93TS1"=W:61T:#H@,C8E.R!T97AT+6%L:6=N.B!R:6=H="<^,C`L,#`P/"]T M9#X\=&0@F4Z M(#$P<'0G/D]C=&]B97(@,30L(#(P,3(\+V9O;G0^/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXS+#`P,#PO=&0^/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('9E6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M)SXQ."PW-3`\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF M(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!R:6=H="<^,BPU,#`\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@F4Z(#$P<'0G/D]C=&]B97(@,30L(#(P,3(\+V9O;G0^/"]T M9#X\=&0@6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P M.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXR+#4P,#PO M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^ M/"]T6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('9E6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT)SXQ-2PP,#`\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^,RPP,#`\+W1D/CQT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@ MF4Z(#$P<'0G/DUA6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('9E M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXR,"PP,#`\+W1D M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT M9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L M969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H M="<^,C`L,#`P/"]T9#X\=&0@6QE/3-$)W9EF4Z(#$P<'0G/DUA6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXR,"PP,#`\+W1D/CQT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\ M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^,C`L,#`P/"]T M9#X\=&0@6QE/3-$)W9E6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE M/3-$)V)O6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T M>6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('9E6QE/3-$)V9O;G0M6QE/3-$)V)O6QE/3-$)W!A9&1I M;F'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL M93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B;&4[('1E>'0M M86QI9VXZ(')I9VAT)SXQ-#$L,#`P/"]T9#X\=&0@6QE/3-$)VUA M'0M86QI9VXZ(&IU6QE/3-$)VUA'0M86QI9VXZ(&IU2<^1'5R:6YG('1H92`@2<^)B,Q-C`[/"]P/@T*#0H\=&%B;&4@8V5L M;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=B;W)D97(M M8V]L;&%P6QE M/3-$)V)O6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]TF4Z M(#$P<'0G/D]C=&]B97(@,30L(#(P,3(\+V9O;G0^/"]T9#X\=&0@6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA M;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$ M)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@ M'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S M='EL93TS1"=W:61T:#H@,C8E.R!T97AT+6%L:6=N.B!R:6=H="<^,2PS,#`\ M+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0G M/B8C,38P.SPO=&0^/"]T6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('9E6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`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`[/"]I/CPO M8CX\+W`^#0H-"CQP('-T>6QE/3-$)VUA'0M86QI9VXZ(&IU M6QE/3-$)V)O6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('9E6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^ M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^ M)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W1E M>'0M86QI9VXZ(&-E;G1E6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[ M('9E6QE/3-$ M)W=I9'1H.B`R,"4[('1E>'0M86QI9VXZ(&QE9G0[('9E6QE/3-$)V9O;G0M'0M86QI9VXZ(&QE9G0[('9E6QE/3-$)W=I9'1H.B`U)2<^)B,Q-C`[/"]T9#X-"B`@ M("`\=&0@6QE/3-$)W=I9'1H.B`Q M)3L@=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H M.B`Q.24[('1E>'0M86QI9VXZ(')I9VAT)SXR-C`\+W1D/CQT9"!S='EL93TS M1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D M('-T>6QE/3-$)W=I9'1H.B`U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W=I9'1H M.B`Q.24[('1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA M;&EG;CH@8V5N=&5R.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SXF(S$V,#L\ M+W1D/CPO='(^#0H\='(@F4Z(#$P<'0G M/D1E8V5M8F5R(#8L(#(P,3(\+V9O;G0^/"]T9#X\=&0@6QE/3-$)W1E>'0M M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('9E6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO M=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT)SXQ+#6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`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`R M+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT)SXR."PQ-34\+W1D/CQT M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M86QI9VXZ M(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I M;F'0M86QI9VXZ(&-E;G1E2<^ M)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.B`P.R!M87)G M:6XM8F]T=&]M.B`P.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!T97AT+6%L:6=N M.B!J=7-T:69Y)SX\8CX\:3X\=3Y3=&]C:R!)2<^)B,Q-C`[/"]P/@T*#0H\<"!S M='EL93TS1"=M87)G:6XM=&]P.B`P.R!M87)G:6XM8F]T=&]M.B`P.R!L:6YE M+6AE:6=H=#H@;F]R;6%L.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY$=7)I;F<@ M=&AE('-I>"!M;VYT:',@96YD960@36%R8V@@,S$L#0HR,#$S+"!T:&4@0V]M M<&%N>2!I6QE/3-$)VUA'0M86QI9VXZ(&IU2<^/&(^/'4^4')E9F5R6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$)VUA'0M M86QI9VXZ(&IUF5D(#0L M,#`P+#`P,"!S:&%R97,-"F]F('!R969E6QE/3-$)VUA'0M86QI9VXZ(&IU2<^3VX@1&5C96UB97(@,3'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO2<^/&(^3D]4 M12`Q,B`F(S$U,#L@4U5"4T51545.5"!%5D5.5%,\+V(^/"]P/@T*#0H\<"!S M='EL93TS1"=M87)G:6XM=&]P.B`P.R!M87)G:6XM8F]T=&]M.B`P.R!L:6YE M+6AE:6=H=#H@;F]R;6%L.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\8CXF(S$V M,#LF(SD[/"]B/CPO<#X-"@T*/'`@3L@9F]N="US='EL93H@:71A;&EC.R!F;VYT+7=E:6=H M=#H@8F]L9#L@=&5X="UD96-O6QE/3-$)VUA'0M86QI9VXZ(&IU2<^3VX@07!R:6P@,C$L M(#(P,30L('1H92!#;VUP86YY(&ES3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\R9C(Y-#,U,E\X.3EC7S1A.&9?83)C95]A-#$X-S@T-C0V M93`-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,F8R.30S-3)?.#DY M8U\T83AF7V$R8V5?830Q.#'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R2<^/&(^57-E(&]F($5S=&EM871E6QE/3-$)VUA'0M86QI9VXZ(&IU2!W:71H(&%C8V]U;G1I M;F<@<')I;F-I<&QE&ES="!A'!E;G-EF5D M(&1U2<^/&(^0V%S:"!A M;F0@0V%S:"!%<75I=F%L96YT6QE/3-$)VUA M'0M86QI9VXZ(&IU2<^5&AE($-O M;7!A;GD@8V]N2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS M1"=M87)G:6XM=&]P.B`P.R!M87)G:6XM8F]T=&]M.B`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`[(&EN<'5T M6QE/3-$)W9E M'0M86QI9VXZ(&IU6QE/3-$)W=I9'1H.B`Q-7!T.R!T97AT+6%L:6=N.B!R:6=H="<^/&9O M;G0@2<^/&9O;G0@0T*:6YC;'5D92!Q=6]T960@<')I8V5S(&9O0T*;W1H97(@=&AA;B!Q=6]T960@<')I8V5S+"!E:71H M97(@9&ER96-T;'D@;W(@:6YD:7)E8W1L>2P@:6YC;'5D:6YG(&EN<'5T6QE M/3-$)V9O;G0M6QE/3-$)W=I9'1H.B`U<'0G/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&IU6QE/3-$)V9O;G0M2<^)B,Q-C`[ M/"]P/@T*#0H\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$ M,"!S='EL93TS1"=B;W)D97(M8V]L;&%P6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E M6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@ M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X\=&0@ M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P M.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W=I9'1H.B`S)3L@<&%D9&EN M9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,3`E M.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@'0M86QI9VXZ M(')I9VAT)SXF(S$U,3LF(S$V,#LF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W M:61T:#H@,24[('!A9&1I;F'0M86QI9VXZ(&QE M9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`S)3L@<&%D9&EN M9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,3`E M.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@'0M86QI9VXZ M(')I9VAT)SXF(S$U,3LF(S$V,#LF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W M:61T:#H@,24[('!A9&1I;F'0M86QI9VXZ(&QE M9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`S)3L@<&%D9&EN M9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,3`E M.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@'0M86QI9VXZ M(')I9VAT)SXW,#$L-C$Q/"]T9#X\=&0@6QE/3-$)W=I9'1H.B`Q)3L@ M8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L M969T)SXD/"]T9#X\=&0@6QE/3-$)W=I9'1H.B`Q)3L@<&%D9&EN9RUB;W1T M;VTZ(#%P=#L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\+W1R/@T* M/'1R('-T>6QE/3-$)W9E'0M:6YD96YT.B`Y+C'0M86QI9VXZ(&QE9G0G/B0\ M+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`R+C5P="!D M;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$U,3LF(S$V,#LF(S$V,#L\ M+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)V)O'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$ M)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)W9E6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^ M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT M9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L M969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H M="<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO M=&0^/'1D/B8C,38P.SPO=&0^#0H@("`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`Q<'0@'0M86QI9VXZ(')I9VAT)SXY,S6QE/3-$)W9E M'0M:6YD96YT.B`Y+C'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL93TS M1"=B;W)D97(M8F]T=&]M.B!";&%C:R`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`@"!P;W-I=&EO;B!F;W(@2X@5&AE('-E8V]N M9"!S=&5P(&ES('1O(&UE87-U"!B96YE9FET(&%S('1H92!L M87)G97-T(&%M;W5N="P-"G=H:6-H(&ES(&UOF5D('5P;VX@=6QT:6UA=&4@2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=M87)G M:6XM=&]P.B`P.R!M87)G:6XM8F]T=&]M.B`P.R!L:6YE+6AE:6=H=#H@;F]R M;6%L.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY,:6-E;G-E(')E=F5N=64@8V]N M2X@ M5&AE('1H:7)D('!A6QE/3-$)VUA M'0M86QI9VXZ(&IU2<^5E-/12!O M9B!F86ER('9A;'5E(&9O2!O=F5R('1H92!T M97)M(&]F('1H92!S=6)S8W)I<'1I;VX@<&5R:6]D+CPO<#X-"@T*/'`@2<^)B,Q-C`[/"]P M/@T*#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.B`P.R!M87)G:6XM8F]T=&]M M.B`P.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!T97AT+6%L:6=N.B!J=7-T:69Y M)SY06%L='D@9F5E2!I6QE/3-$)VUA'0M M86QI9VXZ(&IUF5D(')A=&%B;'D-"F]V97(@ M=&AE('1E6QE/3-$ M)VUA'0M86QI9VXZ(&IU2<^5')A M;G-A8W1I;VX@2<^)B,Q-C`[/"]P/@T*#0H\=&%B;&4@8V5L;'!A9&1I M;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P M<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&UA6QE/3-$)V9O;G0M M6QE/3-$)W=I M9'1H.B`U<'0G/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)V9O;G0M2<^#0H\=&0@6QE/3-$)V9O;G0MF4Z(#$P<'0[ M(&-O;&]R.B`C,#`P,#`T)SY087!EF4Z(#$P<'0[(&-O;&]R.B`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`[/"]P/@T*#0H\ M<"!S='EL93TS1"=M87)G:6XM=&]P.B`P.R!M87)G:6XM8F]T=&]M.B`P.R!L M:6YE+6AE:6=H=#H@;F]R;6%L.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY4:&4@ M86UOF%T:6]N(&]F(&%C<75I2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL M93TS1"=M87)G:6XM=&]P.B`P.R!M87)G:6XM8F]T=&]M.B`P.R!L:6YE+6AE M:6=H=#H@;F]R;6%L.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY$969EF5D M(&]R(&9O2!R96-O M9VYI>F5S(')E=F5N=64@=&\@<')O=FED92!U<"UF0T*86QS;R!R96-O9VYI>F5S M(&%N;G5A;"!S=6)S8W)I<'1I;VX@9F5EF4@=&AE(')E=F5N=64@;W9E2!H87,@9&5F97)R960@'0^)SQP('-T>6QE/3-$)VUA'0M M86QI9VXZ(&IU2<^ M)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.B`P.R!M87)G M:6XM8F]T=&]M.B`P.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!T97AT+6%L:6=N M.B!J=7-T:69Y)SY4:&4@0V]M<&%N>2!P87ES(&-O;6UI2X@5&AE(&-O;6UI2!P86ED(&EN(&9U;&P@:6X@=&AE(&UO;G1H(&]R('%U87)T97(@9F]L;&]W M:6YG(&5X96-U=&EO;B!O9B!T:&4-"F-U2P@86YD("0S-RPP,#`@86YD("0T,"PR-C`@ M9F]R('1H92!S:7@@;6]N=&AS(&5N9&5D($UA'0^)SQP('-T>6QE/3-$)VUA'0M86QI9VXZ(&IU2<^)B,Q M-C`[/"]P/@T*#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.B`P.R!M87)G:6XM M8F]T=&]M.B`P.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!T97AT+6%L:6=N.B!J M=7-T:69Y)SY#87!I=&%L:7IA=&EO;B!O9B!C97)T86EN('-O9G1W87)E#0ID M979E;&]P;65N="!C;W-T2!U6QE M/3-$)VUA'0M86QI9VXZ(&IU&-H86YG92!F;W(@86X@87=AF5D(&]V M97(@=&AE('9E2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.B`P.R!M M87)G:6XM8F]T=&]M.B`P.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!T97AT+6%L M:6=N.B!J=7-T:69Y)SX\8CY"87-I8R!A;F0@1&EL=71E9"!.970@26YC;VUE M("A,;W-S*2!P97(-"D-O;6UO;B!3:&%R93PO8CX\+W`^#0H-"CQP('-T>6QE M/3-$)VUA'0M86QI9VXZ(&IU2<^ M0F%S:6,@:6YC;VUE("AL;W-S*2!P97(@2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL M93TS1"=M87)G:6XM=&]P.B`P.R!M87)G:6XM8F]T=&]M.B`P.R!L:6YE+6AE M:6=H=#H@;F]R;6%L.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY4:&4@0V]M<&%N M>2!H87,@-"PP,#`L,#`P('!R969EF5D('-H87)E2!T86ME('!L86-E('=I=&@@=&AE(&%P<')O=F%L(&]F('1H M92!";V%R9"!O9B!$:7)E8W1O6QE/3-$)VUA'0M86QI9VXZ(&IU2<^1&EL=71E9"!L M;W-S('!E'0^)SQP('-T>6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$)VUA'0M86QI9VXZ M(&IU28C,30V.W,@8V%S:"!A;F0@ M8V%S:"!E<75I=F%L96YT'!O'!E2<^/&(^4W5B6QE/3-$)VUA'0M M86QI9VXZ(&IU2<^/&(^4F5C96YT($%C8V]U M;G1I;F<@4')O;F]U;F-E;65N=',\+V(^/"]P/@T*#0H\<"!S='EL93TS1"=M M87)G:6XM=&]P.B`P.R!M87)G:6XM8F]T=&]M.B`P.R!L:6YE+6AE:6=H=#H@ M;F]R;6%L.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP M('-T>6QE/3-$)VUA'0M86QI9VXZ(&IU'!E8W1E9"!T;R!A(&AA=F4@82!M871E'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'0^)SQT86)L92!C96QL<&%D M9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)V)O6QE/3-$)W!A9&1I;F6QE/3-$ M)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A M9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO M=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L M969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T M6QE/3-$)W=I9'1H M.B`T,"4[('!A9&1I;F'0M:6YD96YT.B`Y+C6QE/3-$)W=I9'1H.B`Q,"4[(&)O6QE/3-$)W=I9'1H.B`Q)3L@<&%D9&EN9RUB;W1T M;VTZ(#%P=#L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W=I9'1H.B`Q,"4[(&)O6QE/3-$)W=I9'1H.B`Q)3L@<&%D9&EN9RUB;W1T M;VTZ(#%P=#L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W=I9'1H.B`Q,"4[(&)O'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H M.B`S)3L@<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@("`\ M=&0@'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL93TS M1"=W:61T:#H@,3`E.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@'0M86QI9VXZ(')I9VAT)SXW,#$L-C$Q/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A M9&1I;F6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)W!A9&1I M;F'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL M93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B;&4[('1E>'0M M86QI9VXZ(')I9VAT)SXF(S$U,3LF(S$V,#LF(S$V,#L\+W1D/CQT9"!S='EL M93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M86QI9VXZ(&QE9G0G M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F6QE M/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0G/B0\+W1D M/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B M;&4[('1E>'0M86QI9VXZ(')I9VAT)SXW,#$L-C$Q/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\ M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[ M/"]T9#X\=&0@6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^ M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T M)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T6QE/3-$)W!A9&1I;F'0M:6YD96YT.B`Y+C6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0G M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)V)O M6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T M=&]M.B!";&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT)SXF M(S$U,3LF(S$V,#LF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O M='1O;3H@,BXU<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D M('-T>6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL93TS1"=B M;W)D97(M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ M(')I9VAT)SXY,S7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQT M86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$ M)V)O6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W!A9&1I;F6QE/3-$)W1E M>'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T M6QE/3-$)W=I9'1H M.B`U-B4[('1E>'0M86QI9VXZ(&IU6QE/3-$ M)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^/'1D('-T>6QE M/3-$)W=I9'1H.B`Q,B4[('1E>'0M86QI9VXZ(')I9VAT)SXV+#`P,#PO=&0^ M/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^)B,Q M-C`[/"]T9#X\=&0@'0M86QI9VXZ(&QE9G0G M/B0\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,3(E.R!T97AT+6%L:6=N.B!R M:6=H="<^)B,Q-3$[)B,Q-C`[)B,Q-C`[/"]T9#X\=&0@6QE/3-$ M)W1E>'0M86QI9VXZ(&IU6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT)SXQ-2PX,#`\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!R:6=H="<^,34L.#`P/"]T9#X\=&0@6QE/3-$)W9E2<^4V]U6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0G/D%C<75I6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P M.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXQ,"PP,#`\ M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D M/CPO='(^#0H\='(@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C M,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT)SXQ+#(P,"PQ,#8\+W1D/CQT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('!A9&1I;F'0M M86QI9VXZ(')I9VAT)SXR,RPP,#`\+W1D/CQT9"!S='EL93TS1"=P861D:6YG M+6)O='1O;3H@,7!T.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$ M)V)O6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0G/E1O=&%L(&EN=&%N9VEB;&4@87-S971S/"]T9#X\=&0^)B,Q-C`[ M/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P M.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT)SXQ+#(U,2PT,#8\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0G/D%C8W5M=6QA=&5D(&%M;W)T:7IA=&EO;B!O9B!I;G1A;F=I8FQE(&%S M6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT)SXH-30U+#6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0G/BD\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!R:6=H="<^*#0R,RPT.#4\+W1D/CQT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T)SXI/"]T9#X\+W1R/@T*/'1R('-T>6QE M/3-$)W9E'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO M=&0^/'1D('-T>6QE/3-$)V)O'0M86QI M9VXZ(')I9VAT)SXH,3`L,#`P/"]T9#X\=&0@6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F'0M86QI9VXZ M(&QE9G0G/B0\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C M:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT)SXX,37!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P M.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P M.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W=I9'1H.B`U-B4[('1E>'0M M86QI9VXZ(&QE9G0[('!A9&1I;F6%B;&4\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@."4[('!A9&1I;F6QE/3-$)W=I9'1H M.B`Q)3L@8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!T97AT+6%L M:6=N.B!L969T)SXD/"]T9#X\=&0@6QE/3-$)W=I9'1H.B`Q)3L@8F]R9&5R M+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T)SXD M/"]T9#X\=&0@6QE/3-$ M)V)O6QE/3-$)W!A9&1I;F2<^/"]P/@T* M#0H-"@T*/'`@6QE/3-$)W9E6QE/3-$)W!A9&1I;F6QE/3-$ M)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C M,38P.SPO=&0^/"]T6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^/'1D M('-T>6QE/3-$)W=I9'1H.B`Q,B4[('1E>'0M86QI9VXZ(')I9VAT)SXU,RPW M-C8\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE M9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`X)2<^)B,Q-C`[ M/"]T9#X-"B`@("`\=&0@6QE/3-$)W=I9'1H.B`Q)3L@ M=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE M/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$U M,3LF(S$V,#LF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L M969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-3$[)B,Q-C`[)B,Q-C`[/"]T9#X\ M=&0@6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0G/BD\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!R:6=H="<^*#DS.#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0G/BD\+W1D/CPO='(^#0H\='(@'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V)O M6QE/3-$)W!A9&1I M;F'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^ M/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)W9E6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0G/CPO M=&0^/'1D('-T>6QE/3-$)W!A9&1I;F2<^)B,Q-C`[/"]P/@T*#0H\=&%B;&4@8V5L;'!A9&1I M;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=B;W)D97(M8V]L;&%P M6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V M,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W=I M9'1H.B`X)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO M=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`X)2<^)B,Q-C`[/"]T9#X-"B`@("`\ M=&0@6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@ M;&5F="<^)B,Q-C`[/"]T9#X\+W1R/@T*#0H\='(@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T M6QE/3-$)W=I9'1H M.B`U-B4[('1E>'0M86QI9VXZ(&QE9G0G/D]P97)A=&EN9R!E>'!E;G-E6QE/3-$)W=I9'1H.B`X)2<^)B,Q-C`[/"]T9#X-"B`@("`\ M=&0@'0M86QI9VXZ(&QE9G0G/BD\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@."4G M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X M="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@'0M86QI9VXZ(&QE9G0G/BD\+W1D/CPO='(^#0H\ M='(@6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W!A9&1I M;F6QE/3-$ M)V)O'0M86QI9VXZ(')I9VAT)SXU."PY M.#0\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!T97AT M+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0G/B0\ M+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`R+C5P="!D M;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT)SXU."PY-#8\+W1D/CQT9"!S='EL M93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M86QI9VXZ(&QE9G0G M/B8C,38P.SPO=&0^/"]T3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R9C(Y-#,U,E\X.3EC7S1A.&9?83)C M95]A-#$X-S@T-C0V93`-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M,F8R.30S-3)?.#DY8U\T83AF7V$R8V5?830Q.#'0O:'1M;#L@8VAA M'0^)SQS<&%N/CPO6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V M,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF M(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W=I9'1H.B`U-B4[('1E>'0M86QI9VXZ(&QE M9G0[('!A9&1I;F'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,3(E M.R!T97AT+6%L:6=N.B!R:6=H="<^-3DL-S`T/"]T9#X\=&0@6QE M/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^/'1D('-T M>6QE/3-$)W=I9'1H.B`Q,B4[('1E>'0M86QI9VXZ(')I9VAT)SXU."PY.#0\ M+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0G M/B8C,38P.SPO=&0^/"]T6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F'0M86QI M9VXZ(')I9VAT)SXF(S$U,3LF(S$V,#LF(S$V,#L\+W1D/CQT9"!S='EL93TS M1"=P861D:6YG+6)O='1O;3H@,7!T.R!T97AT+6%L:6=N.B!L969T)SXF(S$V M,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T)SXF(S$V M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C M:R`Q<'0@'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D M('-T>6QE/3-$)V)O6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE M/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0G/BD\ M+W1D/CPO='(^#0H\='(@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)W!A9&1I;F'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)R9N8G-P.R9N M8G-P.SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P M.SQS<&%N/CPO'0^)SQS M<&%N/CPO7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\R9C(Y-#,U,E\X.3EC7S1A.&9?83)C95]A M-#$X-S@T-C0V93`-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,F8R M.30S-3)?.#DY8U\T83AF7V$R8V5?830Q.#'0O:'1M;#L@8VAA'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6%B;&4\+W1D/@T*("`@("`@ M("`\=&0@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)R9N8G-P M.R9N8G-P.SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P M.SQS<&%N/CPO'!E;G-E'0^)R9N8G-P.R9N8G-P.SQS M<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA3PO=&0^#0H@ M("`@("`@(#QT9"!C;&%S3PO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO2!, M:6%B:6QI=&EE7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA'0^)SQS M<&%N/CPO6UE;G0@;V8@061V86YC97,@9G)O;2!296QA=&5D(%!A3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R9C(Y-#,U,E\X.3EC7S1A.&9? M83)C95]A-#$X-S@T-C0V93`-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO,F8R.30S-3)?.#DY8U\T83AF7V$R8V5?830Q.#'0O:'1M;#L@ M8VAA2`P,BP@,C`Q-#QB'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)S$U,#QS<&%N/CPO'0^)SQS<&%N/CPO'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO M XML 18 R29.htm IDEA: XBRL DOCUMENT v2.4.0.8
6. DISCONTINUED OPERATIONS (Details Narrative) (USD $)
12 Months Ended
Sep. 30, 2011
Discontinued Operations and Disposal Groups [Abstract]  
Sale of Assets, Purchase Price $ 100,000
XML 19 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8
6. DISCONTINUED OPERATIONS - Discontinued Operations (Details) (USD $)
3 Months Ended 6 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Mar. 31, 2014
Mar. 31, 2013
Sep. 30, 2013
Accounts payable $ 699,559   $ 699,559   $ 361,994
Net liabilities of discontinued operations 42,873   42,873   35,356
Revenues 105,118 174,214 222,675 323,571  
Cost of sales 61,155 61,155 122,310 121,160  
Operating expenses 1,136,142 279,454 1,388,218 438,325  
Gain from write-off of debt        (58,984)  
Discontinued Operations [Member]
         
Accounts payable 42,837   42,837   35,356
Net liabilities of discontinued operations 42,837   42,837   35,356
Revenues 53,766 900 131,050 900  
Cost of sales              
Operating expenses (50,568) (938) (138,567) (938)  
Gain from write-off of debt          58,984  
Income (loss) from discontinued operations $ 3,198 $ (38) $ (7,517) $ 58,946  
XML 20 R30.htm IDEA: XBRL DOCUMENT v2.4.0.8
7. LINES OF CREDIT (Details Narrative) (USD $)
6 Months Ended
Mar. 31, 2014
Mutualof Omaha [Member]
 
Revolving Line of Credit, Borrowing Capacity $ 65,000
Line of Credit Interest Rate 4.00%
Line of Credit, Amount Outstanding 50,000
Chase [Member]
 
Revolving Line of Credit, Borrowing Capacity 50,000
Line of Credit Interest Rate 4.25%
Line of Credit, Amount Outstanding $ 18,370
XML 21 R31.htm IDEA: XBRL DOCUMENT v2.4.0.8
8 - DEBT MITIGATION PROGRAM - Debt Mitigation Program (Details) (USD $)
6 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Total debt mitigation program $ 59,704 $ 58,984
Gain on write-off of debt    (58,984)
Additional paid-in capital 59,704 [1]    [1]
Accounts Payable and Accrued Expenses
   
Total debt mitigation program 59,704 58,984
Accrued Interest
   
Total debt mitigation program      
[1] All amounts that were owed to related parties in prior years were recorded to paid-in-capital.
XML 22 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8
3. GOING CONCERN
6 Months Ended
Mar. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
3. GOING CONCERN

NOTE 3 - GOING CONCERN

 

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. However, the Company has recurring losses from operations and an accumulated deficit at March 31, 2014 of $27,838,150 and needs additional cash to maintain its operations.

 

These factors raise doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company’s continued existence is dependent upon management’s ability to develop profitable operations, continued contributions from the Company’s executive officers to finance its operations and the ability to obtain additional funding sources to explore potential strategic relationships and to provide capital and other resources for the further development and marketing of the Company’s products and business.

XML 23 R32.htm IDEA: XBRL DOCUMENT v2.4.0.8
8. DEBT MITIGATION PROGRAM (Details Narrative) (USD $)
6 Months Ended
Mar. 31, 2014
Mar. 31, 2013
OTHER INCOME (EXPENSE)    
Gain on the Write-Off of Liabilities    $ 58,984
Additional Paid-In Capital for Related Party Liabilities $ 59,704 [1]    [1]
[1] All amounts that were owed to related parties in prior years were recorded to paid-in-capital.
XML 24 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8
Balance Sheets (Unaudited) (USD $)
Mar. 31, 2014
Sep. 30, 2013
CURRENT ASSETS:    
Cash $ 7,656 $ 8,587
Accounts receivables 5,176 8,338
Total current assets 12,832 16,925
Software, net 701,611 817,921
TOTAL ASSETS 714,443 834,846
CURRENT LIABILITIES:    
Accounts payables and accrued expenses 699,559 361,994
Liabilities attributed to discontinued operations 42,873 35,356
Lines of credit 87,041 9,796
Total current liabilities 829,473 407,146
TOTAL LIABILITIES 829,473 407,146
COMMITMENTS AND CONTINGENCIES      
STOCKHOLDERS' EQUITY:    
Preferred stock, $0.01 par value, 4,000,000 shares authorized; 4,000,000 issued and outstanding 40,000 40,000
Common stock, $0.01 par value, 650,000,000 shares authorized; 246,829,216 and 214,624,216 issued and outstanding 2,468,292 2,146,242
Additional paid-in capital 25,214,828 24,783,723
Accumulated deficit (27,838,150) (26,542,265)
Total stockholders' equity (deficit) (115,030) 427,700
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) $ 714,443 $ 834,846
XML 25 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8
1. DESCRIPTION OF BUSINESS
6 Months Ended
Mar. 31, 2014
Accounting Policies [Abstract]  
1. DESCRIPTION OF BUSINESS

NOTE 1- DESCRIPTION OF BUSINESS

 

Cloud Medical Doctor Software Corporation (the “Company”) was incorporated in Texas on June 22, 1953 as American Mortgage Company. On May 16, 1996, the Company changed its name to National Scientific Corporation. On April 3, 2012, the Company changed its name to Cloud Medical Doctor Software Corporation. 

 

In the year ended September 30, 2011, Cloud-MD introduced the Cloud-MD Office, a “Cloud Based”, 5010 ready and ICD-10 compliant, fully integrated and interoperable suite of medical software and services, designed by experienced healthcare analysts and programmers for healthcare providers, that produces “Actionable Information” to help Independent Physician Practices, New Care Delivery Models (ACO), Healthcare Systems and Billing Services optimize a wide range of business processes resulting in Increased Profits, Higher Quality, Greater Efficiency, Noticeable Cost Reductions and Better Patient Care. Current software product offerings include Practice Management, Electronic Medical Records, Revenue Management, Patient Financial Solutions, Medical and Pharmaceutical Supply Management, Claims Management and PHI Exchange.

 

In the year ended September 30, 2012, Cloud-MD launched Cloud-MD Billing Services which provides management of medical claims from posting physician charges and payments into our medical billing software. The software uses a continuous insurance claim follow-up system to track and research all rejected or denied medical claims; a Comprehensive Reporting module that includes monthly financial statements sent to our clients so they can see how their practice is performing and a variety of detailed reports giving our clients the necessary information and tools used to assist in the increased production which leads to more profit; and patient account inquiries and support to assist patients with their billing and insurance questions.

XML 26 R35.htm IDEA: XBRL DOCUMENT v2.4.0.8
11. EQUITY (Details Narrative) (USD $)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
May 02, 2014
Dec. 31, 2013
Dec. 31, 2012
Mar. 31, 2014
Mar. 31, 2013
Sep. 30, 2013
Common Stock, Shares Authorized       650,000,000   650,000,000
Preferred Stock Shares Authorized       4,000,000   4,000,000
Common Stock, Par Value       $ 0.01   $ 0.01
Preferred Stock, Par Value       $ 0.01   $ 0.01
Preferred Stock, Shares Issued       4,000,000   4,000,000
Preferred Stock Shares Outstanding       4,000,000   4,000,000
Preferred Stock, Voting Rights           150
Preferred Stock, Trading Price of the Common Stock           $ 0.0095
Compensation Expense           $ 38,000
Stock Issued for Cash, Shares       35,000 197,500  
Stock Issued for Cash, Value       15,000 141,000  
Stock Issued for Software Licensing and Subscription Agreements, Shares       220,000 300,000  
Stock Issued for Software Licensing and Subscription Agreements, Value       5,700 9,350  
Stock Issued for Assets Acquisition, Shares   200,000 100,000 200,000 400,000  
Stock Issued for Assets Acquisition, Value   6,000 2,800 6,000 13,000  
Stock Issued for Replacement, Shares           180,000
Stock Issued for Services, Shares 1,427,506     31,750,000 827,000  
Stock Issued for Services, Value $ 30,684     $ 666,750 $ 28,155  
Antree Systems Limited
           
Stock Issued for Replacement, Shares           160,000
Kimberly Ilicerl
           
Stock Issued for Replacement, Shares           20,000
XML 27 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8
8. DEBT MITIGATION PROGRAM (Tables)
6 Months Ended
Mar. 31, 2014
OTHER INCOME (EXPENSE)  
Debt Mitigation Program
   Six Months Ended
   March  31,  March 31,
   2014  2013
           
Debt Mitigation Program:          
Accounts payable and accrued expenses  $59,704   $58,984 
Accrued interest   —      —   
Total debt mitigation program  $59,704   $58,984 
Gain on write-off of debt  $—     $(58,984)
Additional paid-in capital (1)  $59,704   $—  
XML 28 R36.htm IDEA: XBRL DOCUMENT v2.4.0.8
12. SUBSEQUENT EVENTS (Details Narrative) (USD $)
1 Months Ended 6 Months Ended
May 02, 2014
Mar. 31, 2014
Mar. 31, 2013
Subsequent Events [Abstract]      
Stock Issued for Services, Shares 1,427,506 31,750,000 827,000
Stock Issued for Services, Value $ 30,684 $ 666,750 $ 28,155
XML 29 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8
4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value of Financial Instruments (Details) (USD $)
Mar. 31, 2014
Sep. 30, 2013
Software $ 701,611 $ 937,431
Total Software 701,611 937,431
Level 1
   
Software      
Total Software      
Level 2
   
Software      
Total Software      
Level 3
   
Software 701,611 937,431
Total Software $ 701,611 $ 937,431
XML 30 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 31 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8
2. BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS
6 Months Ended
Mar. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
2. BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS

NOTE 2 – BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS

 

The Company prepares its financial statements in accordance with accounting principles generally accepted in the United States of America.  The accompanying interim unaudited financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X. In our opinion, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included.

 

Operating results for the six months ended March 31, 2014 are not necessarily indicative of the results that may be expected for the year ending September 30, 2014. Notes to the unaudited interim financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the year ended September 30, 2013 have been omitted; this report should be read in conjunction with the audited financial statements and the footnotes thereto for the fiscal year ended September 30, 2013 included within the Company’s Form 10-K as filed with the Securities and Exchange Commission.

XML 32 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8
Balance Sheets (Parenthetical) (USD $)
Mar. 31, 2014
Sep. 30, 2013
Statement of Financial Position [Abstract]    
Preferred Stock, Par Value $ 0.01 $ 0.01
Preferred Stock, Shares Authorized 4,000,000 4,000,000
Preferred Stock, Shares Issued 4,000,000 4,000,000
Preferred Stock, Shares Outstandng 4,000,000 4,000,000
Common Stock, Par Value $ 0.01 $ 0.01
Common Stock, Shares Authorized 650,000,000 650,000,000
Common Stock, Shares Issued 246,829,216 214,624,216
Common Stock, Shares Outstanding 246,829,216 214,624,216
XML 33 R17.htm IDEA: XBRL DOCUMENT v2.4.0.8
12. SUBSEQUENT EVENTS
6 Months Ended
Mar. 31, 2014
Subsequent Events [Abstract]  
12. SUBSEQUENT EVENTS

NOTE 12 – SUBSEQUENT EVENTS

 

Stock Issued for Services

 

On April 21, 2014, the Company issued 1,407,506 shares of common stock as compensation. The fair values of the shares were a total of $21,253 and were recorded at the market price on the date of grant.

XML 34 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8
Document and Entity Information
6 Months Ended
Mar. 31, 2014
May 01, 2014
Document And Entity Information    
Entity Registrant Name NATIONAL SCIENTIFIC CORP/AZ  
Entity Central Index Key 0001022505  
Document Type 10-Q  
Document Period End Date Mar. 31, 2014  
Amendment Flag false  
Current Fiscal Year End Date --09-30  
Is Entity a Well-known Seasoned Issuer? No  
Is Entity a Voluntary Filer? No  
Is Entity's Reporting Status Current? Yes  
Entity Filer Category Smaller Reporting Company  
Entity Common Stock, Shares Outstanding   248,256,722
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2014  
XML 35 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8
4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
6 Months Ended
Mar. 31, 2014
Accounting Policies [Abstract]  
Use of Estimates and Assumptions

Use of Estimates and Assumptions

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and (iii) the reported amount of net revenues and expenses recognized during the periods presented. Adjustments made with respect to the use of estimates often relate to improved information not previously available. Uncertainties with respect to such estimates and assumptions are inherent in the preparation of financial statements; accordingly, actual results could differ from these estimates. The Company’s most significant estimates relate to the valuation of its proprietary technology and its valuation of its common stock.

Cash and Cash Equivalents

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.  At March 31, 2014, cash and cash equivalents include cash on hand and cash in the bank and the FDIC insures these deposits up to $250,000.

Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

 

Long-lived assets are evaluated for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. Each impairment test is based on a comparison of the undiscounted future cash flows to the recorded value of the asset. If impairment is indicated, the asset is written down to its estimated fair value. The acquired software technologies are reviewed annually for impairment.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

The Company's financial instruments consist primarily of cash, accounts payable and accrued expenses, and debt. The carrying amounts of such financial instruments approximate their respective estimated fair value due to the short-term maturities and approximate market interest rates of these instruments.  

 

Fair value is focused on an exit price that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.  Within the measurement of fair value, the use of market-based information is prioritized over entity specific information and a three-level hierarchy for fair value measurements is used based on the nature of inputs used in the valuation of an asset or liability as of the measurement date.

 

The three-level hierarchy for fair value measurements is defined as follows:

 

Level 1 – inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets; liabilities in active markets;
Level 2 – inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability other than quoted prices, either directly or indirectly, including inputs in markets that are not considered to be active; or directly or indirectly including inputs in markets that are not considered to be active;
Level 3 – inputs to the valuation methodology are unobservable and significant to the fair value measurement.

The following table summarizes fair value measurements by level at March 31, 2014 and September 30, 2013 for assets measured at fair value on a recurring basis:

 

   Level 1  Level 2  Level 3  Total
At March 31, 2014                    
Software  $—     $—     $701,611   $701,611 
Total Software  $—     $—     $701,611   $701,611 
                     
At September 30, 2013                    
Software  $—     $—     $937,431   $937,431 
Total Software  $—     $—     $937,431   $937,431 
Accounts Receivable and Allowance for Uncollectible Accounts

Accounts Receivable and Allowance for Uncollectible Accounts

 

Substantially all of the Company’s accounts receivable balance is related to trade receivables. Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in its existing accounts receivable. The Company will maintain allowances for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments for services. Accounts with known financial issues are first reviewed and specific estimates are recorded. The remaining accounts receivable balances are then grouped in categories by the number of days the balance is past due, and the estimated loss is calculated as a percentage of the total category based upon past history. Account balances are charged against the allowance when it is probable the receivable will not be recovered. As of March 31, 2014 and 2013, the Company had no valuation allowance for the Company’s accounts receivable.

Income Taxes

Income Taxes

 

The Company utilizes the asset and liability method in accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for operating loss and tax credit carry-forwards and for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is recorded to reduce the carrying amounts of deferred tax assets unless it is more likely than not that the value of such assets will be realized.

 

The Company uses the two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not, that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount, which is more than 50% likely of being realized upon ultimate settlement. The Company considers many factors when evaluating and estimating the Company's tax positions and tax benefits, which may require periodic adjustments. At March 31, 2014, the Company did not record any liabilities for uncertain tax positions.

Revenue Recognition

Revenue Recognition

 

License revenue consists principally of revenue earned under software license agreements. The Company sells its software to a medical practitioner for direct payment or through a third party leasing company for direct payment to the Company. The third party lease agreement is a non-recourse debt and the Company is not responsible for the default of the medical practitioner. License revenue is generally recognized when a signed contract or other persuasive evidence of an arrangement exists, the software has been electronically delivered, the license fee is fixed or is measured on a paid user basis; and collection of the resulting receivable is probable. When contracts contain multiple elements wherein Vendor-Specific Objective Evidence (“VSOE”) exists for all undelivered elements, we account for the delivered elements in accordance with the “Residual Method.”

 

VSOE of fair value for maintenance and support is established by a stated renewal rate, if substantive, included in the license arrangement or rates charged in stand-alone sales of maintenance and support. Revenue from subscription license agreements, which include software, rights to unspecified future products and maintenance, is recognized ratably over the term of the subscription period.

 

Provided all other revenue criteria are met, the upfront, minimum, non-refundable license fees from customers are generally recognized upon delivery and on-going royalty fees are generally recognized upon reports of new licenses issued. If there is significant uncertainty about the project completion or receipt of payment for professional services, revenue is deferred until the uncertainty is sufficiently resolved. VSOE of fair value of services is based upon stand-alone sales of those services.

Subscription revenue is generated from bandwidth and information storage. In the first year and each year thereafter, the software is purchased and installed the purchaser will pay an annual fee of $1,200, $1,500, $1,800, and $2,400, respectively. Subscription revenue is recognized ratably over the term of the agreement.

 

Transaction revenue is generated from the following services and recognized when a transaction occurs:

 

·Electronic Remittance Advise $0.35 Electronic remittance transaction fee;
·Paper Claims $1.00 Paper claim fee;
·Carrier Direct $0.16 Carrier direct fee;
·Fast Forward $0.35 Fast forward transaction fee; and,
·Patient Credit $2.50 Automatic Debit processing per transaction paid by the patient

 

The Company had not received any transaction revenues in the three and six months ended March 31, 2014.

Cost of License, and Subscriptions Revenues

Cost of License, and Subscriptions Revenues

 

Cost of license revenue is primarily comprised of the license-based royalties to third parties and production and distribution costs for initial product licenses. No costs were incurred for license-based royalties during the three months ended March 31, 2014 and 2013.

 

Cost of subscription revenue is primarily comprised of the costs associated with the customer support personnel that provide maintenance, enhancement and support services to customers. No costs were incurred for customer support during the three months ended March 31, 2014 and 2013.

 

The amortization of acquired technology for products acquired through business combinations are considered as the cost of revenues. The acquired software technologies are amortized over their useful lives of 5 years.

Deferred Revenue

Deferred Revenue

 

Deferred revenue result from fees billed to customers for which revenue has not yet been recognized or for which the conditions of the arrangement have been modified. The Company recognizes revenue to provide up-front capitalization to Cloud-MD for each provider added to the solution set. The Company also recognizes annual subscription fees for virtual servers and subscription and small usage fees and those revenues are based on a 48-month lease, Cloud-MD would amortize the revenue over the life of the agreement of 48 months. In addition, it features incremental monthly revenue, for the duration of the lease (48 months) based on fees assessed for transactions such as eligibility claims processing, etc. The Company has deferred revenue of $0 as of March 31, 2014.

Sales Commissions

Sales Commissions

 

The Company pays commissions, including sales bonuses, to the direct sales force related to revenue transactions under sales compensation plans which are established annually. The commission payments are typically paid in full in the month or quarter following execution of the customer contracts. The Company paid commissions of $0 and $20,000 for the three months ended March 31, 2014 and 2013, respectively, and $37,000 and $40,260 for the six months ended March 31, 2014 and 2013, respectively.

Research and Development and Software Development Costs

Research and Development and Software Development Costs

 

Capitalization of certain software development costs subsequent to the establishment of technological feasibility. Based on our product development process, technological feasibility is established upon the completion of a working model. To date, costs incurred by us from the completion of the working model to the point at which the product is ready for general release have been insignificant. Accordingly, we have charged all such costs to research and development expense in the period incurred.

Share-Based Compensation

Share-Based Compensation

 

The Company measures the cost of services received in exchange for an award of an equity instrument based on the grant-date fair value of the award.  Compensation cost is recognized over the vesting or requisite service period.

 

Basic and Diluted Net Income (Loss) per Common Share

 

Basic income (loss) per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the reporting period. The weighted average number of shares is calculated by taking the number of shares outstanding and weighting them by the amount of time that they were outstanding.  Diluted earnings per share reflects the potential dilution that could occur if stock options, warrants, and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company.

 

The Company has 4,000,000 preferred shares that can be converted subject to the limitation of the Company’s authorized shares at 1 preferred share for 150 common shares. The conversion can only take place with the approval of the Board of Directors. At March 31, 2014, the preferred shares could be converted into 600,000,000 of common shares resulting in dilution of common shareholders. The preferred shares are anti-dilutive since the losses the Company has incurred for the periods ended March 31, 2014 and 2013.

 

Diluted loss per share is the same as basic loss per share during periods where net losses are incurred since the inclusion of the potential common stock equivalents would be anti-dilutive as a result of the net loss.

Concentration of Credit Risk

Concentration of Credit Risk

 

All of the Company’s cash and cash equivalents are maintained in regional and national financial institutions. The Company has exposure to credit risk to the extent that its cash and cash equivalents exceed amounts covered by the U.S. federal deposit insurance; however, the Company has not experienced any losses in such accounts. In management’s opinion, the capitalization and operating history of the financial institutions are such that the likelihood of material loss is remote.

Subsequent Events

Subsequent Events

 

The Company has evaluated all transactions occurring between March 31, 2014 and through the date of issuance of the financial statements for subsequent event disclosure.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

No accounting standards or interpretations issued recently are expected to a have a material impact on the Company’s financial position, operations or cash flows.

ZIP 36 0000721748-14-000493-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000721748-14-000493-xbrl.zip M4$L#!!0````(`$Q^L$0R3Y<=,74``&*S!``1`!P`;G-C="TR,#$T,#,S,2YX M;6Q55`D``_]K=E/_:W93=7@+``$$)0X```0Y`0``[%U;4^-(LGX_$><_U+)Q M)G8B,.AB^0+=O6$,]/A,MV$P,[M[7C:$5+9K1E9Y=0$\O_YDEB1;LF5;-X,! M]P,-4JGRRZS,K[)*I:I/?W^>6.21.B[C]N>C7P>USJ#; MZQV1OW_Y[_\B\._37VHUO:0GY.^/J%GY"NUJ:-[W#DGO^F6 MCU?X-;.H0[I\,K6H1^%&(.F,U$^D!U*K9:CV-VJ;W/GUKC>O=NQYT[/3TZ>G MIQ.;/^I/W/G#/3%XMNH&W'<,.J]+4E59KI/^H'M/9.F7D^;I^IC3.YF5&,IWN^NQ#S+(7_@L<_/3\X%CO#GP1:P';/GEWV M^2BFV9-ZPIW1J2))\ND_OW\;&&,ZT6O,=CW=-NA1])3%[#_2GI/;[?:IN!L5 M72F)PB,9ZBG>?M#=1/W\"_T`P=0R'H\B]T27.7.%X=W1(A#>=C86-;=?P:M$#)\^N>13> M1E&?CUR&`7]$3J.J`GMQ<10%AX'C(&%\6ZD0U+>ZM/`:L%CT4ZKT0;R8>B:XG`$070Y.NMW/'O1F^ M6=L&)..E&"FZ4ZF1(!;;-55ZNT8*%=B-D<*(K2-AO9^(#=79HXB=,^/"SNK; MM[-:Q,[J"]A9B?5`[\#.2I$>:*=V#LE5>>ODJNR27!<]T!MTP&0/M/-N.F3? M?X>I][^O=>:(<5;/GOJ>^XT^4DO^3BDT56H<\6DZ MY+>4NQVWS*O\2O=0[X7X M':_G5-Z^G0NMYU1>P,XI_OR.WXK<49?BNU#@M4M\U\D%LW5[VJQ^TMS\D)C_LX,SP[]KZ]FA9*>*)0NOZ`X M>-\[\[[7^,9$;AS^-&\Q64MT",S!Y]8QX;O:.IC_UVLSR:+%HF MV,$BN>IS3?.]5T\/,T`IE@'*;_(KQD1^(Q7);^07R&^6U^`/`F>Y9"X69K8/ M033%+6;`\=[)M$+/-OB$8JA1,5.J6[BGRF!,*:8^,@\-]*(=[LWN, M'/STX_KIWN[1DK)+V,%//[*?[MLN:^OW$CKXZ7S/URT^O)GHXWW0H'#\L[D#QXV!ORL/T;`F;@ ML!Z4AK&Y=_4\?3]?J6URIE2%#\R4EYD.?O/J?K.W?+/D-V]]$4U1.^]N$#/H<- MEC&FU1H3>DEM/L$5VYO%;K?+LMRTBJ/["2MD,.@MB-G29%/X-7N#F92=78F8 MN:,C!NFP;GMXU"$)G?,.CX7;=*A;OW/?N^EWOI%!MW?5O^]=][JD>W-W>]KY MOT^GZVI?E=Z%P'5TJV>;]/EG.LLL/DX.:VN+B[ODALCX<>^"S%+@TB]!_?'' MTZJ]%8%^%=!`YOKC@[RUM<7%=>"NB26N+7V46MGFS_9`_!9;E.SY[H^]`Z9_9#''6!-;:MB M?^.6;P/3S\21IFY!<4NUI+AW8(<[.N6.Q^Q1\!5&9FG_0J[95MNJ5(&F"^8> M<2=[2`TFNH7'N\ZK%P>]ZO8L#B%1=5H@!$T>./`U7,NN["]*,@A6:EHO#CTL MGS#\/4WS`B4D-!O9T/Q_!N+C9T!J?3N,U M9:T]&EIOJKVEM9K%:EC\1=M`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`7>*L M%A.06WI>7FG(LJ95)3POP50J/"_3R(HL-W9I]S)^N7WV+W]3O#*>2GFE-)Z* M>60;GJ\.=]U;AP^7WF(7Y0Q)4N.OLV/5YY2GR1X0;)`VI9D'Q^I3:XBR6VD)LP6WP>X+%'&GYU6XD'J$I+B2>$ MV417!SAW`BM+#3F^DN>E`>=U.$6IU[7ZZ^'-G3G7536^'+<8WO2#(2ITW$9R M.F"CO-+@\CJI^I+@\CJDIKT@N+S>URX!+NQ<[5%XOY)!NJRVD@2Y(J40C/RT MIR9IKQH8N3E5:SI:DI2!:""F+)RW(`O:W(S?8N ML.2ENIK++YJZ+EG$.3V6N=]6>2Y'5K=$^!Y'5QKM>N- M:J##]+% M[FC1EX#1PJT+W65&91WRNN5DM6#16SX$U>'>ZDZ;<$NOAWNK&^XI[JW^^\*X M%^RX6Q??"'T-B$K1%W;T?0"_.V]_"?2%?;XD^(CR4Y_%]Q+,\KVE]9L5T7E& MT14@+4O@+X>TK!._'-*R)%T0Z3\H&XWA>N<1/'E$^S[.0]\,Q:.QA:VEW7?M M^MIV0VNTI=@@H!BBW>FUV=G7Z:74M7I#59K[J]?FT%C;7DI3:R1>3NV;7IL# M:;U>]:;2K%>NUR6=.B`J^(C7-CL3W`+P3_'G+I9Q;A!7$EG9A8XYD-W1J3X3 MWQCC8KK%KM)XQ$!!HVU;*9=79(81<=4BT3/-VS#8?J+KVDP?^5 M.&I;7=K=,ZOTJI'G-KDLJ_&7@V6P=\S??3?8CN*>K]F03+P)*VARL3D_YUY- M@I++$\#MIA3?1"DKE$IUR&#\N`[R]FXI=>HZP^SV!1URAP8%=_-"IB)D+ZAP MR7<*.U)X$\=%0T9JXA[5U'8KRU0;C493R\BTZ2AVHT?N=?FMQ-=#NU6C8P`C MNJRR5_+:ZJXL&217B3CW"E\UJ]-L0KSTQ>Z"5=A7E1M*XIW@5JE5 M(V1723;O,56+E-@S5I2SH-R'9G3YYVZ+5:BR]!:]`G3[U,*6Z=3B> MB&)>S'YU<2OPG2WV@7PTOJMH#O$5(\\_!%`DK1+@\(Q!J2DZY@&DL3=#D;<% M6Y7+.YJYR"\TMX'4^'+?S?(RMF7/?J0NKDCM&!Y[+$,,V\Q3#D`Y4V67O:E1 M*Y_C:+:4NI;>H!MG$W*!RIU6:S"JX6= M_RNIQ$J\XK"C5<0X-MU1O&X3D4'W[2+"@1%U=ZK(5BD5Z!)+>O'C\UVQ:!8Q MN2->3O-+/KY:*([(V;7/#X](](Y"?]\X)[')^**!3!J8_%RZ(S8W`&% MS@G*J>D6&]EG!*=SV'!V],/(.\>J'_"7_LW]%9%KY/)JT+WKW>(9;^3F^H>_ MRNKYQ:^#7O]J,,"RIP_14Z=3\1L6"'[L$*0^F9[_56Y(+RVX:W'?)-^!V`W= M(I?<\+A#!GSH/>&F:5WN3'F0:@D@?X,\@X18Z\WS\!"MZ$+K_$?RI+N$0=P% MSU$3_B#@#G`5QO[_Z]N4*,HQD=N:2N!:9P*#1T.WR7?N>"-]1*-SN4[(#5S4 M9T1N8.DV_$31D4#$8HQU>X0"(!9L/-[/XZ2O!S-W9&"PX#Q-(ZZ#J+4S=9A% MU&."`9.HEJ15N=%``DA&UJB2L+!\' M=D)+UKY?@DMX#C=]`\H*ZT?7;X;07O28Z'$7$^87,S@+-SLFFB1+!(9FYHSH MMDEZW4M@%6";R=1BNNT=DZ%O63.41$>!'V(Q_-/A.'B`(9S`Y/K,HX0/R21L M8#=R?2SO4N<1$+G'0)LN:`[5/,P(?88:P+T0_YCJEC1OG>[- MC\?DISDV`2@\<5JH<<'$5@+0I($A"`?6G[`_05OR!$H0!P,&[?<0]@VH"A3$ M#VJ@0_`M<=@><$`THC9)L($&X/H)'`R/AY"Z9%#GI![T&CNGCX&C$["%PG<1_=T?8@N\$L! M`5C$LOA3S0<3BP#%^/?`=?\0PIUPVP6B6Q;\\3MX+A`F(@'R`6I@8(FD2N<@ M#OL]AX[Q@/%'&CL<0].=T*:KS.+>"5O&1?P"E[D+*BJJ))]F$"J!W-EAH2^X$-(`-B8K+!_@>&+> M.#1#Y!=!]Q0U^7]\G)X`XHB%^")/SY^'KV3R0=EP4G-YA\Z]2-25J"_4H)Z+ MSJ`W@&2=W-Y=#:[Z]^*`9F%*N-;KWU_=];Z3ZUZ_T^_V\-QF*'#U'1D\THJGZ%82<2-5;J8B"'N?X)65@$@6&]`AK4'%$G%)S`N%7W M35%'*N.,=:"L!TKM2"4S#74*OG1%,$D+)0L4"YEQ.DF1$#"("Z/V,">!F+^& M!P@>L"W"N@.D:@"=MM`*=W2$IXUA98/:/T\@+Q),QJ?,AFO'@K_UQ7*$8-0% MP8DD(FAOW\"$>#BBX8U'^1R+*0GH)FBXH$;73R5`7O+O@AY@10YHW/TQ. M,=^1('!Q:!$85*:H`( MH4_L"ULAX3D6#Z,$@R\/QSK,V<'S453"F)T_&B(`X%+45$3,BR$FFI MF1IS,SYAD*V;T"QCYH9=.G''`N4#%2,ZE`U`?H?\+>B)PR@3(#92@NCL`.$D4\3_CK,90Y"MS M=AA@H`8SR8@PRMZ).,@'L@.<-DCKY9?[Z.5._!N#E`/,,5N<%K;'$V\JJ9&O M-[W^5]*]Z7>O[OKDXTVV+?=WJ6XL0*3W;M"H(D^&S+C2/ODX3'>%TTRFN/@W MR-J#X4C05X2<%B42.HY71CS,'0WJV"?D)_X$XV(G.:DVUMU87P5^BD,=,9[B MBY?(_]_>US:WC21I?K^(^P\(KSO.'4&I24J49'NF(]22W*==6_)9TTP_RM)9&HZS'!Z0GSK=K5(&YI)Q&)2. M3^V#(8'*K1@Y,'%.6C4'(`_6X^=Z+#8V!#N0^28RJ7JI8U$OX4^WWV`3F&_`KJ MU$_8(6(ZH!,TIM.>6:=*RG7+-\FRLL,H#U0^UQ;9$"_%='H[Z\_CXJQWGC17Z.XMN[.QS"+=AYY_^:3I&W+U71//T*P?^,FM\EKT M5:#GD>FP0WX(EBK:-=+K!%]5&H0.#.4(-`>VW_(HNYHH&%.*=:)]-\K;=:R2 M%6"Z)PH,_H[>!>,IX.V4KT4TA%-?#NZ`YA!*!W-&%QAF,=N='68)B MO/7+-#_%2+LP0L9M#PC^*M@:>!`_`\$&: MD1.,/2P#\B!X/D;WC*$%LS>D3+,+B8H1AA432V7G,\CYA'3>N4%^&\+3!5@W MQE`%.ME2-;@-HR"ZX9@T_GGB^0%UKH)I@<7QXO>/.FI\JB)$=M$/5O79=JIZ MDXDB7MR$',*W\`'8A0$9O;"!,'EU5(PFP>4YBGT8'C8%2"XZG!Y8D\5*B3L3 MGG`"C-&#-/<57X]5SG$[><7\=%R^>;?X/5RR\@=D1_.5COY(+N;0RY^6_=YW MPQ_&7??I]/R$8U_LL<,[*>C-!/=+-D9BWW9[[5:[W:[9C?T%MLV#I#F`25P9^/,A&Z"FGTEJ4=X MDM]9F49T/99/P;D,#SDX#6UN),J>3Q@Y`4P4:';'?,0`*;O.F0L;,9\=,`FC MV`EL)XQ>8[B;4J#X*[SOG0'MG/.>2U\L?P]_Q/D\]BD$1%32&=A>1+>GEZ1#F M*-7W)#1%U#VE<8496:[%A6[.4OCA$\;W_M)KEZ\?72D.$X M<(C*(]:>"U9!%D65UL"V",VGG,4^>F@&F5:P(=X3\6Z$J4NHT/F(R0.86*L) MSY(W.7$#VHH8V2#U"#IKC)4(G+L5)GA;<4'`DB/N!P%[:OT M'L-!LH"@XU,?;O.N-KOD9!DI%^THTM%X@:U;QXF7FW[`LD#[K# MQTPA'P)O0'Z$PH975CSP)&:>XG10>"D'NYR2Y;)=NA.@DQC,6S@GP<9DI6Z) MMT5=@F/1*IC#CK*^W%1N^WXXSE)^Q+Y9%FY@]CKD3,^O_)/$-5L+0OY.Q.]#_%N*&<&_:24"V M/SB=]CB=0LSL*1R,4W-,I['^,NP4RO[5DX"79\S*$._I]^]]+[T%JGI(E?U> MC+29`7$"4R9C\VO_/?,+'S'&0>H9LLO#]JPY53XWRU9YC*;/)'@=._HAFWO" M"S-2Z6WDD<^%M6",N9-12KFD:)@HBPF_L@/W'B*AWM2 MUEJ2)LSCDA\=#[\^UJF0!.D@[.0IQW=0BLS"BV&1F):C?`[:PC5LD*+M&]/] MCO_5DC@]EW+0X+ZV1"PZ\/IK91^RDXDG\!$^R*'SR@&>__UF$V[/)MQ[ZLF0 MA=96H31]R^4O7ZBV/G>7(5\KM-C8VJ)P$4TNR49XB?TWZID9)EO_P6$K;S*_ M"ME3D(O>?BRQ37R0N7Y7GW,8MQP*[!/%[*=`3#9'2<@D/JGCX[> M;.WV+Q\=E`^65N?:'P'OL?+N6S1RPQ;_HH7%1_ZPM'.G[GR>/G]WYU[FWH\" M+_\`)KKP_JJ8=]7VD^D:UG:*V[WT:G$(G#>P)_S[F[TW5=MY@+')^*,C_-)# M_!%@E1(,Y"11X'NVC;<99'8W@\R]NI-Y':5N4")2Z\WY=T,?/GP31UGHX8Z, M8CC8;OKONNW]5G?OJ-7M]7Z=<\?,.)$^.IIE@1K")WJ[^\*RB7C8!-/G9FS% M\#C:C)69^IYUM"_VXCP#-A-J)O2B$UJ&3OC'K9^J6;M>3NY]/+@K]*,8%S[E M!G]PWN\>DCT]32T80(A'S..]ZM'FU\8E(_^7QQ1OT4@RO'_[&*&=]H*?GI"' M7L>>T>,R8DUI^GH\06@;SC><7SGG#]N=UD%GNCW;L'C#6+P*NW1>(Q2IFYQ$ M=[>W\+%$%K?SZ.%4.=3"PE.YK/0IJC$*U,)"L^`7GZT(9['\"9NS86O#UGG8 M^IAF:_A7`_Z]R*5DFA[?GKM?,Z%F0AOH;EC$U*O8Y-,\EL=I11#FM:]',Z%F M0ANH`N8^W%?H95R&#V#)%_\7]60MU;?2,+-AYB0SW^\=MO;W%HI<-UQ[":XU M'KM-OL,WKJ6&K9O#UD756<._-?"O?""\<%[F^HO'=<\ZQ^I;2(`ZF"Q*J$>8 MSOD]Q'1&K#+4IB%J6!EG%6L.1SG'.Z[@2O@ M<@P>HLO]/&4]AH`D]*NJ3W#%LQ1C2V6?']Y%_L!`R1@0.$'2ZR.DJ2[KE++J MPC(3S!]6G9L!_60:#EL?2T-UP:FI`S=E[^,XZG/^+#4$(S($UU%`%@E+AXI? M)V=70&)Q[OT@R`$:#;N&V?-#7>&GP5=@I:.18.LA M4I%&,-QK&+,\W1OC#2D9*?*^`]2E$E%K_3] M6UA_^/VNK4^*4^'6"?#]&Q>KCEG$C,0B9@.L&1>8BK0)1(%F#$F.0"X(V`(! M(U$U9RE'4Z\'ND_+Z*0>HBWDA0/%73-E@U2)];JT?$E9KD5?:UJXXYI#+=>V M[_2P]5J6@NKY-P/:2#F67=[U(,486*2BD0@%IXV1Z(F/*?(1(;<\*MOR$REK MP7Y$0Q53%93[&WXT,Z#GN=+,M\",#Z2.)L`4[\"QF<_-%%+$0((L'<."IT"9\=WV1X!`/9CNT\J%X" M6`82)!4CJ?^#4N[ M:7P&'T&H"8&B3F">:`GF?!&=8]C25Z$:^@0]B;\*J*54*AN"VUJQ.M%3I+GU MVK_HN6+[-<6=+%BPV1!#FY@,>%8C5,=8L+USD+D1_E/#@I/M)8LG,L"@'FPF M:E#*'%2G(`R./E!D6HD&ET>$++&W19V`76R!?H/NF,2:L^TOKA_V:*.S-B'< M<%OKH6!-$]+*/?>JM[TQRW2WNF_YGML^Z^PS7.G`:M'`JQKT*='`N'CEUZ>/ M?@9.M+*!.!-A=<]&YN"2S'CSW"_,&"73=AP'T>;/)]7`8&4L)]CV"ZH.O^4J$7Q3M7 MVN%PV?\?L8K/-&\L-.>_KB[/]+\0S9F9Q-7=<#:BO`LCS$B@QHVSBAEBUKW\ MZ+0V6?GXWQ0X9#A7V1^F(Y/=TK;-+FU;_27M4W0(B-32OME?$0IAN&! M>-BZ1`S"F26,!V:HM-L=[IJVJ.2#0QIT?\(*G:GM`@V/HC=GB^,$9"IEH7C0 MBM"5A3X1%C&MTNT&9@3L>B!<,C:W$!Y/-F*!/#9(MN9"\)6;>GCLXB9M:H[% MV,>F8JY!S1BI5,#@QK"LV)T6S?11-FK)F8%=1DB+Z34&52G=3G*/*WZI4M.3 MJ>KISL34723/.[RF(@T5"@.OM[J9K4&!9>#!?.R-\(X MM]<06C';;>+X-]BT*#5]()ZJN03N*,<.1*>R>Z.H;6)J[ISD="$8?;S%TK]H MH=UAJIM1F9,?3]H,[AC$*VFZFH(X<2]RHD'_/>:+(JPQV10$/(MR2+VG.JUN MN]W"__;DOT?X7_SBVVYK'W_./5,!&&'3YC^IKMC^JU)91GENC:*ZMB`PJX3& M8/V+2:)A<,R^X.;(!;L2#6KKL]%@`#;OAD/4+`..JFTNC74%HSJ20'XMP*BL M]O#?%+:U)'/HV+O#IFIOV[M[/<=Z)#:/$)=L`025,GU:>?+"O-EMBR[1DU;E MHR,9<__1QO_97VB55K$DE01]=<&NTV3>:K^VQ:QL^F1<6ZP?T&;H.UBST],IN M(-`]G0-'_U)\0PUWG\K=3YC/\(D#HJ+7Z5<2(W7*JAQ-CE;#ZJ>P^BM8^7B= M.N%8]-ON;J_M'&=@G<`?!LZIZA/T.L59J*69P(W;2T!N.$F&&?/WYEZ,:4F" M]3`(7R`XR-DPJ8&Q%Q]4$8K>="X3=Q*W&&(\3=TYW:GJFKXUMQ83>#G!QF+8 MN(=]$7P_M&^"B7:9K3%=9G9<[+6ND5Z:8#(B85J`&.=/[%//@:'M/I5V".R@ M\I5@T.HHBTY2$5>E;GS@^8GI"`S6D':Z^QB4HV`)/6U\5^SZN8CDT7OR7H6( MK2H)/=-HL9H'%CJ`56U+1V?&;2"P:]?U0]^J.E0U:+CD>`Q%`?93. MTP?+..2%7.FW(FEPY99B/?*#;G76@\D!E"-V^U(>#`>T;N/@,SM-*:+2]]'U M/:%A2)-P>$Z_BB%S-`T?5,JA<\NK&L76"RS?H2?I0-IU;<4:;]T[Q=\811X% M]ZPV1=?BR]4FJ1DF,:187>FS\0X%I71[>KV+X9&3(,J\G2^G7#.`D0%Y*79< M3Q(1.30@&5[4YL[N$DL;+D@BFP8)`Q1.#HYWP2AW?DQ=:5%S4]"+M+GU)/UB M1"'V!)/I.:I%.191;H.PUJ`CG6,!Z++>/]HAQMQ[2BL%R3%@1ID@ M0N`/U400`7^Q?R3'`854T,^,=+8PH6ZHJ+>2Z>K)H/'87A1?H/@4C=+*,T"R MO(4OC4IY)N_,&+_FO9MXXI@ME\BY9=TP$IVUZ2B0:=]*F"9/46)=`>'T3`?% M[!L45*\L^!BR:4NGIS5?2H(:YNU?48P0.#CR*8*YY3<:.D]($U* M.*3:C\*,TCU%D8BGC?\((CU0=@&845ZVG$MB&;V!9B;8\I),&L!3HE"Q#ESR M+TWRAVZ#*;T&#:EY(1.9#P]C26PBKPCO#"XLE(JFPV?J MIQIDUE;FS:?] M=JM[D'_]$3=$_NUBB+91!)@IFBADEDD^.L76`M'87$XT,D'A#WB?VD*5<5*T M.;!?J&0>:P->$BES3O&M#6T"*I\QN9IF;^N#.;?\!Y1UX"9R#NXZ?^A#-,K, M?<2Q!Y'CL57\B&0QF@^5\\DH<82-MSS;!:M([J/X!RH%,-94`%L^HE*/ELS% M7#[[6%M@XO&EKU`N/W^'$QGQ6WKRX\A'Z4HM`U)/BQ(D7(_37"7U![4J61:Y M'>F'5D(/EVW&J*E16]S+@Z;@,&!6D(W!@#.JAT6RQ/K%-L^C6`?AY(=7+SP%WPZIEFLCUUEI5B+\.=XBH\RGH# M*A(_-1EDVY8S:<0=!!TK5_!P].'J"/RZ@#NQE+Z^^QPE<-'1D2DTJ6&9:(=L MWW9@3DF%Y+M`<\9);B45#P^)3.?^8168#Q=T%+B0FE3;[^7U7^BH8+;2=VZC M@&J8).;'%6.HYT&(\8YM*N(+;X%UFJ64)HG#L8^4W2!T?T;/J408_:CDGI@U MA'R[6$*/E+D_M!-VXF&;$%UKQ4/(*R,]MQR"(?5'RE2V/;`;V/J.O>&UD&(M M"_PIL58@5D/,4$KD%$X5(5_`*K!'1/CAHMF"/@;*E*/L\C0:_'`BCF#!"4O. M'=V>DM.)Z1[`A5VX8)2#:Q:`7B>:X:(1#]BW'FL]YW+I,>H>;?Q+Q82)B0H MB1R%"2XEOAI9B$! MV$H)KL\15[M'&F(DAD4Q?H^?*7E!"%="2)A*(%Z2E$'`0AW-=8=B'7W?O=IU MALHC'X&GJ/(;JU\)H?^U@GF2<]Y9A6'(\0T!\* ME8SXAL(X._(@!)>IVJV6E6A,8W0`94]N_?1I'' MQ7A4KQ48\*98C4#'-)Z)&RXZ$D?;V9W:2DB[B0TIJ!RY(ZP0D2`;GSLW"W1/ MA=V@4QXHZB$0<;91/@7M)S%9%)8#%,,B*>9%#0)2%%MCCU@^=SR[--8_::&?W_S*8Y&:*_O M=-H[[4X:X6;<:>_M['7>_/X24@JDX=;.B2,D4>#\B-T`VR>E^OBOJY2X;X$Y_'E\_-4& M+X+T\0UV$GU9P1O$Y&D$)Y"LC?,F3/MD*'M/\XDK,4^*:#GD>EPHLV0;E-Y M&@[6%'/\I^`?MU(J]7UPC`$DV*V(0)EC&@'3/7%02*A9&[X9;Z=\+:)A*I`G MG#1`7K,1.C14L08:K=4Q(HU&68)BHOVBB!.HB\F1>^51R8:E_"/@O8A`3?0K!E%Z0A33OQQ#'UGPH-)CCI:O#24$79'&)VPJ_7S&>1\ M2@7QS5#I$ZQ/!/L*#@JPLO-$3J[YAC]//&]?QRM5>E$YEU7W"9P'QZ&'_SG+ MKRRD\1^,OJ^51C_1]RSZP2)Z.U7Y)"H:YNG=P@<"!!D#]N`^1*]T;LNR(D=4 M"!^&Q]PXS)D3R.%"D@OFZF-R,"$]3MQLK0!#_E.%JW+VW5TCJ=`?091O:8_K MIV4_]]WPAX%U^G1Z?L)79/8G)DI?G!,G&R.Q;[L]8D%`+-`G M.5K@YJ))%2Z&:;QQ;L'.P2@S7?_8H*;X-[E;\E1Z/QYDHR1EV&B-]YA[0DKH MH2;HS50@XJ``1&/>VX.&B78UT#WYR>53Y01ZW@W6?,+("6"BF#X\YK.%`$_/ M,+,XGQTPBY$S@+T1Y"DHO`1OFE0A]K!C:U&-5/*%GY?&B/ M[.<<$OPR>@Q_?P\Z"HW9@T0%33&/+4(@BW,:.?M#ER;I(CY.U:J0RDV/E+KZ`AVK&HWCZU81VZ_R4"%*1JDD4@Q55ET@X"=TLIQV,?N@VEO`;^,T1^@+?>6Y'3U);V_"F^:C.-J M$FBW_Z2MHA,$BK#3Q8TD&]7+C&6:W,)%8X=P?,0\T,6!UJ>1F3\HZ8%;.`@: MFU%$%D65QL*V",VGG,6(QA@-,JUF,8>*RL/]`9\0?-#0[:.O.P<8@"PP5318 M)"E)+.W"_&5NU1$F>%EQ<[AV@C1$.P\,PZ!8#JW]I+*`5/R)<*(FHI(*'B:E M@^50V56K^`^P)W5VMO5\`?:K9=\?>5`I_[1OB5S%&*&PZ8PNOOS#Y1"F8QI3 MV.^02++9NA-@"B18OW!:@@G*JMT2;XLZBCG0*A2RTD*J'J'+53C.4G[$OE@6 M+F#V.N1,SV_\D]RKE;R_E+J<9VWXVEQ:'T\-*9[G)I+EWP!>?7`.+'BHND)> M[;]G?M4"\NHS"5Y')Y?U@*6RN2><,-RH(J^=18/Q7UF$IR1IZ,1YEX6,_JV\ M7]ERQ`Z)E.XN5K>E"WPEJ+)TXK+62SX^\N>IC-.+]ACN1R.4&R.4W:<(I7:8 M%`63`I3^R`\05;+:,STA:RW!DN1QR8V.AU\?P$?X(%%0/<#SO]]L MPNW9A'M//1FRT-HJC"24>_SE"]76YR08WA/D:X466UY3R4*<9".\Q&(I^2R3 MK8\H_FWZ]QW4CXO?2N/3PLET1$E+NH,GO0)3Z#;<" MI0$IHNR[XP0$4O_TT=&;K=W^Y:.#\L'2ZES[(^#]A;IWOD4C-VSQ+UK`TM@? MEG;NHQVD:2O#E'\C[KU;,>^F]OF'>P)[P[V_VWE1M9TR,4/%'9W;S M;MO&VPPRNYM!YE[=R:2NXR4B5]%/?NG:M:NEY-['P_N"OTHQ@7<410>ZN]W#\F> MGJ86-&#!8^;Q7O5H\VOCDI'_RV.*=^%NZ\:B6?#3$_+0Z]@S>EQ&K"E-7X\G M"&W#^8;S*^?\8;O3.NA,MV<;%F\8BU=AE\YKA")UDY/H[O86/I;(XG8>/9PJ MAUI8>"J7E3[E>%$&]^V%A6;!+SY;$Y%+ MR30]OCUWOV9"S80VT-VPB*E7L2R/TXH@S&M?CV9"S80V4`7,?;BOT,NX M#!_`DB_^+^K)6JIOI6%FP\Q)9K[?.VSM[RT4N6ZX]A)<:SQVFWR';UQ+#5LW MAZV+JK.&?VO@7_E`R/,R\T+1N8H\RY6AWZC("S]6ZPKR8UVVF-/+<#J8*TH@ M6IC-^3W$;$8L,M3UROH]XEG?<+-.Z9LK&AB!W%*7<#,1\V06P"$G%6L.QSF' M^VY`O/43NR]+&B-$2_X8PI'0KZH^P67/4I$MA7U^>!?Y`P,D8R"_C..IS^BPA+1(9.8@A%7TC MD@[5OD[.K@C>>.\'@4&"S$E.IM!,3;9,(:P,:K!PN<9=MX:`[2P%?AIZQ?0= M$YPBC6'DY?ULJ"I#T/-W';.#"(&#@8*L\ET$!.,B]:$?)ZDI56?9P/QR7?]H M`>)8:\NLB!7.?PJWM#A)IYU;%3IHL8X9L`F+\&^B&&M%!)W2P'ZS<&"'(8;C M,$(YQJ[27B9=8J4KB,70$JHX0<&.58QIG@A"+M*0DIDJXS](32;5O-+W!7=R MU]8GQ:F8/ADW+A8=LX@9B47@!NP.1O6E(FV"4Z`90Y(CN`N"N$"P2!7-M\QZ M<#N>(C`GMB*VZ@:*NV8:X'2%6.>J*C]=IA\4$W`EA$)_[?ZL\X$BS0>`RG4V M$E[7X6"KK2P%S?)O0.M!2BVP!(6KN`P(&_?A)3ZFR$?$T_*H*,M/ MI&BEE3>6@T>F%8=I12)@8?C='/<5-[*1>OR(@.(2*,&.])3G;VHQ%VP0>C@* M&3>3-FO*K81U4P2&V.*_Z:+T*2!I1$$5#D)^/DR9&VNF(@`"4H9Z!EAV.B=_ M=(D*$9)1,W<5N@S8"&\R^$$!PW$\QKK["/],$Y:EDF+R!SYE305FE(&C3W=@\[+!)>\O/B:A*HY9B%! M5['6'T6Q(!`_<+TB:GJ#HF-0:J2#([U/!P(=!B[NS>UI&5-03!JR/[V/=I)4 MC1G]`]&#TLB(((J']`&1/8+_RC2P'ZV*1B05X#RV<.B+/AE0&GB)1[->((TB MHS!T!6P-A<`D9.5P2>S0ZJ)"TFSZKBALGDI2)2A#LT2BE^Q<]5R"MKW!]M&"SG84F M+]GGK$:H2K%@6N<(('7AXU^!OOSX.[A;J@: M<"R0+YF&Q:7V`@G6A-+],<\"+X-+&R9(:ARV!JEBFOEF=ZN MJ&09E`!T1I(!,^ZL$T`0>ZR>WF0X)JPXS'(@WCSU9U3HQHJC4+K1>@IA]F(- M4R<+S4X"Q(/78U.X%5-M?*O2B>.=*NP\NJ2<2\N9,\\9" M9O[KZO),_PN1F9E)7*J-/_E1?7^)/;Z9ZS9(^?C? M%)PSB,7[A:XONSDMVZ*-<`6*\%G$??)K*;P6J=PEE(T1$;K<%A5L))^4-F%RX][H+VN;H`'&T.[B9<'F(HAO#\3#UB5BN!TT M@7L9*AV+PEU''S3D42LTF)_4F=H,T%@G>G.VV.E/EE$6BC^LB$8I35C9M+"( M:94N,S`C8-=#WC:2L.YD(Q;(V[*6D5_C"+6"QPYKTJ;F6(Q]ZD5@(#!&*A5D MMS$L*QB@#EKEHVS4DC-C".J"M)A>8U"5TF\W]Y_BERHU/5FFHD,8!!L^>A,9 M@SMZ<`,XL^B;LS_"P.DDH+`;-#4).UT]`B5-J3D6"(D-XV'L0P1VZT>97`[B M"#4H.R2LEL$QZ^TQ^[7EQ,6M"R\,%3481X>&.(1;]DEGKK#HV`D$;S4?&\G* MAD-LQ$#=(NBN<8>W4J2A0F%8;5MS8%=&$:*23X6@L3'2RO]BQ;:'::ZJY(Y^?&D MS>!*0;SBSP.SX)`F.X=HT'^/^5X(:TPV!6')HAQ2^_A.J]MNM_"_/?GO$?Z7 M>\JW]O'G0@]W9]K\)]45VW]5*LLHSZU15-<6GF65T!CX("6[ M$@UJZ[/46&C3\6:6@2W5-I?&NB)+'4E4OA;(4F?FZ@!FS\A/"0O<.?;N?-"R M;]N[>SW'>B0VCQ"7;`$$E3)]6GDFPKRI:HLNT9-6Y:,CZ6__T<;_V5]HE5:Q M))4$?76Q3>9)X/JC"8KF^E9G#_[WD+Z5Y$NQ\&K8?536/T5K'R\3DF3W+?=W5[;.<[`.H$_ M#)Q3U2<<=0JK2,_CB=.4W'"2VC+F[\V]&(6,/\L:JX=!^")].$TTA3#IQ0=5 MQ)4W7N=@MP5=%^U*8:._9&A-EJH9[_3M`+TTP&9PPK3V,'RCVJ9?` MT/:D2IL#]E5AV)$B,#K@HM-3Q&NI&QIX?L)I,OB+0:3][SYN`HJ;T-/&C<5> MH(M('KU7=EOW(46>JVFQ>@(6&G]5[5!'I[QMC8-!KWTRQ3WSB`#P8KA)$@U\ M\D>88(=V?1KW/8:KHC!4`2<@C-D%6W1?J_#6E>ZZMF/=N#/XM(MRO^JN,T,B M)DAH1.&Q@]`=`9]T8W0,)NIN4WFC1A/\RJ,0YB&)V.9MPJ)1WP_=O)&E!48N MV1T#$4!]JL[3Y'UJEIHUK/ MX]?D_PF]VY?_8#B@M1M'HMF#2N&5OH]^\`D=0[J$8W7Z58R?HYWXH%*.HULN MUBBV7F`)#SU)!=)^;"OP2!VPZ1NCR*-(G]6`Z%H!_#(R=!E'D[7TZY'`##!/)2[+B>)"%RG$"RNZB-G=W^E;9< MD$0V#1(3*)P='/R"4>[\F-K-HNZF"!CI<^M)^L6(XNT)YLESB(L2+J+<"F&] M08O#0J)9V\,V/\FG=EXHEC MIEPB)Y=UW4ATQJ:C0*9]*UF:W$:)=1^$\S,=%%-Q4%"]LN!C_*8M/9SFN*$\ MKNDF6NY&HY%/H<`Z]OR[HH"@1>/VZ4);1,98\3+(N='2,B[M13A^VH_"C%(Y M15&(6XW_""([4';MEE%.MAQ+%AF]@88D6.N2*!K`4Z(PL8);0T2&0@/8\EB(A<(7,ZQMZB^I+.Z@*WUKPRN))1WIF-EZJ<:9-96Y3B%3<6#2&Q36]J2C^28UYC2:8W]1LZ1Q;$S>5B.K>(7V1?MYOM[H'^=CQ!"VQ_)L%BP*N8_B M'Z@'P/Y2`>SRB"HW6C(77OD*I^?P=3E3$;^G)CR,?I2NU;$(] M+4J`<#U.8Y74'E2D9"SDIJ$?6@D[7&09HW)&!7$O#YKRP(!9068#SX$T,@N^ MM%S-F2G-6$MU+7K64UR63U`#95UR!>0J6NH3ZRRX)-.0;F-8/@FZZBL>#G6T M(I#^'995>P;;IR;L8U%2@HM7^X+WQK1[];$OK!1D4>(MF-P44.(<9BR,H/:N M&EF@V,7T!BR+=`/ES$4>!":C-MOY?7>*%#@ME*W[F-`JI3 MDD`?5X6A\@#^&'B[8,^A(H/8Y2RE,T9B..5<&Q2TX)YKAPA$/V(L>:SWG$19&:\E=;!N.=@9F(2AR6&$6 MM+;D`A_6M^#6J8(ZR-+;**8S180=OMPICTIG7J?7+FY0CG+Q-1=IH&LN4A6% M`6THA;=ENZB$BE7A]-,$_1')&6(E9+-A/`>HV<`V8>,7!" MK12D5>^D\F.BL_@>/3$VN?-A*^[PZW=2DX"9YBD56]$Q):OAVB&W?*W(>918NR17 MLP75A;H/1)<+N6S9*P@"`ZJ(MUX^J&FHO)\\X6HQZ<&DA]B%^\U/?G!*#OY4 MJUM(@4YDCJ0.(:';9WH=SX*?`C6:\/67?K!DSX03-:H2WTYB=EV%\.(2%]__8QP+) M/-LIAZ;BV(-@]U!89.2&+H>N;-Y&8S^D6`E#6!3\1F0?&9P5P3G2ZU3-3K,B M-+X!+*#R?O\VBCRNPJ-"K<$P8Y]7970YH5V>G9DZQ MPR1OW\Z?V'T"M9&[PPJA"#+JN=FRX/%4&`HZFX'"'0+K9EOA4R!\$I,@8;E! M,1Z28LJ3A,ZJSZUY)*\LKA?J_MA@)7V-HS#*)(-F`R07T;Z`+_D$G.(,MD^0 M+R(;^HJNMG0QC`2K$.QFOH!(*)IJ.RE?E6HFRR!*+ON&W5Q9^K!)IRC&9 MB[2&"FG9^$>85X7'TS"([JO-KT4ELBS1!F"4\W#`8ON<(YI\$F?COZ7Y!J=)D^3^:;/^5.0TYL^YW4FL^ESWO0Y;WK:-!/:^`DU?ESO@'\ M:_J<-Y?99D*O<4)-G_-ZK4>_E1M?AFK> M;$4G"WU^Z/O5Z1O'4P-_Y`8)IB?^WNFVVW_[[9&!YJ'G^CY:"CV]Q^B!@>:B MA\!4ED'1T:,4X5#ST/0)@2J60%)W_S&2<*2)>@4$U+&@6T`./RF5+(.@_7;W MH&WEIU>/]`R"@(C.(@2ME)@]BYB]>98+0=Q725#76JYY"-H[?`I!)7BO`B'' MR>5P\:4I?7&BMLY-;C^=GI^$7K<`W@QE@%5#&8 M'%M]FZ^C$U.`>SG\JJM5K](%TLESNOG[-NGG%Y_>_'[0EO\I-.!\#FF3,_74 M$"%UU6<$W1#PY6/3A.RI;#]L=PXZ'9OLV>,L@R[8`N]W]MHSZ0+K`8R'EZ5+ M^/5/^<8_C>%P'HZS-*$,[,X7G'G!3493\^F_8E[]D3`>S+W.`;-U)W4'(+RZOSYR>AFGJP7>N M+C]=_^/XVQDY8?K&/;,&@+.2KV@=M&`1>PY+2UW)/96Z/H%:&"!\5\K,B)I" MP?ID/LB&=W7;53>@EJQ%[![_,:"X=98C`?A)YRI'[DGW*'H-UH91S]9#`CDG@B9&/^)/3 MF"`C'OWRG"*A)Q8!=7^9%A@Z0.BY1]^?-O+\!5,UF_;S"_/S5Z(@ESJ9%U&.3U2(7Y3GPR/I; MC40M^9! MNEGRM=3)O+C&,B29$TYT5=VXW.JVVZU.^^"U2,V2Y[-NS32]PO_LRS?G!&G` MUB&F/46M\HGG6,6G)19W]V;JAM>1C;W!W%N?NN5,:M\T_*3F>X(V62LMU3ML M[;\FK=OK+'$^Z]:Z8@\.LI&TO"@WSZV[@+WK[?=:A^][BZW'KW6;Q3ZHJOVC M9\YB+[T'T[A$;?_Z3:%)R&ZXMSK5UJ]TIQ50+ M'>ROMGJBP8MY'O^..H>M]]VU59^\=)#^T7#]ZN'Z;=^9R7&X=Q/N<\3-AX@< MW8$O2=W8;HR5*&RP;OKZPA$Y]!-L*OJ@W%C:`$UD1G2Y84?!8M.=,''PMP>= M5J?7XXZ[_+.!]5^PIV^Q[VZA3XC5?=`UW8,/3//@XL%?Z+GJHAN2VAYA/U+V M0E;Y'IUWFK^''T\OCO4_CC[^:K7D`$9^"J+[*/):SATZ:+721M M)P-L\%9J63M2'K6:[?M!P&W1[O.V][HWFG,\V6HHIZ+80,7#=%2>L9PR0D-? MRP361%X(5+6DMNU+FZY9Y6VZDK0AO8V<,[+K%9K^NSF]F M6:\.V5-O$_T**@WI0@S[@OD^`+ZWJ%,$[8$,NSC$N-/3!S[EL%]A$.@>E-RO M4VN6%EA6V)4(GHFP07J,-Q!ZX2:*@:@1<(%6E!H7@OGI24]W%P>A/GD_PN@^ MQ(9=--LD<;Y%.#?0#-2G;AS[V$AE$(T?-#5Z2*)DY"8_J(\R-G>.74_!0N#/ M6O?+/ZD3!K8`\R)LV>2$+B9]X2CP+E!U[WO8L+*/&9DX#=S1S)\@&KBD*BV] M^/W;Y\12C*SG4:U6KT%99U$#CJYTQM/=+8?8U*G8[,RE!-/$]Z251MZQ3M:3 M/XS=;(F$0D?;XIM:T[+><5L=LIY\E\(&D\/&:Z>87U=(SDRNV2E5?ALY% M=,<0+`$19S;OM@*>ZK")1I8Z1:(J-*P M3EG%.L]2KT`!:5P^T)&GU8Z]/8TV+&LP2Q/R M(3JG-G1OX(B]J>X8OK!>=(Q.9+&8^&(^\:IO5VE(5I"<@U,SY?0"*FGZ'68K ME=)_9J%RNMTJA40ITJ*.J#6O&Q8/36-) M8;R1Z)XU[8J(ZI`(^:\XPBZ,7^26]<5TB=3F$RM*R^SB-^P;*6ZRWH0A96\? MNJ#![R;O\RUM@K%%6[WYJ/NV[$"7RRNHQQG8)K<^7-YQ`](F]K#*XBUUC*XT MC5Z&XQII(6$W/\Z7UZ-Y,WN@YX!QY M$JP=4^U26'`BV[+9K.Z9X@VPUTF6D(B8LF;:)1&K89;PUH%SC:2YY'1`$V"` M9J@]PE!QJU5L^Q=[U%Q2>SM\AA7!RC!I]RV*43:M+J=5S>AIA"I*41J"I&:0J17 MD];?%"+58!6:0J3Z:::F$*F>\M44(FUBX]YI"I*80 M:9.U;E.(5(]9-(5(K_H@:@J1ZL6U=:O=IA"I*41ZK85(5A>)!0+PDXB[6OZ/ MZ>D3SCIX*B!W!\Q0L-IL%-W*[S^#C'GPMX&,SHK)T)#)@RR!U?TGA\TD:C8' MVO!!J:7$BKBT`'F/XTH_E3=Y>$;[KM#7/@>3.KVC%^52?0DM<=3$).:@K=M[ M41[6B;02UR1_5;SNT5!\[O.L;[D#S(J96&-*2SS5&T6GM]P[?]ZR.@@L/ MO1KBYS%R=O:[>_M'2R6>>W%=#L^-&^$Z.G'C^`&;)\K?OJD;_%`4/_"GGVPJ M%C754X9>%?ESF9C+)[^\:*#^SWX.@@QO$7]&D7?O4S72DCKE/#[6LNB;AYUP MF8*[U//HH_9JYY26?TIU\5_AU(P\;L_V56K$+H<5Z_Z<#G'=4GNXA:A8^A1F M-R2<,H7]6DUAKS`%F-%FKT)WWBET:C6%BE68[S*YJ0ND9V<5;FS==:F,'U25568]$=UH?S)&FK#EF,> MQ?2H2VH%X#>K[-?EDCUQ$%JC M+TH9:&?@II3V3<8YKC,=+^$)`3 M>*[OAW0%/Q8LA&]JH/P[C-4D9TE*Y:+>]U`#95$AY/.F81HD?E4AWJ(^FY+2 M>1PY)=%XSD0J;NW&(7$Y-+$KE5:IDT7;T<.EM]A>0I1 MIWXRCA(W^#..LG%R'LI]&&MT@2@_A'UZ.1;[#BGYU:LP):9`+B(\EHJ=/R(W9KP`K"6`G<9@''T5^.J. MD)D8=0D1$J0(O:^2E*%B\`>!.#`@9Q%6D&O!83`J'LE`,45:F/2[?WZ]8@KT M']P`))N`:?1+N\YYB#7!G19C19F/(5U4J3Y4<J/Z&G#>\SD0P. M\+8C6`[C($N<[B_(@Q@X#:T16PC$QYDA.@CX88FD_:5=)]^5)_!O1H,`,G-J!B(Q M".(PA#,I'/@P1)("`=P?/59#/(*<.6G/1?X1FHD$Q&+BC^*+4V;1\SI MSQ(Y#'.9,(3H--9LBWJ\G(W'(B`Z)8PJ`NHP0H)R$10@K4XOCG>=N?!%9B*) ME-\A"`X+7H0HT!`C!C"$50C!P0CL2!F[<.@'!"(9N/=)!LK=O7'],$D+I.`P M?\3*!N#YF&C_1H@14F\!`6+F7?3YN\006: M_JTG0@4]J6!H/BBAI]4,[7=;1WN'CPY0S8DEX"Z]?@[O]5I[O>GUK\OE<$U* M&O.:H/FU_O84'#VRYYIZK=GL>V1#O8J^4577R^J!\\OA;_S5V7=$31K0!/^+ MKTT?L+G//O=6>/C<6^$U-;_ZPNV@SJC1DWTU--?=9Q\#]>/=LV_4FW#K;^[V MS2VL5K>PI]WM3YN+_.N8T/HN\O34-XG+/WYO?,X5\1E7P.IEZ.VU#@_FNN(] M^[Y3GC=1:JYWDNB%K.-7!-'Z5 MCK=UD[=WO7:K=W"T&,]KAP;V?N^9,ZB)VTQ?0O[$5G"4/G`?PT=WHN&0'&>J MGZ[F0E-+.*LGJHD&X[.F7%VW1I[EICX/!]%(.>^"*$E^G9FY,S>'-M_/VNJ\ MGZY7%W*S;@W/WLTXB1;AV&,'U*/^Z*>[A9OTI\UU%U_Y/QMG<>,L?A%G<>,0 MK._5NE[7Z`7:G6VR%[`#JK7=V\)V9:MW`Z[ZRH"_:MR"VS#)M;9O7,0ON/HM M/[^^F;'WWW5@6_4.YLH@G-.9N"DSG^5U7'36]?.--+[(>GC-7C-7>T>M]T<+ M7;MJ%4QL'(W/^:*E20];OQ\5S#S;/_^M-@^Q4$]@U]Y(/,$5B> M"ZPR@=MD.C(L]&7>Y%>Z4OD/-W##@;JZ52H]#KUC6!@&(<@I2`P)"V&[-/[6 MIMRT*3==]XWUU5W!-^RZW92;-E*UTMMR4VXZZ11IRDWKR>&FW+0I-UUHSS7E MIDVYJ;E*-^6FFWR?;=?L5K\LR: MI>B*3>MD]NL2?%J4KQ>+U?7K9&;++"FW'3EF7-- MN6GC+F[*31MG\>MW%C<.P?I>K>MUC6[*31LW8%-NNH1MW;@%-TV?->6F3;EI M4V[:>,T:7V13;MHX&IMRTR5R;;WEIGF)YQI*,LM5H7A&?88-=1E>N4C()?;F M/>9>LA75FVVK>K.STWZ_L]=^XV2ASP]]OSI]`\?;P!^Y08+^RM\[;?R??,8S MABM3]@\\,R^'0V".XO;LIW!PGB=)AK.E*\>7PVOWY`E)> MF/9>Y_U1H4Q_"7-X.6L5==K>1C-FJ=NYR)A#L-(VES4K5B+[!ZMBC:?\ M#V?P4/IP$HU&47B5@@ET=>N"1729I4GJAFAE%:9\G%P.60)Z,&6+='[-IO[\ MXM.;W[O[1]W>P6&W^[??YAMM8ME`25;`=RR$G;%JS)*+R^LSY]#15WGXSN?S MB[,KY_*3<_+M[/3\FBSNXX?T M/7>$9=?XZ[<'O1:8THZ;PK?V=]OM7^`9'`3.?1!^Y<`><-PPS$;._:T_N(7Q M0G6?$`7X:S<('G:=8RHCS:$^4)"*E-^Z'@94X^@>KM1O#[JM@T[7<6]@!\)` M^&"1^MUM6>_K`H^2J@4E$NQ%/8$'E?.'&_[@?[M.G^]JCENQ#A5KWMUO[7?? MP[)Z^"ZM"H\W\OF!7AN%8M>YEH4A$DJB95%!A([O5\L"<(!67X< M(SLYORUM7:V[RBKN,U!V.3PAFCZY`RQH?CC)P$*$RZN>U(F+:2[IPQ1E3&?. M`-8C&OV3]THTI)TRQQ%ST"O<01>A9L4SH:69YY!LKW0&YR(/WT`<3K,8WOZJ M8C_RYC63YEJ7KR`A$Z=G>[>]_]C,IE'W@C.K7J>I,^KV5C>C8](.CULOS]DP M+=(YVCM\+LWDC6+OVG'HT;_..,BX$0;:D6V@G9[]<>U\.;\^ M__/X^OSRPOGZ[?+/;\=?ML]0LP]N3\'&&\';'IRT+MLS(`QIEIJ3D\Y6OKTX MPRAV!BI.,8X'?[+,))G-_L''1,[:*$XST.?9#AI.1ZI M$"?Q?SHCSF!4E,%8,B_PI4E3E<:*U2"Z"?U_*[0S;FBZ/&XA<&F#D4S:*FT: MX"T'IC@\D][ZL>>,W1@.0^OE%M@6R1BY"AQ91P#;K/3`":8F1?!\-%0KY MS(KUM-@Z,DYO&,[W=N#=@3N&A0S83'K?.FPS!X!.7-88>)TJ(8XHF$H@6U=: MA.[]('`T(;CB\+.7#5"6?%P8-WA(X(>;")<$1KIW@04XL,7*/DBIK.3]K0J= M)!O4)-S7DN&.QX$_H-\%[OU6F>)#V%_:&+;6 M+;V-H^R&F8GR&8W]4/9@H&Y<7+D,U'G07O MML<_*]:N-.E.I_>+F1W2H[]219M6#_BW\OK,I.5P_'-A4:]8AN?0?AP$5GS; M33FZ1K'M-"K$6GV5&))\M&+]*'8>E!LG_(Z)_L)[HD!W1('N3F6/);X%R.8]>-!7H6-(`7Y,/_8%9O^,H5&'ZM!R1)J#7!/2:@%X3T'LI&IN` MWGR.@2;N4G-O1Q/0>ZT3:@)Z34"O">@U`;U7'7IJN+H*KM;'==P$])J`7A/0 M:P)ZF\/,)J#7!/2:@-ZK#>A5`=`M&MFH0C&)XF\JBF_6?QNGB M3-Z#4BB%V:8.^'SRGLGH59,W"T)*^XB^LHL(@1KYLOTYKU^2DD(1R5GR),%ZJ,$RI>OE&@1U2R$<`&[VU@@Y/++U_. MK[^<75Q?.<<7I_#OB^OSBS_/+D[.SZ[HH.N;([!.];HK&O@;K*KV,5-E.U8Q MI[>Q4AH,P`T9APKQ`:8"`^`:4_F]U,<[;A`@()`?>4G]:I]?`"I"$+P<1N\* M'?<&6(I;B#)3,F`@HBH1!@+!UVK\B-.+8TQL^<\L5,C4+L<"AO`QQ\N4XX%B MQ*VGL.`8JT-X5@0T!9_V8](>,3QI..*.X2,_0>&G*GAPWG;;@EEUGG.IA)Z69`30 MD1.*./H*#&\NX(]3(K4?*Q>FAFA7,B3F(.&L40/#+2U+5$Z$P>+(0KS'34QT M8H(S*+?EI*\"7]TA0U+&AN@KQ'-`I@VS`"@G"GPP'`/CZ]MU_F]T#R_%+<#@F8U@&V)PH7>75DQ=8V^)SB:Q@_CX+C_XR?XPDV!H"EK0( M3#%R0_>&E4\_2YT1S!_%C,3SCA^1BP$(]'GHP=]C9LJ?1:PX_?CJ_^':L_WGT\===YROP#`8">:*_$3:-IT)?=J2>*OY,MUM.\+.G M4YXR$0*&HA_0H7*E!EG,(#*H&L]^@B8%:\0A(R5):/_YN"49`F7`N&:L1E-> MI7'DRV]2?Z0*=-$63+(^`N0A1!]M"H8#B61&B-+S$XA(%8/X%5>B3'T)^(?7 M3Q.5"]5M%!"@54%P^*,Y$X@X$K$"^_!=5GZS@*EAFT:1UJL8_XN`ZL0;YAJ<#R42L!LK' MS3!M!>A+1`)\[58!R^G0BFF'R'SU%]VD,"\Z!)67:#P?.KLJ3K\I4[GS4:I; MB.8SA,,+#B=>"UY>/4'16G*B5\W"GK/A??$9A"#26@'Y9%B]-0?"<4)(41D8 M91I^U;D`:7*.RCBG"<5)4H5600DC2D"LQ,:Q4SM:)J_#1L/"ET(8),\`T1A- MCR(1&9M]`?BN(CJ5L258'"C7FJU``TP&8X&\C]P?J/)@C_HC#>`US%*X^^&_ M8".`:"X@%KHQW]*DNXUE^M3E'7B+! MSW1M/I'@;ZPNOB(*WG5^`]H,MU"G;;F%OIU]/KX^.W6^'G^[_F]2?]??CB^N MCD\0_7(+_4+7A7L)77DU1&.WU^J][XAA2W2XWAW*3J)A&RMQ+D_.+O6I4?`O MS?0I54$I5HQV=LET("9?IM!OX:D1F?SP_[T(#U$UN6C68.;UPI<8I([/O MM2V_!WR<:HS`#M/%2KI$R28"#V1-8HG\JF-P@2TT45ADV9QG_\K@;H:6RF;L MO8ZSXYS]O^_GL-FV;F_AIV>4Q$VKI#LVWJA9`/SHA'7YKOYO%DZZ&3@'C/5. M30#T!8YO$"CR^^9OXUABA>;/>!,>PQ7GS@TR@W/[MKW;[NQ2P#ROJ5L;0]>Y MDD9T,_RA7$%66BNB+S/"OA:Q-S07N;9>6N`'O\A(NG2?\ZT6=>J)F]R6V.?7 MA)&&^")'UTL>(\//MHHKO:=R;H\[O%&R3QQ.E MEEV4N++I7!CG*/=5>D53^RJ[[D43CYT_S7D+>[ MM&GE<`B+EYDMGXB]-E-Q.4@C:AS&!_C>.FBI!4,.%R`B!CN$I+^[?.E?+U<$ M.T9CR_1^F6E.=,EB:T2F9B+SMGZ24D]!6;E1\WI,@\H",")'IZ]TNI9?HF[V MRBL863;<5+%\W*[OM%]X%S;KL['KL\F6=IVT9%XN1K76]5C<5SOR+/[77QO8 MU7M$\MY+FTW;*#,O;C(_3R8Z-9*)BD.B#-;ZVB-U,R)-?NB<1&%HLD?36^M*S.%ZE!4 M_G>*45.F]]M>Z[#=SIM=XM=A0C\4YM3"(IK6J-+#_"9VP[3EI!'G/E+W8!4G MKT(4 M;Z41KF>&X=9-VR?<9W]1JLN\-ZN5+O/,@_QIP:^7_N2:8!BK0/8F5\$`ML^- M.-BMAG><]N%3->!DPOW)8,U+DKT"H,1G\"R'-NET)SPH*R)B'5"1,R:^USI8 MQ;1?Q#D^%X33LZ3VF2.PO;(_Z=U>_S26@T.T-DS&3GOV?GT=F&@K8U^WU5DM M\U[ZM)T38VJINVCA,2;\N/68PG)D>0Y(LJ>*\SS89-U'#O`&V^T1:#QT5*R6 M>S7HSE3C3.EY?8.8\'Q,:"W.\>!?F9\0LF/C[,-!SD/'9*5-`+*DMW"ZW-QR MC5;N/LLQ<<@[=ARF6!9V]9`@>)WSV1_YV/8)*ZWU*Q[6'TM-.ARS\%LL+/54 MB\JZ".@D0Z3-.!J#IG[@39:T"#@"W\M273POSK"6,W93=+*U'%A<6.!1%KCT MP@V"7=R.@`OHID,?8HP'N^?`,0F3='$0PC;X$4;W(?K;:+9)XGR+$H'PQU+Z M<>RCAW$0C1\T-7I(]K*YR0_G/HI_P!_2V,6Z-?HY4?$=NBGEGU2VABGV7C1" MF-[0'4GI#KQ+8`0>EJ?UL>83IX&%9\R?(!JX5,5MX79\__8YL6`[N&X-'9C5 M:U"$K-&^62D8REVR/L$;%J$F!E&8^!ZAF2$RAQ2KZ_7,79M$`KDW1V.7J3W2%$M!V_L76PMYD M0L0ZF$3]4?@]:FJ6WOHR&]8F7+%HX%O$,>ZFB`_D^003X(R48I@43PW]T-<. M7M=)8%OZ0S!0".DE@0\DA8_7SVV[.FUT$=VQVV52'8D0=([8;B%],!4K)59C M.,E933\]#FM,Q\UDPN/M"J?/71NU M&SGQI:S^/-OFQ+HWK'C7U"=Z_V;F!!_]Q$+JNXD9S].=K.'@5G%PU02MEUU6\7$%RPF,&8BWYM]:]OK1LIGJG M=.1TU:*D:P[P1H^A+^YW-AU^L4;!I*9TM+ M\[:U,F]5\WX1Y_ZZ3HV5;;Y7<')-XK]L\*FUM\2YO/2!U6R.^LE3YVBFAW&S M-D<7[^PUVAS-<='LB&9'O,+CPL"*'&S;YFALJ>:XF)[<*(C6>UNS'QZYK&[6 M?ECJ9)K3HMD;S=YH#HOI&Z*0&;`-&^*1;*C-VA!+G`AC60:[7FWEJJ-FH)M#:/UEA^JG.#S%;M*N$4LN=R=S,8N8+D9TFO M6RW_ZI/(BX/7+_VTT)&!B"IT97":C@Q/R4I]M_9Z\[=D(#I, M6P;GI5LRT/!3Q&GU+1EL+";3EF%&#XV]FL$RH9YL7[8M@G-8DICS3&V*Q3J]LZVMC8 M2HUWQY8&XE]5W+&SQ.S,;3\M)(+8Q.&;_;"6H^(UA>$7VD1-&'[Q0/*"6$)- M&'X!-=%$X9LH_.N,PN\MV#"QB<(7^4=1P]5R;]TQ^&`)8$9UBMDWC5#6!AMU MU#U<91>4[E&KT^L1"4T3E":FW<2TEQW37A=5Q5VAQ6B&S&Q6TY/U1]5?D?>J M"=&O=D)S[+X%*:[7%U];`D.Y*;-:DEZ.$IO%EGJ_/ ML?/@.C6"F\ES.[VL6SUNRC`K4>HK94"3X==D^-4PPT]R;I[+ MW1%[K,=/JN=)K[EYJS'9T[\\:V*KT8(%:31>C![,4J**9(,AO%"!/E[*.@68)-I(!`C0U#2;Y;A+_5WFUWG+$KN;Z$EY:_CSA4LE?P M#U&6)BG\0&A8"6?XC5..R^ZU!7/*.7-A[]'(.G'8K"3C9]'F0IH[O;9S%Y&X MAXX;!,"3%,Z2!"E-\%CQ$,NKK^@AS^D_T-=NH\##A^#C4187MNRN=.)"1"PIV"KZN0MQJ/AI\\.;MT>(GWCCXZ)Y\ND;Z+Z*XPTS:Q1+B#2&"P MBP.GP\Z3KG-_ZP,;[F&6.=@9@7;%+O*/R)!]STPJJ!Y,JX:5:;_OT2@%O+#0 M43_Q`D9OOMT[PIE6JXF7JP%8E]:X#!V3&=`1R.&BJG='="00(3Z>HVBE!"P4 MYR&P=1S%=)6%MV");E`F\'VR1#64G"5RN58ZUN*%0'11B/:/T\D%_X1_Y6-R M>'$#V"_B%CCAE;\RPFK1SVGQUOB%_933,`"QT$18N?K9&#X\CJ,Q\">,8.;* MI.F[8_C]':?PXQM_1&[LX3].?1"W-(J371P(]V'PT"JS80H9M*5@(`=?DQ$U M$_4`1$$^2"XQ?_LM2W9N7'?\@52$C'8&AV_Z<`$:X-1/!D&49+&Z!G'X(X!G M?O_?_PO-\+\57F3CB>V#KRKV(X]9R[__%,78N1RYA5+U30W__N93'(U0='8Z M[9UV)XW@Y_V=]M[.7N>-DX4^/\0?>>-X:N"#4"9_?W-^\>G-[WL]V'\ETN>B M8+FT=RW:]^:EO?/^L/<"Q%_"\L=+8WBWVYZ?XS3TL=XK@^;AA1:LCC'OU^=VC-HO_G]8![JYZ!EM;.:O323L^KLK6%:3]P% MD]3W#NJ+P3]+X'M3B\FGD;7*A[NE/\XC"^YV]]AQZ\&B!76J&7RG1 M_V1LVW\>AVFLU-5#`G9V\H4LG3GFKVZ$#];?B:)WVL?'.TOB7AS=:*O M_!5A"MXWO''.?:;]WK'%8/KW)MB&@OV5'`_V2,?)Y;#RQ`0^?)VRE\@_83'$ M?+D\YG$`=S4W5;RK_D`/J!U$/A-WQL*G><4:'154U'P#3[`HZR?J7QG<8,_N M$-G=W#;GW<"_OX0/\N+R^LSI=,51!=+PT;GZ_L?5V?_[?G9Q[9S]!?_WJE:> M4OKI_5H\IE(H3)_]X/@I_'5060]/[WKH;2,!^0"R!K8^#O.F,CA3J'#>`B_] MI?9S2I+8?F5$.M%I=7M[SB.($[:?M0IUHM+[-&W_EQ7% MGZX??HZ2Y#(\]9-QQ"&BRZ%$[)YVVO],_`^A'_S]31IGZHWSV[/'Q#/NIV\OY/W.X9].VN*]@8=I@2_WX,(RB-(Q2]1G^X?RD7Z4/8]B10`^Y MI-_(;^,(]^EMFHX__/;;_?W][L]^'.Q&\\#MZ]@J>7W_X2W\A5_VJ<[BWQ:L^4X+@[A MQ@/]&?CQ$9[($[\-W4&ZH[^H7\<6+R4B9*"(?XT/@P2\<2@WY>]O.M.I+)`( M:BC*XH%:9.'*Q%DL,F3\'`7P>\2)4>'.]ZLWOV,0RQU%&>@>CDJ0@HON.4(5 MJP!-&@S:I3XVED$/OP^'T8-RXZ2D#.'YL>M[.Z#S!^X83[[=O_U6F*(6VM\F MI!;^\K??<$[^!_R_\,__#U!+`P04````"`!,?K!$L?`:BNL(``#:30``%0`< M`&YS8W0M,C`Q-#`S,S%?8V%L+GAM;%54"0`#_VMV4_]K=E-U>`L``00E#@`` M!#D!``#-7.MSXC@2_WY5]S_HV+JJV0\&#)F9#3NY+0*&01A8\L8`_F0$%O=^O5#W2TIG6]_O"T=]$(\GS+WH:)6ZQ5$ M7)O-J+MXJ#Q92MOJZ'H%^0%V9]AA+GFHN*SRQW_^^0\$7]_^I2BH1XDS:Z$N MLQ7=G;/?D8&7I(7ZQ"4>#ICW._J.G9`_83WJ$`]UV'+ED(#`B_7$+717K4^1 MHDBP_4[<&?.>3'W']CD(5JU:[?7UM>JR%_S*O)]^U69R["P6>C;9\:HWFZIZ MAPRK,T%J_<_JVQS@=W$`KQIU]>[?C6[],WQ3OTS4^U;S2TO]*CE-@(/0_YCF MK;[Y6I-_IYVSG:-:V<':B8D\+/@)`X^X_QC[(&PSR2@-G9R@4FD+(:,+R#" ME>^/YJ,5#RR@]$P5I5.=#U$'^\\]A[WF`A0C*H:G2WS;HRLNX6C^&/K4)7XF MGE2BHK[D4Y!R[!$?Y,7K*70W(!Y=]J@+WD*Q\Z&/;`<[B5TQ&?H,\F"'@6-[ MF=$A:6Q!#PN72^R]C^867;AT#HL)8H]MLQ""C[L8,X?:E&2[7"XN!1&S>?`* MBS\3T\&X@IY/?9MQ:4(RDX\-Z53%$`WX.H(5[I$9#;*`)`XN&@NFP9`&=!$) M-?;8PL/+[%B00E0,#U1\2QI$"Q.29R=2^P+J3`GWE2`MALTD#@2-&>2LX'WB M8=?'MI3_9-$50Z7]'4*!D85!'%4TVDQ]\G<(BM9>9`+RL?&7B'GGC7UGCH%2 M2*X)+[$T65$I%^V21_-=6:?#SM*+ME[^!MMY%D[.R2XA?UZ[%>-ZGEBA;#_( M&B>#[CRH94B35^/YN)RQ(L\+5(JXA+RB)#Z5]8Z3 M.98@26[7R,.DM+U)7M0GL"IG[Y(7>%X^Y]C;Y,683G7>O4_^+"Q'GX;2QHX= M.I&_0[SY*5"0MX"X,S+;\N&@3SS<=G/]H"(%;:GV/V)WAM8LD,#C[)"3 M#[$%C`T`MCO8@\\;$K2F09^>7!Q"7":S7[>7`5M\#K,%3`Z_C6">:,T-I.C* M88[]:73O$/K*`N-5#:S[9@Y_A= MSF9$S>=U*V>D@.5VITQSCRW3]+71#4O`NJ\VF*2"7@E=/`<`[ZIJWM3B/!\8 M+""^26Q"7_BFSR!I?I).)F>8QI4-(R7[[5DLDBQK"=_.XCBF_$0#W9JR8=<- M(@X@1,(R?VS5EK0/&4.E"6D^Q,ES3VJM!= M;/[WQ-R=R/'#`8?Y MX<-^46W$LL-1W[HU/[`"9O]\ M9@ZHV!=OM^,63AI[1>ACX$5`N[,(5Q2/CV-/''Q]QSNN_@.72A'VYGR*'\LR M]P/H*`RBOV>&L)ER`I)&=/WZ0=I0$L+?G,':,RAC0078&6,*.Z0.7M'@XR]) M$V+],8+KYW5I0V4(?7-&,OD9MTMF&O9<<"8?,E2X#*-[A"Z94SMMGR5#*V>Z MNULPG;PJ;LZ*>Z4!5!)YLF\VY?73F:QT)^RY4LLO*2M?==.91QTI`U,%_58[ ME',`OY=Z@Y3<>2!<)S4SKI,$%K^6<.65T90@@+T[`/M!B]@BM"HHL>VI5L<_-C4+,V8M+?"Z,9$,_4AZNE&V^CH[0&R MX*4VA#%E")C8%R&@_^T0?;.*^B/=Z*/.R.AHIE&&1^?KBA#PWA_BO:LBZVDX M;)L_N'XMO6_H/;W3-B:HW>F,GHP)EV4\&N@=72M#Q;%VBGVX:OT0[F>`.^I- M_MLVM3)67GI?A0!-/83V!9:>;H'9065/6A>-QIH9.6X9:ALD-EX(`!N'`+]6 MT8"'`F[HCJEU]4DIP2NM$T,`V#P$^!L/7H\3--0G>G^]YL?FJ&^VAR4`E6G. M$.#>'<*]K\(B'P+8*/R@MM%%:^OW-:.DU9+9N"$@_AS+#O4J,K4!1,PN&K?- MR0\T,=N&U>Z4Y:8')9>`+IZ[('EI?S[IDQ^E!,TC+1\"IE@R4AL\/CY:@`N, MC+3O)66:$[L]!/"Q7)0KMD/UN.%>2A5V2C>((%VQS(4^K7F7(EMR)\D^^D9: M(BL3FU17B8`T1UXK%;A$QXF`.Y;NCF>3,G%+-:,(P&-I\+"$1)\VC-".T_66 M:-Z^$T'46`K-MX85Q"=?_R,*OB/;S8_V`.RT=3T=R=D]EIUS!K3+.$56OXL@ M4BRE[T)1KHJQ>&`%Q+.$+N1V`N$XID3C MY&R;$:2+%0!IB>DBEAM(]=;L"]&,U0'Q3=FEW.[T'AM!HEB]$'GAD<0+;V`" M]#$#VDQ1KM?EZL@1I,M555S$;JJ-K'WLA03+W<@C2!4K+=+WNA>2 M*:/Q1Y`@OEO?[8Q-:QBUH([VBVA/T*^AI8B M_"OXJED>_03=FQ;$H(7F"PNZD'RQ:O@67%;/GT&E(E#M5V@;"#\.U76U,]== MW-9JKZ^O51N]:*\(?W>J.A*K;H0\K,-U7>>-1KU^"7JCUAC4S[]4WR8$?EMS MR5<7Y_7+?UZTSZ_(C_KUN'YSV[B^K7\0;,;57,_9-/-V'OQ;B7^R3/O[+?WQ MK#D0$$YLY_;-,3^?;2GWVJ@B/*U=G)_7:__M=D;Z#,ZUBFE3;G1X%DK16I+D MZCM&Z5 M4E^C']8(A]X28=#"<@5I&='>:12TXFD'H.FEP$@OGV/Y`PT39&71-7;,R@4F4/`P9 M'6N0&M_I3_H+.@<1HZ>:B"^5'Z*6YLSN+?2:"5!,Z#`\;>CHV%Q0#?N3.\\Q M;>BDXN$*'=J7')-H.<#0(?IJJR94VX78G-^;-NDMIF9M[)'>P?:J[C`='A!9 M,EN(=&R<.CLDE3VPAWGSN8:7_YRC#7;T72A_I,F=Q@JY8='-AAI&**E#IUMGAWXPR.&5EY$)F16 M^6/,>?G.?3G/@4)MCK5G*R_\T;KRF<$%\266+F(V%\,C(EO`S"H(+ETTO]U* M&[J::3D]#5,CO*2NR"*RQQ@7E7O-Q/X#=7^RWM:IY,D2^X]>3H`MGX&3L;%C MZ)^5M\-JS6>NJ(2_B)*3(I/)YMLF+D M2^7[[)-]%1:3YZ'4L!X"32J\#8#A*0\=]M1%?N7CFI$JL.X]PXIADF[I^([J MH*%M2ZQK,6VW1HK6@C*UQ`J*Q[UNK&*@N69F!!V7/@)BOZ7*',Z?(^!"%C)@)\?;P;F0!FH"- M=+$6YL?#(H"ON("I,/"EBP7,#YA%`%_3$44><2SD>!B2/^I5T%9&K:$Z&*O] M'NC?@[O'D=I31J,BNNY^X;*(!A]V-;BH@KOF2!U1[(.A,E)ZXV:HB]H;*T.U M"^[57K/74IL=,")?*EU2I@#]$J-M$?`?=\$WJN"AK_8>0*O?:RG#7@&].5NH M+0+W9A?N916,'KO=YO`;M>Y(?>BI]VJKV1N#9JO5?^R-J2J#?D=MJ4H!!HZ% MZ+;1UL]WT5X1M/W[\>_-H5+`H..'ZB+(ZKO(KLFH4T>$*&]"+[&+KZ/=-:Z&X.N.E8? M5J-],.P_#)O=_'&*!/LB:"]WT=Y4R?#N$JS^O`.:O3984?^@](H9**EQP`C@ MJ]BB<%X%0Z5#9LHV'XV]@/&SV1LU605UT)V08`1=?LD<,(]M@*E&E*)]O%H/8B]EW[!!8C MRAVV7H&?5W47H5IR3'(;_`5O^2H0FE!X,@(TPVI6)&Z!R&4$=FR18R\B!<(6 MBFE&<,<6O]T](_@YJ`BL:RIM=&:-7D8TC2V# MSHQ,,6C.8J@XVQ?G?SFZG^H).N?%>!A1V'.>/EZ7\*W`ZA4-27J%:B\\U_'U MKG>#J%QJ'X@+/>5.>#10F$9FIB'*X#19*\DG\2W0%_OP%P@]) MGU(<0V*^KE@D(J,#]RB.L+1,\8A&L?#%ME>W`L(ZWMU2[VZI/[];:H#1`F)W M.;"T54;8#\]<4%WNEF/2-M\G)20LMT,J@_ZR/<@PH5/@:4X)(>%R/$]9*!$D M,VX1Z9Q-1;,ILV.I4,:+\27%D_OI=N2I27:%$(Z6#ETNF$^DM&A"R9(\05E& M#4I5(.^YDF%HQ=;QTL^O#/=K+61`KL5Y(F4YAS]VKPK!O&^FDJ-.#+CW:#$V:/)V5YM@XLBW_,>XKO#EL$N.^_H!;B3^Z)A!KM/R,-[:["6Y`A,%GNI7TKL`.<#E=-C> M;SR6N^B;NN[-/3\IN3E'I-/]$7D#+"&`DKDN^2G=5R[_8DZ7V@F M]J<;U-(P7IKV-/QN"*=4*827*S79?.]3F_R,[Z\5[SB M/5Z1`TM#Z$":%$'VU&V:ZH#\776X8I-=-H9&WYU!/)YI]GB&D3>=A>_?MM#\ MV;3]5?QN^QTL?I"CN!;ECHP4;6G9-D\DF,->XS$E\'/,F$/+7)">-9J;*5&'6+FG)/I/P.#) MBC#[N/0AB)+"/X?2D*Y4[E&A?-:NSOJ=W-55-/S];G)IN?>J/`UE<]CL8DW; M,[#*E[-WY%J:3XKD.[Q\>)%YUW8P=S*_EC6`-G7W;8"GO0_"$'CZ4,[JE#): MD#!V%C\?RIWVMF,H_4D':@XT_+67&X!(%GFJYS_*'4(?FBW\F MF.*XYISFZ3S:.K(LJ+LF-X)[2*WR\WNX=JR^<'W<)(F#[JV))%#$3ECD'(^W M*ADV$#GA^OU]T/?\BC][?H5*IH,Y7&NP?;1]TS::AN%;7K,VP\FY6Y(_%LC1 MK`>,O(5#JEBE7B6/5+[W^5CMR^W//BX+LCVH9E*DI\U37X_GCJQ+24Q0!*F>4HX4<_^TL'RC/)[M5 M3'J[Q]'*&8\(!J@]5=X6](UP3I^/%96>A&3$<@8G?L>F"_N327_2AA.(,33H MQ1LTJ$)W[;0[L9E)EY6>*D$5Y`QH)*YX#\0\'>0X?3M<)HEN205[D,P48^V- MNXO(H7[I^T".:DH=[!![/S1VQQ+O]I]CG,?9V;[?3DB'1NRJI?A]=^^ONKZ' M8OY*H9C5\+G7=/H8M.2'39+*RAWB8&LGVS->%&F:>SBY=#F!!(Z->61([M$_ MG`^9??$'<7;4EQ^['CW]'$WZIB/.>H%AO.-*T4_Z[ MC9L29;U&*FK*7:C,6:7LE^1L&&Y90Z6"`[[N$,;HE5X2J2W(-YMK<9->"A*O MY4GV8W4R*R.GPSY)#?^*>^BX0V**[13A;,RR:CE)9KG*R+DS2U(C.,/+!UEI>&E#:SL&5BRI]N%SR9!=#Z-PL3B M9?E),M+%QBZIX\0_YVV=/[%*)0[`]WBG._#EI`]!"\"7TQWRGCYR2/I(R6G' MQO\\QZ5J.F.TRCFRIH];M$GZ[2&X]`L]<&JRR6 M!Z5WO.MDA]"_]6&@87?[@%)!I2YWE:J?5\%0Z33'2AL,FL/Q-S`>-GNC9NN( M&3GT_AEW*:9`[,;?>KT*E"^/*D'^GH+S[C;["[G-6#/!W7+[F[3SX\7KD-O- MEMT:LNV?MG&FG]4=+UO6>>V9[QX*X#%$SKKO+0SGYD]/^5$ M\V/>\OD?DS9I+57+U,G_7.,FEBTK2"UF7C9DEH&O2L[XW!R1%9P9Y[DSA,T_ M>">Q<83*NOISGS/!$K'+Z5]JB,CI_Y.]C!*XU6<*J,, M37AA+/D8#392_-20=-E3Y7!7!29Y\M[0LA]W&]%3I6Y'`R9S$M^_4M3522?* M*$<;)KLE7\5R_)N33I1;MC),:LMUM'#[:`^^^E_M.V+7\J=*9Y(:3"++=;^( M[<='$+^0Q^5]"8W5<]K$)JO#)+ADWXW(]GQO?I.K.55Z.=HPV=WR$ATC$7KD M/3OPAT=T5%YH!K%8;NIU+#?UH@I&CWR0I% M/OD_4$L#!!0````(`$Q^L$0ZU-DF-RP``+%5`@`5`!P`;G-C="TR,#$T,#,S M,5]L86(N>&UL550)``/_:W93_VMV4W5X"P`!!"4.```$.0$``-U=^W/C1G+^ M/57Y'R:;I,ZNDK1Z[#G9O7.N*(J26:9('4G9<;E2+@@82HA!@,9#6MU?GYD! M0`*8)T!JT,I5W9V6[&Y^/?C0T_/J^>O?OJX#](SCQ(_"[S^N_'!^C:Q\'WA=T M%;G'XW`5_05-G37^@FYPB&,GC>*_H)^<(*.?1-=^@&,TC-:;`*>8?)'_\!?T MZ>3T`1T?&YC]"8=>%-_/QUNS3VFZ^?+QX\O+RTD8/3LO4?Q[&OK].+B[.P3FBZ&2W1V^O>3KRL"_\I)R5?GIV>?_OW\ZO3/Y'_.OEN>??YR M\=V7L_\P_)G42;-D]S-?3XO_Y.I_#?SP]R_T?QZ)_21B\2>0Z*:.6]F>05(+^Z[@4.Z8?'9^='U^< MG7Q-O`]EX[,6C*,`S_$*,3>_I*\;0M?$IVS[4'SV%..5&$P0QQ^I_L<0/Y(' M[M$?^DQ_Z.P[^D/_6GP\<1YP\`%124)"J5^?:[8*I8^VP=[AV(^\4=@-=5.[ M)_CDW8G3/1RHZEMW81FE3M`)?%73.NPI[M;B.SW[+4WZ$MRMI2N:==@!_7!" M_JH!QU]3T@EAKX1.;2D"'/LI%G<+VUOKD5NS&]!@&<7"%F$F5T[RP.QFR?&C MXVR(_;.+CSA(D_*38_K)\>E9$1W_M?CXMVO'CUG?,PXW69I,\#,.SF[Q^@%O M?X[Y^OT'(XV/34^H[B`NW7%B5],FA<1'-R(=QB8]#O+6S]57<;0V!%(T7V0D M_EOPL/V-O,4)#(DS-;$8)RQ-:/7`JQZ9MVV!<1T0'9J"X?#X?O'AOY@(.OOK MQYTY`&2Z?-W^^8-/DKW8?7IE2`=?_43GNT:Y%XH9.21DFU(3'O%,X#8Y2#7R M!/8(;970KU3C?X`1L_)>G;>.E%/E$IP880>CDP&^#,(TQ7KPF*5XG0E;(Q6Q0 M00>2/G^93.\/70.L^:1S252(HHF_]DE6#R.*W,71!L?IZQU!G`Y";_1'YF_6 M.$PO7Y?DMQ6)DI&FS:C2PI5J=#%0ZYUP[;$V.5AJ'B&FBYS00UOM(T2U#Y0J M20+2*'3CUPV=:UM$J_3%B?$P\K`\,JGEK84H$]C;6*42[IU#I@B;S-FIH%(' M4:4WXLDM]OQ%E*5/QC/7`RJ^9BW4F_T7*\BEX@F4YS2 M!9!H-5CCV'<=^5/6*%A[YD;`MPQ02L/@@PG$)CL*'50HH6B%"K4WHDL9:B:^ MB\-$T4](!*W10PET2PNA%`PZJ*`U:;#M``KAM\H5;N=#DJSX*S]?G5-D"1)) M>_F!$NHN,Q"*P2"`$AN7#=S.44T:QC!FCA-,Y_M(3GQ%Q]41RVL'28+39."2 M/#?&WBQ]PO'RR0F73W&4/3Y=9HD?XB091NL'/V3.D#0Z=L+$<>D_%&.?M_LY MFP.FMVZTZBCKK7ZK]U?(DH/-][#\.3:0J_P@RG\1E3^)V&^BE/PH*GX5E3^+ M*K^+'EY1Y9??=BPX]#<$U&+MJ[)\@9"UJ"X%N`WHG$3O1%3":M(GET-,$/V: MBRJ?]GO(KL^M/H-G'#]$VW7YMFGVN5FBO!,_]1_E.9I6 MVNK\H!IR;4Y0+-K[.VZ&CYO[RZ713AP8F7;`\GV(BLQ++&J31BJP50Z)Y,`0 M2`&.6Z?:L2:7!;6DOL"/-.VY\A/RZ%(_S$B6M:'[>@E>\;I7*TV;Q&KA2I5G M!FI@:&>.E>L7*RIHIP,LD(U#-UIC^II@MBKC!'3#\>()8[I:,_`\GZ)V`NI- M$"49:=_+5_*/390XP0W)SC<),1%D-%R+&TD1&FW]N,UWPFZ#5E\K.[\,YLVT MZJ[@Y69V$#/$CB2\[0#T-DLS)XA6L[7SI%B"$(K96VR2@]PM./$RO5-*`XQ; M>"HD$1,%%M"',2;,OW9'-7B4^UK>[-3/*C=O-3NN]X?K000]T"I!+#W?N"Z41:FR9WSZCP$F':! MKAN3_FSB.P^4=SY6CR[:&+`9)]H[5HT?YMJ]DZ\S9&[W7F$`%1;8C'MA`XV^ M;N@Z:`*#M5?X(1V'21IG;.U!WEN)!&VR4`ZTRC9>"@RKI-"XU)8(HITDJ+F3 M<9ABTC!I06)E/)/(VAT+*N#6AVX"03#44:$3Q!X69DH=&+R9XX"=7G7BM+I: M20:$U6^4R^?F!NPNB+=UK+[$;:H-AHNM(?/+T$P,,;FW3<5_].F+$KR.`]\E M_R]/RB6"UM)S)=!MHBZ4ZIT86FA-`I2RJ!!^N]VC>4\;>J,P)<,^6KPB7K.9 MI<$#Z5T)<26+L`9Z-O>2&KM17?36*L$@3@ND@G7O/$$:T(,)3!E5M`_9\278 M/7F,GC]ZV,_[//)'LZLC'_V6HYCC1Y\B#U,Z+=GP6BYF@U(ZD)1!,IG>":,! MQI]"8)38R;)9XOYH,21H<)V>7&!*8=68TA`!10XQ,PHU" M&#%I1,3[8$<9Q^B!*H%;]:]M<4$$JJ1`]3L03UX`2-I94)D^G_*V`A$MP:7P MI2%G^[D+838)4!,"Q001,BDEZE(NC7!Y1A5Z#0YZL_(R#X,

@D7V$FB$'OC),FXZ0P#>;OII`9V M/:V4"(,@D0G")I/&23DP=1#5//Z=JJ)2%^7*?^N/5#]%01:F3OS*RI@V)U\5 MAC%,MG0!I2=KDCA%BG3$T$ M$%-$N"0S'T79ZD*V/T+<90^![UX'D=.3^OGAR2'/,LI259R>Q2QX6E4J6^QL#!QJ]CD(#$)$,8,JF M5IDF8JI'*%=&%>T^Y^#R@5T^[7--/A.E,PI9VW-Q4KC-^3A.$`23=.BD\W+% M^+N8GF,J_;.&S@:8<:8BV0]C.*ABOFS%`+*EB4W'%397P7*FC4I76NMHJHU(;_5KJ M`]G,650:4=.P*61UY[D08&UW>4T"#(F$L+B5B,5BM%Q`HD(Q/V#$"$[6/C$D M<'E^-`2!T42,CEN4N)_/1],EREGS!09MAD[R)/$M_\KJ>;8*F-H)-O(YF$=> M`<,]8?(5C,=:GE\9A-XT2G$RQR[VG^E)EBF61@6U3A\'EI3P16>4A`I@J&." M4GH2*=X*`\F,:['/)#[VV,-H>Q:K'$DKMVCIFTU"#'85%W*+E6Z':<`@!DF< M_11/_&?LC<.48/;I&3P&4!Y]=$I6KZHP7X\EX.1XMT&!ZA1;+V?#''V:3J]%\\2/D+^N9J=#T>CI??PB.M.3][IZ(AZR`3S)A+,(AB4JO`<%JGBR5H=2A, MIH3:FP%#U.[89=-)%4(#F5,R\7%[==JNMM@>+2:T!HW9"I?;LEM@ZETQ7(Y? M.OVQR]R"/=KI6#V,0CF?3B$ M%WQYWJT$LPPGA!)GZ(9ZN\EILTD:N*V,V">7#U M]'?W/1AR"4#Q7`D)2Z(5A4]46+#KOZ85XQA/N/%E4:EA=R-=#KZWOR\7!]+1ZC-P`?79[.U[>DC%Z/FLYG$V7X^G- M:#H$0['6<^E09L_;S9>_@QGRUG/BHCEP(/,_=\06)@$WG^AGXWR)UT))N]>' M2Z'6KPOGQ,`P1XZ-OPZ\D$1)?J;CWTY/3L_0QHG1,U4[0I^.3D]/Z7]1DA_W M<++T*8K]?V#O+Y4O?7KHV6,S,=';G`?9K]TV) M.!ARZC%RO69^ZDC&T._^?*KBZ/FG[X[^\_SST?G9=XR>YV>?CKX[_\3^#9FU MN[LV[AS?&X=#9^.3)%B6_\JDK0Y+U)!KHPZQ*!B6JO%Q4]);:4),WSOV0^3F M"C"X-,>IXX?8&SEQ2`B>D+%1MLY8R=8KO/)=Z=R;B:+=RKRFCM0K\NJTP/#. M&*I@5:041%XN"8-[?!IKG._V/8`P&SC`F@B1XA//ZR45\3\AS!30-P6!`.Z; M$6T5ZKC#"-;FKBZ;NF`QSQ"M=JKMW>SGJ@^S[IQX%K/3@A[+:^]PS`[(&XW1 MY,K]#7UU#LE'PS)-,+UL*[CR,7-1!X'H(Z8(D99YD8;!=D!DU"*\4G\TE#D@ MIU]3`RCM)#"U="O*;NP4X=*.E<)K0[E2H6^ZU8'KJ)9+@Z99#:(IQ7(EN/32 M3^1IM?HFFF9"3Z,"FG+ZB3T9[TI-*%-QE2G+EEF>D69/$\IM\CL#-3!<-,2YFT04 M+JF469N04)!2MA85(,U4>J65^=(KW#2M0^5'FR4?][G"U(W6>%NK2[-E22IM M]QI3)>3Z1:9"43"T4N/CJEDS:;0KK`:MA-HR@['H=1DLY6!61IX*S)V.V(!/#J/4]%``P%1*CX[;"+ M)9I=(UA\N(FC)+F+HY5T5T1-PB87!-"J3*A\#88'/*8F"V[FL\4"WY(A4&PQP=PB:/9G>C^8!NIT>C_[X;31=@ M#K\O<$!L/M[@D#@4T*,IWMH/V?VEJ?^,"_=D^SD,E:WNE&GE4&WWC)$F&`JV M@LMMQ\^5C]!CKIX?4Z\9@,'/.4XP:>`GXM\5Z:^#:$/3/X MX81DCK,P+Y;`ME?/5LHJ?QH=JXFZ"?Q:ZJY2`,,M$Y1<>D]T4!2B]`G34A2L M\`6M/0"I/.GVGK*ME+=.*A"N/33@P,B^38Y"G]A(P1@7"%$#G. MD9.NV72$J%&RRB`C!VID4FK`X94)3(YBRQ]&#F>W(_1-,7($LL%X'*:8 M-)(F%>>D[*YB""'65R]J(F#H(L;%KU;D4F5^!(,9C.JZ-+HN8SW$*-/GJ@`8 M1HA02=)F*HG\?"4+%#-V?>HU>21Y48J,]+7;BF(RNI@HVE\?-7&$7RI5:8%A MFS%4KGP7G2^_GL]NB_HA]S1!*E*EV11(FE3W3EC;CA:8GZV6SE>C!M*9Z(^; M9L[)6:K6!\I7(]!<9UJD693!W^84OAHO"A:/KL"1F+BC'1$V9&S24`BORK.: M`!@BB5`UF3(=+0&-^%#2;+H9+,4J#`4%;91LDZ^80Y5@[S=XIU@DNOV>W M%#U@O>OV,_<W-V"1@5R>KC&QK M`PQ%.P)O('N($CSI2'^M%V\^`#I4H;KB0-)L16_MO@ZB M%]VROEK%;O$Z/?AZ&3NY/)B@:P"2VW2[/546K1!50DS+\(P9G+G:]R]?[A-X#O]VA.7!3_]GDQN*W^2F[Q>BV#D(N#8;@>(S0ON<.Q'>\-H33R`H:^G:&K M+F4I[U$A>2^)MSM5^.0>N']D?GZ,2;:_RUP="I%%3IG2MZK[+D@K`&Q*U21: MI2^$\BAQ`BCG'DF>%&/R"E[A_/])9D2WFN_2(W9JCG0\E6K[)+W2%[S:SZKE MS;6':(+&X'0?DV!>A,/XP;T?3^1?.$'TG.8N#6:F6+Y2N?,72$K,MT-Y_RL9 MCJ<_C1:L-L5@N!S_Q*XN`Y(>$V==C#VV MJK4@8]O9B@T3\M'!F:2A=$IV;THQ<:!^48I*`PP;C6#RUZ3D2OE*!:VC0RH4?Y+=^JU3L MUO;4@Z^7]I3+@V&A`4B^L&>APGI][YG0%1?Y0+1:^2Z.89"MFM],_!`3#X6;0MBR5+,F#(9@.H3J!)-89,FERU1@\*KZRICP2B'?5_C2\DHJ M#(97.H3*J`615JJ%Y?SCZRBF&4.'A>F&/I3-`4*W3'<'U)3!T+(M8N.M+$0% M!D_-\]:]$U^H(Y+]1B)@N-H:LM'8>E6J@QM;4V<'H4?_;_1'YC\[`>T^\A>T MN8HF:;)V)JQ>S=3!N=K-32WTP3"X`VA!&;CY:+`8H6^N1OE?WZ+Q%-%!=4]G M7F2=(>LU[)Y;V;"67*1D1#C1/`;IZ13:DD?H>[U35GF4VUK6:R M[5RJY;%FJF#B:CN\W+GG^[N[R>AV-%T.)JRFYF2VN)^/8!"SK*%]Y_BRHA!U MD3XJF%?!B*J)M'O`7&B#'53\FS(G[M%QM`3#(KH@>L@2C)M"=;]S=H>2!RB$9JYU3XV MP?#Z0(YP`^G9E*WB5?;QD)1.M)`'XT6I':T=>!X[\N($]%4?AT-GXY.\@6TF MD31C"_W>CEV;N"4]2ZU2!D/FMHBY`F*QG^+C:+6B4^EQOGA(HGF M+IC,Y),W8D-`/SD)WI[X@_$B5(XNTMO29?3FQ:S&9PG(6AANR(`AF`28X`1& MG.6W$F[/A#H[5>1272B<88=%Z+L2!;YK4)A%H6"71SK@=4;)I`%Q2P-1S1ZS)+Z+I^T2M/V5L#0MS/T)JW/3M#5:#&CJ#VUGH>Q;?5JOD,V1^U*OT,8!O-Z M'-(;[LK1BNTC5+/.SGY6[=.<9/L+:/<3\'J./'+L.CE9W.'EK,9]&;I\@VUBDV&F8"ODDTE#X9W!B";%+PX031S%39ZJ12*X=J$TA&FF`HV`INDXR?3M#B_O9V,/^%1L#% M^&8ZOAX/!],E&@R'L_LIF_^_FTW&0S#S_7.2!)"FIGNMKO`S#J(-[?@U":E. MR>[F=Q,'ZCO@51I@F&@$D]\+GRNQ#*^B!BZ1*X%670M91<`LQ?&BF!\S[YGW ML-<'6SN[+2)R:V/@.-[5@R;]_TP"\.QZ^?,`RIXD\?W%[.Z29!,E3G`31]E& M-P'0VDKOM?[U+FIK^LM-@*%O-]S**^UV9O(07AA"N25P8;SNZ#AT@XS>T"-N M&/-HOK]9RV_`01JA\4KL91/2.W((1YHOS7LC;>1R83M%E%7`:[7 M3Q=)PB&<"AY?-?TA13MI>/&UYHPV;,JD^R.2.LB)18%221>2_N,$3>B*%!W[ M#^>CJ_&RIW,P;&=7OD^7Y"*CHK:C'_I`OAETMT.UZ.;_+5EKOY M[&8^N(7!7+HYSL^WGK*A/)M`Q:';:EM].QM6]]!W<:^V8;Z-`3#,[8):M&VR ML,&";\T*Y"3,R'E=-&YK!!RIE?&XG87W16M=1/Y\PB[6'B_9VC8[WY&/2V]& M4T@+/;L28,O8"1-:PX'.5NF6>G1J=J?/S9RHSY*K=<"0T1`HO^23'\]@>JBJ M""Z0RCQLL\S3P@($9AHOY1BK@^>K>>0\.SU!\]%DL!Q=H;O!?/D+6LX'TP4] M$P=F(H]6'TE?-5&R*623>6*`57+5)<#P1PBK29%<"%PD8V>*GJ+`PW&20YQ& M:8NQ>0M]ZV?'VKC%'14S40;#P+:(N?AU=H)&?[\?+W\!PLKL(<%_9"2='3T; M["N7B]LMOJ(&7:^V(I:%PR@U0*Z>RE8D?%748A!RO-XX?TXG"65SN:)FM)E'X./&?L9??K&/& MSVZFK%:GVL/96@FK#G;`D'D/\%R-M*TI&GJIB6-F`PT`7:QT32"RDAB5LX;C MD.2BV7KW%DO:RE#7)H=;N5,EK9$B&):V0=ND)=5%3+E^_+.B#X.:N[M[#4.L M2L'NI+`.>'T.6"8-AFY:B-);9W>:><89!-$+O5Z&E<"_#]TH"+";^O3[4@<& M^;;U#@U[=ZEX+_4E37IIB2P8TFD`\A5)V?8N5H$2!H7FF`S:,TQ>@>@Q9+5^ M3,.85L]N-#-THQ[4-$I@:&:*E%]_97JHH@B#=C=1Y+WX04"&9.,P)9!I=&TS M4FECP"81VSM69:2Y-AAJMH;,;[U*\K&'[]+=AD>L#Z:3BF51'MI!,QH#"9E7 M>(7C&'L%JC9;X/6*=G?#FSI2WQBOTP+#36.H_-&+7+%D'@SBL1UA24)?">60 M5R!G?<>>"":W*:\J!(8T,F3<^IA#1AJH(@V#)&;'EDV3O$ZVX!U:-TH&.Q@" M0]I]T!O7:6`=_YY>. MTK^DO9A"PVXVH(5>SPNDXF!8I\?(CW$J&G2PDVL@J@*#8,T6##IO%T'S*3&2E$Q\Y\$/V$T]M]BALQ'>+"3. M9'&<7^DSC<*X_">K=KJD2U,ZPK_%#_6R*'[PAA*NH!_L5Z"5'W@S#]_M$OW" M?<)>%N#9JKA=:$(OYJ6[9&@#&;U<[4Q8370Z.%?+=UKH@^E!.H#FLA]0]^#L M'&I5DBI?3MZ61+]T`KIM8?&$,9W]V=VMM9OXUN^1[P-)/R^,]:86OW?68`!\ M?6W[;EC>$%I08-58"GCA(YUMW546NGRETU512%K$_-UN;["?5[2KX^(WK:TU M@"],1Q>$I>5NR?ORF,](D9'38^RL>ZH)-L>IXX?8&SEQ2+Q*R)`N6V?L`/<5 M7OFN+ZF=H-."5QNL!6;!;L52%!6R0,)4&9!9WB5C<$/([L%A$<#ZZ>"J!)S7 M7@2+2V1+(?0K$X-R-K.$-2%\'Y,_Y5>7\H*]L(,#*F3(5@H>2YK0%$RAHHC) M`J'+./1(3`O]%+/3)\5>L,%CC//)/(GO>C6[.YO-G*CO<%;K0.O!#/'"'FXW MG*"UM>BQ]LP)YO[CDRG;!&H]LDWJA()MG`Z8H&8(M$FS9932.^)`D8T>&KV^ M&@_'(9MZ':SISSB)$MF&"+01MQC>^SBQQ,[(5([(#$+O&DLK:TFEKHP%L.,@7C&;%[0"2BCHC`'.DC3V'_(4K91)QI&(6DKRK79JMXB MTLFA/:U:+G=QB"9H5,78QV3O*=%A_="\',AE!NBRJ1^F$/U*DH?LT;1=*,W4S99/H^SE:YWL6.';9_SMD>XD=*0E7R MO(?+6G.!U]+7;,EE5X#/LSL6J?R8+*&57F(-(#$Y=;@-7F M%$>(:,,@8K4CF:VV9R^P+#M5R%L.GFK8C0@I%@9#+AU"+LA5^_-BRS`,/K%A MUSA),NQ=9?00VAV._'%H^7MEWM[1A_>*:MNYQE]>8&@##SRZH M^2V+=`3O,R.HU*'],M,JA^^@6E+!&5E*0`P8/BG4#2EH62B7.\6*V"V**0#;K M859EP/!"`DS)#5#]VF66^"%.Z`KX@Q^RX0\+:VQ+Q?;*@/+2*:]6[U_2)ON9 MM$F]0SA?I>D^]L!0^@!."`;769BBJPPC^@"J'6=/^R?*FRKNG%?J#CTA[[IQ MAJOE8+:U8G9'YH5S(=U,P=MOL:\CTAM$-KG!GAYUK8J"NH@"[Z]P1]P^!N$] M]L.XTWSX4YRB8"='!W5>M9Q$9%1.X@UI45;-%SWA\CMX#XM#)KG3HJ]6I347 MZ,*2=#MI30!>^XKAR2YE2.ANP)Y:>EOFHIBL%A*9$X+7XG*(S5;?2B)C>. M'^:IZPLU<1RM5JQ'(]HP."CLKBGJ290DLW!W#:90D'36L]72^2K/$`YBW.K) MAH,V2"/].X!E,._$0=V1W.CV#1DI)-_F+U"'+-#BQ5M;O^E&_Z*@E')12JEA M]6HM/?3:75IR<3#4U&,4'<_8KA\E1[LUI;O8=X',N$W\D);F9"7NKQV7#I!> MBQVTEU$<1R^T=)FS(=^DLLLWVIFPR<(NSE5IV48?#$\[@!8,VZ+@F>:VU-CN M#H0CM+6`2A-P:3P.4TP:-YT[*:ZNK[5H-[F)OFFLO%2_/, MN9@3F4HWC^J4;'+1S(':])12`PS[C&"*BVW1&0*TWI62W?1:2O;-)GC`S2JV MP"R4#[=HN2'+A9ZN5,#F0<3.]T:(]D\9"\:HB9/)[E,;&R#/S_.S1>6'W6 M9,ATJ,!XH0^,5.MX'*)"#ZVB&,UQ?MCOSHG35]/';'$(1P_S$/+.66V$(A&3 M#1S$LE:':"JXM2&92!!,F%&AXV>SZ+6)D`Y1#8(@>J&IWW443R*'7G_+'*+3 MRW@;*:5'GTVUK1[8:^=2+?29J8+A7CN\7,F3?/M9WGDA*MC;EJ.-\\KB-MUB MPF(L"[&T%Q9O0Y++P\O7C=#RD:)08JLVWC-]R$F^4%CMA?I+,41%J`99^A3% M_C_$YQ?4&O">FR%>72&A8HO[3A/0`]NS,AJP_,\4KN$3`S<16O?OIXA.NBEO M'E`IV.R1]<#EK*M*@^EWM1"UI?=R'90KP:`7HSW;#R#QNBI@_6!<#1AW+(Y] M"X8>'"0M'9:QX^5W41,EVN73205XY>5HONG2Y(-Y>$EK1]#+X\APALVNJ(>< MILJVQPKF#C6'"GI-,)1L!9??UKV3A#5\59Y;SC\G0R-Z.8?L56UA`,SYMQM/3NWOP M,@M=6$WA.)X6II.L>;P'%9 M9_,NTJ+&N'.!XV?2CW8BJL`(&,)*'6P_FU!:>!\$EL'6YU6%_+M@<7W`W8W$ M,AL`.*QVK_5PU'3AP2;Q+B3CD=[;O#_/`S^7Q[B+KV M*-MI_N9%KK5G2'XK8Q<2"6Y#Z02[^1!+?40$44(M'*$':N.(/5)W:ZERTG<0C=^90PH%PZ&D8&0I7Z>"JWV/,7498^21Y$XWM8;2\&UVSNK50?[7L5N6D4TPNV7J+X M]V@U6),!MNM(6ELI#:OM3:!R=\'')PDJ--BI@URGEXZY>/'RM4M9&!)*P7H. M*HA<-UQ?L>UG9N9V/L1QZJ_(@Z<^R3H`H1BLIE=BY(+^[1S5I/MH_*&_><+Q M8NU+XSTG`:O)9?"X_:1,#C'!7KK5+,V<(%K-ULZ3+-@+9&`UMAP@U\4R21K2 MF6POU*:+VS)2[[Z#U<(\,([(K(;BI1,J]^>_5:/^Z%-HP>LX(!U&'$B:5R@% MJZ%5$)M-7LJB0KBO"@NZN^KK-\#;W8RB6E,2X^(&I$6=T$*NUT:6MRZX9M6T M9T_-6"E4H2`L+P6H>17@^+)V6]'>^6MP<4R!D'PW)085\:2C+4`/<6\7I!?I ME)4,Z`[7PB:`*CQLZ?TI"CP<)Z,_,DEE7UX*T"-3@!-N-"A$_X1R831(T]A_ MR%+V=-*(UBSH[W6L,(+PR^SIZ'0`/2MCJ(J(R=Z@7+RO4HR8'HG&WN`9Q\XC MGF8TW9NMV+)ZY40^6V&GA;K\($O%]2:Z60+T0/=TH/F82W.HL(=R@W1D/GFB2C/Y5O+$.%X>)\R=8XHU35//J5V4;4.&+6 M_Z,:2[;?BD4!/0L=0M&%*@FJ*+"P1E7Z&FOF5=]7X_6&A&#Z3BZCH1/' MKS2>%]_-\6,6T"WHKXJ9E0YV`#W'O>!+KNJH? M3`L``00E#@`` M!#D!``#M75MS(KF2?M^(_0^U?6(C9A^PC=USZ3XS>P(#]B$&`P-X9N=IHEP( MJ--%B:F+WVN_KIP^.LU9EU!X,/AA^8[L)TL(M^^N#B#__XW__\#X/\ M^?&_6BWCSD;.XK/1PU9KX"[QWXV1N4&?C7OD(L\,L/=WXU?3">DG^,YVD&=T M\6;KH`"17T1?_-GX>''U9+1:@&Y_1>X">X_3P:';=1!L/U]>OKR\7+CXV7S! MWA?_PL*P[F8X]"QTZ.OJYJ;=_FB,9MVYT;[ZY>+KDK#?,P/RJ^NK]L?_ONY= M?4O^:G\W;W_Z?//=Y_;WP*\)S"#TCU_S]2K^$Y'_Z-CNE\_TKR?31P;!Q/4_ M?_7MGSXDA'NYN<#>ZO+ZZJI]^7\/PYFU1ANS9;L4&PM]V%/17K+HVI\^?;ID MO]TW/6OY]MA!4[0TZ+_$1`[?2O&\I!]>$F#"#7*#CKOH MNX$=["A*WH8Q21AGO:P]M"1F[EM!BX).;8)^U=\@M,%N2US$MZF%?S`N);F[ M-1VJP=D:H<`7L9/9N,+OGY@>$7:-`MLR'2EF,BG+<48="%'E^^/E>$L'%J)T MH8KX5-5QU#7]]9V#7Z08.B,JQT\/^99G;ZF$X^5MZ-LN\H7\<(G*VI)O$RDG M'O*)O&;T%0,W0)Z]N;-=8BVVZ1SU(3:P0MV5D^$>DWFPBXEA>\+1(:MM20L+ M-QO3VXV7,WOEVDOB3&3LL2P>>9& M/!9PB,KQ0U9\&SM@CDDFSRY3^XJL,P'F"R`MQ]L4.6306)`Y*]C-/=/U30MD M/R*Z=6.?16/@:#OG)M/ M3E7\G_95S0@.Y"^S=1VC.8P?"&T-(RN0.3%I=:N5'@I,V_%'ID>5\"R;P\+.L&9&?IL:V7'_-6C>-(?MEKR"^+6[E>JQDK6OL?H.`( MZ*KA2EJ3`KHZ1K56]L=`/9;ILPYI9#4NUTN%*W)91D'$-1I9'/E6U>Q_Y61A&S^-RFXALD0'G MRPD)^AH@=X$6^XXHUP6CV^1C2AN?/[2-EK&G2OYHN@LCZL)(]A%SO.?9P=8) MFPX-]V-/I"[*\!\\7CM/9`U&;'#?D6,^(8=U_P>EA9%>%F$V5BD[@/"1=;'" MSY<+9%\2_F_H#U20F]95.SY^^!OYZ(^(ARE:V?2KW8`>^61P3IIFMTPSFK2$ MCF<9V%L@CR"V[]/TK!/\ST],XA:76Q:(;UEKVSF8SM+#&UE5QFK#`D&2VB4L MO#H$72*(1U?P"_3U9[3C87#6%`A"6S\4CCGI-EO[IRV`2K_62>E9 M,JK4]01Y-B82+.@Q-5_IJ:9`[=_HJ/U,J57`T"'<+"A'=XZYRE9_J@E0[1]U M4GNFE"K4W0T]*N(=V3J:SN_(]+B&G]\:",*W.H$@DEW=Q/L;>2`)'Y3B=D0%I0!\^OV`F)!KT=R[_R>;"<-07"\;U^<.1( MK7!Y&OGO%&VQ1R,#45(8=Y6:0P$$Y0?]0.'K0!TVS$:Z9#!=88^[<4@U!"+Q M23\D,B56!\`D?')LZ\[!9M:N_\#U23/PGDT_[6>(JW!@PIL-=F.+20='1<4L-4(C*/5^T!(SV0'?DLYQ)A-,<"HZ66^]<\=5C M0I?E8$02C:%X:+D9SQ$]`XT?+\^D&Y(/*@^$9^=>2^KXV6<<@7)3_')$9$ M8WSSZ)KAP@[0XG\*1;V3IK0T_2<&2^BW5J:YC>P).8&__R1M6/''?QP83"0H M3+!O"X+D,3F,NK2G%!>OX_M$UV)!TNU41)I:#^CQ8`HW%W9Q*HB2;G>):)3%KB7010FO$Z.)?(HA7'Y MJA9=;\6SAK;Y9#M$;D3';1:D6&.'*-^/4J3$*S=X#\JB_^5!EU63'MZ8Y%H* M1UG(JC\;**KW?-BT1&B_9IJ8.[I0(C*23[R0C"%'SN%[J"*=*3MS`$"4O;XL MH*OF@'TH(J'Y[`[V0R\K&T%"(YD=JCOKJ`!+>:O@*%4/RR!\;;%O.O<>#K<# MUW)">CB06=)P+EV^?93L5MV92^564HF"];"5H>VB=(%WUFR>;*7N@*9R)+/$ MUP68M"B@Q99L>*&&4QOIJ3A?U*;OAV0,E<:Y7$L81"K<(]0@:@LXE5Q]E]5E MTVT)<-M$1BR>1P2UB-H"5B4M`GS_ANJQO$@@I(+01[NV@%=)X)H2\9CLQPG& M,%OSYP.6V1B*5(U1*DEL.#+K`4HB`2JZ'X&;$)88*G*)H"#5%I"]C?9-'``6IMM"2_(*%+[L>`$UI.;"+%GW3 MCV-*J36BN&[505^D(&VN(+"55GOU8,GK9[_D1P0GX:!!&K M3ITM@:2$$]\9HZ)9+Y>@P;FU`B5HBI1L/+OX3*=C M:FS!\N;7VIT+7FTYV9E_3.W,C[0&7AI':DWJ.0>NA3?HP*1X2YY+H#2<_8S< MD'",P;;[0Z::9Z\RNG^4P9]5#_O8=]?^+A M)>^4YJ21Z@VLG.HSY--#\?'@[:[Z7[?(]2$%$1P2U1M3.5"$LNL!T0PYI,]5 M]-2C0[/%%AO;97?"TFN/8^8Y`6<@O>J]J!@.7$@NG;"<$I42'M:$VQX9AQV\ MI78JA%!`IGH?*HL<2`MZ`'8FFL2XJ'[+67(\U`N*>]-VAV0:';M1U8(=/4\H M*JT5D*G>84JN(R`ZT`.N@S5%$E*N`;Z3;*RZR+*@]YS+JPD@P1IY$7/T"BKX M>D]`I[I24A(FD!;T0(R]O(I\\?K@K*'R0D:@FC%?#)W`8!(!5@&GS937"A;P M#CVG_^.P>D=DC&HD0C+2O(]*:_2DUN]%%65_D`GF`>[;='^E!?^%881 M;@UB?18N$B/?]H1]I*A,+)F(1J^OOG/P2TX>VK?3&YBK[`M59=05L MIF+EZC&]:Q)Q?XT:-"C.A:+N#1TP.HM_A7YT*=4<3Q$Q7LMF;Q8HC`8-D1".ZB MLZ&O5/[%_LN977A$JE,7:\4,P_6@$\JL\B6J4^J%'A$Q>DJ.%0CN8QAHT<4; M>M@L`+](7ZJ3(E_1)HJK6G]3Z5A_AG:4Y\99;L![4)V2J8E99*E5#V-XFVF> MKPA[@W)$B?`>(F-3#T7_$G%I`M)1YN@=(#=Y,R[1&:BBKUS'JG-/B^U-JE"F MKI:QOS7Y^'R:#/Q9U!HDKE8"F,@,\C6G.]:\&[*+H,_O3WG2[&L;!$2]>I@( MD3)K5YP"6#2UVE!-*0'FG"AJ_!<#=*+*T-97G-: M(Q[?I%/)F,WM2WDJF`^15MS%Z=S3!&[;'QB>L&NAYZX%[#SJ)3G M-)<`)5WY+M:.'C@F9Y:A[2)?_+8:AT1YTG-E"`KUH@=\24,#PL1L=*E-04.]D/(C0_E>X;B M_AJWL]I)(\:4WOW.LX+PEN&ZF8=CFZ43A M0QP]Y%N>O8V2=&]#GP:E<^J?OS-:QE%4\I_VA='KS[K3P60^&(^,\9UQ^S@; MC/JSF<*RYSB[C#H.=FP+5OW%H5'H0GLX$A@1`Z3U]_YX.4F`/R=@WQ)&ON2+ M6*0OQ<738B13[E5<7PH=,(.]\9+MV^S-X=&?XU4#V:[Y?=HUKR^,V\YL,*-. M.9GV9_W1O+-WTL%HWI\.'HR[P:@SZ@XZ0V-&?ME_(&U4.N[86YEN7$M&)S:" M^6)?9W:JG0RU`.X1KJ9[E<-!9"E'M^!X^WE3Q$#R*H MA3PWVV=_2/OLS85Q/QZ,[HWN>-3M3T?OOJBO+PYMLI(C6[?=$4'`),RG>L,> M"E&7RM?HPLW&]';CYN?;2MDPW.%]]9+OQI[0;?[PP9H\/#YWI[W2RG0WN M1X.[0;"74/JF+8CE]*+2`?$R M>$D^V9MTL?95VL6^)2XVOIO_UIGV%3I0]CM"8B<2T6GP0%22+Y>5[H=D0[)' M26K.*]&E8G>#X9OSN%1A#:J,!67>^9[MD^VT3WYW8?0&,[)T)?/;8[]GC"?] M*=MRJISCLB5BEQ?2VG33N?=PN`5,?-(=J;UJ+<'2P+6TA_/KUBI1L$)7'V8F'Y]X^'7:P[^_,(8TNDN7M=UIOS>8J_1L]!3(G#_G MM5=Z$562)8C[Y1&H]BHN%F,' M>A1R.S<>!O/!?11IG4S']]/.@\HHSBL]N:9,I.1[45*>)-F-ZLA,D=?,"FE* MH?>1)?+&CM(BV(*9[561FQMX:7],^^"G"Z,[?B`>R$XRC,ZH9T3+T?O^2'&L MA2.<5!*57#'DNU4YT#N<8. M,5<_8FN$`[F5IT07BMTF&Y^L;$49C2@]Y7ORT9\AZ:;_G)M*TSY+I6E?TP.] MVQEQ&+*N-/J_*LZ328L!*47*HU!:8'7*%,1W\DE4O_,AP.2L?$H@N_9GX=PS M\?99:HO4F;CQS;YWE<_GO*'C\4VG'JDP^?4 MEU/!=I!],(Q<]=LUTI!)J44/)`>;K6E[K`[,VY\$C9=#[*Z&]C-:1)??@8$M MUIOJMVND<2ZC-#U@OR/\LR*<1/[;P"5"AYNCR>;C#"17_6*,-+!2:M$#R>-% MU'`WY=$H?_Y%%C.Q`O0`ZE`J#1]-07I`6POOG4GMD?)+!,QK>KW2:2!A"M$#P#9(:#OT_,&T]W%!B2A3K0`ZST84ID M4.#!&$BN_-$.>2^4T8L>4([02T),#[OD1PMM"J`JWY/R]SJD`2ZJ+>T/%^=%UR>-L.OM_\ON;6"` M`#RZCN]JV@%G??HN?&7O,_*>L(]2%_:^=MTP9\2XYE4/ZS`>O,$RXIFU1HN0 MO@<6WVFTU,^:K90CY?K17F2:8%BX2)ZTJX^F.=[$E7".KCBOV6Y\-$( MI>I:H_.IPPTPMR;9S%MHMD:(QGB.]YH>X0>E^*E@1G7Y9"5%R0IAU*UFDS0A:+EKT3<\E MQN"3G7"X"5F]50\MR5:8N^\1TZKVZ1JOTH.KKJE[>E",L"5(/(S'@^SQY*QT M7"Z(V#+HEQOLVPV\-`[?;R08.`Q)[['&BFKO8@=ABS+.4B#53C04G/F*'J&^ MM!C)PWT=4"#>C0;D1^[K#N=M]4`CVY;R$$BPGWR94H>X^^WN\.,_;;(&]*SU M;DC#3YVO-@<9*'V#T(**E*B`T0'`.&C/9HQSOGMX0^9Z`(ZP;O2`4\YX\V"& M27Q2\-562E(7?#57=(\4FL[47JTET,Z@5#UI%H4[ M5PG:YW'!@KMG%X))9G1I%?E]0P$7]@9>CRC996E%G0UEDI/^G-V\:2E67*G+ M3HFN;P54W1^O;F)E4Y=B&F-W:PP%Z7@$:@>YN`:%TFB0N?S M%RRGEEZ8:JMZ1EZW'?S@YF9CK(3Y2STA>#$>_2K5R"QEU^(!"]^=A. M]FRS6R]9E:,_#@,_,-T%]SE.(6'C+D8`JJ+YF`]<*XJPF0XU;>Q&LG:"P+.? MPH"E:&.R12<,^RRCXU0SO(!%R8X;=P=#1:K4X)FZUN$=+UZ6R=FUR\G"DY:Q M[T.+1)&W6(32Z(218O4D[TDC[TDC^:L7O$5>L*.W+K`DX3]#FQG5[6Y.OIN? M,0(B;A!.('GTR!7)994R*LH0`1'K@9N$?4+!3`I9,A4D)[#2<0,/H=G.IZZ> M>ZI,FV:V5!VLE;"M9$2%(W5-`:P^63ON6`1GOVSJX@7B*IQ/HCIT6%#S$#W4 M!,$#6M@S'`9KKM;/6JD.3154=(ZT->FVARW2U!^AX`5[7_"RLT&>;9E<30MH M5(<4"NH=I(FZHN2Q2\4)%ESMY[15??->0:US):]K2'^8=@FK+'N`JH<_F.40-"?1BBNQ'K#<'5.#TOPF:L$Z&TS, M*RI!RT>L2%^JUZQ@-(LK2@^@H]R3\?+X=L(<=TW/V]&;?>+?3=&*BH&]7208 M)\NH4&^J,QO`8)=1EOPIQ:C,0ZX7/>"OVZ'@AI2AHB8?G=2V'"UBJVK/4+KVEAC0;&,+0O@9[50G M_)95=J[H;RZ>7]LY2ED(9`/[#NCS5S79K?68DD`KDFP!$E$A MC:`0K1ORVNL!!\^P!*!H=1O&!+$,X2./HEK\7`+5";!\^TKGJ/#%UB;B?(B% MCY>'RZ@1KW@UGZ0IISY"J?4`AR5!#WP_1(M>2*_SGY`)%"^B).I)2*9FD[Y_ M+CH'D.RF,:<]A=2C-;+L?H[2P.;TTIB#G2+*T1K6N.J!;NI]=KEV46<][4+U M?K@:1\U2BR9H,OXBOCF`G;12O6V&8Y(AG!YJCRN%J,TPE\]7_7E+U5MFL/KS MA-0#@HPXXSXDF7A)ON\']H:>AC^Z%G8<9`4V]ZBL7*^JBV/!T%:A/)7O*V0^ M&M'*_IA;#?>#Q%,P4*[._R)N:/C)_4'R_)"E'Q/]G!% M\-%!.,<`13MLS"%!.8TU_V#[Q&/X#G.N&>`D(]^MZG$$;#^5J*_Y5A3?]\9- M]-RW:,P115JHYL-$WQ&D]3*">PA3S1IS!)$I7O-1.SP#N7]%,A^YC*:-.:S( M%;/Y"/[FV0$:+Y?CY?Z"3/K`+3V7H7L7:K;YD$)H&W,B`E>$'@OJS(G\GNP8 MAMCWQ^Y^]F>/,Y\W'"$R',W-KY*AX@+]-^;"`BOZ^R1Q9J)7#>"_ MY1G)T3SI5;CQV\RBM!TND>+=<37')@"U*/1/.A#YXV673#%V`'++FZNT6WY_ M80P'H_Z,OE?2G?9[@[EN[D@FSR/'`*_+::_#*5;$!:/>TM"'D+YVAI?C MC;GF%\UEME0=%.99Q\D=@_EBUE4"2K.E^<6?R1:J`WI016:(I4=8@$X?^[7E M7HSX4K%;['GXQ79777-+?A/L\LMS$]Y M"!M!L`ZIQ&(`=A[G$?D)V#0'Z+"QRD1L5T2OIX0U&02B.V)LB0FRZ\955S+[/Q[([VR7#&(VA MDX&,Y>S$*0ALXDK^7X7]L2H!#RKS<7D.6\LIF` M7C5C1U(2U719=M\*N?3Y;MA\<).>#SY=&-WQ`YD-'OJC^.:IL^BPQ3$>^4)VH'J(;H*0"6UI?",J0-G$R2PL>LSMOJ`8Z\27*`>PM/3=7X]$Z>O:A]4.IGFWZ)LQLXMD7^ MY2HVIZWJ>G28:KF"ZA$Y2%PA'=^D'@9K[-E_\6XKYQ(UY>P=(+D>$$WV&Q]) ME$1TJD,Y8*1@"FC^87O"(LG`,O:8@N(7*Y#'Y`;Y9#YQ8P[8)52AHY/*PP>E M5YV#5M!IFP@B[.4.'DUCKL82"ZXO0*`B*R&AZK5Z*:CXA57E#YF5(_TKIL<\ M4WNUYJ6@\&A4;Q@*XILEN!ZNR"QOXI&-#2>NEV@#!.![Y0"<"Z:'PNFII44G M4,;@+7UMD*R2Z&$TTZ'P@!Y*K_IY3'@2II1"]`"1^XA9]/D=]KJFO^9%R^%] M`,'\I!Q,><5H#2A;Y);#,ZL+\)9=5SSS]=+\[3O7A`5)DA!:*/CJ`S9P3>CO MQ,6`2Y)"<5,?=0'K06O8-'G96'T(INS3QF]K'-;A6>2V^E!/R7>1WY9-1*XP M0B_L5T7'B`0]U`[4QY'D--*``?^PJIPA[YGLWHNBF=$/%%7UT:-B&M(:W=,M M0V%P\[J!8JM!8*J(?A0FK\_")Q_]&9)N^L\TRQ>6#OO=63KL]84Q>[R=]7]Y M[(_F1O]75BZD5V9L6E1QCFP^A7X>J,OX6IL'"M!['V-?:8S5&^`*!]KX-_2O M)[+>)I_\/U!+`P04````"`!,?K!$1#G4W5P)``"@3P``$0`<`&YS8W0M,C`Q M-#`S,S$N>'-D550)``/_:W93_VMV4W5X"P`!!"4.```$.0$``.U<;6_CN!'^ MW`+]#ZR!`EL<9%MQDMWXDCLXLIQ3Z[>5G.WETX&6:)LXB?125!+WUY?4BVV] MF+&S&Z17-1\"F9P9SCPSI&9(T]<_/P<^>$0LQ)3<-/1FNP$0<:F'R?*F<>]H M/<>PK`;X^:>__!F(O^N_:AH88.1[7="GKF:1!?T1C&&`NN`.$<0@I^Q'\`7Z MD6RA`^PC!@P:K'W$D>A(1NJ"\V9[#C3M"+%?$/$HN[>MK=@5Y^MNJ_7T]-0D M]!$^4?9[V'3I<>(<&C$7;66U.QU=/P=CQY@!O?VY^;P0ZO6ZG?\>QCW#H;IE_@,L+^O'9QK^N(O(I MZL%?;'<"@PF<3[RG?]C_-A[\6WZV^F$!@\O%QO39YU&PP=/>E\[3W6AF39(A MKT-WA0((A,-)>-/8`_&ITZ1LV3IKM_76KZ.A$],U$L+NLX_)[U7D^M7552ON MS4A+E,]SYF>B.RW9/89LHSR.C=1/R4_R\9B@48F*FH6A(&5.2`TPN]-W(/XUG MITHE2]J0H7P2[K?0ES/*62'$PP3H?),:V3,!IUS84`IMR@L29O#AGL#(PQQY M?Z\OJE/(A#TKQ+'0L@+B?+\:[\X+>.=DU0OS+2SA9#%9R[Q#C)*&]($^-=;G M!:QW0@!=@)V8VD;Y/JH&#%<#GSY5`+[K4N-]H<1;2@&QF-KBW4>AR_!:RIXL M;J,0$Q2F>%=WJ?&^E*]"D57Z-(P8$A_T)NB;CF%;4Y$BCL%D`&[O'6ML.DZM M8+Z%(19A.]TS9;*P"!?Y53#`1*RW&/J[X,Q6]-.8U*[Y6'3-61/<]AS+D4Z9 MVJ9CCF>]S$G6>&;:U@@,K'%O;%B](7!$ISD2-/5RW!T5-:I!Q?N0I3ECKD4- M^:!P'&>..=3>V!I;1&\]`SS`F]^.9=,UT,K0, MRZQ7F#MTP9]$GI>BGWU2XJNWB_A>"'PG@]F_>K99*_0D"%1&9B2D%=+$`WUJ M9/4BLI?B-6HY8M40(7IO]L%D:MKQ8EVO,!W*'$1D?PR)5"W!-]^DAO6L".O' M)AC*9$0N!X9M]JU9K>#LHSD?"='+6*,IHTL&@RSYJ^I2P]LIPOM))G^W,S"R M9M9=DEM,[N,^2%:-.W-:C80NR)M"QCEG,N&]=02@8C4`YI?:E6_'U1&OJ3V.JT'T4@EX4@T" M/F3#U&M7ZC@7S.#9JT,-E4CVQW]]A[2,.L1^.(9/A_8C* M>[`E"C7ZI2*UN"<+/J02P59DO>`_[E6J#2!F\5>')HOM881%0L[B[T&$*8BG MO)V/%:EV<*DD/NWUK0&I1?*E*'E&N%4$[&FRC9'_1T;9C=53]I6\:E^7:O$3 M4[6ZS_0T0].RA_RD/=2K]DFII-_/Y#20":OK%,IC69PDAWK5D)<*_USR7/,@ MK\Z2M>KFW`1X%:?:4Z7M`$7>G5!F(^6^'%3+J:/$O3"1CJ15.ZNT$:`JDFH^ MRX;[QW#5/E&3*%W1*6T/E$_N:N^"RHI4JVS-+W.G\ZF=5=I]`Q6NZ!$C M@=U0(!VKKJN<`O?B(G<4J=I7)VU&U'R"*8YIJQUT"H/:3:5=BY?.>6OOK$.G MN]6>.II:[:;2WH/Z;+CV3DK.B*M=P&W&_" MM.9SX&1+T6AE/&`2G=9%5=+$ZN1`^I&XM2L,A/ M6L:GR29-/],Z>O,Y]'::GJ+$#H;3E,CX7J%$+"U$;G-)'X53<>[*\@$M*GGD M@[9C/G9\Y95IU?B5C"WD\S!K^49MY.0)OY,ZL:Q7Z'/$]?!C(F6?H0SA)Q-R%$0CE`P1ZP1*WG3J.["OB]/ MXV\:G$5R89&_+-`5"PZFWBQ>%[THV6AL@&2=3*[F=ST:0$PL(4N2";M$BB76 MHTB2WC$:K6\:B2PL2%0:F\1EF_A"7G908%`/Y55_@>;=;1@A#SLTXJN\VN7F M=]>T3UU.63A&7/[V!UWTX@"#>;U?(GIW*[(H&&(7D;`0+(]NX;_Q%(3?V/Y8DXQ/Z_KH4?0PO0IL^ET&Q,* M(063Y?=84B`C0E(X%=-P)=8\>;O:3?9D(]&^?V\O765.8#C=@<)[ZU3P6QFW M.P0]WK[#/.]MHMR8RGZ/P$:/B$3H`4$V(6C[-E-1G*!^TC=/?@;EIN&FMPWW MHS*@!''(-F]GU^R)OF!70O&'LVLE,NN7+$MI_FBV#6C$7C`M)?DOL.RZE=17 MXO$_4$L!`AX#%`````@`3'ZP1#)/EQTQ=0``8K,$`!$`&````````0```*2! M`````&YS8W0M,C`Q-#`S,S$N>&UL550%``/_:W93=7@+``$$)0X```0Y`0`` M4$L!`AX#%`````@`3'ZP1+'P&HKK"```VDT``!4`&````````0```*2!?'4` M`&YS8W0M,C`Q-#`S,S%?8V%L+GAM;%54!0`#_VMV4W5X"P`!!"4.```$.0$` M`%!+`0(>`Q0````(`$Q^L$3;I&@G(A$```;C```5`!@```````$```"D@;9^ M``!N`L``00E#@``!#D! M``!02P$"'@,4````"`!,?K!$.M39)C`Q0````(`$Q^L$1$.=3=7`D``*!/```1`!@```````$```"D M@8/=``!N XML 37 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8
Statements of Operations (Unaudited) (USD $)
3 Months Ended 6 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Mar. 31, 2014
Mar. 31, 2013
Income Statement [Abstract]        
REVENUES $ 105,118 $ 174,214 $ 222,675 $ 323,571
COST OF REVENUES 61,155 61,155 122,310 121,160
GROSS PROFIT 43,963 113,059 100,365 202,411
OPERATING EXPENSES:        
Selling, general and administrative 1,106,142 224,454 1,328,218 343,325
Research and development 30,000 55,000 60,000 95,000
Total operating expenses 1,136,142 279,454 1,388,218 438,325
Gain on the disposal of assets    1,353    1,353
OPERATING LOSS (1,092,179) (165,042) (1,287,853) (234,561)
OTHER INCOME (EXPENSE)        
Interest expense (279) (69) (515) (196)
Total other income expense (279) (69) (515) (196)
LOSS FROM CONTINUING OPERATIONS (1,092,458) (165,111) (1,288,368) (234,757)
INCOME (LOSS) FROM DISCONTINUED OPERATIONS 3,198 (38) (7,517) 58,946
NET LOSS $ (1,089,260) $ (165,149) $ (1,295,885) $ (175,811)
Basic and diluted        
Continuing operations $ 0.00 $ 0.00 $ (0.01) $ 0.00
Discontinued operations $ 0.00 $ 0.00 $ 0.00 $ 0.00
Total $ 0.00 $ 0.00 $ (0.01) $ 0.00
WEIGHTED AVERAGE NUMBER COMMON SHARES OUTSTANDING        
Basic and diluted 224,546,327 212,756,568 219,656,908 212,472,748

XML 38 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8
7. LINES OF CREDIT
6 Months Ended
Mar. 31, 2014
Debt Disclosure [Abstract]  
7. LINES OF CREDIT

NOTE 7 – LINES OF CREDIT

 

In November 2013, the Company entered into a revolving line of credit with Mutual of Omaha in the amount of $65,000 at a 4.00% interest rate per annum which renews annually. As of March 31, 2014, the Company had borrowed $62,612 against the line of credit.

 

The Company has a revolving line of credit with Chase Bank with a balance as of March 31, 2014 in the amount of $24,429 and a borrowing limit of $50,000. The line of credit with Chase Bank has an interest rate of 4.25% per annum and renews annually.

XML 39 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8
6. DISCONTINUED OPERATIONS
6 Months Ended
Mar. 31, 2014
Discontinued Operations and Disposal Groups [Abstract]  
6. DISCONTINUED OPERATIONS

NOTE 6- DISCONTINUED OPERATIONS

 

The Company’s former Board of Directors believed that it was in the best interest of the Company to discontinue the former business operation of the GPS operational device business. In 2011, this business was transferred to National Scientific, LLC, a company owned by the Company’s prior CEO, by prior management in which the Company’s former CEO was to pay $100,000 plus 2% of revenues for that technology. The former officer never paid the specific consideration for this transaction.

Accordingly, the Company reclassified the assets, liabilities and operations related to its GPS operational device business as discontinued operations.  Consequently, the accompanying financial statements reflect the assets, liabilities and operations of the GPS operational device business as net assets of discontinued operations, net liabilities of discontinued operations and results from discontinued operations.

 

On March 16, 2013, the Company closed the acquisition with the final payment for DNA. Subsequent to the transaction closing, the sellers refused to pay the transaction fees for medical billing contracts that were processed. The Company filed a lawsuit against the sellers for Breach of Contract among other things in June of 2013. During that time, the Company believes the sellers began contacting all billing contract holders and interfered with the acquisition of all the assets from the transaction. Consequently, the accompanying consolidated financial statements reflect the assets, liabilities and operations of DNA as net assets of discontinued operations, net liabilities of discontinued operations and results from discontinued operations.

 

Details of the classifications for net assets, liabilities and operations are shown below.

 

   March 31,
2014
  September 30,
2013
           
Net liabilities of discontinued operations:          
Accounts payable  $42,837   $35,356 
Net liabilities of discontinued operations  $42,837   $35,356 

   Three Months Ended
March 31,
   2014  2013
           
Discontinued operations:          
Revenues  $53,766   $900 
Cost of sales   —      —   
Operating expenses   (50,568)   (938)
Gain from write-off of debt   —      —   
Income (loss) from discontinued operations  $3,198  $(38)

 

   Six Months Ended
March 31,
   2014  2013
Discontinued operations:          
Revenues  $131,050   $900 
Cost of sales   —      —   
Operating expenses   (138,567)   (938)
Gain from write-off of debt   —      58,984 
Income (loss) from discontinued operations  $(7,517)  $58,946 

 

XML 40 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8
3. GOING CONCERN (Details Narrative) (USD $)
Mar. 31, 2014
Sep. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Accumulated Deficit $ (27,838,150) $ (26,542,265)
XML 41 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8
4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
6 Months Ended
Mar. 31, 2014
Accounting Policies [Abstract]  
Fair Value of Financial Instruments
   Level 1  Level 2  Level 3  Total
At March 31, 2014                    
Software  $—     $—     $701,611   $701,611 
Total Software  $—     $—     $701,611   $701,611 
                     
At September 30, 2013                    
Software  $—     $—     $937,431   $937,431 
Total Software  $—     $—     $937,431   $937,431 
XML 42 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8
10. RELATED PARTY TRANSACTIONS
6 Months Ended
Mar. 31, 2014
Related Party Transactions [Abstract]  
10. RELATED PARTY TRANSACTIONS

NOTE 10– RELATED PARTY TRANSACTIONS

 

The Company repaid $0 and $25,591 of the advances from the Company’s CEO in the three months ended March 31, 2014 and 2013, respectively. The advances from the CEO are due on demand and do not accrue interest. As of March 31, 2014 and September 30, 2013, there were no amounts owed to the CEO for advances, respectively.

XML 43 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8
8. DEBT MITIGATION PROGRAM
6 Months Ended
Mar. 31, 2014
OTHER INCOME (EXPENSE)  
8. DEBT MITIGATION PROGRAM

NOTE 8 – DEBT MITIGATION PROGRAM

 

The Company determined that the statute of limitations for certain of the Company’s creditors to enforce collection of any amounts they might be owed has now elapsed. Based on the determinations and findings, during six months ended March 31, 2014 and 2013, the Company recognized a gain on the write-off of liabilities in the amount of $0 and $58,984 from third party liabilities, respectively, which was recorded in income from discontinued operations, and additional paid-in capital of $59,704 and $0 for related party liabilities, respectively. The Company will continue to conduct this analysis going forward and write-off obligations when such obligations are no longer enforceable based on applicable law.

 

The following liabilities, through the opinion of legal counsel, were determined by the Company as unenforceable.

 

   Six Months Ended
   March  31,  March 31,
   2014  2013
           
Debt Mitigation Program:          
Accounts payable and accrued expenses  $59,704   $58,984 
Accrued interest   —      —   
Total debt mitigation program  $59,704   $58,984 
Gain on write-off of debt  $—     $(58,984)
Additional paid-in capital (1)  $59,704   $—  

(1)   All amounts that were owed to related parties in prior years were recorded to paid-in-capital.
XML 44 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8
9. COMMITMENTS AND CONTINGENCIES
6 Months Ended
Mar. 31, 2014
Commitments and Contingencies Disclosure [Abstract]  
9. COMMITMENTS AND CONTINGENCIES

NOTE 9 – COMMITMENTS AND CONTINGENCIES

 

Rent expense for the three months and six ended March 31, 2014 and 2013 was $0 for all periods.

 

The Company entered into an agreement to purchase the assets of DNA in June 2012 and after due diligence by both parties the transaction closed on March 16, 2013. Subsequent to the transaction closing on March 16, 2013, the sellers refused to pay for medical billing process transaction fees in accordance with their contracts of approximately $200,000. In June 2013, the Company sued the sellers in federal court for breach of contract among other causes of action of unpaid medical billing transaction fees of approximately $200,000. The Company believes it will be successful in its litigation. However, if the Company is successful, the collectability of the judgment is highly questionable.

 

The Company has issued shares to new investors since January 2, 2011, that have an anti-reverse common stock split clause if the Company reverse splits the common stock. The reverse split of common stock is determined by management but must be approved by Financial Industry Regulation Authority (“FINRA”). Presently FINRA has denied the Company the right to reverse split the common stock until all Securities and Exchange Commission filings are current and at that point and time the Company will submit a request to FINRA to execute a reverse split of the common stock of the Company. The current investors holding anti-reverse split stock will have the right to hold the same number of shares of common stock as status quo after the reverse split. The anti-reverse split common stock protection is only for stock subject to reverse split and once the Company declares a reverse split and it is completed, the anti-reverse split protection will be terminate and shareholders that received anti-reverse split stock will be held with regular stockholders as the Company proceeds forward. In accordance with the anti-reverse split provision, no further shares will be issued to the anti-reverse split shareholders once the reverse split is approved and completed.

 

As discussed in Note 8, the Company has written off $59,704 and $58,984 in accounts payable, accrued liabilities and notes payable based on the opinion of legal counsel for the six months ended March 31, 2014 and 2013, respectively. However, the related creditors could make a claim in the future in regards to these liabilities.

XML 45 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8
11. EQUITY
6 Months Ended
Mar. 31, 2014
Equity [Abstract]  
11. EQUITY

NOTE 11 - EQUITY

 

As of March 31, 2014, the Company was authorized to issue 650,000,000 common shares and 4,000,000 preferred shares at a par value of $0.01.  

 

Six Months Ended March 31, 2014

 

Stock Issued for Cash

 

During the six months ended March 31, 2014, the Company issued 35,000 shares of common stock for $15,000 in net cash proceeds as follows:

 

Date   Number of Shares   Proceeds
         
  October 21, 2013       25,000     $ 5,000  
  January 12, 2014     10,000     10,000  
  Total       35,000     $ 15,000  

 

Stock Issued in Connection with Software Licensing and Subscription Agreements

 

During the six months ended March 31, 2014, the Company issued 220,000 shares of common stock valued at $5,700 based on the market price on the date of grant, to customers, in regards to the purchase of software from the Company in accordance with the Software Licensing and Subscription Agreements. The fair values of the shares issued were recorded as a reduction of software revenue recognized during the three months ended March 31, 2014.

 

Date  Number of Shares  Fair Value
       
 December 4, 2013    120,000   $3,600 
 March 4, 2014    100,000    2,100 
 Total    220,000   $5,700 

 

Stock Issued for Assets Acquisition

 

In October 2013, the Company through a purchase agreement with Antree Systems Limited has purchased a complete source code, intellectual property rights, all computer software, patents, or formulas, algorithm licensed or sold under a project known as Compass Rose and appropriate copyrights, patents, mask works, trademarks, service marks, internet domain names and world wide web uniform resource locators (“URLs”) from Antree Systems Limited. The Company issued 200,000 shares of its common stock as consideration for the purchase. The fair value of the consideration and the assets acquired is based on the fair value of the common stock issued in exchange for the software. The total fair value, based on the market price on the date of grant, was $6,000. The Company evaluated this acquisition and determined that it did not meet the definition of a significant business acquisition.

 

In November 2013, the Company issued 180,000 shares of common stock as replacement shares for the 160,000 shares of common stock issued to Antree Systems Limited and 20,000 shares of common stock to Kimberly Ilicerl. The Company intends to cancel the original shares issued because the shares were lost during delivery to Antree Systems.

 

Stock Issued for Services

 

During the six months ended March 31, 2014, the Company issued 31,750,000 shares of common stock as compensation. The fair values of the shares were a total of $666,750 and were recorded at the market price on the date of grant. The issuances of stock were as follows:

 

Date  Number of Shares  Fair Value  Description of Services
                  
 March 5, 2014    31,750,000   $666,750    Compensation 
                 
 Total    31,750,000   $666,750      

  

Six Months Ended March 31, 2013

 

Stock Issued for Cash

 

During the six months ended March 31, 2013, the Company issued 197,500 shares of common stock for $141,000 in net cash proceeds as follows:

 

Date  Number of Shares  Proceeds
             
 October 14, 2012    20,000   $20,000 
 October 14, 2012    15,000    3,000 
 October 14, 2012    18,750    2,500 
 October 14, 2012    18,750    2,500 
 December 6, 2012    15,000    3,000 
 March 12, 2013    20,000    20,000 
 March 12, 2013    20,000    20,000 
 March 31, 2013    50,000    50,000 
 March 27, 2013    20,000    20,000 
 Total    197,500   $141,000 

 

Stock Issued in Connection with Software Licensing and Subscription Agreements

 

During the six months ended March 31, 2013, the Company issued 300,000 shares of common stock valued at $9,350 based on the market price on the date of grant, to customers, in regards to the purchase of software from the Company in accordance with the Software Licensing and Subscription Agreements. The fair values of the shares issued were recorded as a reduction of software revenue recognized during the three months ended March 31, 2013.

 

Date  Number of Shares  Fair Value
             
 October 14, 2012    50,000   $1,300 
 December 6, 2012    100,000    2,800 
 March 12, 2013    50,000    1,750 
 March 21, 2013    50,000    1,750 
 March 21, 2013    50,000    1,750 
 Total    300,000   $9,350 

 

Stock Issued for Services

 

During the six months ended March 31, 2013, the Company issued 827,000 shares of common stock as compensation. The fair values of the shares were a total of $28,155 and were recorded at the market price on the date of grant. The issuances of stock were as follows:

 

Date  Number of Shares  Fair Value  Description of Services
                  
 October 14, 2012    10,000   $260    Commission 
 December 6, 2012    100,000    2,800    Compensation 
 March 12, 2013    50,000    1,750    Consulting 
 March 21, 2013    167,000    5,845    Compensation 
 March 21, 2013    500,000    17,500    Compensation 
 Total    827,000   $28,155      

 

Stock Issued for Assets Acquisition

 

During the six months ended March 31, 2013, the Company issued 400,000 shares of common stock for the acquisition of CipherSmith software. Those shares were valued at $13,000 based on the market price on the dates of grant.

 

Preferred Stock

 

The Company has authorized 4,000,000 shares of preferred stock, at $0.01 par value and 4,000,000 are issued and outstanding as of September 30, 2013. Each share of the Preferred Stock has 150 votes on all matters presented to be voted by the holders of our common stock. All 4,000,000 shares of preferred stock have been granted to our CEO & CFO on November 30, 2010 and issued on April 11, 2012 which was valued at the trading price of the common stock of $0.0095 and recorded as an expense of $38,000.

 

On December 17, 2013, the Company amended its Articles of Incorporation that gave the right to the holders of Preferred A shares to convert 1 share of Convertible Preferred A shares to 150 Common Shares of the Company. The holders of the Preferred A shares can convert the shares upon proper notice and approval of the Board of Directors. Presently, the holders of the Preferred A shares have not sent notice to the Board of Directors.

XML 46 R34.htm IDEA: XBRL DOCUMENT v2.4.0.8
10. RELATED PARTY TRANSACTIONS (Details Narrative) (USD $)
3 Months Ended 6 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Mar. 31, 2014
Mar. 31, 2013
Related Party Transactions [Abstract]        
Repayment of Advances from Related Parties    $ (25,591)    $ (25,591)
XML 47 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8
6. DISCONTINUED OPERATIONS (Tables)
6 Months Ended
Mar. 31, 2014
Discontinued Operations and Disposal Groups [Abstract]  
Discontinued Operations
   March 31,
2014
  September 30,
2013
           
Net liabilities of discontinued operations:          
Accounts payable  $42,837   $35,356 
Net liabilities of discontinued operations  $42,837   $35,356 

   Three Months Ended
March 31,
   2014  2013
           
Discontinued operations:          
Revenues  $53,766   $900 
Cost of sales   —      —   
Operating expenses   (50,568)   (938)
Gain from write-off of debt   —      —   
Income (loss) from discontinued operations  $3,198  $(38)

 

   Six Months Ended
March 31,
   2014  2013
Discontinued operations:          
Revenues  $131,050   $900 
Cost of sales   —      —   
Operating expenses   (138,567)   (938)
Gain from write-off of debt   —      58,984 
Income (loss) from discontinued operations  $(7,517)  $58,946 
XML 48 R26.htm IDEA: XBRL DOCUMENT v2.4.0.8
5. SOFTWARE - Software (Details) (USD $)
Mar. 31, 2014
Sep. 30, 2013
Intangible assets $ 1,257,406 $ 1,251,406
Accumulated amortization of intangible assets (545,795) (423,485)
Accumulated impairment of assets (10,000) (10,000)
Intangible assets, Net 701,611 817,921
Antree Systems Limited
   
Intangible assets 6,000   
Encryption Software Code
   
Intangible assets 15,800 15,800
MediSouth
   
Intangible assets 2,500 2,500
Doctors Network of America
   
Intangible assets 10,000 10,000
Software License
   
Intangible assets 1,200,106 1,200,106
EMR Certification
   
Intangible assets $ 23,000 $ 23,000
XML 49 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8
Statements of Cash Flows (Unaudited) (USD $)
6 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Statement of Cash Flows [Abstract]    
Net Loss $ (1,295,885) $ (175,811)
Income from discontinued operations (7,517) 58,946
Loss from continuing operations (1,288,368) (234,757)
Adjustments to reconcile net loss from continuing operations to net cash from operating activities:    
Depreciation and amortization 122,310 121,160
Common stock issued for compensation 666,750 28,155
Common stock issued for software sales 5,700 9,350
Gain on the disposal of assets    1,353
Changes in operating assets and liabilities:    
Accounts receivable 3,162 3,012
Accounts payable and accrued expenses 397,270 88,638
Net cash (used in) provided by operating activities (93,176) 14,205
CASH FLOWS FROM INVESTING ACTIVITIES:    
Proceeds from the sale of assets    1,353
Net cash provided by investing activities    1,353
CASH FLOWS FROM FINANCING ACTIVITIES:    
Repayment of advances from officer    (25,591)
Proceeds from line of credit 78,245 2,500
Repayment of line of credit (1,000) (22,152)
Common stock issued for cash 15,000 141,000
Net cash provided by financing activities 92,245 95,757
INCREASE (DECREASE) IN CASH (931) 111,315
CASH, BEGINNING OF PERIOD 8,587 51,356
CASH, END OF PERIOD 7,656 162,671
SUPPLEMENTAL DISCLOSURE    
Interest paid      
Taxes paid      
NONCASH INVESTING AND FINANCING ACTIVITIES    
Write-off of related party debt to additional paid-in capital 59,704 [1]    [1]
Common stock issued to purchase software 6,000 13,000
Accrual of software acquisition costs    $ 23,000
[1] All amounts that were owed to related parties in prior years were recorded to paid-in-capital.
XML 50 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8
5. SOFTWARE
6 Months Ended
Mar. 31, 2014
Research and Development [Abstract]  
5. SOFTWARE

NOTE 5 – SOFTWARE

 

The following is a detail of software at March 31, 2014 and September 30, 2013:

 

   March 31, 2014  September 30,
2013
           
Source Code License – Antree Systems Limited  $6,000   $—   
Encryption Software Code   15,800    15,800 
Source Code License – MediSouth, LLC   2,500    2,500 
Acquisition of Doctor’s Network of America   10,000    10,000 
Software License   1,200,106    1,200,106 
EMR Certification   23,000    23,000 
Total intangible assets   1,257,406    1,251,406 
Accumulated amortization of intangible assets   (545,795)   (423,485)
Accumulated impairment of assets   (10,000)   (10,000)
Total intangible assets  $701,611   $817,921 

  

The Company’s software was placed into service starting in the second quarter of fiscal year ended September 30, 2012. The amortization expense was $61,155 and $61,155 for the three months ended March 31, 2014 and 2013, respectively. The Company recognized a $0 and $6,000 for impairment of software acquired from Doctors Network of America (“DNA”) operating in Flowood, Mississippi during the six months ended March 31, 2014 and the year ended September 30, 2013, respectively. The Company is currently in litigation with the sellers of DNA relating to the collection of certain medical billings owed to the Company. As a result of the litigation, the Company deemed the assets to be impaired.

 

Source Code License

 

In October 2013, the Company through a purchase agreement with Antree Systems Limited has purchased a complete source code, intellectual property rights, all computer software, patents, or formulas, algorithm licensed or sold under a project known as Compass Rose and appropriate copyrights, patents, mask works, trademarks, service marks, internet domain names and world wide web uniform resource locators (“URLs”) from Antree Systems Limited. The Company issued 200,000 shares of its common stock as consideration for the purchase. The fair value of the consideration and the assets acquired is based on the fair value of the common stock issued in exchange for the software. The total fair value, based on the market price on the date of grant, was $6,000. The Company evaluated this acquisition and determined that it did not meet the definition of a significant business acquisition.

 

Encryption Software Code

 

On November 21, 2012, the Company purchased from CipherSmith, LLC a complete source code, intellectual property rights, all computer software or algorithm licensed or sold under CipherSmith, and appropriate copy rights, patents, mask works, trademarks, service marks, internet domain names or world wide web URS. The Company issued 500,004 shares of its common stock as payment for the acquisition. The fair value of the consideration and the assets acquired is based on the aggregate fair value of the common stock issued in exchange for the software. The total fair value of the shares of common stock issued on the date of grant was $15,800.

 

Doctors Network of America

 

On June 22, 2012, the Company entered into an acquisition agreement that closed on March 16, 2013. The Company agreed to acquire DNA in Flowood, Mississippi from Krooss Medical Management Systems, LLC (“Krooss”) for 500,000 shares of common stock. As of September 30, 2012, 200,000 shares of common stock were issued as a deposit, which was valued at $4,000 based on the market value on the date of grant. At the closing of the transaction on March 16, 2013, the Company issued an additional 300,000 shares of common stock which were valued at $6,000 based on the market value on the date of grant.

 

Subsequent to the transaction closing on March 16, 2013, the sellers refused to pay for medical billing process transaction fees in accordance with their contracts in the amount of approximately $200,000. The Company and the sellers are currently in litigation over the disputed transaction fees of $200,000.

XML 51 R27.htm IDEA: XBRL DOCUMENT v2.4.0.8
5. SOFTWARE (Details Narrative) (USD $)
3 Months Ended 6 Months Ended 3 Months Ended 12 Months Ended
Mar. 31, 2014
Dec. 31, 2013
Mar. 31, 2013
Dec. 31, 2012
Mar. 31, 2014
Mar. 31, 2013
Dec. 31, 2013
Antree Systems Limited
Dec. 31, 2012
Cipher Smith [Member]
Sep. 30, 2012
Doctors Networkof America [Member]
Mar. 16, 2013
Doctors Networkof America [Member]
Mar. 16, 2013
Doctors Networkof America [Member]
Pending Litigation [Member]
Amortization Expense $ 61,155   $ 60,005                
Stock issued Purchase of Asset, Shares   200,000   100,000 200,000 400,000 200,000 500,004      
Stock Issued Purchase of Asset, Value   6,000   2,800 6,000 13,000 6,000 15,800      
Stock Issued, Acquisition, Shares                 500,000    
Shares Issued                 200,000 300,000  
Shares Issued, Value                 4,000 6,000  
Amount Due from Acquisition                     $ 200,000
XML 52 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 54 146 1 true 20 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://NSCT/role/DocumentAndEntityInformation Document and Entity Information true false R2.htm 00000002 - Statement - Balance Sheets (Unaudited) Sheet http://NSCT/role/BalanceSheets Balance Sheets (Unaudited) false false R3.htm 00000003 - Statement - Balance Sheets (Parenthetical) Sheet http://NSCT/role/BalanceSheetsParenthetical Balance Sheets (Parenthetical) false false R4.htm 00000004 - Statement - Statements of Operations (Unaudited) Sheet http://NSCT/role/StatementsOfOperations Statements of Operations (Unaudited) false false R5.htm 00000005 - Statement - Statements of Cash Flows (Unaudited) Sheet http://NSCT/role/StatementsOfCashFlows Statements of Cash Flows (Unaudited) false false R6.htm 00000006 - Disclosure - 1. DESCRIPTION OF BUSINESS Sheet http://NSCT/role/DescriptionOfBusiness 1. DESCRIPTION OF BUSINESS false false R7.htm 00000007 - Disclosure - 2. BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS Sheet http://NSCT/role/BasisOfPresentationOfInterimFinancialStatements 2. BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS false false R8.htm 00000008 - Disclosure - 3. GOING CONCERN Sheet http://NSCT/role/GoingConcern 3. GOING CONCERN false false R9.htm 00000009 - Disclosure - 4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://NSCT/role/SummaryOfSignificantAccountingPolicies 4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES false false R10.htm 00000010 - Disclosure - 5. SOFTWARE Sheet http://NSCT/role/Software 5. SOFTWARE false false R11.htm 00000011 - Disclosure - 6. DISCONTINUED OPERATIONS Sheet http://NSCT/role/DiscontinuedOperations 6. DISCONTINUED OPERATIONS false false R12.htm 00000012 - Disclosure - 7. LINES OF CREDIT Sheet http://NSCT/role/LinesOfCredit 7. LINES OF CREDIT false false R13.htm 00000013 - Disclosure - 8. DEBT MITIGATION PROGRAM Sheet http://NSCT/role/DebtMitigationProgram 8. DEBT MITIGATION PROGRAM false false R14.htm 00000014 - Disclosure - 9. COMMITMENTS AND CONTINGENCIES Sheet http://NSCT/role/CommitmentsAndContingencies 9. COMMITMENTS AND CONTINGENCIES false false R15.htm 00000015 - Disclosure - 10. RELATED PARTY TRANSACTIONS Sheet http://NSCT/role/RelatedPartyTransactions 10. RELATED PARTY TRANSACTIONS false false R16.htm 00000016 - Disclosure - 11. EQUITY Sheet http://NSCT/role/Equity 11. EQUITY false false R17.htm 00000017 - Disclosure - 12. SUBSEQUENT EVENTS Sheet http://NSCT/role/SubsequentEvents 12. SUBSEQUENT EVENTS false false R18.htm 00000018 - Disclosure - 4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://NSCT/role/SummaryOfSignificantAccountingPoliciesPolicies 4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) false false R19.htm 00000019 - Disclosure - 4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://NSCT/role/SummaryOfSignificantAccountingPoliciesTables 4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) false false R20.htm 00000020 - Disclosure - 5. SOFTWARE (Tables) Sheet http://NSCT/role/SoftwareTables 5. SOFTWARE (Tables) false false R21.htm 00000021 - Disclosure - 6. DISCONTINUED OPERATIONS (Tables) Sheet http://NSCT/role/DiscontinuedOperationsTables 6. DISCONTINUED OPERATIONS (Tables) false false R22.htm 00000022 - Disclosure - 8. DEBT MITIGATION PROGRAM (Tables) Sheet http://NSCT/role/DebtMitigationProgramTables 8. DEBT MITIGATION PROGRAM (Tables) false false R23.htm 00000023 - Disclosure - 3. GOING CONCERN (Details Narrative) Sheet http://NSCT/role/GoingConcernDetailsNarrative 3. GOING CONCERN (Details Narrative) false false R24.htm 00000024 - Disclosure - 4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value of Financial Instruments (Details) Sheet http://NSCT/role/SummaryOfSignificantAccountingPolicies-FairValueOfFinancialInstrumentsDetails 4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value of Financial Instruments (Details) false false R25.htm 00000025 - Disclosure - 4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://NSCT/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative 4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) false false R26.htm 00000026 - Disclosure - 5. SOFTWARE - Software (Details) Sheet http://NSCT/role/Software-SoftwareDetails 5. SOFTWARE - Software (Details) false false R27.htm 00000027 - Disclosure - 5. SOFTWARE (Details Narrative) Sheet http://NSCT/role/SoftwareDetailsNarrative 5. SOFTWARE (Details Narrative) false false R28.htm 00000028 - Disclosure - 6. DISCONTINUED OPERATIONS - Discontinued Operations (Details) Sheet http://NSCT/role/DiscontinuedOperations-DiscontinuedOperationsDetails 6. DISCONTINUED OPERATIONS - Discontinued Operations (Details) false false R29.htm 00000029 - Disclosure - 6. DISCONTINUED OPERATIONS (Details Narrative) Sheet http://NSCT/role/DiscontinuedOperationsDetailsNarrative 6. DISCONTINUED OPERATIONS (Details Narrative) false false R30.htm 00000030 - Disclosure - 7. LINES OF CREDIT (Details Narrative) Sheet http://NSCT/role/LinesOfCreditDetailsNarrative 7. LINES OF CREDIT (Details Narrative) false false R31.htm 00000031 - Disclosure - 8 - DEBT MITIGATION PROGRAM - Debt Mitigation Program (Details) Sheet http://NSCT/role/DebtMitigationProgram-DebtMitigationProgramDetails 8 - DEBT MITIGATION PROGRAM - Debt Mitigation Program (Details) false false R32.htm 00000032 - Disclosure - 8. DEBT MITIGATION PROGRAM (Details Narrative) Sheet http://NSCT/role/DebtMitigationProgramDetailsNarrative 8. DEBT MITIGATION PROGRAM (Details Narrative) false false R33.htm 00000033 - Disclosure - 9. COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://NSCT/role/CommitmentsAndContingenciesDetailsNarrative 9. COMMITMENTS AND CONTINGENCIES (Details Narrative) false false R34.htm 00000034 - Disclosure - 10. RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://NSCT/role/RelatedPartyTransactionsDetailsNarrative 10. RELATED PARTY TRANSACTIONS (Details Narrative) false false R35.htm 00000035 - Disclosure - 11. EQUITY (Details Narrative) Sheet http://NSCT/role/EquityDetailsNarrative 11. EQUITY (Details Narrative) false false R36.htm 00000036 - Disclosure - 12. SUBSEQUENT EVENTS (Details Narrative) Sheet http://NSCT/role/SubsequentEventsDetailsNarrative 12. SUBSEQUENT EVENTS (Details Narrative) false false All Reports Book All Reports Process Flow-Through: 00000002 - Statement - Balance Sheets (Unaudited) Process Flow-Through: Removing column 'Mar. 31, 2013' Process Flow-Through: Removing column 'Sep. 30, 2012' Process Flow-Through: 00000003 - Statement - Balance Sheets (Parenthetical) Process Flow-Through: 00000004 - Statement - Statements of Operations (Unaudited) Process Flow-Through: 00000005 - Statement - Statements of Cash Flows (Unaudited) nsct-20140331.xml nsct-20140331.xsd nsct-20140331_cal.xml nsct-20140331_def.xml nsct-20140331_lab.xml nsct-20140331_pre.xml true true XML 53 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8
5. SOFTWARE (Tables)
6 Months Ended
Mar. 31, 2014
Research and Development [Abstract]  
Software
   March 31, 2014  September 30,
2013
           
Source Code License – Antree Systems Limited  $6,000   $—   
Encryption Software Code   15,800    15,800 
Source Code License – MediSouth, LLC   2,500    2,500 
Acquisition of Doctor’s Network of America   10,000    10,000 
Software License   1,200,106    1,200,106 
EMR Certification   23,000    23,000 
Total intangible assets   1,257,406    1,251,406 
Accumulated amortization of intangible assets   (545,795)   (423,485)
Accumulated impairment of assets   (10,000)   (10,000)
Total intangible assets  $701,611   $817,921